<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006612.pub5" GROUP_ID="VASC" ID="064906073111263806" MERGED_FROM="" MODIFIED="2017-08-08 16:54:30 +0100" MODIFIED_BY="Abigail Baldridge" REVIEW_NO="0604C" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2017-08-08 16:54:27 +0100" MODIFIED_BY="Abigail Baldridge">
<TITLE MODIFIED="2012-11-22 05:58:40 -0600" MODIFIED_BY="Heather Maxwell">Homocysteine-lowering interventions for preventing cardiovascular events</TITLE>
<CONTACT MODIFIED="2017-08-08 16:54:27 +0100" MODIFIED_BY="Abigail Baldridge"><PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Arturo</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Martí-Carvajal</LAST_NAME><SUFFIX>MD, MSc, PhD</SUFFIX><EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION><CITY>Valencia</CITY><COUNTRY CODE="VE">Venezuela</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-08-08 16:54:27 +0100" MODIFIED_BY="Abigail Baldridge"><PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Arturo</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Martí-Carvajal</LAST_NAME><SUFFIX>MD, MSc, PhD</SUFFIX><EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION><CITY>Valencia</CITY><COUNTRY CODE="VE">Venezuela</COUNTRY></ADDRESS></PERSON><PERSON ID="12177" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Ivan</FIRST_NAME><LAST_NAME>Solà</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>isola@santpau.cat</EMAIL_1><EMAIL_2>ensayos@cochrane.es</EMAIL_2><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP) - Universitat Autònoma de Barcelona</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret 167</ADDRESS_1><ADDRESS_2>Pavilion 18</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08025</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 935 537 814</PHONE_1><FAX_1>+34 935 537 809</FAX_1></ADDRESS></PERSON><PERSON ID="21562E5782E26AA200DA2AF3AD698E2D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dimitrios</FIRST_NAME><LAST_NAME>Lathyris</LAST_NAME><POSITION>Anaesthesiologist-Intensivist</POSITION><EMAIL_1>lathyrisd@hotmail.com</EMAIL_1><ADDRESS><ORGANISATION>"George Gennimatas" General Hospital</ORGANISATION><CITY>Thessaloniki</CITY><COUNTRY CODE="GR">Greece</COUNTRY><PHONE_1>+30 2313 307658</PHONE_1></ADDRESS></PERSON><PERSON ID="56653224019996182310111213170033" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mark</FIRST_NAME><LAST_NAME>Dayer</LAST_NAME><SUFFIX>PHD FRCP</SUFFIX><POSITION>Consultant</POSITION><EMAIL_1>markdayer@me.com</EMAIL_1><EMAIL_2>mark.dayer@tst.nhs.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Cardiology</DEPARTMENT><ORGANISATION>Taunton and Somerset NHS Trust</ORGANISATION><ADDRESS_1>Musgrove Park</ADDRESS_1><CITY>Taunton</CITY><ZIP>TA1 5DA</ZIP><REGION>Somerset</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01823 480994</PHONE_1><FAX_1>01823 480994</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-06-01 13:11:12 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<UP_TO_DATE>
<DATE DAY="1" MONTH="6" YEAR="2017"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="6" YEAR="2017"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="6" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-08-07 15:51:11 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2017-08-07 15:51:11 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="6" YEAR="2017"/>
<DESCRIPTION>
<P>There is new information on stroke. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-06-01 13:11:47 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<DATE DAY="1" MONTH="6" YEAR="2017"/>
<DESCRIPTION>
<P>We updated the searches to June 2017.<BR/>
<BR/>We found three new trials.<BR/>
<BR/>This updated Cochrane Review now has four authors.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-10-03 14:28:26 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-10-03 14:28:23 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="10" YEAR="2014"/>
<DESCRIPTION>
<P>We found no new trials for inclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-10-03 14:28:26 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>We updated the searches to February 2014. </P>
<P>This updated Cochrane Review now has only three authors.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>This new updated version includes four additional RCTs and the conclusions are not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="2" YEAR="2012"/>
<DESCRIPTION>
<P>We updated the searches to 21 February 2012.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-07-11 11:35:22 -0500" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2014-07-11 11:35:22 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-04-14 14:12:27 -0500" MODIFIED_BY="[Empty name]">
<NAME>Iberoamerican Cochrane Centre</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>Academic</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2012-03-07 04:40:32 -0600" MODIFIED_BY="[Empty name]">
<NAME>Cochrane Heart Group</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Academic</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-08-08 09:27:04 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2017-07-11 09:54:37 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<TITLE MODIFIED="2014-12-19 05:18:47 -0600" MODIFIED_BY="[Empty name]">Homocysteine-lowering interventions (B-complex vitamin therapy) for preventing cardiovascular events</TITLE>
<SUMMARY_BODY MODIFIED="2017-07-11 09:54:37 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>
<B>Review question</B>
<BR/>We reviewed whether particular vitamins, which lower homocysteine, prevent cardiovascular events such as heart attack and stroke.</P>
<P>
<B>Background</B>
<BR/>Cardiovascular disease, which includes heart attacks and strokes, is the number one cause of death worldwide. Many people with cardiovascular disease may not have symptoms, but be at high risk. Diabetes mellitus, high blood pressure, smoking and a high cholesterol, as well as a family history of cardiovascular disease are well known risk factors. Elevated total homocysteine levels have recently been identified as a risk factor for cardiovascular disease. Homocysteine is an amino acid, its levels in the blood are influenced by blood levels of B vitamins: cyanocobalamin (B12), folic acid (B9) and pyridoxine (B6). This report is an update from a previous review published in 2015.</P>
<P>
<B>Study characteristics</B>
<BR/>The evidence is current to June 2017. We included 15 studies involving 71,422 participants living in countries with or without mandatory supplementation of foods with vitamins. These studies compared different regimens of B vitamins (cyanocobalamin (B12), folic acid (B9) and pyridoxine (B6)) with a control or any other comparison group. The studies were published between 2002 and 2015.</P>
<P>
<B>Key results</B>
<BR/>We found no evidence that homocysteine-lowering interventions, in the form of supplements of vitamins B6, B9 or B12 given alone or in combination, at any dosage compared with placebo, or standard care, prevented heart attack or reduced death rates in participants at risk of, or living with cardiovascular disease. Homocysteine-lowering interventions combined with antihypertensive medication had uncertain effects on stroke, approximately 143 people would need to be treated for 5.4 years to prevent 1 stroke. Homocysteine-lowering interventions compared with placebo or any other comparison did not affect serious adverse events (cancer).</P>
<P>
<B>Quality of evidence</B>
<BR/>The quality of evidence from these studies was generally high.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-08-07 16:02:45 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2017-01-10 12:06:21 -0600" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>Cardiovascular disease, which includes coronary artery disease, stroke and peripheral vascular disease, is a leading cause of death worldwide. Homocysteine is an amino acid with biological functions in methionine metabolism. A postulated risk factor for cardiovascular disease is an elevated circulating total homocysteine level. The impact of homocysteine-lowering interventions, given to patients in the form of vitamins B6, B9 or B12 supplements, on cardiovascular events has been investigated. This is an update of a review previously published in 2009, 2013, and 2015.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-08-02 09:35:10 -0500" MODIFIED_BY="Heather Maxwell">
<P>To determine whether homocysteine-lowering interventions, provided to patients with and without pre-existing cardiovascular disease are effective in preventing cardiovascular events, as well as reducing all-cause mortality, and to evaluate their safety.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-08-02 09:41:40 -0500" MODIFIED_BY="Heather Maxwell">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2017, Issue 5), MEDLINE (1946 to 1 June 2017), Embase (1980 to 2017 week 22) and LILACS (1986 to 1 June 2017). We also searched Web of Science (1970 to 1 June 2017). We handsearched the reference lists of included papers. We also contacted researchers in the field. There was no language restriction in the search.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-09-06 09:24:51 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>We included randomised controlled trials assessing the effects of homocysteine-lowering interventions for preventing cardiovascular events with a follow-up period of one year or longer. We considered myocardial infarction and stroke as the primary outcomes. We excluded studies in patients with end-stage renal disease.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-08-07 09:48:23 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>We performed study selection, 'Risk of bias' assessment and data extraction in duplicate. We estimated risk ratios (RR) for dichotomous outcomes. We calculated the number needed to treat for an additional beneficial outcome (NNTB). We measured statistical heterogeneity using the I<SUP>2 </SUP>statistic. We used a random-effects model. We conducted trial sequential analyses, Bayes factor, and fragility indices where appropriate.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-08-07 16:02:45 -0500" MODIFIED_BY="[Empty name]">
<P>In this third update, we identified three new randomised controlled trials, for a total of 15 randomised controlled trials involving 71,422 participants. Nine trials (60%) had low risk of bias, length of follow-up ranged from one to 7.3 years. Compared with placebo, there were no differences in effects of homocysteine-lowering interventions on myocardial infarction (homocysteine-lowering = 7.1% versus placebo = 6.0%; RR 1.02, 95% confidence interval (CI) 0.95 to 1.10, I<SUP>2</SUP> = 0%, 12 trials; N = 46,699; Bayes factor 1.04, high-quality evidence), death from any cause (homocysteine-lowering = 11.7% versus placebo = 12.3%, RR 1.01, 95% CI 0.96 to 1.06, I<SUP>2 </SUP>= 0%, 11 trials, N = 44,817; Bayes factor = 1.05, high-quality evidence), or serious adverse events (homocysteine-lowering = 8.3% versus comparator = 8.5%, RR 1.07, 95% CI 1.00 to 1.14, I<SUP>2 </SUP>= 0%, eight trials, N = 35,788; high-quality evidence). Compared with placebo, homocysteine-lowering interventions were associated with reduced stroke outcome (homocysteine-lowering = 4.3% versus comparator = 5.1%, RR 0.90, 95% CI 0.82 to 0.99, I<SUP>2 </SUP>= 8%, 10 trials, N = 44,224; high-quality evidence). Compared with low doses, there were uncertain effects of high doses of homocysteine-lowering interventions on stroke (high = 10.8% versus low = 11.2%, RR 0.90, 95% CI 0.66 to 1.22, I<SUP>2 </SUP>= 72%, two trials, N = 3929; very low-quality evidence).</P>
<P>We found no evidence of publication bias.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-08-02 09:42:09 -0500" MODIFIED_BY="Heather Maxwell">
<P>In this third update of the Cochrane review, there were no differences in effects of homocysteine-lowering interventions in the form of supplements of vitamins B6, B9 or B12 given alone or in combination comparing with placebo on myocardial infarction, death from any cause or adverse events. In terms of stroke, this review found a small difference in effect favouring to homocysteine-lowering interventions in the form of supplements of vitamins B6, B9 or B12 given alone or in combination comparing with placebo.</P>
<P>There were uncertain effects of enalapril plus folic acid compared with enalapril on stroke; approximately 143 (95% CI 85 to 428) people would need to be treated for 5.4 years to prevent 1 stroke, this evidence emerged from one mega-trial.</P>
<P>Trial sequential analyses showed that additional trials are unlikely to increase the certainty about the findings of this issue regarding homocysteine-lowering interventions versus placebo. There is a need for additional trials comparing homocysteine-lowering interventions combined with antihypertensive medication versus antihypertensive medication, and homocysteine-lowering interventions at high doses versus homocysteine-lowering interventions at low doses. Potential trials should be large and co-operative.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-08-08 09:27:04 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2017-08-07 10:08:41 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<CONDITION MODIFIED="2017-08-07 10:08:41 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<SUBSECTION>
<HEADING LEVEL="3">The burden of cardiovascular disease</HEADING>
<P>Cardiovascular disease is the number one cause of death worldwide (<LINK REF="REF-Barquera-2015" TYPE="REFERENCE">Barquera 2015</LINK>; <LINK REF="REF-Smith-2012" TYPE="REFERENCE">Smith 2012</LINK>). The term cardiovascular disease covers a wide array of disorders, including diseases of the cardiac muscle and of the vascular system supplying the heart, brain and other vital organs. The most common causes of cardiovascular disease-related morbidity and mortality are ischaemic heart disease and stroke (<LINK REF="REF-Li-2016" TYPE="REFERENCE">Li 2016</LINK>; <LINK REF="REF-Maredza-2015" TYPE="REFERENCE">Maredza 2015</LINK>; <LINK REF="REF-Oliveira-2015" TYPE="REFERENCE">Oliveira 2015</LINK>; <LINK REF="REF-Prabhakaran-2016" TYPE="REFERENCE">Prabhakaran 2016</LINK>).</P>
<P>The burden of cardiovascular disease is significant and ischaemic heart disease is the single largest cause of death worldwide (<LINK REF="REF-Bansilal-2015" TYPE="REFERENCE">Bansilal 2015</LINK>; <LINK REF="REF-Kwan-2016" TYPE="REFERENCE">Kwan 2016</LINK>). Global deaths from cardiovascular disease increased by 41% between 1990 and 2013 (<LINK REF="REF-Roth-2015a" TYPE="REFERENCE">Roth 2015a</LINK>). It has been pointed out that cardiovascular diseases cause more than 4 million deaths/year in the 53 countries of the World Health Organization European Region and over 1.9 million deaths in the European Union (<LINK REF="REF-Bansilal-2015" TYPE="REFERENCE">Bansilal 2015</LINK>). It has been estimated that there will be 7.8 million premature cardiovascular deaths in 2025 (<LINK REF="REF-Roth-2015b" TYPE="REFERENCE">Roth 2015b</LINK>).</P>
<P>Cardiovascular diseases account for about one-half of non communicable diseases deaths (<LINK REF="REF-Benziger-2016" TYPE="REFERENCE">Benziger 2016</LINK>). The majority of cardiovascular disease deaths occur in low- and middle-income countries (<LINK REF="REF-Barquera-2015" TYPE="REFERENCE">Barquera 2015</LINK>; <LINK REF="REF-Benziger-2016" TYPE="REFERENCE">Benziger 2016</LINK>; <LINK REF="REF-Oliveira-2015" TYPE="REFERENCE">Oliveira 2015</LINK>; <LINK REF="REF-Prabhakaran-2016" TYPE="REFERENCE">Prabhakaran 2016</LINK>). The major risk factors for cardiovascular diseases include tobacco use, high blood pressure, high blood glucose, lipid abnormalities, high levels of body mass index and physical inactivity (<LINK REF="REF-Barquera-2015" TYPE="REFERENCE">Barquera 2015</LINK>; <LINK REF="REF-Lackland-2015" TYPE="REFERENCE">Lackland 2015</LINK>; <LINK REF="REF-Li-2016" TYPE="REFERENCE">Li 2016</LINK>; <LINK REF="REF-Roth-2015b" TYPE="REFERENCE">Roth 2015b</LINK>; <LINK REF="REF-Singh-2015" TYPE="REFERENCE">Singh 2015</LINK>; <LINK REF="REF-Tzoulaki-2016" TYPE="REFERENCE">Tzoulaki 2016</LINK>; <LINK REF="REF-Yeates-2015" TYPE="REFERENCE">Yeates 2015</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Homocysteine as a risk factor for cardiovascular disease</HEADING>
<P>In 1962, it was hypothesised that increased levels of total homocysteine may cause vascular disease: the homocysteine theory of arteriosclerosis (<LINK REF="REF-McCully-2015a" TYPE="REFERENCE">McCully 2015a</LINK>). The pathways through which total homocysteine levels may cause damage to endothelial cells and lead to atherosclerosis have been widely described (<LINK REF="REF-Ganguly-2015" TYPE="REFERENCE">Ganguly 2015</LINK>; <LINK REF="REF-McCully-2015b" TYPE="REFERENCE">McCully 2015b;</LINK> <LINK REF="REF-Pushpakumar-2014" TYPE="REFERENCE">Pushpakumar 2014</LINK>). It has been pointed out that homocysteine reduces the bioavailability of the nitric oxide, a potent vasodilator (<LINK REF="REF-Lai-2015b" TYPE="REFERENCE">Lai 2015b</LINK>). Another mechanism would be through an integration of the roles of homocysteine and folic acid in cardiovascular pathobiology, known as methoxistasis (<LINK REF="REF-Joseph-2013" TYPE="REFERENCE">Joseph 2013</LINK>). The molecular and cellular effect of homocysteine metabolism imbalance yields oxidative stress which is cytotoxic (<LINK REF="REF-Skovierova-2016" TYPE="REFERENCE">Skovierova 2016</LINK>). The cellular status of homocysteine is not correlated with the homocysteine levels in plasma, which may explain the considerable differences that there are between epidemiological, intervention and basic research reports (<LINK REF="REF-Hannibal-2016" TYPE="REFERENCE">Hannibal 2016</LINK>).</P>
<P>Homocysteine is a non-proteinogenic amino acid derived in methionine metabolism (<LINK REF="REF-Skovierova-2016" TYPE="REFERENCE">Skovierova 2016</LINK>). Several observational studies had shown that a raised blood homocysteine level was a risk factor for cardiovascular events (<LINK REF="REF-Casas-2005" TYPE="REFERENCE">Casas 2005</LINK>; <LINK REF="REF-Danesh-1998" TYPE="REFERENCE">Danesh 1998</LINK>; <LINK REF="REF-Eikelboom-1999" TYPE="REFERENCE">Eikelboom 1999</LINK>; <LINK REF="REF-Ford-2002" TYPE="REFERENCE">Ford 2002</LINK>; <LINK REF="REF-Guthikonda-2006" TYPE="REFERENCE">Guthikonda 2006</LINK>; <LINK REF="REF-HSC-2002" TYPE="REFERENCE">HSC 2002</LINK>; <LINK REF="REF-Jacobsen-2005" TYPE="REFERENCE">Jacobsen 2005</LINK>; <LINK REF="REF-Kardesoglu-2011" TYPE="REFERENCE">Kardesoglu 2011</LINK>; <LINK REF="REF-Refsum-1998" TYPE="REFERENCE">Refsum 1998</LINK>; <LINK REF="REF-Splaver--2004" TYPE="REFERENCE">Splaver 2004</LINK>; <LINK REF="REF-Stampfer-1992" TYPE="REFERENCE">Stampfer 1992</LINK>; <LINK REF="REF-Wald-2002" TYPE="REFERENCE">Wald 2002</LINK>; <LINK REF="REF-Wang-2005" TYPE="REFERENCE">Wang 2005</LINK>; <LINK REF="REF-Williams-2010" TYPE="REFERENCE">Williams 2010</LINK>; <LINK REF="REF-Wu-2013" TYPE="REFERENCE">Wu 2013</LINK>). The public significance of raised circulating blood homocysteine levels has been considered (<LINK REF="REF-Shelhub-2008" TYPE="REFERENCE">Shelhub 2008</LINK>). Currently, there is no evidence to support cardiovascular risk reduction by homocysteine-lowering interventions (<LINK REF="REF-Cybulska-2015" TYPE="REFERENCE">Cybulska 2015</LINK>; <LINK REF="STD-Li-2015" TYPE="STUDY">Li 2015</LINK>; <LINK REF="REF-Mart_x00ed__x002d_Carvajal-2009" TYPE="REFERENCE">Martí-Carvajal 2009</LINK>; <LINK REF="REF-Mart_x00ed__x002d_Carvajal-2013" TYPE="REFERENCE">Martí-Carvajal 2013</LINK>; <LINK REF="REF-Mart_x00ed__x002d_Carvajal-2015" TYPE="REFERENCE">Martí-Carvajal 2015</LINK> (three previous versions of this review)). The American College of Cardiology/American Heart Association Task Force on Practice Guidelines (<LINK REF="REF-Goff-2014" TYPE="REFERENCE">Goff 2014</LINK>) and The European Guidelines on cardiovascular disease prevention in clinical practice (<LINK REF="REF-Perk-2012" TYPE="REFERENCE">Perk 2012</LINK>) ratify that homocysteine is not a causal risk factor for cardiovascular disease.</P>
<P>Circulating total homocysteine levels are composed of protein (albumin)-homocysteine mixed disulfide, sulfhydryl form and low molecular weight disulfides (<LINK REF="REF-Mudd-2000" TYPE="REFERENCE">Mudd 2000</LINK>). The normal levels of total homocysteine are close to 10 µmol/L (<LINK REF="REF-Mudd-2000" TYPE="REFERENCE">Mudd 2000</LINK>). Hyperhomocysteinaemia is defined as the presence of an abnormally elevated concentration of plasma or serum total homocysteine (<LINK REF="REF-Mudd-2000" TYPE="REFERENCE">Mudd 2000</LINK>). However, there is some controversy about the definition of the degree of hyperhomocysteinaemia. Fasting total homocysteine level concentrations between 12 µmol/L and 30 µmol/L are termed mild or moderate, while intermediate hyperhomocysteinaemia includes levels between 31 µmol/L to 100 µmol/L, and severe hyperhomocysteinaemia reflects values above 100 µmol/L (<LINK REF="REF-Maron-2006" TYPE="REFERENCE">Maron 2006</LINK>; <LINK REF="REF-Maron-2009" TYPE="REFERENCE">Maron 2009</LINK>). In the general population, the prevalence of hyperhomocysteinaemia is between 5% and 10% (<LINK REF="REF-Refsum-1998" TYPE="REFERENCE">Refsum 1998</LINK>). However, rates may be as high as 30% to 40% in the elderly population (<LINK REF="REF-Selhub-1993" TYPE="REFERENCE">Selhub 1993</LINK>).</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2017-01-04 12:00:32 -0600" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>B-complex vitamins, cyanocobalamin (B12) (<LINK REF="REF-Fedosov-2012" TYPE="REFERENCE">Fedosov 2012</LINK>; <LINK REF="REF-Herrmann-2012" TYPE="REFERENCE">Herrmann 2012</LINK>; <LINK REF="REF-Kr_x00e4_utler-2012" TYPE="REFERENCE">Kräutler 2012</LINK>), folic acid (B9) (<LINK REF="REF-Crider-2011" TYPE="REFERENCE">Crider 2011</LINK>; <LINK REF="REF-Molloy-2012" TYPE="REFERENCE">Molloy 2012</LINK>; <LINK REF="REF-Ohrvik-2011" TYPE="REFERENCE">Ohrvik 2011</LINK>; <LINK REF="REF-Yetley-2011" TYPE="REFERENCE">Yetley 2011</LINK>), and pyridoxine (B6) (<LINK REF="REF-di-Salvo-2011" TYPE="REFERENCE">di Salvo 2011</LINK>; <LINK REF="REF-di-Salvo-2012" TYPE="REFERENCE">di Salvo 2012</LINK>; <LINK REF="REF-Friso-2012" TYPE="REFERENCE">Friso 2012</LINK>; <LINK REF="REF-Mukherjee-2011" TYPE="REFERENCE">Mukherjee 2011</LINK>), given as a supplement. </P>
</INTERVENTION>
<THEORY MODIFIED="2017-01-10 12:09:57 -0600" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>The B-complex vitamins are essential for homocysteine metabolism; they are involved in both the transformation and excretion pathways of homocysteine (<LINK REF="REF-McCully-2015a" TYPE="REFERENCE">McCully 2015a</LINK>; <LINK REF="REF-McCully-2015b" TYPE="REFERENCE">McCully 2015b</LINK>). Supplementation with B-complex vitamins reduces total homocysteine levels (<LINK REF="REF-Clarke-2007" TYPE="REFERENCE">Clarke 2007</LINK>; <LINK REF="REF-HLTC-2005" TYPE="REFERENCE">HLTC 2005</LINK>). There is some ambiguity regarding the function of pyridoxine (vitamin B6). Vitamin B6 supplementation has been shown to lower total homocysteine levels after a methionine load, which occurs in experimental situations. However, at least two studies have shown the contrary (<LINK REF="REF-Gori-2007" TYPE="REFERENCE">Gori 2007</LINK>; <LINK REF="REF-Sofi-2008" TYPE="REFERENCE">Sofi 2008</LINK>). It is, as a result, believed to be a weak determinant of circulating total homocysteine levels.</P>
</THEORY>
<IMPORTANCE MODIFIED="2017-08-02 09:43:21 -0500" MODIFIED_BY="Heather Maxwell">
<P>This is the third update of this Cochrane review and has been performed to identify and review the latest evidence.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-08-08 09:25:47 -0500" MODIFIED_BY="[Empty name]">
<P>To determine whether homocysteine-lowering interventions, provided to patients with and without pre-existing cardiovascular disease:</P>
<OL>
<LI>are effective in preventing cardiovascular events and/or all-cause mortality;</LI>
<LI>are safe;</LI>
<LI>differ in efficacy or safety.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2017-08-08 09:27:04 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2017-08-02 09:47:55 -0500" MODIFIED_BY="Heather Maxwell">
<CRIT_STUDIES MODIFIED="2017-08-02 09:47:55 -0500" MODIFIED_BY="Heather Maxwell">
<P>Randomised controlled trials (RCTs) with a follow-up period of one year or longer.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-08-02 05:15:31 -0500" MODIFIED_BY="Heather Maxwell">
<P>Adults (over 18 years) at risk of, or with established cardiovascular disease. We excluded studies in patients with end-stage renal disease.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-03-21 11:48:07 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>The interventions considered were vitamins B6 (pyridoxine; pyridoxal), B9 (folic acid) or B12 (cyanocobalamin) given alone or in combination, at any dosage, and via any administration route.</P>
<P>We made comparisons with placebo, or with differing regimens of vitamins B6, B9 or B12. When the included population was at risk of cardiovascular disease, we considered combinations of homocysteine-lowering interventions with standard treatment (such as antihypertensives and statins) versus standard treatment alone.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-09-06 09:32:06 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-11-21 11:24:47 -0600" MODIFIED_BY="Joey Kwong">
<OL>
<LI>Non-fatal or fatal myocardial infarction.</LI>
<LI>Non-fatal or fatal stroke (ischaemic or haemorrhagic stroke).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-09-06 09:32:06 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<OL>
<LI>First unstable angina pectoris episode requiring hospitalisation.</LI>
<LI>Hospitalisation for heart failure.</LI>
<LI>Death from any cause.</LI>
<LI>Serious or non-serious adverse events.</LI>
</OL>
<P>We defined serious adverse events according to the International Conference on Harmonisation (ICH) Guidelines (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>), as any event that leads to death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation and/or results in persistent or significant disability. We considered all other adverse events non-serious.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-08-02 09:48:21 -0500" MODIFIED_BY="Heather Maxwell">
<ELECTRONIC_SEARCHES MODIFIED="2017-08-02 09:48:11 -0500" MODIFIED_BY="Heather Maxwell">
<P>We reran the searches previously run in 2008 (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), 2012 (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), and 2014 (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). Search strategies for 2017 are shown in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P>
<P>We updated the searches of the Cochrane Central Register of Controlled Trials (CENTRAL 2017, Issue 5), MEDLINE OVID (1946 to 1 June 2017), Embase OVID (1980 to 2017 week 22) and Web of Science (Thomson Reuters, 1970 to 1 June 2017). The search of LILACS was last run on 1 June 2017. In a previous version (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2009" TYPE="REFERENCE">Martí-Carvajal 2009</LINK>), we searched Allied and Complementary Medicine - AMED (accessed through Ovid) and the Cochrane Stroke Group Specialised Register.</P>
<P>We used the Cochrane sensitive-maximising RCT filters to search MEDLINE and Embase (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>).</P>
<P>We imposed no language restrictions.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-08-02 09:48:21 -0500" MODIFIED_BY="Heather Maxwell">
<P>We also checked the reference lists of all trials identified.</P>
<P>We also searched the World Health Organization International Clinical Trials Platform search portal (<A HREF="http://apps.who.int./trialsearch">http://apps.who.int./trialsearch</A>) and ClinicalTrials.gov (<A HREF="https://clinicaltrials.gov/">https://clinicaltrials.gov/</A>).</P>
<P>We also searched websites of U.S. Food and Drug Administration (<A HREF="http://www.fda.gov">www.fda.gov</A>) and European Medicines Agency (<A HREF="http://www.ema.europa.eu">www.ema.europa.eu</A>) for unpublished information on homocysteine-lowering interventions.</P>
<P>We contacted authors and researchers to obtain further details for published studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-08-08 09:27:04 -0500" MODIFIED_BY="[Empty name]">
<P>We conducted data collection and analysis according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<STUDY_SELECTION MODIFIED="2016-09-19 13:33:37 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>Two authors (AMC and IS) independently screened the results of the search strategy for potentially relevant trials and independently assessed them for inclusion based on the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-08-02 09:48:42 -0500" MODIFIED_BY="Heather Maxwell">
<P>Two review authors (AMC and IS) carried out data extraction using a pre-designed data extraction form that included publication details, patient population, randomisation, allocation concealment, details of blinding measures, description of interventions and results. We resolved discrepancies through discussion. We involved a third review author (DL) to check the data entered into the Review Manager software. Two review authors (AMC and IS) assessed the included studies and entered the information into tables; see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-08-02 09:48:48 -0500" MODIFIED_BY="Heather Maxwell">
<P>All review authors independently assessed the risk of bias of the trials according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We assessed the following domains.</P>
<OL>
<LI>Generation of the allocation sequence</LI>
<LI>Allocation concealment</LI>
<LI>Blinding (or masking)</LI>
<LI>Incomplete outcome data</LI>
<LI>Selective outcome reporting</LI>
<LI>Other bias</LI>
</OL>
<P>See <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> for details of domains.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-08-07 18:01:15 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>We pooled the risk ratios (RR) with 95% confidence interval (CI) for the following binary outcomes: non-fatal or fatal myocardial infarction, non-fatal or fatal stroke (ischaemic or haemorrhagic), first unstable angina pectoris episode requiring hospitalisation, hospitalisation for heart failure, death from any cause and serious or non-serious adverse events as recommended by <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>. We calculated the number needed to treat for an additional beneficial outcome (NNTB) if the RR was significant (P value = &lt; 0.05). NNTB is a measure of assessment of clinical useful of the consequences of treatment (<LINK REF="REF-Laupacis-1988" TYPE="REFERENCE">Laupacis 1988</LINK>). We estimated NNTB with <A HREF="https://graphpad.com/quickcalcs/NNT2/">GraphPad software</A>.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>For all included trials, we noted the levels of attrition. We contacted the first author of the paper if data were missing. We extracted data on the number of participants by allocated treatment group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow-up. If we were not able to do so, we recorded for each study whether the results pertained to an intention-to-treat analysis or to available-case analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>We quantified statistical heterogeneity using the I<SUP>2 </SUP>statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We considered statistical heterogeneity to be present if the I<SUP>2 </SUP>value was greater than 50% (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). When significant heterogeneity was detected (I<SUP>2 </SUP>&gt; 50%), we attempted to identify the possible causes.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2017-08-07 12:35:28 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>We assessed asymmetry in funnel plots for myocardial infarction, stroke and death from any cause, and devoted to detect potential publication bias and other causes of asymmetry (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>). We used the contour-enhanced funnel plot for differentiating asymmetry due to publication bias from that due to other factors (<LINK REF="REF-Peters-2008" TYPE="REFERENCE">Peters 2008</LINK>). We assessed likelihood of publication bias with Harbord and Peters tests (<LINK REF="REF-Sterne-2011a" TYPE="REFERENCE">Sterne 2011a</LINK>; <LINK REF="REF-Sterne-2011b" TYPE="REFERENCE">Sterne 2011b</LINK>). We used STATA statistical software V.14.0 (StataCorp LP) to perform conventional and contour funnel plots.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-03-21 13:19:06 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>We pooled the results from the trials using the Review Manager software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We summarised the findings using a random-effects model.</P>
<SUBSECTION>
<HEADING LEVEL="3">Trial Sequential Analysis</HEADING>
<P>Meta-analysis of cumulative data may run the risk of random errors ('play of chance') due to sparse data and repetitive analyses of the same data (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Wetterslev-2017" TYPE="REFERENCE">Wetterslev 2017</LINK>). In order to assess the risks of random errors in our cumulative meta-analyses, we conducted diversity-adjusted trial sequential analyses based upon the proportion with the outcome in the control group, an a priori set relative risk reduction of 20%, an alpha of 5%, a beta of 20% and the diversity in the meta-analysis (<LINK REF="REF-CTU-2011" TYPE="REFERENCE">CTU 2011</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>). We conducted sensitivity analysis of the trial sequential analysis to estimate the potential need for further trials.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2017-01-04 12:59:22 -0600" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>We performed subgroup analysis according to the type of intervention, and by trials including participants without cardiovascular disease versus trials including participants with cardiovascular disease. </P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-08-08 09:27:04 -0500" MODIFIED_BY="[Empty name]">
<P>We conducted a sensitivity analysis comparing the results using all studies and using only those with a low risk of bias.</P>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings' tables</HEADING>
<P>We used The Grading of Recommendations Assessment, Development and Evaluation (GRADE) proposals to assess the quality of the body of evidence associated with the following outcomes: myocardial infarction, stroke, death from any cause and cancer (<LINK REF="REF-Guyatt-2011" TYPE="REFERENCE">Guyatt 2011</LINK>). One review author constructed <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK> using the GRADEpro software (<LINK REF="REF-GRADEpro-2008" TYPE="REFERENCE">GRADEpro 2008</LINK>). We involved a second review author to check the data.</P>
<P>GRADE classifies the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the outcome being assessed (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>; <LINK REF="REF-Guyatt-2013" TYPE="REFERENCE">Guyatt 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Fragility Index</HEADING>
<P>We calculated the fragility index (FI) if the RR was significant (P value = &lt; 0.05). FI is a measure to identify the number of events required to change statistically significant results to non-significant results (<LINK REF="REF-Walsh-2014" TYPE="REFERENCE">Walsh 2014</LINK>). The FI was only applied to RCTs where the allocation 1:1 and to binary data. We estimated the FI with the <A HREF="http://clincalc.com/Stats/FragilityIndex.aspx">Fragility Index Calculator</A>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Bayes Factors</HEADING>
<P>We estimated the threshold for clinical relevance using a Bayes factor (<LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>). This is a likelihood ratio indicate the relative strength of evidence for two theories (<LINK REF="REF-Dienes-2014" TYPE="REFERENCE">Dienes 2014</LINK>; <LINK REF="REF-Goodman-1999" TYPE="REFERENCE">Goodman 1999</LINK>; <LINK REF="REF-Goodman-2005" TYPE="REFERENCE">Goodman 2005</LINK>). A Bayes factor is a comparison of how well two hypotheses (the null hypothesis -H0- and the alternative hypothesis -H1-) predict the data (<LINK REF="REF-Goodman-1999" TYPE="REFERENCE">Goodman 1999</LINK>). A Bayes factor provides a continuous measure of evidence for H1 over H0. When a Bayes factor is 1, the evidence does not favour either model over the other. As a Bayes factor increase above 1 (towards infinity) the evidence favours H1 over H0. As a Bayes factor decreases below 1 (towards 0) the evidence favours H0 over H1 (<LINK REF="REF-Dienes-2008" TYPE="REFERENCE">Dienes 2008</LINK>; <LINK REF="REF-Dienes-2014" TYPE="REFERENCE">Dienes 2014</LINK>; <LINK REF="REF-Dienes-2017" TYPE="REFERENCE">Dienes 2017</LINK>). We used <A HREF="http://www.lifesci.sussex.ac.uk/home/Zoltan_Dienes/inference/Bayes.htm">Dienes' Calculator</A> for estimating Bayes factors.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-08-07 16:52:30 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2017-08-07 15:54:55 -0500" MODIFIED_BY="[Empty name]">
<P>The search in June 2017 identified 1464 records, which resulted in 1073 unique references after duplicates were removed. After examining the titles and abstracts we excluded 1036 references. We obtained full reprints of the remaining 37 references for more detailed examination, of which 22 reports were excluded. The remaining 15 references identified were for three new randomised clinical trials (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>), 11 of which related to one of the new trials (<LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>).</P>
<P>In total, this updated review includes 15 randomised clinical trials, published between 2002 and 2015, involving 71,422 participants (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for details.</P>
<P>These trials are described in the section <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. The length of follow-up ranged from one to 7.3 years. The trials varied in size, characteristics of participant populations, duration, drug dosage and experimental design.</P>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-08-07 15:54:55 -0500" MODIFIED_BY="[Empty name]">
<P>Thirteen trials were conducted in participants with known cardiovascular disease, such as coronary artery disease, myocardial infarction, stable angina, unstable angina, stroke or intermittent claudication (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>), one trial included participants without any history of cardiovascular disease (<LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>); a further trial explicitly included participants with a history of non-disabling cerebral infarction (<LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>).</P>
<P>Fourteen trials included participants with at least one of the following known cardiovascular risk factors: diabetes mellitus, hypertension, elevated total cholesterol, current smoking, or low high-density lipoprotein (HDL) cholesterol (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). This aspect was unclear for <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>. One trial (<LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>) included participants with three or more coronary risk factors. One trial explicitly excluded participants with previously known hyperhomocysteinaemia (total plasma homocysteine &gt; 18 &#956;mol/L) (<LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>).</P>
<P>
<LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK> included participants with hyperhomocysteinaemia without diabetes and cardiovascular disease. <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK> included participants without a history of coronary heart disease (CHD). <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK> only included female participants. <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK> included hypertensive females with hyperhomocysteinaemia.</P>
<P>Eleven trials included more than 1000 participants (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). Two trials only included elderly participants (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>).</P>
<P>Ten trials were compared with placebo (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>), and two with standard care (<LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>), while two trials were randomised controlled trials (<LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>), which compared doses of homocysteine-lowering interventions. One trial compared antihypertensive medication plus a homocysteine-lowering intervention versus antihypertensive medication alone (<LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>).</P>
<P>The intervention assessed by most of the trials was a combination of vitamins B6, B9 and B12 (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). Five trials only included vitamin B9 as intervention (<LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>). <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK> used 5-methyltetrahydrofolate instead of folic acid.</P>
<P>
<LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>, <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>, <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>, <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>, <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>, <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK> and <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK> described lipid-lowering drugs used as concomitant medications. <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK> reported omega 3 polyunsaturated fatty acids used as concomitant medications. <LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK> reported vitamin D3 use as a concomitant medication. <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK> reported restriction of salt intake and administration of vitamin B12 as a concomitant medication. <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK> described the use of antihypertensive medications, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, diuretics, &#946;-Blockers, lipid-lowering medications, glucose-lowering medications and antiplatelet medications concomitantly.</P>
<P>Three trials were conducted in a "fortified" population (<LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>). The programme was described as a "...nutritional intervention programme with a specifically defined target, and fortified food products are expected to become a main source of the specific added nutrient" (<LINK REF="REF-Wirakartakusumah-1998" TYPE="REFERENCE">Wirakartakusumah 1998</LINK>). Two trials were performed in a mixed population (<LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>), and 10 were carried out in non-fortified populations (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>).</P>
<P>Twelve trials used composite outcomes in their analyses (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). Four trials included revascularisation or other vascular procedures (<LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). Fourteen trials had stroke as the endpoint (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). Fourteen trials assessed the impact of the intervention on myocardial infarction rates (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). One trial included angina pectoris as a component of composite outcomes (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>).</P>
<P>Thirteen studies reported the sample size calculation (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). The trials used 80% or 90% power to detect between a 20% and 50% reduction in endpoints.</P>
<P>Concentrations of total homocysteine blood levels at baseline were reported in 13 trials (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008;</LINK> <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). Six trials reported the total homocysteine blood levels at the end of follow-up (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>). <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK> described total homocysteine blood levels after one year of the intervention. <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK> did not report total homocysteine blood levels at baseline or at the end of follow-up in the control arm. <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK> reported total homocysteine blood levels at baseline and at the end follow-up, but only for the intervention arm and not for the control arm. <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK> and <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK> did not report the circulating total homocysteine blood levels in either group.</P>
<P>Definitions used for defining myocardial infarction, stroke, unstable angina and death (all-cause) are described in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-08-02 09:57:44 -0500" MODIFIED_BY="Heather Maxwell">
<P>This review has 66 references excluded (44 in the prior versions and 22 in this update), which are described in the table of <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. These studies were mainly systematic reviews, RCTs with a follow-up of less of one year, and non-RCTs.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-08-02 09:58:12 -0500" MODIFIED_BY="Heather Maxwell">
<P>The risk of bias in the included trials is summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, and detailed in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables. See <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> for details.</P>
<ALLOCATION MODIFIED="2017-08-02 09:58:01 -0500" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="4">Random sequence generation</HEADING>
<P>The risk of bias arising from the method of generation of the allocation sequence was low in 10 trials (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>). Five trials had an unclear risk for this domain (<LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>We rated the risk of bias arising from the method of allocation concealment as low in 10 trials (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). Five trials showed an unclear risk for this domain (<LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>).</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2017-08-02 09:58:12 -0500" MODIFIED_BY="Heather Maxwell">
<P>We rated the risk of bias arising from lack of blinding of participants and personnel as low in 11 trials (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). The risk of bias from blinding was unclear in two trials (<LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>). We rated the risk of bias arising from lack of blinding as high in two trials (<LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of outcome assessment <I>(detection bias)</I>
</HEADING>
<P>We rated the risk of bias arising from lack of blinding of outcome assessment as low in 12 trials (<LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). The risk of bias from unblinding was unclear in three trials (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>).</P>
</SUBSECTION>
</BLINDING>
<EXCLUSIONS MODIFIED="2017-03-21 12:39:36 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>We rated the risk of attrition bias as low in eight trials (<LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>). We rated the risk of attrition bias as high in three trials (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). We rated the risk of bias as unclear in four trials (<LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-07-10 16:34:31 -0500" MODIFIED_BY="[Empty name]">
<P>Fourteen trials had a low risk of bias in this domain. One trial was rated as having high risk of bias for selective reporting (<LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>) due to lack of information on adverse events.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-07-12 15:57:26 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>Ten trials had a low risk of bias due to other sources of bias not identified (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). Four trials had an unclear risk of bias (<LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>). One trial was rated as having high risk of bias (<LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Overall risk of bias</HEADING>
<P>Nine trials were rated as having low risk of bias (<LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>).</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-08-07 16:52:30 -0500" MODIFIED_BY="[Empty name]">
<P>The results are based on 71,422 participants in 15 randomised clinical trials (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>).<BR/>
<BR/>See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK> and <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK> for details.</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Non-fatal or fatal myocardial infarction</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Homocysteine-lowering interventions compared with placebo or conventional care</HEADING>
<P>A meta-analysis of 12 randomised clinical trials (46,699 participants) showed uncertainty in the effect on non-fatal or fatal myocardial infarction between homocysteine-lowering interventions and placebo or conventional care (1788/25,051 (7.14%) versus 1290/21,648 (5.96%); risk ratio (RR) 1.02, 95% confidence interval (CI) 0.95 to 1.10; P value = 0.56, I<SUP>2</SUP> = 0%; high-quality evidence) (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The Bayes factor was 1.04, which means that evidence is insensitive, the data are equally well predicted by both models and the evidence does not favour either model over the other. Trial sequential analysis for myocardial infarction suggested that no more trials are needed to disprove a 10% relative risk reduction with the intervention. Smaller risk reductions might still require further trials (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). There was a low risk of publication bias (P value = 0.88, Harbord test; P value = 0.86, Peters test). <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK> and <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> show funnel and contour-enhanced funnel plots, respectively.</P>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup trials with a low risk of bias</HEADING>
<P>A meta-analysis of six trials (37,442 participants) found uncertainty over the effect of intervention in non-fatal or fatal myocardial infarction rates (1517/19,649 (7.72%) versus 1161/17,793 (6.53%); RR 1.01, 95% CI 0.94 to 1.09, P value = 0.79, I<SUP>2</SUP> = 0%) (<LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>). (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>
<I>Subgroup analysis comparing trials including participants without or with history of cardiovascular disease</I>
</P>
<P>One trial (490 participants) including participants without cardiovascular disease found uncertainty between intervention and placebo groups regarding non-fatal or fatal myocardial infarction (2/248 (0.81%) versus 2/242 (0.83%); RR 0.98, 95% 0.14 to 6.87, P value = 0.98) (<LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>). A meta-analysis of 11 trials (46,209 participants) including participants with a history of cardiovascular disease showed that there was no difference in non-fatal or fatal myocardial infarction between intervention and placebo groups (1786/24,803 (7.20%) versus 1288/21,406 (6.02%); RR 1.02, 95% CI 0.95 to 1.10, I<SUP>2</SUP> = 9%) (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). Testing for subgroup differences found no significant difference (P value = 0.96 and I<SUP>2</SUP> = 0%). <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Homocysteine-lowering interventions (high dose) compared with homocysteine-lowering interventions (low dose)</HEADING>
<P>One trial (3649 participants) found a lower proportion had non-fatal or fatal myocardial infarctions in participants assigned to a high dose of homocysteine-lowering interventions compared with those receiving a low dose of homocysteine-lowering interventions (72/1814 (3.97%) versus 81/1835 (4.41%); RR 0.90, 95% CI 0.66 to 1.23, P value = 0.50; moderate-quality evidence) (<LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The Bayes factor was 1.06, which means that evidence is insensitive, the data are equally well predicted by both models and the evidence does not favour either model over the other.</P>
<P>
<B>Homocysteine-lowering treatment (folic acid) plus antihypertensive therapy (enalapril) versus antihypertensive therapy (enalapril)</B>
</P>
<P>One trial (20,702 participants) found uncertainty in the rates of non-fatal or fatal myocardial infarction between intervention and control groups (25/10,348) (0.24%) versus 24/10,354 (0.23%); RR 1.04, 95% CI 0.60 to 1.82, P value = 0.88; moderate-quality evidence) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The Bayes factor was 0.97 which means that evidence is insensitive, the data are equally well predicted by both models and the evidence does not favour either model over the other.</P>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup analysis for missing data</HEADING>
<P>One trial (20,635 participants) comparing the combination of folic acid plus enalapril with enalapril alone showed inconsistent results in terms of non-fatal or fatal myocardial infarction, according to per protocol analysis (25/10,316 (0.24%) versus 24/10,319 (0.23%); RR 1.04, 95% CI 0.60 to 1.82, P value = 0.89), best-worst case scenario (25/10,348 (0.24%) versus 59/10,354 (0.57%); RR 0.42, 95% CI 0.27 to 0.68, P value = 0.0003) and worst-best case scenario (57/10,348 (0.55%) versus 24/10,354 (0.23%); RR 2.38, 95% CI 1.48 to 3.83, P value = 0.0004). Testing for subgroup differences found a significant difference (P value &lt;0.0001 and I<SUP>2</SUP> = 92%) (<LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>). <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Non-fatal or fatal stroke</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Homocysteine-lowering interventions compared with placebo</HEADING>
<P>A meta-analysis of ten trials (44,224 participants) showed a risk reduction in non-fatal or fatal stroke in participants assigned to homocysteine-lowering interventions compared with placebo (1014/23,809 (4.26%) versus 1034/20,415 (5.06%); RR 0.90, 95% CI 0.82 to 0.99, P value = 0.03, I<SUP>2</SUP> = 8%, high-quality evidence) (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The Bayes factor was 5.84 which means that it is 5.84 times more likely that homocysteine-lowering interventions reduce non-fatal or fatal stroke compared with placebo. Trial sequential analysis for stroke suggested that no more trials are needed to disprove a 10% relative risk reduction with intervention. Smaller risk reductions might still require further trials (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). There was a low risk of publication bias (P value = 0.368, Harbord test; P value = 0.393, Peters test). <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK> and <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK> show funnel and contour-enhanced funnel plots, respectively.</P>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup trials with a low risk of bias</HEADING>
<P>A meta-analysis of six trials (37,442 participants) found uncertainty in differences between non-fatal or fatal stroke rates between intervention and placebo groups (919/19,649 (4.68%) versus 953/17,793 (5.36%); RR 0.90, 95% CI 0.80 to 1.02, P value = 0.10, I<SUP>2</SUP> = 32%) (<LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>). (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>
<I>Subgroup analysis comparing trials including participants without or with history of cardiovascular disease </I>
</P>
<P>One trial (490 participants) including participants without cardiovascular disease found uncertainty between intervention and placebo groups regarding the rates of non-fatal or fatal stroke (0/248 (0%) versus 2/242 (0.83%); RR 0.20, 95% 0.01 to 4.04, P value = 0.29) (<LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>). A meta-analysis of nine trials (43,734 participants) including participants with history of cardiovascular disease showed evidence of effect favouring intervention group versus placebo group in terms of non-fatal or fatal stroke rates (1014/23,561 (4.30%) versus 1032/20,173 (5.12%); RR 0.90, 95% CI 0.82 to 0.99, I<SUP>2</SUP> = 9%) (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). Testing for subgroup differences found no significant difference (P 0.32 and I<SUP>2</SUP> = 0%). <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Homocysteine-lowering interventions (high dose) compared with homocysteine-lowering interventions (low dose)</HEADING>
<P>A meta-analysis of two trials (3929 participants) showed uncertainty between the effects of high dose versus low dose of homocysteine-lowering interventions with regards to non-fatal or fatal stroke (211/1958 (10.78%) versus 221/1971 (11.21%); RR 0.90, 95% CI 0.66 to 1.22; I<SUP>2</SUP> = 72%; very low-quality evidence) (<LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The Bayes factor was 1.06, which means that evidence is insensitive, the data are equally well predicted by both models and the evidence does not favour either model over the other.</P>
<P>We detected high statistical heterogeneity, as conveyed by the I<SUP>2</SUP> value (72%), and therefore we further explored by type of planned intervention.</P>
<P>One trial (3649 participants) comparing a combination of homocysteine-lowering interventions (folic acid, vitamin B6 and vitamin B12), either at high dose (2.5 mg folic acid; 0.4 mg vitamin B12; 25 mg vitamin B6), or low dose (20 micrograms folic acid; 6 micrograms vitamin B12; 200 micrograms vitamin B6) found uncertainty over the effects on non-fatal or fatal stroke rates (152/1814 (8.38%) versus 148/1835 (8.07%); RR 1.04, 95% CI 0.84 to 1.29; P value = 0.73) (<LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>). <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>
</P>
<P>One trial (280 participants) conducted only with elderly female participants, compared folic acid at high dose (0.8 mg) plus vitamin B12 (500 &#956;g) versus folic acid at low dose (0.4 mg) plus vitamin B12 (500 &#956;g). It found a lower proportion of non-fatal or fatal strokes in participants assigned to high-dose folic acid than those receiving a low-dose folic acid (59/144 (40.97%) versus 73/136 (53.68%); RR 0.76, 95% CI 0.59 to 0.98; P value = 0.03) (<LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>). <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>
</P>
<P>
<B>Homocysteine-lowering treatment (folic acid) plus antihypertensive therapy (enalapril) versus antihypertensive therapy (enalapril)</B>
</P>
<P>One trial (20,702 participants) found a reduced risk of non-fatal or fatal stroke in participants receiving enalapril plus folic acid compared with participants receiving enalapril as monotherapy (281/10348 (2.72%) versus 354/10354 (3.42%); RR 0.79, 95% CI 0.68 to 0.93, P value = 0.003; NNTB 143, 95% CI 85 to 428, high-quality evidence) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The Bayes factor was 31.9 which means that it is 31.9 times more likely that homocysteine-lowering treatment (folic acid) plus antihypertensive therapy (enalapril) versus antihypertensive therapy (enalapril) alone reduces non-fatal or fatal stroke. The fragility Index was 23.</P>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup analysis for missing data</HEADING>
<P>The overall incidence of non-fatal or fatal stroke seemed to be reduced in people assigned to a combination of folic acid plus enalapril versus those allocated to enalapril alone: per protocol analysis (281/10,316 (2.72%) versus 354/10,319 (3.43%); RR 0.79, 95% CI 0.68 to 0.93; P value = 0.003), best-worst case scenario (281/10,348 (2.72%) versus 389/10,354 (3.76%); RR 0.72, 95% CI 0.62 to 0.84; P value = 0.0001) and worst-best case scenario (313/10,348 (3.02%) versus 354/10,354 (3.42%); RR 0.88, 95% CI 0.76 to 1.03; P value = 0.11). Test for subgroup differences: P = 0.18, I² = 42.5%. (<LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>). <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">First unstable angina pectoris episode requiring hospitalisation</HEADING>
<P>
<B>Homocysteine-lowering interventions compared with placebo</B>
</P>
<P>A meta-analysis of four trials (12,644 participants) showed uncertainty between the effects intervention compared with placebo on the rate of unstable angina requiring hospitalisation (910/8015 (11.35%) versus 468/4629 (10.11%); RR 0.98, 95% CI 0.80 to 1.21, P value = 0.87, I<SUP>2</SUP> = 66%) (<LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3)</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hospitalisation for heart failure</HEADING>
<P>One trial found an uncertain effect in the hospitalisation for heart failure rates between intervention and placebo groups (202/2758 (7.32%) versus 174/2764 (6.30%); RR 1.16, 95% CI 0.96 to 1.41, P value = 0.13) (<LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Death from any cause</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Homocysteine-lowering interventions compared with placebo</HEADING>
<P>A meta-analysis of 11 trials (44,817 participants) found uncertainty between the effects of intervention versus placebo on the rates of death from any cause (2821/24,109 (11.70%) versus 2544/20,708 (12.29%); RR 1.01, 95% CI 0.96 to 1.06, P value = 0.68, I<SUP>2 </SUP>= 0%, high-quality evidence) (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). The Bayes factor was 1.05, which means that evidence is insensitive, the data are equally well predicted by both models and the evidence does not favour either model over the other. Trial sequential analysis for stroke suggested that no more trials are needed to disprove a 10% relative risk reduction with intervention. Smaller risk reductions might still require further trials (<LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>). There was a low risk of publication bias (P value = 0.95, Harbord test; P value = 0.82, Peters test). <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK> and <LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK> show funnel and contour-enhanced funnel plots, respectively.</P>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup trials with a low risk of bias</HEADING>
<P>A meta-analysis of seven trials (37,932 participants) found uncertainty between the effects of intervention versus placebo in rates of death from any cause (2145/19,897 (10.78%) versus 1923/18,035 (10.66%); RR 1.03, 95% CI 0.95 to 1.12; P value = 0.48; I<SUP>2 </SUP>= 41%) (<LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>). (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
<P>
<I>Subgroup analysis comparing trials including participants without or with history of cardiovascular disease </I>
</P>
<P>One trial (490 participants) including participants without cardiovascular disease found uncertainty between the effects of intervention versus placebo in rates of death from any cause (0/248 (0%) versus 2/242 (0.83%); RR 0.20, 95% 0.01 to 4.04, P value = 0.29) (<LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>). A meta-analysis of 10 trials (44,327 participants) including participants with history of cardiovascular disease showed conclusive evidence that there was no difference in rates of death from any cause between intervention and placebo groups (2821/23,861 (11.82%) versus 2542/20,466 (12.42%); RR 1.01, 95% CI 0.96 to 1.06, I<SUP>2</SUP> = 0%) (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>). Testing for subgroup differences found no significant difference (P 0.32 and I<SUP>2</SUP> = 0%). <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Homocysteine-lowering interventions (high dose) compared with homocysteine-lowering interventions (low dose)</HEADING>
<P>One trial (3649 participants) found uncertainty in mortality from any cause between intervention and control groups (99/1814 (5.46%) versus 117/1835 (6.38%); RR 0.86; 95% CI 0.66 to 1.11; P value = 0.24; moderate-quality evidence) (<LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). The Bayes factor was 1.07 which means that evidence is insensitive, the data are equally well predicted by both models and the evidence does not favour either model over the other.</P>
<P>
<B>Homocysteine-lowering treatment (folic acid) plus antihypertensive therapy (enalapril) versus antihypertensive therapy (enalapril)</B>
</P>
<P>One trial (20,702 participants) found uncertainty between the effects of enalapril plus folic acid compared with participants receiving enalapril as monotherapy on mortality from any cause (302/10,348 (2.92%) versus 320/10,354 (3.09%); RR 0.94, 95% CI 0.81 to 1.10; P value = 0.47; high-quality evidence) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). The Bayes factor was 1.08 which means that evidence is insensitive, the data are equally well predicted by both models and the evidence does not favour either model over the other.</P>
<P>The combination of folic acid and enalapril seemed not to affect the incidence of death from any cause compared with enalapril alone. Per protocol analysis (302/10,316 (2.93%) versus 320/10,319 (3.10%); RR 0.94, 95% CI 0.81 to 1.10; P value = 0.47), best-worst case scenario (302/10,348 (2.92%) versus 355/10,354 (3.43%); RR 0.85, 95% CI 0.73 to 0.99; P value = 0.04) and (334/10,348 (3.23%) versus 320/10,354 (3.09%); RR 1.04, 95% CI 0.90 to 1.21; P value = 0.57). Test for subgroup differences: P = 0.17, I² = 43.3%. (<LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>). <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Serious or non-serious adverse events</HEADING>
<P>
<B>Homocysteine-lowering interventions compared with placebo</B>
</P>
<P>A meta-analysis of eight trials (35,788 participants) assessing cancer incidence found uncertainty in the incidence of cancer in intervention and placebo groups (1621/19,591 (8.27%) versus 1376/16,197 (8.50%); RR 1.07, 95% CI 1.00 to 1.14, P value = 0.07, I<SUP>2 </SUP>= 0%, high-quality evidence) (<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). Trial sequential analysis for adverse events suggested that no more trials are needed to disprove a 10% relative risk reduction (<LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>).</P>
<P>A meta-analysis of three trials (13,802 participants) found uncertainty in terms of serious or non-serious adverse events rather than cancer between intervention and placebo groups (322/6903 (4.66%) versus 312/6899 (4.52%); RR 1.02, 95% 0.88 to 1.19; P value = 0.77, I<SUP>2 </SUP>= 0%, high-quality evidence) (<LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>). <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>.</P>
<P>
<B>Homocysteine-lowering treatment (folic acid) plus antihypertensive therapy (enalapril) versus antihypertensive therapy (enalapril)</B>
</P>
<P>One trial (20,243 participants) found uncertainty in terms of cancer incidence between participants receiving enalapril plus folic acid compared with participants receiving enalapril as monotherapy (79/10,119 (0.78%) versus 82/10,124 (0.81%); RR 0.96, 95% CI 0.71 to 1.31; P value = 0.81; moderate-quality evidence) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-08-08 09:14:43 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2017-08-02 10:04:55 -0500" MODIFIED_BY="Heather Maxwell">
<P>This updated Cochrane review of homocysteine-lowering interventions (B vitamins) for preventing cardiovascular events identified 15 randomised controlled trials incorporating 71,422 participants. Trials reported different combinations of homocysteine-lowering interventions compared with different control interventions (placebo: <LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>; <LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>; <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>; <LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>; <LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>; <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>, homocysteine-lowering interventions at low dose: <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>; <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>, and antihypertensive medication (enalapril): (<LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>)). Overall, the trials had a low risk of bias and were adequately powered. Participants differed somewhat in cardiovascular risk levels (some with established cardiovascular disease (CVD), others at high risk of CVD), baseline total homocysteine blood levels, access to foods fortified with folic acid or not, different dosages of vitamins and different control groups, with treatment periods varying from two to seven years.</P>
<P>1. This review found no reduction of the incidence of either myocardial infarction (fatal or non-fatal) and death from any cause or an increasing risk of adverse events (cancer).</P>
<P>2. With regard to stroke (fatal or non-fatal), a meta-analysis of homocysteine-lowering interventions compared with placebo, and one mega-trial comparing folic acid plus enalapril with enalapril alone found a reduction of risk stroke in those treated. A meta-analysis of two trials comparing high dose versus low dose of homocysteine-lowering interventions did not find a difference in the rates of fatal or non-fatal strokes.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-08-08 09:14:43 -0500" MODIFIED_BY="[Empty name]">
<P>This updated review found evidence suggesting that homocysteine-lowering interventions (vitamins B6, B12 and folic acid (B9)) are not useful for preventing myocardial infarction (fatal or non-fatal) or death from any cause. We conducted a sensitivity analysis restricted to trials with low risk of bias for myocardial infarction and death from any cause. These results show consistency and are based on data from trials that included a broad range of participants with different co-morbidities who received different treatment approaches. Although these aspects could be considered as a threat to applicability, the consistency in the results derived from our analyses showed that the included trials may represent a broad picture of participants with a high risk of cardiovascular events.</P>
<P>With reference to stroke (non-fatal or fatal stroke), this update found that homocysteine-lowering interventions reduce the incidence of stroke compared with placebo or enalapril alone (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). However, this result should be viewed with caution. In the trial sequential analysis graph called '<I>Trial sequential analysis on stroke in 10 trials investigating homocysteine-lowering interventions versus placebo</I>' (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>), it was observed that after 44,224 participants the Z curve crossed the upper conventional alpha of 5%, but also the cumulative Z-curve crossed no the trial sequential alpha-spending monitoring boundaries also called as monitoring efficacy boundary (<LINK REF="REF-Roshanov-2017" TYPE="REFERENCE">Roshanov 2017</LINK>). This positive result appears to be weak, due to the 95% confidence interval reduction of risk of any stroke ranging between 1% and 18% and the very low basal risk. As is shown into <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>, in the control group 51 people out of 1000 had a stroke (non-fatal or fatal) over 1 to 7.3 years, compared with 46 (95% CI 42 to 50) out of 1000 for the active treatment group.</P>
<P>
<LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK> also found a positive result of enalapril plus folic acid compared with enalapril on incidence of any stroke. The trial had a duration of follow-up of five years. The absolute risk reduction in this trial was very low (0.7%), which explains the high number needed to treat for an additional beneficial outcome in this trial of 143 (95% CI 85 to 428). During five years between 85 and 428 hypertensive participants would need to take enalapril plus folic acid for to prevent one stroke. According to the <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>, in the control group 34 people out of 1000 had a stroke (non-fatal or fatal) over five years, compared to 27 (95% CI 23 to 32) out of 1000 in the active treatment group. Therefore, the clinical difference is small between the groups, which is reflected in the sensitivity analysis shown into <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>. We estimated the fragility index of <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK> as 23, which denotes that if 23 patients in the experimental group were converted from not having the primary endpoint to having the primary endpoint, the study would lose statistical significance (P &gt; 0.05). Furthermore, it is unknown whether such treatment would benefit a non-Chinese population. In both cases (meta-analysis with more than 40,000 and a trial with 20,000 participants) shows a highly significant statistical result, but it "may not represent a clinically important effect when treating patients in our daily lives." (<LINK REF="REF-Fuster-2015" TYPE="REFERENCE">Fuster 2015</LINK>).</P>
<P>In conclusion, this updated version showed the same findings as the previous version (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2015" TYPE="REFERENCE">Martí-Carvajal 2015</LINK>). It showed that supplementary vitamin B6, B12 and folic acid administration did not prevent cardiovascular events in participants with or without pre-existing cardiovascular disease. The trial sequential analysis for the same outcomes suggested that no further randomised trials were needed to assess the benefits and harms of homocysteine-lowering interventions to preventing cardiovascular events (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>; <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>). <LINK REF="REF-Mart_x00ed__x002d_Carvajal-2013" TYPE="REFERENCE">Martí-Carvajal 2013 </LINK>and <LINK REF="REF-Mart_x00ed__x002d_Carvajal-2015" TYPE="REFERENCE">Martí-Carvajal 2015</LINK> found no effect of vitamin B-complex supplementation on rates of cancer (<LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>). Bayes factors give prominence to these findings. There is a likelihood for reducing the stroke rate.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2017-08-02 10:02:41 -0500" MODIFIED_BY="Heather Maxwell">
<P>We conducted GRADE assessments on outcomes using the meta-analysed trials.</P>
<P>
<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> shows the quality of evidence for homocysteine-lowering interventions compared with placebo or standard care for preventing cardiovascular events. The evidence available in this setting can be considered high quality due to the consistency of the results of the 12 trials for the main outcomes assessed (myocardial infarction, stroke and death from any cause), the precision in the pooled estimates, and the design and execution of these trials, which can be judged to be free of major threats to their validity.</P>
<P>
<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK> shows the quality of evidence for homocysteine-lowering interventions (high dose) compared with homocysteine-lowering interventions (low dose) for preventing cardiovascular events. The evidence was rated as moderate or very low due to imprecision i.e. low number of events, for risk of bias as one trial (<LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>) for having unclear risk of selection, conduction and detection biases, and for inconsistency (I<SUP>2 </SUP>= 72%).</P>
<P>
<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK> shows the quality of evidence for enalapril plus folic acid compared with enalapril for adults with hypertension. The evidence for stroke was rated as high.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2017-08-02 10:02:48 -0500" MODIFIED_BY="Heather Maxwell">
<P>In a systematic review process, there are a group of biases called significance-chasing biases, such as publication bias and selective outcome reporting bias (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>). Selective outcome reporting bias operates through suppression of information on specific outcomes and has similarities to study publication bias in that 'negative' results remain unpublished (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>). This Cochrane review found that overall, the included randomised trials had a low risk of attrition bias and a low risk of selective outcome reporting bias (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). This review might have a limitation due to paucity of data in terms of trials comparing 'head-to-head' homocysteine-lowering interventions. A strength of this new updated Cochrane review is to have shown an absence of asymmetry in almost all funnel plots and to discard publication bias using appropriate statistical methodology i.e. Harbord and Peters tests.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-08-07 18:44:45 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>Our results are similar to other non-Cochrane reviews (<LINK REF="STD-Clarke-2010" TYPE="STUDY">Clarke 2010</LINK>; <LINK REF="STD-Huang-2012" TYPE="STUDY">Huang 2012</LINK>; <LINK REF="STD-Huo-2012" TYPE="STUDY">Huo 2012</LINK>; <LINK REF="STD-Ji-2013" TYPE="STUDY">Ji 2013</LINK>). These four reviews differed in their eligibility criteria, i) resulting in the inclusion by <LINK REF="STD-Clarke-2010" TYPE="STUDY">Clarke 2010</LINK>, <LINK REF="STD-Huang-2012" TYPE="STUDY">Huang 2012</LINK>, <LINK REF="STD-Huo-2012" TYPE="STUDY">Huo 2012</LINK> and <LINK REF="STD-Ji-2013" TYPE="STUDY">Ji 2013</LINK> of the HOST trial (<LINK REF="REF-Jamison-2007" TYPE="REFERENCE">Jamison 2007</LINK>), designed to assess the effects of homocysteine in participants with kidney or renal disease, which is beyond our scope; ii) <LINK REF="STD-Clarke-2010" TYPE="STUDY">Clarke 2010</LINK> and <LINK REF="STD-Huo-2012" TYPE="STUDY">Huo 2012</LINK> included all the trials in their pooled analysis (whereas we preferred to present the results from trials controlled with placebo separately from the results of the trials that compared different doses of homocysteine-lowering drugs (<LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>)); iii) it can be concluded from the <LINK REF="STD-Clarke-2010" TYPE="STUDY">Clarke 2010</LINK> publication that the authors had access to some additional data from <LINK REF="STD-CHAOS-2002" TYPE="STUDY">CHAOS 2002</LINK>, which we had to extract from an abstract; and finally iv) our systematic review included five additional trials not considered in <LINK REF="STD-Clarke-2010" TYPE="STUDY">Clarke 2010</LINK>, with 12,031 more participants, that allowed us to obtain more accurate estimates for our outcomes of interest (<LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>; <LINK REF="STD-FOLARDA-2004" TYPE="STUDY">FOLARDA 2004</LINK>; <LINK REF="STD-GOES-2003" TYPE="STUDY">GOES 2003</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="STD-VITATOPS-2010" TYPE="STUDY">VITATOPS 2010</LINK>). <LINK REF="REF-Lai-2015b" TYPE="REFERENCE">Lai 2015b</LINK> and colleagues reported any affect on the risk of cardiovascular disease such as suggested this Cochrane review.</P>
<P>Two randomised controlled trials (<LINK REF="REF-Jamison-2007" TYPE="REFERENCE">Jamison 2007</LINK>; <LINK REF="REF-Vianna-2007" TYPE="REFERENCE">Vianna 2007</LINK>), and two systematic reviews, (<LINK REF="STD-Jardine-2012" TYPE="STUDY">Jardine 2012</LINK>; <LINK REF="STD-Pan-2012" TYPE="STUDY">Pan 2012</LINK>) involving participants with end-stage renal disease, found no effect of homocysteine-lowering interventions in preventing cardiovascular events.</P>
<P>Regarding cancer, this Cochrane review showed similar results to a recent meta-analysis involving data on 50,000 individuals (<LINK REF="REF-Vollset-2013" TYPE="REFERENCE">Vollset 2013</LINK>). Both meta-analyses found no increased risk of cancer associated with homocysteine-lowering interventions.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-08-02 10:03:13 -0500" MODIFIED_BY="Heather Maxwell">
<IMPLICATIONS_PRACTICE MODIFIED="2017-08-02 10:03:07 -0500" MODIFIED_BY="Heather Maxwell">
<P>In this third update of the review, there were no differences in effects of homocysteine-lowering interventions in the form of supplements of vitamins B6, B9 or B12 given alone or in combination comparing with placebo on myocardial infarction, death from any cause or adverse events. In terms of stroke, this review found a small difference in effect favouring homocysteine-lowering interventions in the form of supplements of vitamins B6, B9 or B12 given alone or in combination compared with placebo. There were uncertain effects of folic acid compared with enalapril plus folic acid on stroke; approximately 143 (95% CI 85 to 428) people would need to be treated for 5.4 years to prevent 1 stroke, this evidence emerged from one mega-trial. Trial sequential analyses showed that additional trials are unlikely to increase the certainty about the findings of this issue regarding homocysteine-lowering interventions versus placebo.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-08-02 10:03:13 -0500" MODIFIED_BY="Heather Maxwell">
<P>The association between both the lack of clinical effectiveness and harm of homocysteine-lowering interventions might require further investigation into other homocysteine pathways. There is the need for additional trials comparing homocysteine-lowering interventions combined with antihypertensive medication versus antihypertensive medication, and homocysteine-lowering interventions at high doses versus homocysteine-lowering interventions at low doses. Potential trials should be large and co-operative.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-08-07 18:47:52 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>We express our gratitude to the Cochrane Heart Group and peer referees for the suggestions made to enhance the quality of this review. In addition, we acknowledge Carmen Verônica Abdala from BIREME/OPS/OMS for her help in developing the search strategy for LILACS. In addition, we want express our deep gratitude to Georgia Salanti for teaching us how to conduct the first version of this Cochrane review.</P>
<P>We want express our gratitude to Dr. Zoltan Dienes for helping us to conduct the Bayes factor estimation.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-08-02 10:03:39 -0500" MODIFIED_BY="Heather Maxwell">
<P>Arturo Marti-Carvajal: In 2004, Arturo Martí-Carvajal was employed by Eli Lilly to run a four-hour workshop on 'How to critically appraise clinical trials on osteoporosis and how to teach this'. This activity was not related to his work with Cochrane or any Cochrane review. In 2007, Arturo Martí-Carvajal was employed by Merck to run a four-hour workshop 'How to critically appraise clinical trials and how to teach this'. This activity was not related to his work with Cochrane or any Cochrane review.<BR/>Ivan Solà: none known.<BR/>Dimitris Lathyris: none known.<BR/>Mark Dayer: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-08-02 10:03:32 -0500" MODIFIED_BY="Heather Maxwell">
<P>Arturo Marti-Carvajal took the lead on writing up the review.<BR/>Ivan Solà identified trials, extracted data, edited the 'Summary of findings' tables and drafted the review.<BR/>Dimitris Lathyris extracted and checked the data and reviewed the review.<BR/>Mark Dayer critically reviewed and amended the manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-08-07 11:07:00 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<OL>
<LI>Number needed to treat for an additional beneficial outcome if the risk reduction was significant (P value = &lt; 0.05)</LI>
<LI>Harbord and Peters tests for estimation publication bias.</LI>
<LI>Bayes factors</LI>
<LI>Fragility Indices</LI>
<LI>Trials including participants without cardiovascular disease versus trials including participants with cardiovascular disease (considered post-hoc).</LI>
<LI>We considered studies to have an overall low risk of bias if they did not have high risk of bias in any of six individual domains (random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data or selective reporting), and if a definitive 'Risk of bias' assessment could be made for the majority (at least five of six) of domains. We did not include &#8216;Other bias&#8217; in our overall assessment.</LI>
</OL>
<P>Second update (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2015" TYPE="REFERENCE">Martí-Carvajal 2015</LINK>): included trial sequential analyses.</P>
<P>First update (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2013" TYPE="REFERENCE">Martí-Carvajal 2013</LINK>): In the first version of the review (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2009" TYPE="REFERENCE">Martí-Carvajal 2009</LINK>), we searched the Allied and Complementary Medicine - AMED database (accessed through Ovid) and the Cochrane Stroke Group Specialised Register. For this update, we did not search either database.</P>
<P>This review has been updated at each step to current recommendations of Cochrane, including updates to the Plain Language Summary and inclusion of the quality of the evidence assessed according to GRADE ('Summary of findings').</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-08-08 16:54:30 +0100" MODIFIED_BY="Abigail Baldridge">
<STUDIES MODIFIED="2017-08-04 09:48:56 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2017-08-04 09:48:56 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-B_x002d_PROOF-2015" MODIFIED="2017-07-31 07:04:45 -0500" MODIFIED_BY="Heather Maxwell" NAME="B-PROOF 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-02-19 13:19:13 -0600" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Enneman AW, Swart KM, van Wijngaarden JP, van Dijk SC, Ham AC, Brouwer-Brolsma EM, et al</AU>
<TI>Effect of vitamin B12 and folic acid supplementation on bone mineral density and quantitative ultrasound parameters in older people with an elevated plasma homocysteine level: B-PROOF, a randomized controlled trial</TI>
<SO>Calcified Tissue International</SO>
<YR>2015</YR>
<VL>96</VL>
<NO>5</NO>
<PG>401-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055558"/><IDENTIFIER TYPE="PUBMED" VALUE="25712255"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-19 13:19:13 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Dijk SC, Enneman AW, Swart KM, van Wijngaarden JP, Ham AC, Brouwer-Brolsma EM, et al</AU>
<TI>Effects of 2-year vitamin B12 and folic acid supplementation in hyperhomocysteinemic elderly on arterial stiffness and cardiovascular outcomes within the B-PROOF trial</TI>
<SO>Journal of Hypertension</SO>
<YR>2015</YR>
<VL>33</VL>
<NO>9</NO>
<PG>1897-906; discussion 1906</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055559"/><IDENTIFIER TYPE="PUBMED" VALUE="26147383"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-23 15:05:17 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Wijngaarden JP, Dhonukshe-Rutten RA, van Schoor NM, van der Velde N, Swart KM, Enneman AW, et al</AU>
<TI>Rationale and design of the B-PROOF study, a randomized controlled trial on the effect of supplemental intake of vitamin B12 and folic acid on fracture incidence</TI>
<SO>BMC Geriatrics</SO>
<YR>2011</YR>
<VL>11</VL>
<PG>80</PG>
<IDENTIFIERS MODIFIED="2016-02-23 15:05:17 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055560"/><IDENTIFIER MODIFIED="2016-02-23 15:05:17 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22136481"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-07-31 07:04:45 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Wijngaarden JP, Swart KM, Enneman AW, Dhonukshe-Rutten RA, van Dijk SC, Ham AC, et al</AU>
<TI>Effect of daily vitamin B-12 and folic acid supplementation on fracture incidence in elderly individuals with an elevated plasma homocysteine concentration: B-PROOF, a randomized controlled trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2014</YR>
<VL>100</VL>
<NO>6</NO>
<PG>1578-86</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055561"/><IDENTIFIER TYPE="PUBMED" VALUE="25411293"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055557"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BVAIT-2009" MODIFIED="2012-03-02 09:24:07 -0600" MODIFIED_BY="[Empty name]" NAME="BVAIT 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-03-02 09:23:41 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hodis HN, Mack WJ, Dustin L, Mahrer PR, Azen SP, Detrano R; BVAIT Research Group</AU>
<TI>High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial</TI>
<SO>Stroke</SO>
<YR>2009</YR>
<VL>40</VL>
<NO>3</NO>
<PG>730-6</PG>
<IDENTIFIERS MODIFIED="2012-03-02 09:22:17 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055563"/><IDENTIFIER TYPE="PUBMED" VALUE="19118243"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055562"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CHAOS-2002" MODIFIED="2014-02-03 10:07:53 -0600" MODIFIED_BY="[Empty name]" NAME="CHAOS 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-02-03 10:07:53 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baker F, Picton D, Blackwood S, Hunt J, Erskine M, Dyas M, et al</AU>
<TI>Blinded comparison of folic acid and placebo in patients with ischaemic heart disease: an outcome trial</TI>
<SO>Circulation</SO>
<YR>2002</YR>
<VL>106</VL>
<NO>Suppl II</NO>
<PG>741</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055565"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055564"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CSPPT-2015" MODIFIED="2017-08-04 09:48:31 -0500" MODIFIED_BY="[Empty name]" NAME="CSPPT 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-07-31 07:05:40 -0500" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;ISI Document Delivery No.: EP4HT Times Cited: 0 Cited Reference Count: 0 Huang, Xiao Wang, Hong Qin, Xianhui Yang, Wenbin Jiang, Shanqun Liu, Lishun Song, Yun Zhao, Min Wang, Yu Zhang, Yan Li, Jianping Bao, Huihui Su, Hai Li, Ping Yang, Renqiang Wu, Yanqing Hong, Kui Wu, Qinhua Tang, Genfu Wang, Binyan Hou, Fanfan Huo, Yong Wang, Xiaobin Cheng, Xiaoshu 66th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) Mar 17-19, 2017 Washington, DC Amer Coll Cardiol 0 Elsevier science inc New york 1558-3597 S&lt;/p&gt;" NOTES_MODIFIED="2017-07-31 07:05:40 -0500" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang X, Wang H, Qin XH, Yang WB, Jiang SQ, Liu LS, et al</AU>
<TI>Serum homocysteine lowering by long-term low-dose folic acid: new insight on MTHFR gene-folate interaction from China stroke primary prevention trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2017</YR>
<VL>69</VL>
<NO>11</NO>
<PG>1770</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6484364"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-18 14:44:13 -0600" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, et al</AU>
<TI>Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial</TI>
<SO>JAMA</SO>
<YR>2015</YR>
<VL>313</VL>
<NO>13</NO>
<PG>1325-35</PG>
<IDENTIFIERS MODIFIED="2015-04-17 09:03:22 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055567"/><IDENTIFIER TYPE="PUBMED" VALUE="25771069"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-18 14:43:55 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li H, Qin X, Xie D, Tang G, Zhang Y, Li J, et al</AU>
<TI>Effects of combined enalapril and folic acid therapy on the serum uric acid levels in hypertensive patients: a multicenter, randomized, double-blind, parallel-controlled clinical trial</TI>
<SO>Internal Medicine</SO>
<YR>2015</YR>
<VL>54</VL>
<NO>1</NO>
<PG>17-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055568"/><IDENTIFIER TYPE="PUBMED" VALUE="25742888"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-18 15:18:04 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu X, Shi M, Xia F, Han J, Liu Z, Wang B, et al</AU>
<TI>The China Stroke Secondary Prevention Trial (CSSPT) protocol: a double-blinded, randomized, controlled trial of combined folic acid and B vitamins for secondary prevention of stroke</TI>
<SO>International Journal of Stroke</SO>
<YR>2015</YR>
<VL>10</VL>
<NO>2</NO>
<PG>264-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055569"/><IDENTIFIER TYPE="PUBMED" VALUE="23490255"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-07-31 07:06:31 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qin X, Li J, Spence JD, Zhang Y, Li Y, Wang X, et al</AU>
<TI>Folic acid therapy reduces the first stroke risk associated with hypercholesterolemia among hypertensive patients</TI>
<SO>Stroke</SO>
<YR>2016</YR>
<VL>47</VL>
<NO>11</NO>
<PG>2805-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6484365"/><IDENTIFIER TYPE="PUBMED" VALUE="27729579 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-01 12:29:49 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qin X, Li Y, Sun N, Wang H, Zhang Y, Wang J, et al</AU>
<TI>Elevated homocysteine concentrations decrease the antihypertensive effect of angiotensin-converting enzyme inhibitors in hypertensive patients</TI>
<SO>Arteriosclerosis, Thrombosis, and Vascular Biology</SO>
<YR>2017</YR>
<VL>37</VL>
<NO>1</NO>
<PG>166-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6484366"/><IDENTIFIER TYPE="PUBMED" VALUE=" 27834686"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-07-31 07:10:12 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qin X, Shen L, Zhang R, Li Y, Wang X, Wang B, et al</AU>
<TI>Effect of folic acid supplementation on cancer risk among adults with hypertension in China: A randomized clinical trial</TI>
<SO>International Journal of Cancer</SO>
<YR>2017</YR>
<VL>141</VL>
<NO>4</NO>
<PG>837-47</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055570"/><IDENTIFIER TYPE="PUBMED" VALUE="26991917"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-18 16:44:06 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wang M, Bie Z, Guo L, Wang J</AU>
<TI>A 3-year clinical study reveals that enalapril folic acid tablet effectively controls H-type hypertension and improves ventricular structure and function</TI>
<SO>Experimental and Clinical Cardiology</SO>
<YR>2014</YR>
<VL>20</VL>
<NO>6</NO>
<PG>3723-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055571"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-01 12:48:01 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NOTES="&lt;p&gt;Xu, Benjamin Kong, Xiangyi Xu, Richard Song, Yun Liu, Lishun Zhou, Ziyi Gu, Rui Shi, Xiuli Zhao, Min Huang, Xiao He, Mingli Fu, Jia Cai, Yefeng Li, Ping Cheng, Xiaoshu Wu, Changyan Chen, Fang Zhang, Yan Tang, Genfu Qin, Xianhui Wang, Binyan Xue, Hao Chen, Yundai Tian, Ye Sun, Ningling Cui, Yimin Hou, Fan Fan Li, Jianping Huo, Yong 00005792-201702240-00002&lt;/p&gt;" NOTES_MODIFIED="2017-06-01 12:48:01 -0500" NOTES_MODIFIED_BY="Arturo J Martí-Carvajal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu B, Kong X, Xu R, Song Y, Liu L, Zhou Z, et al</AU>
<TI>Homocysteine and all-cause mortality in hypertensive adults without pre-existing cardiovascular conditions: Effect modification by MTHFR C677T polymorphism</TI>
<SO>Medicine</SO>
<YR>2017</YR>
<VL>96</VL>
<NO>8</NO>
<PG>e5862</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6484367"/><IDENTIFIER TYPE="PUBMED" VALUE=""/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-01 12:45:34 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" PRIMARY="NO" TYPE="OTHER">
<AU>Xu B, Kong X, Xu R, Zhao M, Song Y, Zhang C, et al</AU>
<TI>Impact of folic-acid intervention and MTHFRC677T gene polymorphism on all-cause mortality associated with elevated serum homocysteine levels in chinese adults with hypertension</TI>
<SO>FASEB Journal</SO>
<YR>2016</YR>
<VL>30</VL>
<NO>1 Suppl</NO>
<PG>422.3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6484368"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-08-04 09:48:31 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;(CSPPT) Xu, Xin Qin, Xianhui Li, Youbao Sun, Danhua Wang, Jun Liang, Min Wang, Binyan Huo, Yong Hou, Fan Fan investigators of the Renal Substudy of the China Stroke Primary Prevention Trial (CSPPT) 2544880&lt;/p&gt;" NOTES_MODIFIED="2017-08-04 09:48:31 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu X, Qin X, Li Y, Sun D, Wang J, Liang M, et al;investigators of the Renal Substudy of the China Stroke Primary Prevention Trial (CSPPT)</AU>
<TI>Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney Disease: the Renal Substudy of the China Stroke Primary Prevention Trial</TI>
<SO>JAMA Internal Medicine</SO>
<YR>2016</YR>
<VL>176</VL>
<NO>10</NO>
<PG>1443-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6484369"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055566"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FOLARDA-2004" MODIFIED="2014-08-18 14:01:05 -0500" MODIFIED_BY="[Empty name]" NAME="FOLARDA 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-08-18 14:01:05 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, Robles de Medina RM, Tijssen JG, et al</AU>
<TI>Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial</TI>
<SO>International Journal of Cardiology</SO>
<YR>2004</YR>
<VL>93</VL>
<PG>175-9</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:01:05 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055573"/><IDENTIFIER MODIFIED="2014-08-18 14:01:05 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14975544 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055572"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GOES-2003" MODIFIED="2014-08-18 14:01:22 -0500" MODIFIED_BY="[Empty name]" NAME="GOES 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-08-18 14:01:15 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ</AU>
<TI>Secondary prevention with folic acid: effects on clinical outcomes</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2003</YR>
<VL>41</VL>
<PG>2105-13</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:01:15 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055575"/><IDENTIFIER MODIFIED="2014-08-18 14:01:15 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12821232"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-18 14:01:22 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ</AU>
<TI>Secondary prevention with folic acid: results of the Goes extension study</TI>
<SO>Heart</SO>
<YR>2005</YR>
<VL>91</VL>
<PG>1213-4</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:01:22 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055576"/><IDENTIFIER MODIFIED="2014-08-18 14:01:22 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16103563"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055574"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HOPE_x002d_2-2006" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="HOPE-2 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lonn E, Held C, Arnold JM, Probstfield J, McQueen M; HOPE-2 Investigators</AU>
<TI>Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>1</NO>
<PG>47-53</PG>
<IDENTIFIERS MODIFIED="2014-07-11 11:07:12 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055578"/><IDENTIFIER MODIFIED="2014-07-11 11:07:12 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16450017"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-18 14:01:31 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al</AU>
<TI>Homocysteine lowering with folic acid and B vitamins in vascular disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<PG>1567-77</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:01:31 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055579"/><IDENTIFIER MODIFIED="2014-08-18 14:01:31 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16531613"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-19 03:48:14 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saposnik G, Ray J, Sheridan P, McQueen M, Lonn E</AU>
<TI>Homocysteine lowering therapy and stroke risk, severity and disability: results from the HOPE-2 trial</TI>
<SO>Stroke</SO>
<YR>2009</YR>
<VL>40</VL>
<NO>4</NO>
<PG>e131</PG>
<IDENTIFIERS MODIFIED="2012-03-08 03:41:53 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055580"/><IDENTIFIER MODIFIED="2012-03-08 03:41:53 -0600" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1161"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2014-12-19 05:03:51 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E; Heart Outcomes Prevention Evaluation Investigators</AU>
<TI>Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial</TI>
<SO>Stroke</SO>
<YR>2009</YR>
<VL>40</VL>
<NO>4</NO>
<PG>1365-72</PG>
<IDENTIFIERS MODIFIED="2012-03-08 03:30:38 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055581"/><IDENTIFIER MODIFIED="2012-03-08 03:30:38 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19228852"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055577"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2015a" MODIFIED="2016-02-19 13:38:05 -0600" MODIFIED_BY="[Empty name]" NAME="Li 2015a" YEAR="Ovid">
<REFERENCE MODIFIED="2016-02-18 15:14:18 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li F, Hao YM, Zu XG, Liu JM</AU>
<TI>Prevention of cerebrovascular events by high-dose folic acid supplement in elderly female patients with hypertensive emergency and hyperhomocysteinemia</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2015</YR>
<VL>63</VL>
<NO>Suppl 2</NO>
<PG>S334</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055583"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055582"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NORVIT-2006" MODIFIED="2014-08-18 14:01:45 -0500" MODIFIED_BY="[Empty name]" NAME="NORVIT 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-08-18 14:01:45 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al</AU>
<TI>Homocysteine lowering and cardiovascular events after acute myocardial infarction</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<PG>1578-88</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:01:45 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055585"/><IDENTIFIER MODIFIED="2014-08-18 14:01:45 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16531614"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055584"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SEARCH-2010" MODIFIED="2017-07-31 07:25:06 -0500" MODIFIED_BY="Heather Maxwell" NAME="SEARCH 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-18 14:03:27 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R; Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group</AU>
<TI>Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial</TI>
<SO>JAMA</SO>
<YR>2010</YR>
<VL>303</VL>
<PG>2486-94</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:03:27 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055587"/><IDENTIFIER MODIFIED="2014-08-18 14:03:27 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20571015"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-07 10:26:05 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Clinical Trial Service Unit &amp; Epidemiological Studies Unit</AU>
<TI>SEARCH Study Protocol</TI>
<SO>https://www.ctsu.ox.ac.uk/research/research-archive/searchs/search-study-protocol/view</SO>
<YR>(accessed 7 January 2015)</YR>
<PG>1-36</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055588"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-07-31 07:25:06 -0500" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Times Cited: 0&lt;/p&gt;" NOTES_MODIFIED="2017-07-31 07:25:06 -0500" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Group Search Collaborative</AU>
<TI>Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised</TI>
<SO>Lancet</SO>
<YR>2011</YR>
<VL>377</VL>
<NO>9760</NO>
<PG>126</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:03:18 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055589"/><IDENTIFIER MODIFIED="2014-08-18 14:03:18 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21067805"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055586"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SU.FOL.OM3-2010" MODIFIED="2017-08-04 09:48:56 -0500" MODIFIED_BY="[Empty name]" NAME="SU.FOL.OM3 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-07-31 07:26:15 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="OTHER">
<AU>Andreeva VA, Latarche C, Hercberg S, Briançon S, Galan P, Kesse-Guyot E</AU>
<TI>B vitamin and/or n-3 fatty acid supplementation and health-related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial</TI>
<SO>PLOS One</SO>
<YR>2014</YR>
<VL>9</VL>
<NO>1</NO>
<PG>e84844</PG>
<IDENTIFIERS MODIFIED="2016-02-10 15:13:15 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055591"/><IDENTIFIER MODIFIED="2016-02-10 15:13:15 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 24465438"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-19 03:50:28 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andreeva VA, Touvier M, Kesse-Guyot E, Julia C, Galan P, Hercberg S</AU>
<TI>B vitamin and/or &#969;-3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega-3 fatty acids (SU.FOL.OM3) randomized trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2012</YR>
<VL>172</VL>
<NO>7</NO>
<PG>540-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055592"/><IDENTIFIER TYPE="PUBMED" VALUE="22331983"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-09 09:58:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blacher J, Czernichow S, Paillard F, Ducimetiere P, Hercberg S, Galan P; on behalf of the SU.FOL.OM3 Study Research Group</AU>
<TI>Cardiovascular effects of B-vitamins and/or N-3 fatty acids: the Su.Fol.OM3 trial</TI>
<SO>International Journal of Cardiology</SO>
<YR>2013</YR>
<VL>167</VL>
<NO>2</NO>
<PG>508-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055593"/><IDENTIFIER TYPE="PUBMED" VALUE="22365647"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-09 04:26:24 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galan P, Briancon S, Blacher J, Czernichow S, Hercberg S</AU>
<TI>The SU.FOL.OM3 Study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/or Omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics</TI>
<SO>Trials</SO>
<YR>2008</YR>
<VL>9</VL>
<PG>35</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055594"/><IDENTIFIER TYPE="PUBMED" VALUE="18544171"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-19 05:05:09 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Times Cited: 0&lt;/p&gt;" NOTES_MODIFIED="2014-12-19 05:05:09 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galan P, Briancon S, Blacher J, Czernichow S, Hercberg S</AU>
<TI>The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega 3 fatty acid supplements in the prevention of recurrent ischemic events</TI>
<TO>Bases scientifiques de l&#8217;étude SUFOLOM3: essai de prévention secondaire visant à tester l&#8217;impact d&#8217;une supplémentation en folates, vitamines B6 et B12 et/ou acides gras oméga-3 dans la prévention de la récidive de pathologies ischémiques</TO>
<SO>Sang Thrombose Vaisseaux</SO>
<YR>2009</YR>
<VL>21</VL>
<NO>4</NO>
<PG>207-13</PG>
<IDENTIFIERS MODIFIED="2012-03-08 04:06:36 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055595"/><IDENTIFIER MODIFIED="2012-03-08 04:06:36 -0600" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISSN 0999-7385"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-09 04:26:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S; SU.FOL.OM3 Collaborative Group</AU>
<TI>Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>341</VL>
<PG>1-9</PG>
<IDENTIFIERS MODIFIED="2012-02-09 04:16:53 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055597"/><IDENTIFIER TYPE="PUBMED" VALUE="21115589"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-08-04 09:48:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S; SU.FOL.OM3 Collaborative Group</AU>
<TI>Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>341</VL>
<PG>c6273</PG>
<IDENTIFIERS MODIFIED="2012-03-08 04:08:27 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055596"/><IDENTIFIER MODIFIED="2012-03-08 04:08:27 -0600" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISSN 0959-8146"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galan P, de Bree A, Mennen L, Potier de Courcy G, Preziozi P, Bertrais S, et al</AU>
<TI>Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries</TI>
<SO>Journal of Nutrition, Health &amp; Aging</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>6</NO>
<PG>428-35</PG>
<IDENTIFIERS MODIFIED="2012-03-08 04:14:29 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055598"/><IDENTIFIER MODIFIED="2012-03-08 04:14:29 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14625623"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szabo de Edelenyi F, Vergnaud AC, Ahluwalia N, Julia C, Hercberg S, Blacher J, et al</AU>
<TI>Effect of B-vitamins and n-3 PUFA supplementation for 5 years on blood pressure in patients with CVD</TI>
<SO>British Journal of Nutrition</SO>
<YR>2012</YR>
<VL>107</VL>
<NO>6</NO>
<PG>921-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055599"/><IDENTIFIER TYPE="PUBMED" VALUE="21801476"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-19 03:52:13 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Comparative Study; Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2014-12-19 03:52:13 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vesin C, Galan P, Gautier B, Czernichow S, Hercberg S, Blacher J</AU>
<TI>Control of baseline cardiovascular risk factors in the SU-FOL-OM3 study cohort: does the localization of the arterial event matter?</TI>
<SO>European Journal of Cardiovascular Prevention and Rehabilitation</SO>
<YR>2010</YR>
<VL>17</VL>
<NO>5</NO>
<PG>541-8</PG>
<IDENTIFIERS MODIFIED="2012-03-04 06:09:26 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055600"/><IDENTIFIER MODIFIED="2012-03-04 06:09:26 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20216318"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055590"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VISP-2004" MODIFIED="2017-07-31 07:38:31 -0500" MODIFIED_BY="Heather Maxwell" NAME="VISP 2004" YEAR="2004">
<REFERENCE MODIFIED="2017-07-31 07:38:31 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al</AU>
<TI>Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>5</NO>
<PG>565-75</PG>
<IDENTIFIERS MODIFIED="2016-02-18 17:10:50 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055602"/><IDENTIFIER TYPE="PUBMED" VALUE="14762035"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055601"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VITATOPS-2010" MODIFIED="2014-08-18 14:27:40 -0500" MODIFIED_BY="[Empty name]" NAME="VITATOPS 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-07-09 10:09:47 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavalieri M, Schmidt R, Chen C, Mok V, de Freitas GR, Song S, et al</AU>
<TI>B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudy</TI>
<SO>Stroke</SO>
<YR>2012</YR>
<VL>43</VL>
<NO>12</NO>
<PG>3266-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055604"/><IDENTIFIER TYPE="PUBMED" VALUE="23093615"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-09 10:24:55 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dusitanond P, Eikelboom JW, Hankey GJ, Thom J, Gilmore G, Loh K, et al</AU>
<TI>Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial</TI>
<SO>Stroke</SO>
<YR>2005</YR>
<VL>36</VL>
<NO>1</NO>
<PG>144-6</PG>
<IDENTIFIERS MODIFIED="2012-03-05 05:01:14 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055605"/><IDENTIFIER MODIFIED="2012-03-05 05:01:14 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15569860"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-08 04:39:20 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Group Vitatops Study</AU>
<TI>The VITATOPS (VITAmins TO Prevent Stroke) trial: rationale, design and progress of an international, large simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient attack or stroke [Abstract]</TI>
<SO>Internal Medicine Journal</SO>
<YR>2007</YR>
<VL>Suppl 4</VL>
<PG>A110</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055606"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-09 10:23:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hankey GJ, Eikelboom JW, Yi Q, Lees KR, Chen C, Xavier D, et al</AU>
<TI>Treatment with B vitamins and incidence of cancer in patients with previous stroke or transient ischemic attack: results of a randomized placebo-controlled trial</TI>
<SO>Stroke</SO>
<YR>2012</YR>
<VL>43</VL>
<NO>6</NO>
<PG>1572-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055607"/><IDENTIFIER TYPE="PUBMED" VALUE="22474057"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-05 04:52:35 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hankey GJ</AU>
<TI>The vitamins to prevent stroke (VITATOPS) trial: results of a double-blind, placebo-controlled, randomised trial of B-vitamin therapy in 8,164 patients with recent transient ischaemic attack or stroke</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2010</YR>
<VL>29</VL>
<PG>11</PG>
<IDENTIFIERS MODIFIED="2012-03-05 04:52:35 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055608"/><IDENTIFIER MODIFIED="2012-03-05 04:52:35 -0600" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1159/000321266"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-02 10:31:01 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Potter K&lt;br&gt;Hankey GJ&lt;br&gt;Green DJ&lt;br&gt;Eikelboom J&lt;br&gt;Jamrozik K&lt;br&gt;Arnolda LF&lt;br&gt;(United Kingdom Medical Research Council)&lt;/p&gt;" NOTES_MODIFIED="2012-03-02 10:31:01 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Potter K, Hankey GJ, Green DJ, Eikelboom J, Jamrozik K, Arnolda LF</AU>
<TI>The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis</TI>
<SO>BMC Cardiovascular Disorders</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>24</PG>
<IDENTIFIERS MODIFIED="2012-03-02 10:31:01 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055609"/><IDENTIFIER MODIFIED="2012-03-02 10:31:01 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 18803866"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-02 10:38:31 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Potter K, Lenzo N, Eikelboom JW, Arnolda LF, Beer C, Hankey GJ</AU>
<TI>Effect of long-term homocysteine reduction with B vitamins on arterial wall inflammation assessed by fluorodeoxyglucose positron emission tomography: a randomised double-blind, placebo-controlled trial</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>3</NO>
<PG>259-65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055610"/><IDENTIFIER TYPE="PUBMED" VALUE="19202330"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-09 01:23:37 -0500" MODIFIED_BY="Arturo J Marti-Carvajal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saposnik G</AU>
<TI>The role of vitamin B in stroke prevention: a journey from observational studies to clinical trials and critique of the VITAmins TO Prevent Stroke (VITATOPS)</TI>
<SO>Stroke</SO>
<YR>2011</YR>
<VL>42</VL>
<NO>3</NO>
<PG>838-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055611"/><IDENTIFIER TYPE="PUBMED" VALUE="21273566"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-05 04:37:40 -0600" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The VITATOPS Trial Study Group</AU>
<TI>B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial:a randomised, double-blind, parallel, placebo-controlled trial</TI>
<SO>Lancet Neurology</SO>
<YR>2010</YR>
<VL>9</VL>
<NO>9</NO>
<PG>855&#8211;65</PG>
<IDENTIFIERS MODIFIED="2012-03-05 04:37:40 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055612"/><IDENTIFIER MODIFIED="2012-03-05 04:37:40 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20688574"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-18 14:27:40 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>VITATOPS Trial Study Group, Hankey GJ, Algra A, Chen C, Wong MC, Cheung R, et al</AU>
<TI>VITATOPS, the VITAmins TO prevent stroke trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444)</TI>
<SO>International Journal of Stroke</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>2</NO>
<PG>144-50</PG>
<IDENTIFIERS MODIFIED="2012-03-05 04:31:41 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055613"/><IDENTIFIER MODIFIED="2012-03-05 04:31:41 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18705976"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055603"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WAFACS-2008" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="WAFACS 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-08-18 14:09:16 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al</AU>
<TI>Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial</TI>
<SO>JAMA</SO>
<YR>2008</YR>
<VL>299</VL>
<NO>17</NO>
<PG>2027-36</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:09:09 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055615"/><IDENTIFIER MODIFIED="2014-08-18 14:09:09 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18460663"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Times Cited: 0&lt;br&gt;81st Annual Scientific Session of the American-Heart-Association&lt;br&gt;Nov 08-12, 2008&lt;br&gt;New Orleans, LA&lt;br&gt;Amer Heart Assoc&lt;/p&gt;" NOTES_MODIFIED="2014-12-19 05:03:51 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glynn RJ, Manson JE, Women&#8217;s Antioxidant and Folic Acid Cardiovascular Study Group</AU>
<TI>Effect of folic acid and B vitamins on the occurrence of venous thromboembolism: a randomized trial in women at high cardiovascular risk</TI>
<SO>Circulation</SO>
<YR>2008</YR>
<VL>118</VL>
<PG>S1137</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055616"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-19 03:57:45 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Redbeg RF, Block PC</AU>
<TI>A randomized trial of folic acid and B-vitamins in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)</TI>
<SO>ACC Cardiosource Review Journal</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>7</NO>
<PG>52-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055617"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-19 03:58:02 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural&lt;/p&gt;" NOTES_MODIFIED="2014-12-19 03:58:02 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE</AU>
<TI>Effect of homocysteine-lowering treatment with folic acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial</TI>
<SO>Diabetes</SO>
<YR>2009</YR>
<VL>58</VL>
<NO>8</NO>
<PG>1921-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055618"/><IDENTIFIER TYPE="PUBMED" VALUE=" 19491213"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Times Cited: 0&lt;br&gt;Joint Nutrition, Physical Activity and Metabolism Conference/49th Cardiovascular Disease Epidemiology and Prevention of the American-Heart-Association&lt;br&gt;Mar 10-14, 2009&lt;br&gt;Palm Harbor, FL&lt;br&gt;Amer Heart Assoc&lt;/p&gt;" NOTES_MODIFIED="2014-12-19 05:03:51 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE</AU>
<TI>Effect of homocysteine-lowering treatment with folic acid and B vitamins on risk of type 2 diabetes mellitus in women: a randomized controlled trial</TI>
<SO>Circulation</SO>
<YR>2009</YR>
<VL>119</VL>
<PG>E273</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055619"/><IDENTIFIER TYPE="OTHER" VALUE="ISSN 0009-7322"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-19 03:58:29 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't&lt;/p&gt;" NOTES_MODIFIED="2014-12-19 03:58:29 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang SM, Cook NR, Albert CM, Gaziano JM, Buring JE, Manson JE</AU>
<TI>Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial</TI>
<SO>JAMA</SO>
<YR>2008</YR>
<VL>300</VL>
<NO>17</NO>
<PG>2012-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055620"/><IDENTIFIER TYPE="PUBMED" VALUE="18984888"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055614"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WENBIT-2008" MODIFIED="2017-06-01 11:47:20 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="WENBIT 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-12-19 03:58:38 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;/p&gt;" NOTES_MODIFIED="2014-12-19 03:58:38 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bleie Ø, Strand E, Ueland PM, Vollset SE, Refsum H, Igland J, et al</AU>
<TI>Coronary blood flow in patients with stable coronary artery disease treated long term with folic acid and vitamin B12</TI>
<SO>Coronary Artery Disease</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>4</NO>
<PG>270-8</PG>
<IDENTIFIERS MODIFIED="2012-03-04 03:14:43 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055622"/><IDENTIFIER MODIFIED="2012-03-04 03:14:43 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21389855"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-01 11:47:20 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ding YP, Pedersen EK, Johansson S, Gregory JF 3rd, Ueland PM, Svingen GF, et al</AU>
<TI>B vitamin treatments modify the risk of myocardial infarction associated with a MTHFD1 polymorphism in patients with stable angina pectoris</TI>
<SO>Nutrition, Metabolism, and Cardiovascular Diseases</SO>
<YR>2016</YR>
<VL>26</VL>
<NO>6</NO>
<PG>495-501</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6484370"/><IDENTIFIER TYPE="PUBMED" VALUE="26803590"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-18 14:10:47 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ebbing M, Bleie Ø, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, et al</AU>
<TI>Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2008</YR>
<VL>300</VL>
<PG>795-804</PG>
<IDENTIFIERS MODIFIED="2008-08-28 13:54:50 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055623"/><IDENTIFIER MODIFIED="2008-08-28 13:54:50 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18714059"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-02-03 08:55:38 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ebbing M, Bonaa KH, Arnesen E, Ueland PM, Nordrehaug JE, Rasmussen K, et al</AU>
<TI>Combined analyses and extended follow-up of two randomized controlled homocysteine-lowering B-vitamin trials</TI>
<SO>Journal of Internal Medicine</SO>
<YR>2010</YR>
<VL>268</VL>
<NO>4</NO>
<PG>367-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055624"/><IDENTIFIER TYPE="PUBMED" VALUE="20698927"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-18 14:11:06 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Loland KH&lt;br&gt;Bleie O&lt;br&gt;Blix AJ&lt;br&gt;Strand E&lt;br&gt;Ueland PM&lt;br&gt;Refsum H&lt;br&gt;Ebbing M&lt;br&gt;Nordrehaug JE&lt;br&gt;Nygard O&lt;/p&gt;" NOTES_MODIFIED="2014-08-18 14:11:06 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loland KH, Bleie O, Blix AJ, Strand E, Ueland PM, Refsum H, et al</AU>
<TI>Effect of homocysteine-lowering B vitamin treatment on angiographic progression of coronary artery disease: a Western Norway B Vitamin Intervention Trial (WENBIT) substudy</TI>
<SO>American Journal of Cardiology</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>11</NO>
<PG>1577-84</PG>
<IDENTIFIERS MODIFIED="2012-03-02 06:42:36 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055625"/><IDENTIFIER MODIFIED="2012-03-02 06:42:36 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20494665"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055621"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-08-04 09:47:04 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bahmani-2014" MODIFIED="2016-02-19 12:30:12 -0600" MODIFIED_BY="[Empty name]" NAME="Bahmani 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-02-19 12:30:12 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bahmani F, Karamali M, Shakeri H, Asemi Z</AU>
<TI>The effects of folate supplementation on inflammatory factors and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled clinical trial</TI>
<SO>Clinical Endocrinology</SO>
<YR>2014</YR>
<VL>81</VL>
<NO>4</NO>
<PG>582-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055627"/><IDENTIFIER TYPE="PUBMED" VALUE="24628390"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055626"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bailey-2015" MODIFIED="2017-07-31 07:57:08 -0500" MODIFIED_BY="Heather Maxwell" NAME="Bailey 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-07-31 07:57:08 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailey RL, Fakhouri TH, Park Y, Dwyer JT, Thomas PR, Gahche JJ, et al</AU>
<TI>Multivitamin-mineral use is associated with reduced risk of cardiovascular disease mortality among women in the United States</TI>
<SO>Journal of Nutrition</SO>
<YR>2015</YR>
<VL>145</VL>
<NO>3</NO>
<PG>572-8</PG>
<IDENTIFIERS MODIFIED="2016-02-16 16:00:34 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055629"/><IDENTIFIER TYPE="PUBMED" VALUE="25733474"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055628"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baszczuk-2014" MODIFIED="2016-02-16 16:14:10 -0600" MODIFIED_BY="[Empty name]" NAME="Baszczuk 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-02-16 16:14:10 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baszczuk A, Kopczynski Z</AU>
<TI>[Hyperhomocysteinemia in patients with cardiovascular disease]</TI>
<TO>Hiperhomocysteinemia u chorych na schorzenia ukladu krazenia</TO>
<SO>Postepy Higieny i Medycyny Doswiadczalnej</SO>
<YR>2014</YR>
<VL>68</VL>
<PG>579-89</PG>
<IDENTIFIERS MODIFIED="2016-02-16 16:13:26 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055631"/><IDENTIFIER TYPE="PUBMED" VALUE="24864108"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055630"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baszczuk-2015" MODIFIED="2016-02-16 16:18:37 -0600" MODIFIED_BY="[Empty name]" NAME="Baszczuk 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-02-16 16:18:37 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baszczuk A, Kopczynski Z, Kopczynski J, Cymerys M, Thielemann A, Bielawska L, et al</AU>
<TI>Impact of administration of folic acid on selected indicators of inflammation in patients with primary arterial hypertension</TI>
<SO>Postepy Higieny i Medycyny Doswiadczalnej</SO>
<YR>2015</YR>
<VL>69</VL>
<PG>429-35</PG>
<IDENTIFIERS MODIFIED="2016-02-16 16:16:34 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055633"/><IDENTIFIER TYPE="PUBMED" VALUE="25897102"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055632"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bazzano-2006" MODIFIED="2009-07-15 20:34:34 -0500" MODIFIED_BY="[Empty name]" NAME="Bazzano 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-15 20:34:34 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bazzano LA, Reynolds K, Holder KN, He J</AU>
<TI>Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>296</VL>
<PG>2720-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055635"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055634"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bobak-2014" MODIFIED="2016-02-16 16:10:39 -0600" MODIFIED_BY="[Empty name]" NAME="Bobak 2014" YEAR="Ovid">
<REFERENCE MODIFIED="2016-02-16 16:10:14 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bobak M, Pajak A, Tamosiunas A, Kubinova R, Gardiner J, Jansen E</AU>
<TI>Plasma concentrations of folate and vitamin B12 and risk of fatal and non-fatal cardiovascular disease: A nested case-control study nested in a population-based cohort</TI>
<SO>European Society of Cardiology annual meeting (http://congress365.escardio.org/Search-Results?vgnextkeyword=C365PRESENTATION101078#.VsOczh0X3IU)</SO>
<YR>2014</YR>
<NO>4170</NO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055637"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055636"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-2010" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Clarke 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JAE; for the B-Vitamin Treatment Trialists&#8217; Collaboration</AU>
<TI>Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2010</YR>
<VL>170</VL>
<NO>18</NO>
<PG>1622-31</PG>
<IDENTIFIERS MODIFIED="2012-03-04 04:04:41 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055639"/><IDENTIFIER MODIFIED="2012-03-04 04:04:41 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20937919"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055638"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cui-2010" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Cui 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cui R, Iso H, Date C, Kikuchi S, Tamakoshi A</AU>
<TI>Dietary folate and vitamin b6 and B12 intake in relation to mortality from cardiovascular diseases: Japan Collaborative Cohort Study</TI>
<SO>Stroke</SO>
<YR>2010</YR>
<VL>41</VL>
<NO>6</NO>
<PG>1285-9</PG>
<IDENTIFIERS MODIFIED="2014-08-18 11:39:22 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055641"/><IDENTIFIER TYPE="PUBMED" VALUE="20395608"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055640"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Debreceni-2014" MODIFIED="2016-02-19 12:32:09 -0600" MODIFIED_BY="[Empty name]" NAME="Debreceni 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-02-19 12:32:09 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Debreceni B, Debreceni L</AU>
<TI>The role of homocysteine-lowering B-vitamins in the primary prevention of cardiovascular disease</TI>
<SO>Cardiovascular Therapeutics</SO>
<YR>2014</YR>
<VL>32</VL>
<NO>3</NO>
<PG>130-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055643"/><IDENTIFIER TYPE="PUBMED" VALUE="24571382"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055642"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dell_x0027_edera-2013" MODIFIED="2016-02-19 12:36:41 -0600" MODIFIED_BY="[Empty name]" NAME="Dell'edera 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-02-19 12:36:41 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dell'edera D, Tinelli A, Milazzo GN, Malvasi A, Domenico C, Pacella E, et al</AU>
<TI>Effect of multivitamins on plasma homocysteine in patients with the 5,10 methylenetetrahydrofolate reductase C677T homozygous state</TI>
<SO>Molecular Medicine Reports</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>2</NO>
<PG>609-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055645"/><IDENTIFIER TYPE="PUBMED" VALUE="23818036"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055644"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deshmukh-2010" MODIFIED="2014-08-18 14:11:33 -0500" MODIFIED_BY="[Empty name]" NAME="Deshmukh 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-18 14:11:33 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Deshmukh US&lt;br&gt;Joglekar CV&lt;br&gt;Lubree HG&lt;br&gt;Ramdas LV&lt;br&gt;Bhat DS&lt;br&gt;Naik SS&lt;br&gt;Hardikar PS&lt;br&gt;Raut DA&lt;br&gt;Konde TB&lt;br&gt;Wills AK&lt;br&gt;Jackson AA&lt;br&gt;Refsum H&lt;br&gt;Nanivadekar AS&lt;br&gt;Fall CH&lt;br&gt;Yajnik CS&lt;br&gt;079877 (United Kingdom Wellcome Trust)&lt;br&gt;(United Kingdom Wellcome Trust)&lt;/p&gt;" NOTES_MODIFIED="2014-08-18 14:11:33 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deshmukh US, Joglekar CV, Lubree HG, Ramdas LV, Bhat DS, Naik SS, et al</AU>
<TI>Effect of physiological doses of oral vitamin B12 on plasma homocysteine: a randomized, placebo-controlled, double-blind trial in India</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2010</YR>
<VL>64</VL>
<NO>5</NO>
<PG>495-502</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055647"/><IDENTIFIER TYPE="PUBMED" VALUE="20216560"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055646"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dong-2015" MODIFIED="2017-07-31 08:08:23 -0500" MODIFIED_BY="Heather Maxwell" NAME="Dong 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-07-31 08:08:23 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dong H, Pi F, Ding Z, Chen W, Pang S, Dong W, et al</AU>
<TI>Efficacy of supplementation with B vitamins for stroke prevention: A network meta-analysis of randomized controlled trials</TI>
<SO>PLOS One</SO>
<YR>2015</YR>
<VL>10</VL>
<NO>9</NO>
<PG>e0137533</PG>
<IDENTIFIERS MODIFIED="2016-02-16 16:33:59 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055649"/><IDENTIFIER TYPE="PUBMED" VALUE="26355679"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055648"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Durga-2011" MODIFIED="2012-03-04 04:31:31 -0600" MODIFIED_BY="[Empty name]" NAME="Durga 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-03-04 04:31:31 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Durga J&lt;br&gt;Bots ML&lt;br&gt;Schouten EG&lt;br&gt;Grobbee DE&lt;br&gt;Kok FJ&lt;br&gt;Verhoef P&lt;/p&gt;" NOTES_MODIFIED="2012-03-04 04:31:31 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Durga J, Bots ML, Schouten EG, Grobbee DE, Kok FJ, Verhoef P</AU>
<TI>Effect of 3 y of folic acid supplementation on the progression of carotid intima-media thickness and carotid arterial stiffness in older adults</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2011</YR>
<VL>93</VL>
<NO>5</NO>
<PG>941-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055651"/><IDENTIFIER TYPE="PUBMED" VALUE=" 21430116"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055650"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Earnest-2012" MODIFIED="2014-08-18 10:54:25 -0500" MODIFIED_BY="[Empty name]" NAME="Earnest 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-08-18 10:54:25 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Earnest CP, Kupper JS, Thompson AM, Guo W, Church T</AU>
<TI>Complementary effects of multivitamin and omega-3 fatty acid supplementation on indices of cardiovascular health in individuals with elevated homocysteine</TI>
<SO>International Journal for Vitamin and Nutrition Research</SO>
<YR>2012</YR>
<VL>82</VL>
<NO>1</NO>
<PG>41-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055653"/><IDENTIFIER TYPE="PUBMED" VALUE="22811376"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055652"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ebbing-2009" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Ebbing 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ebbing M, Bonaa KH, Nordrehaug JE, Ueland PM, Arnesen E, Refsum H, et al</AU>
<TI>Combined results and long-term follow-up in NORVIT and WENBIT with 6837 coronary artery disease patients: homocysteine-lowering B-vitamin treatment does not prevent major cardiovascular events</TI>
<SO>Journal of Internal Medicine</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>4</NO>
<PG>184</PG>
<IDENTIFIERS MODIFIED="2012-03-04 04:45:16 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055655"/><IDENTIFIER MODIFIED="2012-03-04 04:45:16 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20698927"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055654"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ebbing-2009a" MODIFIED="2014-08-18 14:12:05 -0500" MODIFIED_BY="[Empty name]" NAME="Ebbing 2009a" YEAR="2009">
<REFERENCE MODIFIED="2014-08-18 14:12:05 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ebbing M&lt;br&gt;Bonaa KH&lt;br&gt;Nygard O&lt;br&gt;Arnesen E&lt;br&gt;Ueland PM&lt;br&gt;Nordrehaug JE&lt;br&gt;Rasmussen K&lt;br&gt;Njolstad I&lt;br&gt;Refsum H&lt;br&gt;Nilsen DW&lt;br&gt;Tverdal A&lt;br&gt;Meyer K&lt;br&gt;Vollset SE&lt;br&gt;Comment in: JAMA. 2009 Nov 18;302(19):2152-3; PMID: 19920243&lt;/p&gt;" NOTES_MODIFIED="2014-08-18 14:12:05 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ebbing M, Bonaa KH, Nygard O, Arnesen E, Ueland PM, Nordrehaug JE, et al</AU>
<TI>Cancer incidence and mortality after treatment with folic acid and vitamin B12</TI>
<SO>JAMA</SO>
<YR>2009</YR>
<VL>302</VL>
<NO>19</NO>
<PG>2119-26</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055657"/><IDENTIFIER TYPE="PUBMED" VALUE="19920236"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055656"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-FINEST-2006" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="FINEST 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Nevado J</AU>
<TI>Folate intervention in non-ST elevation myocardial infarction and unstable angina: a randomised placebo-controlled trial</TI>
<TO>2006</TO>
<SO>http://controlled-trials.com/ISRCTN30249553/homocysteine (accessed 12 October 2007)</SO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055659"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055658"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goel-2015" MODIFIED="2016-02-18 14:22:13 -0600" MODIFIED_BY="[Empty name]" NAME="Goel 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-02-18 14:22:13 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Goel S, Messerli FH</AU>
<TI>Efficacy of folic acid in primary prevention of stroke among patients with hypertension in China</TI>
<SO>Journal of the American Society of Hypertension</SO>
<YR>2015</YR>
<VL>9</VL>
<NO>9</NO>
<PG>665-7</PG>
<IDENTIFIERS MODIFIED="2016-02-18 14:21:24 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055661"/><IDENTIFIER TYPE="PUBMED" VALUE="26369441"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055660"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Green-2010" MODIFIED="2014-12-19 04:01:15 -0600" MODIFIED_BY="[Empty name]" NAME="Green 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-19 04:01:15 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;/p&gt;" NOTES_MODIFIED="2014-12-19 04:01:15 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green TJ, Skeaff CM, McMahon JA, Venn BJ, Williams SM, Devlin AM, et al</AU>
<TI>Homocysteine-lowering vitamins do not lower plasma S-adenosylhomocysteine in older people with elevated homocysteine concentrations</TI>
<SO>British Journal of Nutrition</SO>
<YR>2010</YR>
<VL>103</VL>
<NO>11</NO>
<PG>1629-34</PG>
<IDENTIFIERS MODIFIED="2012-03-04 05:02:34 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055663"/><IDENTIFIER MODIFIED="2012-03-04 05:02:34 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20089204"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055662"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holmes-2011" MODIFIED="2014-08-18 14:12:39 -0500" MODIFIED_BY="[Empty name]" NAME="Holmes 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-18 14:12:39 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J, et al</AU>
<TI>Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials</TI>
<SO>Lancet</SO>
<YR>2011</YR>
<VL>378</VL>
<NO>9791</NO>
<PG>584-94</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055665"/><IDENTIFIER TYPE="PUBMED" VALUE="21803414"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055664"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2012" MODIFIED="2014-12-19 04:01:50 -0600" MODIFIED_BY="[Empty name]" NAME="Huang 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-07-09 10:32:24 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huang T, Chen Y, Yang B, Yang J, Wahlqvist ML, Li D</AU>
<TI>Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality</TI>
<SO>Clinical Nutrition</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>4</NO>
<PG>448-54</PG>
<IDENTIFIERS MODIFIED="2014-07-09 10:30:39 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055667"/><IDENTIFIER TYPE="PUBMED" VALUE="22652362"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-19 04:01:43 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang T, Li D</AU>
<TI>Reply to Fang SK--Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality</TI>
<SO>Clinical Nutrition</SO>
<YR>2013</YR>
<VL>32</VL>
<NO>2</NO>
<PG>315-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055668"/><IDENTIFIER TYPE="PUBMED" VALUE="23391457"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-19 04:01:50 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou C, Wu J, Fang S</AU>
<TI>Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality</TI>
<SO>Clinical Nutrition</SO>
<YR>2013</YR>
<VL>32</VL>
<NO>2</NO>
<PG>314</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055669"/><IDENTIFIER TYPE="PUBMED" VALUE="23433911"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055666"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2015" MODIFIED="2016-02-18 14:31:09 -0600" MODIFIED_BY="[Empty name]" NAME="Huang 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-02-18 14:31:09 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang T, Li K, Asimi S, Chen Q, Li D</AU>
<TI>Effect of vitamin B-12 and n-3 polyunsaturated fatty acids on plasma homocysteine, ferritin, C-reaction protein, and other cardiovascular risk factors: a randomized controlled trial</TI>
<SO>Asia Pacific Journal of Clinical Nutrition</SO>
<YR>2015</YR>
<VL>24</VL>
<NO>3</NO>
<PG>403-11</PG>
<IDENTIFIERS MODIFIED="2016-02-18 14:30:40 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055671"/><IDENTIFIER TYPE="PUBMED" VALUE="26420180"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055670"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huo-2012" MODIFIED="2014-07-09 10:39:14 -0500" MODIFIED_BY="[Empty name]" NAME="Huo 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-07-09 10:39:14 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huo Y, Qin X, Wang J, Sun N, Zeng Q, Xu X, et al</AU>
<TI>Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2012</YR>
<VL>66</VL>
<NO>6</NO>
<PG>544-51</PG>
<IDENTIFIERS MODIFIED="2014-07-09 10:38:26 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055673"/><IDENTIFIER TYPE="PUBMED" VALUE="22607506"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055672"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Imasa-2009" MODIFIED="2014-12-19 04:02:07 -0600" MODIFIED_BY="[Empty name]" NAME="Imasa 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-12-19 04:02:07 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;/p&gt;" NOTES_MODIFIED="2014-12-19 04:02:07 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Imasa MS, Gomez NT, Nevado JB</AU>
<TI>Folic acid-based intervention in non-ST elevation acute coronary syndromes</TI>
<SO>Asian Cardiovascular &amp; Thoracic Annals</SO>
<YR>2009</YR>
<VL>17</VL>
<NO>1</NO>
<PG>13-21</PG>
<IDENTIFIERS MODIFIED="2012-03-02 06:11:15 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055675"/><IDENTIFIER MODIFIED="2012-03-02 06:11:15 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 19515873"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055674"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jardine-2012" MODIFIED="2014-08-18 14:12:56 -0500" MODIFIED_BY="[Empty name]" NAME="Jardine 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-08-18 14:12:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Ninomiya T, Nigwekar SU, et al</AU>
<TI>The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis</TI>
<SO>BMJ</SO>
<YR>2012</YR>
<VL>344</VL>
<PG>e3533</PG>
<IDENTIFIERS MODIFIED="2012-07-16 09:13:04 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055677"/><IDENTIFIER TYPE="PUBMED" VALUE="22695899"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055676"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ji-2013" MODIFIED="2014-02-03 08:48:06 -0600" MODIFIED_BY="[Empty name]" NAME="Ji 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-02-03 08:48:06 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ji Y, Tan S, Xu Y, Chandra A, Shi C, Song B, et al</AU>
<TI>Vitamin B supplementation, homocysteine levels, and the risk of cerebrovascular disease: a meta-analysis</TI>
<SO>Neurology</SO>
<YR>2013</YR>
<VL>81</VL>
<NO>15</NO>
<PG>1298-307</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055679"/><IDENTIFIER TYPE="PUBMED" VALUE="24049135"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055678"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lange-2004" MODIFIED="2014-08-18 14:31:25 -0500" MODIFIED_BY="[Empty name]" NAME="Lange 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-08-18 14:31:25 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lange H, Suryapranata H, De Luca G, Börner C, Dille J, Kallmayer K, et al</AU>
<TI>Folate therapy and in-stent restenosis after coronary stenting</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>350</VL>
<PG>2673-81</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:31:25 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055681"/><IDENTIFIER MODIFIED="2014-08-18 14:31:25 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15215483"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055680"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2010" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Lee 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lee M, Hong KS, Chang SC, Saver JL</AU>
<TI>Efficacy of homocysteine lowering therapy with folic acid in stroke prevention: a meta-analysis of randomized controlled trials</TI>
<SO>Stroke</SO>
<YR>2010</YR>
<VL>41</VL>
<PG>e291</PG>
<IDENTIFIERS MODIFIED="2012-03-02 07:15:56 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055683"/><IDENTIFIER MODIFIED="2012-03-02 07:15:56 -0600" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISSN: 0039-2499"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-02 07:09:27 -0600" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lee M, Hong KS, Chang SC, Saver JL</AU>
<TI>Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: a meta-analysis</TI>
<SO>Stroke</SO>
<YR>2010</YR>
<VL>41</VL>
<NO>6</NO>
<PG>1205-12</PG>
<IDENTIFIERS MODIFIED="2012-03-02 07:07:40 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055684"/><IDENTIFIER TYPE="PUBMED" VALUE="20413740"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055682"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2014" MODIFIED="2016-02-18 14:47:28 -0600" MODIFIED_BY="[Empty name]" NAME="Li 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-02-18 14:47:28 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li WF, Zhang DD, Xia JT, Wen SF, Guo J, Li ZC</AU>
<TI>The association between B vitamins supplementation and adverse cardiovascular events: a meta-analysis</TI>
<SO>International Journal of Clinical and Experimental Medicine</SO>
<YR>2014</YR>
<VL>7</VL>
<NO>8</NO>
<PG>1923-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055686"/><IDENTIFIER TYPE="PUBMED" VALUE="25232372"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055685"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2015" MODIFIED="2016-02-18 14:52:45 -0600" MODIFIED_BY="[Empty name]" NAME="Li 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-02-18 14:52:45 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li J, Li B, Qi J, Shen B</AU>
<TI>[Meta-analysis of clinical trials of folic acid, vitamin B12 and B6 supplementation on plasma homocysteine level and risk of cardiovascular disease]</TI>
<SO>Zhonghua Xin Xue guan Bing Za Zhi</SO>
<YR>2015</YR>
<VL>43</VL>
<NO>6</NO>
<PG>554-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055688"/><IDENTIFIER TYPE="PUBMED" VALUE="26420127"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055687"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2014" MODIFIED="2016-02-18 15:21:18 -0600" MODIFIED_BY="[Empty name]" NAME="Liu 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-02-18 15:21:18 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Y, Tian T, Zhang H, Gao L, Zhou X</AU>
<TI>The effect of homocysteine-lowering therapy with folic acid on flow-mediated vasodilation in patients with coronary artery disease: a meta-analysis of randomized controlled trials</TI>
<SO>Atherosclerosis</SO>
<YR>2014</YR>
<VL>235</VL>
<NO>1</NO>
<PG>31-5</PG>
<IDENTIFIERS MODIFIED="2016-02-18 15:21:16 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055690"/><IDENTIFIER TYPE="PUBMED" VALUE="24814647"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055689"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lonn-2007" MODIFIED="2014-08-18 11:45:01 -0500" MODIFIED_BY="[Empty name]" NAME="Lonn 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-18 11:45:01 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lonn E</AU>
<TI>Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction?</TI>
<SO>Current Opinion in Hematology</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>5</NO>
<PG>481-7</PG>
<IDENTIFIERS MODIFIED="2014-08-18 11:43:57 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055692"/><IDENTIFIER TYPE="PUBMED" VALUE="17934354"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055691"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mager-2009" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Mager 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mager A, Orvin K, Koren-Morag N, Lev IE, Assali A, Kornowski R, et al</AU>
<TI>Impact of homocysteine-lowering vitamin therapy on long-term outcome of patients with coronary artery disease</TI>
<SO>American Journal of Cardiology</SO>
<YR>2009</YR>
<VL>104</VL>
<NO>6</NO>
<PG>745-9</PG>
<IDENTIFIERS MODIFIED="2014-08-18 11:47:13 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055694"/><IDENTIFIER TYPE="PUBMED" VALUE="19733705"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055693"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manolescu-2010" MODIFIED="2014-08-18 11:50:18 -0500" MODIFIED_BY="[Empty name]" NAME="Manolescu 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-18 11:50:18 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manolescu BN, Oprea E, Farcasanu IC, Berteanu M, Cercasov C</AU>
<TI>Homocysteine and vitamin therapy in stroke prevention and treatment: a review</TI>
<SO>Acta Biochimica Polonica</SO>
<YR>2010</YR>
<VL>57</VL>
<NO>4</NO>
<PG>467-77</PG>
<IDENTIFIERS MODIFIED="2014-08-18 11:49:54 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055696"/><IDENTIFIER TYPE="PUBMED" VALUE="21140003"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055695"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mei-2010" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Mei 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mei W, Rong Y, Jinming L, Yongjun L, Hui Z</AU>
<TI>Effect of homocysteine interventions on risk of cardiocerebrovascular events: a meta-analysis of randomized controlled trials</TI>
<SO>Circulation</SO>
<YR>2010</YR>
<VL>122</VL>
<NO>2</NO>
<PG>e140-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055698"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-02 08:51:16 -0600" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mei W, Rong Y, Jinming L, Yongjun L, Hui Z</AU>
<TI>Effect of homocysteine interventions on the risk of cardiocerebrovascular events: a meta-analysis of randomised controlled trials</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2010</YR>
<VL>64</VL>
<NO>2</NO>
<PG>208-15</PG>
<IDENTIFIERS MODIFIED="2012-03-02 08:21:29 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055699"/><IDENTIFIER TYPE="PUBMED" VALUE="19912385"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055697"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00e9_ndez_x002d_Gonz_x00e1_lez-2010" MODIFIED="2017-07-31 08:13:49 -0500" MODIFIED_BY="Heather Maxwell" NAME="Méndez-González 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-07-31 08:13:49 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Méndez-González J, Rodríguez-Millán E, Julve J, Blanco-Vaca F</AU>
<TI>Vitamin treatments that lower homocysteine concentration: can they decrease cerebrovascular disease in primary prevention?</TI>
<TO>Tratamientos vitamínicos para disminuir la concentración de homocisteína: reducen el riesgo de enfermedad cerebrovascular en prevención primaria?</TO>
<SO>Revista de Neurologia</SO>
<YR>2010</YR>
<VL>50</VL>
<NO>4</NO>
<PG>235-44</PG>
<IDENTIFIERS MODIFIED="2014-08-18 11:53:11 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055701"/><IDENTIFIER TYPE="PUBMED" VALUE="20198596"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055700"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-2010" MODIFIED="2012-05-07 07:24:38 -0500" MODIFIED_BY="[Empty name]" NAME="Miller 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-05-07 07:24:38 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Miller ER 3rd&lt;br&gt;Juraschek S&lt;br&gt;Pastor-Barriuso R&lt;br&gt;Bazzano LA&lt;br&gt;Appel LJ&lt;br&gt;Guallar E&lt;br&gt;Comment in: Am J Cardiol. 2010 Dec 1;106(11):1673-4; PMID: 21094373&lt;/p&gt;" NOTES_MODIFIED="2012-05-07 07:24:38 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller ER 3rd, Juraschek S, Pastor-Barriuso R, Bazzano LA, Appel LJ, Guallar E</AU>
<TI>Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels</TI>
<SO>American Journal of Cardiology</SO>
<YR>2010</YR>
<VL>106</VL>
<PG>517-27</PG>
<IDENTIFIERS MODIFIED="2012-05-07 07:24:38 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055703"/><IDENTIFIER MODIFIED="2012-05-07 07:24:38 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20691310"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055702"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mishchenko-2015" MODIFIED="2016-02-18 15:55:01 -0600" MODIFIED_BY="[Empty name]" NAME="Mishchenko 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-02-18 15:55:01 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mishchenko O, Iakovlieva L, Kyrychenko O, Gerasymova O, Bezditko N, Tkachova O</AU>
<TI>Pharmacoeconomic analysis of the combined homocysteine-lowering and standard therapy versus standard therapy of patients with CHD, postpercutaneous coronary intervention (Pci) and B12 deficiency</TI>
<SO>Value in Health</SO>
<YR>2015</YR>
<VL>18</VL>
<NO>7</NO>
<PG>A404</PG>
<IDENTIFIERS MODIFIED="2016-02-18 15:53:29 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055705"/><IDENTIFIER TYPE="PUBMED" VALUE="26532279"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055704"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moghaddasi-2010" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Moghaddasi 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moghaddasi M, Mamarabad M</AU>
<TI>Homocysteine, vitamin B12 and folic acid levels in cerebrovascular accident: a case-control study</TI>
<SO>Journal of Neurology</SO>
<YR>2009</YR>
<VL>256</VL>
<NO>Suppl 2</NO>
<PG>S171</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055707"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-18 12:00:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moghaddasi M, Mamarabadi M, Mirzadeh S, Freydoonnejad AA, Razjouyan H</AU>
<TI>Homocysteine, vitamin B12 and folate levels in Iranian patients with ischemic stroke</TI>
<SO>Neurological Research</SO>
<YR>2010</YR>
<VL>32</VL>
<NO>9</NO>
<PG>953-6</PG>
<IDENTIFIERS MODIFIED="2014-08-18 11:59:32 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055708"/><IDENTIFIER TYPE="PUBMED" VALUE="20433777"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055706"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ntaios-2009" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Ntaios 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ntaios G, Savopoulos C, Grekas D, Hatzitolios A</AU>
<TI>The controversial role of B-vitamins in cardiovascular risk: an update</TI>
<SO>Archives of Cardiovascular Diseases</SO>
<YR>2009</YR>
<VL>102</VL>
<NO>12</NO>
<PG>847-54</PG>
<IDENTIFIERS MODIFIED="2014-08-18 12:11:33 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055710"/><IDENTIFIER TYPE="PUBMED" VALUE="19963194"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055709"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ntaios-2010" MODIFIED="2014-08-18 14:13:43 -0500" MODIFIED_BY="[Empty name]" NAME="Ntaios 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-18 14:13:43 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ntaios G, Savopoulos C, Karamitsos D, Economou I, Destanis E, Chryssogonidis I, et al</AU>
<TI>The effect of folic acid supplementation on carotid intima-media thickness in patients with cardiovascular risk: a randomized, placebo-controlled trial</TI>
<SO>International Journal of Cardiology</SO>
<YR>2010</YR>
<VL>143</VL>
<NO>1</NO>
<PG>16-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055712"/><IDENTIFIER TYPE="PUBMED" VALUE="19201496"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055711"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PACIFIC-2002" MODIFIED="2009-02-09 07:39:36 -0600" MODIFIED_BY="[Empty name]" NAME="PACIFIC 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-02-09 07:39:36 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neal B, MacMahon S, Ohkubo T, Tonkin A, Wilcken D; PACIFIC Study Group</AU>
<TI>Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease</TI>
<SO>European Heart Journal</SO>
<YR>2002</YR>
<VL>23</VL>
<PG>1509-15</PG>
<IDENTIFIERS MODIFIED="2009-02-09 07:39:36 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055714"/><IDENTIFIER MODIFIED="2009-02-09 07:39:36 -0600" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12395803"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055713"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-2012" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Pan 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan Y, Guo LL, Cai LL, Zhu XJ, Shu JL, Liu XL, et al</AU>
<TI>Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials</TI>
<SO>British Journal of Nutrition</SO>
<YR>2012</YR>
<VL>108</VL>
<NO>3</NO>
<PG>400-7</PG>
<IDENTIFIERS MODIFIED="2014-07-09 10:51:41 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055716"/><IDENTIFIER TYPE="PUBMED" VALUE="22244447"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055715"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Park-2016" MODIFIED="2016-02-18 16:03:53 -0600" MODIFIED_BY="[Empty name]" NAME="Park 2016" YEAR="2016">
<REFERENCE MODIFIED="2016-02-18 16:03:53 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Park JH, Saposnik G, Ovbiagele B, Markovic D, Towfighi A</AU>
<TI>Effect of B-vitamins on stroke risk among individuals with vascular disease who are not on antiplatelets: A meta-analysis</TI>
<SO>International Journal of Stroke</SO>
<YR>2016</YR>
<VL>11</VL>
<NO>2</NO>
<PG>206-11</PG>
<IDENTIFIERS MODIFIED="2016-02-18 16:03:28 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055718"/><IDENTIFIER TYPE="PUBMED" VALUE="26783312"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055717"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qin-2014" MODIFIED="2016-02-18 15:58:20 -0600" MODIFIED_BY="[Empty name]" NAME="Qin 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-02-18 15:58:20 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qin X, Fan F, Cui Y, Chen F, Chen Y, Cheng X, et al</AU>
<TI>Folic acid supplementation with and without vitamin B6 and revascularization risk: a meta-analysis of randomized controlled trials</TI>
<SO>Clinical Nutrition</SO>
<YR>2014</YR>
<VL>33</VL>
<NO>4</NO>
<PG>603-12</PG>
<IDENTIFIERS MODIFIED="2016-02-18 15:57:59 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055720"/><IDENTIFIER TYPE="PUBMED" VALUE="24461473"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055719"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rautiainen-2010" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Rautiainen 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rautiainen S, Akesson A, Levitan EB, Morgenstern R, Mittleman MA, Wolk A</AU>
<TI>Multivitamin use and the risk of myocardial infarction: a population-based cohort of Swedish women</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2010</YR>
<VL>92</VL>
<NO>5</NO>
<PG>1251-6</PG>
<IDENTIFIERS MODIFIED="2014-08-18 12:14:38 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055722"/><IDENTIFIER TYPE="PUBMED" VALUE="20861174"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055721"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharifi-2010" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Sharifi 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharifi F, Fakhrzadeh H, Mirarefin M, Pourebrahim R, Nouri M, Forouzanfar MH, et al</AU>
<TI>The effects of high-dose folic acid on blood pressure of hypertensive adults with hyperhomocysteinemia: a randomized double-blind placebo controlled clinical trial (Tehran homocysteine survey)</TI>
<SO>Iranian Journal of Diabetes and Lipid Disorders</SO>
<YR>2010</YR>
<VL>9</VL>
<PG>13-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055724"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055723"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shidfar-2009" MODIFIED="2014-12-19 04:05:46 -0600" MODIFIED_BY="[Empty name]" NAME="Shidfar 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-12-19 04:05:46 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2014-12-19 04:05:46 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shidfar F, Homayounfar R, Fereshtehnejad SM, Kalani A</AU>
<TI>Effect of folate supplementation on serum homocysteine and plasma total antioxidant capacity in hypercholesterolemic adults under lovastatin treatment: a double-blind randomized controlled clinical trial</TI>
<SO>Archives of Medical Research</SO>
<YR>2009</YR>
<VL>40</VL>
<NO>5</NO>
<PG>380-6</PG>
<IDENTIFIERS MODIFIED="2012-03-04 05:26:06 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055726"/><IDENTIFIER MODIFIED="2012-03-04 05:26:06 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19766902"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055725"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sudchada-2012" MODIFIED="2014-07-09 11:11:03 -0500" MODIFIED_BY="[Empty name]" NAME="Sudchada 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-07-09 11:11:03 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sudchada P, Saokaew S, Sridetch S, Incampa S, Jaiyen S, Khaithong W</AU>
<TI>Effect of folic acid supplementation on plasma total homocysteine levels and glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis</TI>
<SO>Diabetes Research and Clinical Practice</SO>
<YR>2012</YR>
<VL>98</VL>
<NO>1</NO>
<PG>151-8</PG>
<IDENTIFIERS MODIFIED="2014-07-09 11:10:25 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055728"/><IDENTIFIER TYPE="PUBMED" VALUE="22727498"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055727"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swiss-2002" MODIFIED="2014-08-18 12:04:16 -0500" MODIFIED_BY="[Empty name]" NAME="Swiss 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-08-18 12:04:16 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM</AU>
<TI>Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<PG>973-9</PG>
<IDENTIFIERS MODIFIED="2014-08-18 12:04:16 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055730"/><IDENTIFIER MODIFIED="2014-08-18 12:04:16 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12190367"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055729"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tighe-2011" MODIFIED="2014-12-19 04:06:09 -0600" MODIFIED_BY="[Empty name]" NAME="Tighe 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-12-19 04:06:09 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;/p&gt;" NOTES_MODIFIED="2014-12-19 04:06:09 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tighe P, Ward M, McNulty H, Finnegan O, Dunne A, Strain J, et al</AU>
<TI>A dose-finding trial of the effect of long-term folic acid intervention: implications for food fortification policy</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2011</YR>
<VL>93</VL>
<NO>1</NO>
<PG>11-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055732"/><IDENTIFIER TYPE="PUBMED" VALUE="20980493"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055731"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vesin-2007" MODIFIED="2017-08-04 09:47:04 -0500" MODIFIED_BY="[Empty name]" NAME="Vesin 2007" YEAR="2007">
<REFERENCE MODIFIED="2017-08-04 09:47:04 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vesin C, Mairesse S, Iaria P, Blacher J</AU>
<TI>Efficacy of folic acid in prevention of cerebrovascular disease</TI>
<TO>Efficacite de l&#8217;acide folique dans la prevention cerebrovasculaire</TO>
<SO>Medecinedes Maladies Metaboliques</SO>
<YR>2007</YR>
<VL>1</VL>
<PG>50-2</PG>
<IDENTIFIERS MODIFIED="2017-08-04 09:47:04 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055734"/><IDENTIFIER MODIFIED="2017-08-04 09:47:04 -0500" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2007490543"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055733"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2007" MODIFIED="2014-08-18 14:14:41 -0500" MODIFIED_BY="[Empty name]" NAME="Wang 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-18 14:14:41 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, et al</AU>
<TI>Efficacy of folic acid supplementation in stroke prevention: a meta-analysis</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>369</VL>
<PG>876-82</PG>
<IDENTIFIERS MODIFIED="2014-08-18 12:04:26 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055736"/><IDENTIFIER MODIFIED="2014-08-18 12:04:26 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17544768"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055735"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2012" MODIFIED="2014-07-09 11:18:28 -0500" MODIFIED_BY="[Empty name]" NAME="Wang 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-07-09 11:18:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang ZM, Zhou B, Nie ZL, Gao W, Wang YS, Zhao H, et al</AU>
<TI>Folate and risk of coronary heart disease: a meta-analysis of prospective studies</TI>
<SO>Nutrition, Metabolism, and Cardiovascular Diseases</SO>
<YR>2012</YR>
<VL>22</VL>
<NO>10</NO>
<PG>890-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055738"/><IDENTIFIER TYPE="PUBMED" VALUE="21924595"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055737"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2015a" MODIFIED="2016-02-19 14:24:42 -0600" MODIFIED_BY="[Empty name]" NAME="Wang 2015a" YEAR="2015">
<REFERENCE MODIFIED="2016-02-19 12:52:20 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang L, Li H, Zhou Y, Jin L, Liu J</AU>
<TI>Low-dose B vitamins supplementation ameliorates cardiovascular risk: a double-blind randomized controlled trial in healthy Chinese elderly</TI>
<SO>European Journal of Nutrition</SO>
<YR>2015</YR>
<VL>54</VL>
<NO>3</NO>
<PG>455-64</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055740"/><IDENTIFIER TYPE="PUBMED" VALUE="24916013"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055739"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2015b" MODIFIED="2016-02-19 13:36:17 -0600" MODIFIED_BY="[Empty name]" NAME="Wang 2015b" YEAR="2015">
<REFERENCE MODIFIED="2016-02-19 13:36:17 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wang LP, Cui WW, Nan GX, Yu Y</AU>
<TI>Meta-analysis reveals protective effects of vitamin B on stroke patients</TI>
<SO>Translational Neuroscience</SO>
<YR>2015</YR>
<VL>6</VL>
<NO>1</NO>
<PG>150-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055742"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055741"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wierzbicki-2007" MODIFIED="2014-08-18 12:43:58 -0500" MODIFIED_BY="[Empty name]" NAME="Wierzbicki 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-18 12:43:58 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wierzbicki AS</AU>
<TI>Homocysteine and cardiovascular disease: a review of the evidence</TI>
<SO>Diabetes &amp; Vascular Disease Research</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>2</NO>
<PG>143-50</PG>
<IDENTIFIERS MODIFIED="2014-08-18 12:42:38 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055744"/><IDENTIFIER TYPE="PUBMED" VALUE="17654449"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055743"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wise-2015" MODIFIED="2016-02-18 16:46:12 -0600" MODIFIED_BY="[Empty name]" NAME="Wise 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-02-18 16:46:12 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wise J</AU>
<TI>Folic acid significantly reduces risk of first stroke, large Chinese study finds</TI>
<SO>BMJ</SO>
<YR>2015</YR>
<VL>350</VL>
<PG>h1461</PG>
<IDENTIFIERS MODIFIED="2016-02-18 16:45:36 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055746"/><IDENTIFIER TYPE="PUBMED" VALUE="25778787"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055745"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2012" MODIFIED="2014-07-09 11:55:00 -0500" MODIFIED_BY="[Empty name]" NAME="Yang 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-07-09 11:55:00 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang HT, Lee M, Hong KS, Ovbiagele B, Saver JL</AU>
<TI>Efficacy of folic acid supplementation in cardiovascular disease prevention: an updated meta-analysis of randomized controlled trials</TI>
<SO>European Journal of Internal Medicine</SO>
<YR>2012</YR>
<VL>23</VL>
<NO>8</NO>
<PG>745-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055748"/><IDENTIFIER TYPE="PUBMED" VALUE="22884409"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055747"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yi-2014" MODIFIED="2016-02-18 16:32:23 -0600" MODIFIED_BY="[Empty name]" NAME="Yi 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-02-18 16:32:23 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yi X, Zhou Y, Jiang D, Li X, Guo Y, Jiang X</AU>
<TI>Efficacy of folic acid supplementation on endothelial function and plasma homocysteine concentration in coronary artery disease: A meta-analysis of randomized controlled trials</TI>
<SO>Experimental and Therapeutic Medicine</SO>
<YR>2014</YR>
<VL>7</VL>
<NO>5</NO>
<PG>1100-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055750"/><IDENTIFIER TYPE="PUBMED" VALUE="24940394"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055749"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zappacosta-2013" MODIFIED="2014-07-09 11:49:28 -0500" MODIFIED_BY="[Empty name]" NAME="Zappacosta 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-07-09 11:49:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zappacosta B, Mastroiacovo P, Persichilli S, Pounis G, Ruggeri S, Minucci A, et al</AU>
<TI>Homocysteine lowering by folate-rich diet or pharmacological supplementations in subjects with moderate hyperhomocysteinemia</TI>
<SO>Nutrients</SO>
<YR>2013</YR>
<VL>5</VL>
<NO>5</NO>
<PG>1531-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055752"/><IDENTIFIER TYPE="PUBMED" VALUE="23698160"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055751"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zeng-2015" MODIFIED="2016-02-18 16:24:14 -0600" MODIFIED_BY="[Empty name]" NAME="Zeng 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-02-18 16:24:14 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeng R, Xu CH, Xu YN, Wang YL, Wang M</AU>
<TI>The effect of folate fortification on folic acid-based homocysteine-lowering intervention and stroke risk: a meta-analysis</TI>
<SO>Public Health Nutrition</SO>
<YR>2015</YR>
<VL>18</VL>
<NO>8</NO>
<PG>1514-21</PG>
<IDENTIFIERS MODIFIED="2016-02-18 16:23:47 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055754"/><IDENTIFIER TYPE="PUBMED" VALUE="25323814"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055753"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2009" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Zhang 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang C, Zhu HL</AU>
<TI>Effect of B vitamins supplementation on cardiovascular and cerebrovascular disease by lowering plasma homocysteine concentration: a meta-analysis [Chinese]</TI>
<SO>Chinese Journal of Evidence-Based Medicine</SO>
<YR>2009</YR>
<VL>1</VL>
<PG>55-62</PG>
<IDENTIFIERS MODIFIED="2012-03-04 06:26:09 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055756"/><IDENTIFIER MODIFIED="2012-03-04 06:26:09 -0600" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISSN: 1672-2531"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055755"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2013" MODIFIED="2017-07-31 08:20:12 -0500" MODIFIED_BY="Heather Maxwell" NAME="Zhang 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-07-31 08:20:12 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang C, Chi FL, Xie TH, Zhou YH</AU>
<TI>Effect of B-vitamin supplementation on stroke: a meta-analysis of randomized controlled trials</TI>
<SO>PLOS One</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>11</NO>
<PG>e81577</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055758"/><IDENTIFIER TYPE="PUBMED" VALUE="24282609"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055757"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2014" MODIFIED="2017-07-31 08:20:26 -0500" MODIFIED_BY="Heather Maxwell" NAME="Zhang 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-07-31 08:20:26 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang C, Wang ZY, Qin YY, Yu FF, Zhou YH</AU>
<TI>Association between B vitamins supplementation and risk of cardiovascular outcomes: a cumulative meta-analysis of randomized controlled trials</TI>
<SO>PLOS One</SO>
<YR>2014</YR>
<VL>9</VL>
<NO>9</NO>
<PG>e107060</PG>
<IDENTIFIERS MODIFIED="2016-02-18 16:27:11 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055760"/><IDENTIFIER TYPE="PUBMED" VALUE="25238614"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055759"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2011" MODIFIED="2017-07-31 08:20:41 -0500" MODIFIED_BY="Heather Maxwell" NAME="Zhou 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-07-31 08:20:41 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou YH, Tang JY, Wu MJ, Lu J, Wei X, Qin YY, et al</AU>
<TI>Effect of folic acid supplementation on cardiovascular outcomes: a systematic review and meta-analysis</TI>
<SO>PLOS One</SO>
<YR>2011</YR>
<VL>6</VL>
<NO>9</NO>
<PG>e25142</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3055762"/><IDENTIFIER TYPE="PUBMED" VALUE="21980387"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055761"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2017-06-01 11:47:29 -0500" MODIFIED_BY="Arturo J Martí-Carvajal"/>
<ONGOING_STUDIES MODIFIED="2015-04-22 14:37:54 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01956786" MODIFIED="2015-04-22 14:37:54 -0500" MODIFIED_BY="[Empty name]" NAME="NCT01956786" YEAR="6786">
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3055763"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-08-07 19:03:19 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<ADDITIONAL_REFERENCES MODIFIED="2017-08-07 19:03:19 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<REFERENCE ID="REF-Bansilal-2015" MODIFIED="2017-01-10 11:15:14 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Bansilal 2015" TYPE="JOURNAL_ARTICLE">
<AU>Bansilal S, Castellano JM, Fuster V</AU>
<TI>Global burden of CVD: focus on secondary prevention of cardiovascular disease</TI>
<SO>International Journal of Cardiology</SO>
<YR>2015</YR>
<VL>201 Suppl 1</VL>
<PG>S1-7</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="26747389"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barquera-2015" MODIFIED="2017-01-10 11:19:39 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Barquera 2015" TYPE="JOURNAL_ARTICLE">
<AU>Barquera S, Pedroza-Tobias A, Medina C, Hernandez-Barrera L, Bibbins-Domingo K, Lozano R, et al</AU>
<TI>Global overview of the epidemiology of atherosclerotic cardiovascular disease</TI>
<SO>Archives of Medical Research</SO>
<YR>2015</YR>
<VL>46</VL>
<NO>5</NO>
<PG>328-38</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="26135634"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Benziger-2016" MODIFIED="2017-01-10 11:28:06 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Benziger 2016" TYPE="JOURNAL_ARTICLE">
<AU>Benziger CP, Roth GA, Moran AE</AU>
<TI>The Global burden of disease study and the preventable burden of NCD</TI>
<SO>Global Heart</SO>
<YR>2016</YR>
<VL>11</VL>
<NO>4</NO>
<PG>393-7</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="27938824"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bowman-2007" MODIFIED="2012-02-09 03:53:29 -0600" MODIFIED_BY="[Empty name]" NAME="Bowman 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bowman L, Armitage J, Bulbulia R, Parish S, Collins R; SEARCH Study Collaborative Group</AU>
<TI>Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors</TI>
<SO>American Heart Journal</SO>
<YR>2007</YR>
<VL>154</VL>
<NO>5</NO>
<PG>815-23, 823.e1-6</PG>
<IDENTIFIERS MODIFIED="2012-02-09 03:42:07 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="17967584"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brok-2008" MODIFIED="2012-08-31 13:37:35 -0500" MODIFIED_BY="[Empty name]" NAME="Brok 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Gluud C, Wetterslev J</AU>
<TI>Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>8</NO>
<PG>763-9</PG>
<IDENTIFIERS MODIFIED="2012-08-31 13:37:16 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="18411040"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brok-2009" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Brok 2009" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Wetterslev J, Gluud C</AU>
<TI>Apparently conclusive meta-analyses may be inconclusive--trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>287-98</PG>
<IDENTIFIERS MODIFIED="2012-08-31 13:31:54 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="18824466"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CAPRIE-1996" MODIFIED="2012-07-09 02:20:49 -0500" MODIFIED_BY="[Empty name]" NAME="CAPRIE 1996" TYPE="JOURNAL_ARTICLE">
<AU>No authors listed</AU>
<TI>A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<NO>9038</NO>
<PG>1329-39</PG>
<IDENTIFIERS MODIFIED="2012-07-09 02:20:47 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-07-09 02:20:47 -0500" MODIFIED_BY="Arturo J Marti-Carvajal" TYPE="PUBMED" VALUE="8918275"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Casas-2005" NAME="Casas 2005" TYPE="JOURNAL_ARTICLE">
<AU>Casas JP, Bautista LE, Smeeth L, Sharma, P, Hingorani AD</AU>
<TI>Homocysteine and stroke: evidence on a causal link from mendelian randomisation</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<PG>224-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2007" MODIFIED="2014-08-18 12:05:35 -0500" MODIFIED_BY="[Empty name]" NAME="Clarke 2007" TYPE="JOURNAL_ARTICLE">
<AU>Clarke R, Lewington S, Sherliker P, Armitage J</AU>
<TI>Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia</TI>
<SO>Current Opinion in Clinical Nutrition and Metabolic Care</SO>
<YR>2007</YR>
<VL>10</VL>
<PG>32-9</PG>
<IDENTIFIERS MODIFIED="2014-08-18 12:05:35 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-08-18 12:05:35 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17143052"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Crider-2011" MODIFIED="2012-09-04 12:07:56 -0500" MODIFIED_BY="[Empty name]" NAME="Crider 2011" TYPE="JOURNAL_ARTICLE">
<AU>Crider KS, Bailey LB, Berry RJ</AU>
<TI>Folic acid food fortification-its history, effect, concerns, and future directions</TI>
<SO>Nutrients</SO>
<YR>2011</YR>
<VL>3</VL>
<NO>3</NO>
<PG>370-84</PG>
<IDENTIFIERS MODIFIED="2012-09-04 12:07:54 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22254102"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CTU-2011" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="CTU 2011" TYPE="COMPUTER_PROGRAM">
<AU>Copenhagen Trial Unit</AU>
<TI>TSA - Trial Sequential Analysis</TI>
<YR>2011 (accessed 29 September 2011)</YR>
<PB>http://ctu.dk/tsa/</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cybulska-2015" MODIFIED="2017-01-10 10:23:13 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Cybulska 2015" TYPE="JOURNAL_ARTICLE">
<AU>Cybulska B, Klosiewicz-Latoszek L</AU>
<TI>Homocysteine--is it still an important risk factor for cardiovascular disease?</TI>
<SO>Kardiologia Polska</SO>
<YR>2015</YR>
<VL>73</VL>
<NO>11</NO>
<PG>1092-6</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="26726726"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Danesh-1998" MODIFIED="2014-08-18 12:06:11 -0500" MODIFIED_BY="[Empty name]" NAME="Danesh 1998" TYPE="JOURNAL_ARTICLE">
<AU>Danesh J, Lewington S</AU>
<TI>Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies</TI>
<SO>Journal of Cardiovascular Risk</SO>
<YR>1998</YR>
<VL>5</VL>
<PG>229-32</PG>
<IDENTIFIERS MODIFIED="2014-08-18 12:06:11 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-08-18 12:06:11 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9919470"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-di-Salvo-2011" MODIFIED="2012-09-04 12:41:57 -0500" MODIFIED_BY="[Empty name]" NAME="di Salvo 2011" TYPE="JOURNAL_ARTICLE">
<AU>di Salvo ML, Contestabile R, Safo MK</AU>
<TI>Vitamin B(6) salvage enzymes: mechanism, structure and regulation</TI>
<SO>Biochimica et Biophysica Acta</SO>
<YR>2011</YR>
<VL>1814</VL>
<NO>11</NO>
<PG>1597-608</PG>
<IDENTIFIERS MODIFIED="2012-09-04 12:41:21 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21182989"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-di-Salvo-2012" MODIFIED="2012-09-04 12:42:18 -0500" MODIFIED_BY="[Empty name]" NAME="di Salvo 2012" TYPE="JOURNAL_ARTICLE">
<AU>di Salvo ML, Safo MK, Contestabile R</AU>
<TI>Biomedical aspects of pyridoxal 5'-phosphate availability</TI>
<SO>Frontiers in Bioscience</SO>
<YR>2012</YR>
<VL>4</VL>
<PG>897-913</PG>
<IDENTIFIERS MODIFIED="2012-09-04 12:41:21 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22201923"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dienes-2008" MODIFIED="2017-07-31 08:42:58 -0500" MODIFIED_BY="Heather Maxwell" NAME="Dienes 2008" TYPE="BOOK">
<AU>Dienes Z</AU>
<SO>Understanding Psychology as a Science: An Introduction to Scientific and Statistical Inference</SO>
<YR>2008</YR>
<EN>First</EN>
<PB>Palgrave Macmillan</PB>
<CY>London</CY>
<IDENTIFIERS MODIFIED="2017-01-11 08:07:25 -0600" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER MODIFIED="2017-01-11 08:07:25 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" TYPE="OTHER" VALUE="9780230542303"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dienes-2014" MODIFIED="2017-01-11 08:03:24 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Dienes 2014" TYPE="JOURNAL_ARTICLE">
<AU>Dienes Z</AU>
<TI>Using Bayes to get the most out of non-significant results</TI>
<SO>Frontiers in Psychology</SO>
<YR>2014</YR>
<VL>5</VL>
<PG>781</PG>
<IDENTIFIERS MODIFIED="2017-01-11 08:03:24 -0600" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER MODIFIED="2017-01-11 08:02:54 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" TYPE="DOI" VALUE="10.3389/fpsyg.2014.00781"/><IDENTIFIER MODIFIED="2017-01-11 08:03:24 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" TYPE="OTHER" VALUE="PMC4114196"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dienes-2017" MODIFIED="2017-08-07 18:53:21 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Dienes 2017" TYPE="JOURNAL_ARTICLE">
<AU>Dienes Z, Mclatchie N</AU>
<TI>Four reasons to prefer Bayesian analyses over significance testing</TI>
<SO>Psychonomic Bulletin and Review</SO>
<YR>2017</YR>
<VL>Mar 28</VL>
<PG>Epub ahead of print</PG>
<IDENTIFIERS MODIFIED="2017-08-07 18:51:55 -0500" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="28353065"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Eikelboom-1999" NAME="Eikelboom 1999" TYPE="JOURNAL_ARTICLE">
<AU>Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S</AU>
<TI>Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1999</YR>
<VL>131</VL>
<PG>363-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fedosov-2012" MODIFIED="2012-09-04 10:43:20 -0500" MODIFIED_BY="[Empty name]" NAME="Fedosov 2012" TYPE="JOURNAL_ARTICLE">
<AU>Fedosov SN</AU>
<TI>Physiological and molecular aspects of cobalamin transport</TI>
<SO>Sub-cellular Biochemistry</SO>
<YR>2012</YR>
<VL>56</VL>
<PG>347-67</PG>
<IDENTIFIERS MODIFIED="2012-09-04 10:42:47 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22116708"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ford-2002" MODIFIED="2014-08-18 12:06:34 -0500" MODIFIED_BY="[Empty name]" NAME="Ford 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB</AU>
<TI>Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>59-70</PG>
<IDENTIFIERS MODIFIED="2014-08-18 12:06:34 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-08-18 12:06:34 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11914295"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Friso-2012" MODIFIED="2012-09-04 13:11:11 -0500" MODIFIED_BY="[Empty name]" NAME="Friso 2012" TYPE="JOURNAL_ARTICLE">
<AU>Friso S, Lotto V, Corrocher R, Choi SW</AU>
<TI>Vitamin B6 and cardiovascular disease</TI>
<SO>Sub-cellular Biochemistry</SO>
<YR>2012</YR>
<VL>56</VL>
<PG>265-90</PG>
<IDENTIFIERS MODIFIED="2012-09-04 12:56:33 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22116704"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fuster-2015" MODIFIED="2016-09-13 14:38:08 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Fuster 2015" TYPE="JOURNAL_ARTICLE">
<AU>Fuster V</AU>
<TI>Unraveling the complexities of statistical presentation: Why it is important</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2015</YR>
<VL>66</VL>
<NO>25</NO>
<PG>2909-10</PG>
<IDENTIFIERS MODIFIED="2016-09-13 14:36:49 -0500" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="26718679"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ganguly-2015" MODIFIED="2017-01-06 15:31:16 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Ganguly 2015" TYPE="JOURNAL_ARTICLE">
<AU>Ganguly P, Alam SF</AU>
<TI>Role of homocysteine in the development of cardiovascular disease</TI>
<SO>Nutrition Journal</SO>
<YR>2015</YR>
<VL>14</VL>
<PG>6</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="25577237"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goff-2014" MODIFIED="2017-01-10 10:44:55 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Goff 2014" TYPE="JOURNAL_ARTICLE">
<AU>Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, et al</AU>
<TI>2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2014</YR>
<VL>63</VL>
<NO>25 Pt B</NO>
<PG>2935-59</PG>
<IDENTIFIERS MODIFIED="2017-01-10 10:44:53 -0600" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="24239921"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goodman-1999" MODIFIED="2017-01-11 08:13:14 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Goodman 1999" TYPE="JOURNAL_ARTICLE">
<AU>Goodman SN</AU>
<TI>Toward evidence-based medical statistics. 2: The Bayes factor</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1999</YR>
<VL>130</VL>
<NO>12</NO>
<PG>1005-13</PG>
<IDENTIFIERS MODIFIED="2017-01-11 08:12:16 -0600" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="10383350"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goodman-2005" MODIFIED="2017-01-11 08:13:32 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Goodman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Goodman SN</AU>
<TI>Introduction to Bayesian methods I: measuring the strength of evidence</TI>
<SO>Clinical Trials</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>4</NO>
<PG>282-90; discussion 301-4, 364-78</PG>
<IDENTIFIERS MODIFIED="2017-01-11 08:12:37 -0600" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="16281426"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gori-2007" MODIFIED="2014-08-18 14:32:17 -0500" MODIFIED_BY="[Empty name]" NAME="Gori 2007" TYPE="JOURNAL_ARTICLE">
<AU>Gori AM, Sofi F, Marcucci R, Giusti B, Franco Gensini G, Abbate R</AU>
<TI>Association between homocysteine, vitamin B(6) concentrations and inflammation</TI>
<SO>Clinical Chemistry and Laboratory Medicine</SO>
<YR>2007</YR>
<VL>45</VL>
<PG>1728-36</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:32:17 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-08-18 14:32:17 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17990948"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2008" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2008" TYPE="COMPUTER_PROGRAM">
<AU>Brozek J, Oxman A, Schünemann H</AU>
<TI>GRADEpro</TI>
<YR>2008</YR>
<EN>3.2 for Windows</EN>
<PB>The GRADE Working Group</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guthikonda-2006" NAME="Guthikonda 2006" TYPE="JOURNAL_ARTICLE">
<AU>Guthikonda S, Haynes WG</AU>
<TI>Homocysteine: role and implications in atherosclerosis</TI>
<SO>Current Atherosclerosis Reports</SO>
<YR>2006</YR>
<VL>8</VL>
<PG>100-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2017-03-21 11:38:27 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS MODIFIED="2017-03-21 11:37:57 -0500" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="18436948"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011" MODIFIED="2014-08-18 14:16:07 -0500" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al</AU>
<TI>GRADE guidelines: 2. Framing the question and deciding on important outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>395-400</PG>
<IDENTIFIERS MODIFIED="2012-02-09 13:51:55 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21194891"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013" MODIFIED="2017-03-21 11:41:51 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Guyatt 2013" TYPE="OTHER">
<AU>Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al</AU>
<TI>GRADE guidelines 12. Preparing summary of findings tables-binary outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>2</NO>
<PG>158-72</PG>
<IDENTIFIERS MODIFIED="2012-08-31 13:30:32 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-08-31 13:30:32 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22609141"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hannibal-2016" MODIFIED="2017-01-11 09:52:03 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Hannibal 2016" TYPE="JOURNAL_ARTICLE">
<AU>Hannibal L, Blom HJ</AU>
<TI>Homocysteine and disease: Causal associations or epiphenomenons?</TI>
<SO>Molecular Aspects of Medicine</SO>
<YR>2016</YR>
<VL>Nov 19</VL>
<PG>in press</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="27876556"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Herrmann-2012" MODIFIED="2012-09-04 11:18:21 -0500" MODIFIED_BY="[Empty name]" NAME="Herrmann 2012" TYPE="JOURNAL_ARTICLE">
<AU>Herrmann W, Obeid R</AU>
<TI>Cobalamin deficiency</TI>
<SO>Sub-cellular Biochemistry</SO>
<YR>2012</YR>
<VL>56</VL>
<PG>301-22</PG>
<IDENTIFIERS MODIFIED="2012-09-04 11:17:45 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22116706"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-HLTC-2005" NAME="HLTC 2005" TYPE="JOURNAL_ARTICLE">
<AU>Homocysteine Lowering Trialists' Collaboration</AU>
<TI>Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2005</YR>
<VL>82</VL>
<PG>806-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-HSC-2002" NAME="HSC 2002" TYPE="JOURNAL_ARTICLE">
<AU>Homocysteine Studies Collaboration</AU>
<TI>Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<PG>2015-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" NAME="ICH-GCP 1997" TYPE="BOOK">
<AU>International Committee on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use</AU>
<SO>Code of Federal Regulations &amp; International Conference on Harmonisation Guidelines</SO>
<YR>1997</YR>
<PB>Barnett International/PAREXEL</PB>
<CY>Philadelphia, US</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2010" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Ioannidis 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP</AU>
<TI>Meta-research: the art of getting it wrong</TI>
<SO>Research Synthesis Methods</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>3-4</NO>
<PG>169-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacobsen-2005" NAME="Jacobsen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Jacobsen DW, Catanescu O, Dibello PM, Barbato JC</AU>
<TI>Molecular targeting by homocysteine: a mechanism for vascular pathogenesis</TI>
<SO>Clinical Chemistry &amp; Laboratory Medicine</SO>
<YR>2005</YR>
<VL>43</VL>
<PG>1076-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jakobsen-2014" MODIFIED="2017-01-11 08:11:37 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Jakobsen 2014" TYPE="JOURNAL_ARTICLE">
<AU>Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C</AU>
<TI>Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2014</YR>
<VL>14</VL>
<PG>120</PG>
<IDENTIFIERS MODIFIED="2017-01-11 08:10:56 -0600" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="25416419"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jamison-2007" MODIFIED="2012-11-21 04:23:46 -0600" MODIFIED_BY="[Empty name]" NAME="Jamison 2007" TYPE="JOURNAL_ARTICLE">
<AU>Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, et al</AU>
<TI>Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>298</VL>
<NO>10</NO>
<PG>1163-70</PG>
<IDENTIFIERS MODIFIED="2012-10-26 11:57:49 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="17848650"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Joseph-2013" MODIFIED="2014-07-11 13:25:19 -0500" MODIFIED_BY="[Empty name]" NAME="Joseph 2013" TYPE="JOURNAL_ARTICLE">
<AU>Joseph J, Loscalzo J</AU>
<TI>Methoxistasis: integrating the roles of homocysteine and folic acid in cardiovascular pathobiology</TI>
<SO>Nutrients</SO>
<YR>2013</YR>
<VL>5</VL>
<NO>8</NO>
<PG>3235-56</PG>
<IDENTIFIERS MODIFIED="2014-07-11 13:25:13 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23955381"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kardesoglu-2011" MODIFIED="2012-03-02 06:18:58 -0600" MODIFIED_BY="[Empty name]" NAME="Kardesoglu 2011" TYPE="JOURNAL_ARTICLE">
<AU>Kardesoglu E, Uz O, Isilak Z, Cebeci BS</AU>
<TI>Homocysteine as a new risk factor for cardiovascular events in heart failure</TI>
<SO>International Journal of Cardiology</SO>
<YR>2011</YR>
<VL>146</VL>
<NO>1</NO>
<PG>126-7</PG>
<IDENTIFIERS MODIFIED="2012-03-02 06:18:11 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-03-02 06:18:11 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 21074871"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kr_x00e4_utler-2012" MODIFIED="2012-09-04 11:12:16 -0500" MODIFIED_BY="[Empty name]" NAME="Kräutler 2012" TYPE="JOURNAL_ARTICLE">
<AU>Kräutler B</AU>
<TI>Biochemistry of B12-cofactors in human metabolism</TI>
<SO>Sub-cellular Biochemistry</SO>
<YR>2012</YR>
<VL>56</VL>
<PG>323-46</PG>
<IDENTIFIERS MODIFIED="2012-09-04 11:11:13 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22116707"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kwan-2016" MODIFIED="2017-01-10 11:31:16 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Kwan 2016" TYPE="JOURNAL_ARTICLE">
<AU>Kwan GF, Mayosi BM, Mocumbi AO, Miranda JJ, Ezzati M, Jain Y, et al</AU>
<TI>Endemic cardiovascular diseases of the poorest billion</TI>
<SO>Circulation</SO>
<YR>2016</YR>
<VL>133</VL>
<NO>24</NO>
<PG>2561-75</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="27297348"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lackland-2015" MODIFIED="2017-07-31 08:47:10 -0500" MODIFIED_BY="Heather Maxwell" NAME="Lackland 2015" TYPE="OTHER">
<AU>Lackland DT, Weber MA</AU>
<TI>Global burden of cardiovascular disease and stroke: hypertension at the core</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>2015</YR>
<VL>31</VL>
<NO>5</NO>
<PG>569-71</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="25795106"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lai-2015b" MODIFIED="2017-01-06 15:48:20 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Lai 2015b" TYPE="JOURNAL_ARTICLE">
<AU>Lai WK, Kan MY</AU>
<TI>Homocysteine-induced endothelial dysfunction</TI>
<SO>Annals of Nutrition &amp; Metabolism</SO>
<YR>2015</YR>
<VL>67</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="26201664"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Laupacis-1988" MODIFIED="2016-09-14 11:41:32 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Laupacis 1988" TYPE="JOURNAL_ARTICLE">
<AU>Laupacis A, Sackett DL, Roberts RS</AU>
<TI>An assessment of clinically useful measures of the consequences of treatment</TI>
<SO>New England Journal of Medicine</SO>
<YR>1988</YR>
<VL>318</VL>
<NO>26</NO>
<PG>1728-33</PG>
<IDENTIFIERS MODIFIED="2016-09-14 11:40:31 -0500" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="3374545"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>In: Higgins JPT, Green S(editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-2016" MODIFIED="2017-01-10 11:36:52 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Li 2016" TYPE="JOURNAL_ARTICLE">
<AU>Li Y, Wang DD, Ley SH, Howard AG, He Y, Lu Y, et al</AU>
<TI>Potential impact of time trend of life-style factors on cardiovascular disease burden in China</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2016</YR>
<VL>68</VL>
<NO>8</NO>
<PG>818-33</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="27539174"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Maredza-2015" MODIFIED="2017-01-10 11:40:34 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Maredza 2015" TYPE="JOURNAL_ARTICLE">
<AU>Maredza M, Bertram MY, Tollman SM</AU>
<TI>Disease burden of stroke in rural South Africa: an estimate of incidence, mortality and disability adjusted life years</TI>
<SO>BMC Neurology</SO>
<YR>2015</YR>
<VL>15</VL>
<PG>54</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="25880843"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Maron-2006" MODIFIED="2014-08-18 12:07:23 -0500" MODIFIED_BY="[Empty name]" NAME="Maron 2006" TYPE="JOURNAL_ARTICLE">
<AU>Maron BA, Loscalzo J</AU>
<TI>Homocysteine</TI>
<SO>Clinics in Laboratory Medicine</SO>
<YR>2006</YR>
<VL>26</VL>
<PG>591-609</PG>
<IDENTIFIERS MODIFIED="2014-08-18 12:07:23 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-08-18 12:07:23 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16938586"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Maron-2009" MODIFIED="2012-05-07 07:30:46 -0500" MODIFIED_BY="[Empty name]" NAME="Maron 2009" TYPE="JOURNAL_ARTICLE">
<AU>Maron BA, Loscalzo J</AU>
<TI>The treatment of hyperhomocysteinemia</TI>
<SO>Annual Review of Medicine</SO>
<YR>2009</YR>
<VL>60</VL>
<PG>39-54</PG>
<IDENTIFIERS MODIFIED="2012-05-07 07:30:46 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-05-07 07:30:46 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18729731"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McCully-2015a" MODIFIED="2016-09-14 15:16:17 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="McCully 2015a" TYPE="JOURNAL_ARTICLE">
<AU>McCully KS</AU>
<TI>Homocysteine and the pathogenesis of atherosclerosis</TI>
<SO>Expert Review of Clinical Pharmacology</SO>
<YR>2015</YR>
<VL>8</VL>
<NO>2</NO>
<PG>211-9</PG>
<IDENTIFIERS MODIFIED="2016-09-14 15:14:30 -0500" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="25653125"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McCully-2015b" MODIFIED="2016-09-14 15:16:30 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="McCully 2015b" TYPE="JOURNAL_ARTICLE">
<AU>McCully KS</AU>
<TI>Homocysteine metabolism, atherosclerosis, and diseases of aging</TI>
<SO>Comprehensive Physiology</SO>
<YR>2015</YR>
<VL>6</VL>
<NO>1</NO>
<PG>471-505</PG>
<IDENTIFIERS MODIFIED="2016-09-14 15:14:30 -0500" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="26756640"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Molloy-2012" MODIFIED="2012-11-21 04:17:41 -0600" MODIFIED_BY="[Empty name]" NAME="Molloy 2012" TYPE="JOURNAL_ARTICLE">
<AU>Molloy AM</AU>
<TI>Genetic aspects of folate metabolism</TI>
<SO>Sub-cellular Biochemistry</SO>
<YR>2012</YR>
<VL>56</VL>
<PG>105-30</PG>
<IDENTIFIERS MODIFIED="2012-09-04 11:44:41 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22116697"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mudd-2000" MODIFIED="2014-08-18 14:18:24 -0500" MODIFIED_BY="[Empty name]" NAME="Mudd 2000" TYPE="JOURNAL_ARTICLE">
<AU>Mudd SH, Finkelstein JD, Refsum H, Ueland PM, Malinow MR, Lentz SR, et al</AU>
<TI>Homocysteine and its disulfide derivatives: a suggested consensus terminology</TI>
<SO>Arteriosclerosis, Thrombosis, and Vascular Biology</SO>
<YR>2000</YR>
<VL>20</VL>
<PG>704-6</PG>
<IDENTIFIERS MODIFIED="2014-08-18 12:07:33 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-08-18 12:07:33 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10894806"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mukherjee-2011" MODIFIED="2012-09-04 12:32:49 -0500" MODIFIED_BY="[Empty name]" NAME="Mukherjee 2011" TYPE="JOURNAL_ARTICLE">
<AU>Mukherjee T, Hanes J, Tews I, Ealick SE, Begley TP</AU>
<TI>Pyridoxal phosphate: biosynthesis and catabolism</TI>
<SO>Biochimica et Biophysica Acta</SO>
<YR>2011</YR>
<VL>1814</VL>
<NO>11</NO>
<PG>1585-96</PG>
<IDENTIFIERS MODIFIED="2012-09-04 12:32:01 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21767669"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ohrvik-2011" MODIFIED="2012-09-04 11:54:04 -0500" MODIFIED_BY="[Empty name]" NAME="Ohrvik 2011" TYPE="JOURNAL_ARTICLE">
<AU>Ohrvik VE, Witthoft CM</AU>
<TI>Human folate bioavailability</TI>
<SO>Nutrients</SO>
<YR>2011</YR>
<VL>3</VL>
<NO>4</NO>
<PG>475-90</PG>
<IDENTIFIERS MODIFIED="2012-09-04 11:54:01 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22254106"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oliveira-2015" MODIFIED="2017-01-10 11:45:47 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Oliveira 2015" TYPE="JOURNAL_ARTICLE">
<AU>Oliveira GB, Avezum A, Roever L</AU>
<TI>Cardiovascular disease burden: evolving knowledge of risk factors in myocardial infarction and stroke through population-based research and perspectives in global prevention</TI>
<SO>Frontiers in Cardiovascular Medicine</SO>
<YR>2015</YR>
<VL>2</VL>
<PG>32</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="26664903"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Perk-2012" MODIFIED="2017-01-10 10:47:34 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Perk 2012" TYPE="JOURNAL_ARTICLE">
<AU>Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al</AU>
<TI>European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)</TI>
<SO>European Heart Journal</SO>
<YR>2012</YR>
<VL>33</VL>
<NO>13</NO>
<PG>1635-701</PG>
<IDENTIFIERS MODIFIED="2017-01-10 10:44:34 -0600" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="22555213"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Peters-2008" MODIFIED="2017-01-03 10:26:48 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Peters 2008" TYPE="JOURNAL_ARTICLE">
<AU>Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L</AU>
<TI>Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>10</NO>
<PG>991-6</PG>
<IDENTIFIERS MODIFIED="2017-01-03 10:26:14 -0600" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="18538991"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Prabhakaran-2016" MODIFIED="2017-01-10 11:47:07 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Prabhakaran 2016" TYPE="JOURNAL_ARTICLE">
<AU>Prabhakaran D, Jeemon P, Roy A</AU>
<TI>Cardiovascular diseases in India: current epidemiology and future directions</TI>
<SO>Circulation</SO>
<YR>2016</YR>
<VL>133</VL>
<NO>16</NO>
<PG>1605-20</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="27142605"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pushpakumar-2014" MODIFIED="2014-11-14 08:36:09 -0600" MODIFIED_BY="[Empty name]" NAME="Pushpakumar 2014" TYPE="JOURNAL_ARTICLE">
<AU>Pushpakumar S, Kundu S, Sen U</AU>
<TI>Endothelial dysfunction: the link between homocysteine and hydrogen sulfide</TI>
<SO>Current Medicinal Chemistry</SO>
<YR>2014</YR>
<VL>21</VL>
<NO>32</NO>
<PG>3662-72</PG>
<IDENTIFIERS MODIFIED="2014-11-14 08:35:24 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="25005183"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Refsum-1998" NAME="Refsum 1998" TYPE="JOURNAL_ARTICLE">
<AU>Refsum H, Ueland PM, Nygard O, Vollset SE</AU>
<TI>Homocysteine and cardiovascular disease</TI>
<SO>Annual Review of Medicine</SO>
<YR>1998</YR>
<VL>49</VL>
<PG>31-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roshanov-2017" MODIFIED="2017-08-07 19:03:19 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Roshanov 2017" TYPE="JOURNAL_ARTICLE">
<AU>Roshanov PS, Dennis BB, Pasic N, Garg AX, Walsh M</AU>
<TI>When is a meta-analysis conclusive? A guide to Trial Sequential Analysis with an example of remote ischemic preconditioning for renoprotection in patients undergoing cardiac surgery</TI>
<SO>Nephrology, Dialysis, Transplantation</SO>
<YR>2017</YR>
<VL>32</VL>
<NO>Suppl 2</NO>
<PG>23-30</PG>
<IDENTIFIERS MODIFIED="2017-08-07 18:30:26 -0500" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="28380638"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Roth-2015a" MODIFIED="2017-01-10 11:58:07 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Roth 2015a" TYPE="JOURNAL_ARTICLE">
<AU>Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al</AU>
<TI>Demographic and epidemiologic drivers of global cardiovascular mortality</TI>
<SO>New England journal of Medicine</SO>
<YR>2015</YR>
<VL>372</VL>
<NO>14</NO>
<PG>1333-41</PG>
<IDENTIFIERS MODIFIED="2017-01-10 11:57:35 -0600" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="25830423"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Roth-2015b" MODIFIED="2017-01-10 11:57:53 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Roth 2015b" TYPE="JOURNAL_ARTICLE">
<AU>Roth GA, Nguyen G, Forouzanfar MH, Mokdad AH, Naghavi M, Murray CJ</AU>
<TI>Estimates of global and regional premature cardiovascular mortality in 2025</TI>
<SO>Circulation</SO>
<YR>2015</YR>
<VL>132</VL>
<NO>13</NO>
<PG>1270-82</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="26408271"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Selhub-1993" MODIFIED="2014-08-18 14:36:28 -0500" MODIFIED_BY="[Empty name]" NAME="Selhub 1993" TYPE="JOURNAL_ARTICLE">
<AU>Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH</AU>
<TI>Vitamin status and intake as primary determinants of homocysteinemia in an elderly population</TI>
<SO>JAMA</SO>
<YR>1993</YR>
<VL>270</VL>
<PG>2693-8</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:36:28 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-08-18 14:36:28 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8133587"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shelhub-2008" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Shelhub 2008" TYPE="JOURNAL_ARTICLE">
<AU>Shelhub J</AU>
<TI>Public health significance of elevated homocysteine</TI>
<SO>Food and Nutrition Bulletin</SO>
<YR>2008</YR>
<VL>29 Suppl 2</VL>
<PG>116-25</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:35:38 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-08-18 14:35:38 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18709886"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Singh-2015" MODIFIED="2017-01-10 12:03:05 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Singh 2015" TYPE="JOURNAL_ARTICLE">
<AU>Singh GK, Siahpush M, Azuine RE, Williams SD</AU>
<TI>Widening socioeconomic and racial disparities in cardiovascular disease mortality in the United States, 1969-2013</TI>
<SO>International Journal of MCH and AIDS</SO>
<YR>2015</YR>
<VL>3</VL>
<NO>2</NO>
<PG>106-18</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="27621991"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Skovierova-2016" MODIFIED="2017-01-06 15:56:04 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Skovierova 2016" TYPE="JOURNAL_ARTICLE">
<AU>Skovierova H, Vidomanova E, Mahmood S, Sopkova J, Drgova A, Cervenova T, et al</AU>
<TI>The molecular and cellular effect of homocysteine metabolism imbalance on human health</TI>
<SO>International Journal of Molecular Sciences</SO>
<YR>2016</YR>
<VL>17</VL>
<NO>10</NO>
<PG>E1733</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="27775595"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smith-2012" MODIFIED="2017-01-10 11:10:01 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Smith 2012" TYPE="JOURNAL_ARTICLE">
<AU>Smith SC Jr, Collins A, Ferrari R, Holmes DR Jr, Logstrup S, McGhie DV, et al</AU>
<TI>Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke)</TI>
<SO>Global Heart</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>4</NO>
<PG>297-305</PG>
<IDENTIFIERS MODIFIED="2017-01-10 11:09:24 -0600" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="25689941"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sofi-2008" MODIFIED="2014-08-18 14:19:17 -0500" MODIFIED_BY="[Empty name]" NAME="Sofi 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sofi F, Marcucci R, Bolli P, Giambene B, Sodi A, Fedi S, et al</AU>
<TI>Low vitamin B6 and folic acid levels are associated with retinal vein occlusion independently of homocysteine levels</TI>
<SO>Atherosclerosis</SO>
<YR>2008</YR>
<VL>198</VL>
<PG>223-7</PG>
<IDENTIFIERS MODIFIED="2014-08-18 12:08:21 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-08-18 12:08:21 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17945240"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Splaver--2004" MODIFIED="2014-08-18 14:37:59 -0500" MODIFIED_BY="[Empty name]" NAME="Splaver  2004" TYPE="JOURNAL_ARTICLE">
<AU>Splaver A, Lamas GA, Hennekens CH</AU>
<TI>Homocysteine and cardiovascular disease: biological mechanism, observational epidemiology, and the need for randomised trials</TI>
<SO>American Heart Journal</SO>
<YR>2004</YR>
<VL>148</VL>
<PG>34-40</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:37:59 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-08-18 14:37:59 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15215789"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SSSS-1994" MODIFIED="2012-07-09 01:18:58 -0500" MODIFIED_BY="[Empty name]" NAME="SSSS 1994" TYPE="JOURNAL_ARTICLE">
<AU>No authors listed</AU>
<TI>Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>344</VL>
<NO>8934</NO>
<PG>1383-9</PG>
<IDENTIFIERS MODIFIED="2012-07-09 01:18:53 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-07-09 01:18:53 -0500" MODIFIED_BY="Arturo J Marti-Carvajal" TYPE="PUBMED" VALUE="7968073"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stampfer-1992" MODIFIED="2014-08-18 14:39:20 -0500" MODIFIED_BY="[Empty name]" NAME="Stampfer 1992" TYPE="JOURNAL_ARTICLE">
<AU>Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al</AU>
<TI>prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians</TI>
<SO>JAMA</SO>
<YR>1992</YR>
<VL>268</VL>
<PG>877-81</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:39:20 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-08-18 14:39:20 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1640615"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" MODIFIED="2017-01-03 10:52:34 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Sterne 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Egger M</AU>
<TI>Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis</TI>
<SO>Journal of clinical epidemiology</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>10</NO>
<PG>1046-55</PG>
<IDENTIFIERS MODIFIED="2017-01-03 10:52:32 -0600" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="11576817"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011a" MODIFIED="2017-01-03 10:49:58 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Sterne 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al</AU>
<TI>Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials</TI>
<SO>BMJ (Clinical research ed.)</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d4002</PG>
<IDENTIFIERS MODIFIED="2017-01-03 10:49:56 -0600" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="21784880"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011b" MODIFIED="2017-07-10 18:35:06 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Sterne 2011b" TYPE="BOOK_SECTION">
<AU>Sterne JAC, Egger M, Moher D (editors)</AU>
<TI>Chapter 10: Addressing reporting biases</TI>
<SO>Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). Available from www.cochrane-handbook.org</SO>
<YR>The Cochrane Collaboration, 2011</YR>
<PB>Wiley-Blackwell</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2009" MODIFIED="2014-08-18 14:19:41 -0500" MODIFIED_BY="[Empty name]" NAME="Thorlund 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al</AU>
<TI>Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>276-86</PG>
<IDENTIFIERS MODIFIED="2012-08-31 13:32:57 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="18824467"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2010" MODIFIED="2012-11-21 04:20:45 -0600" MODIFIED_BY="[Empty name]" NAME="Thorlund 2010" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Anema A, Mills E</AU>
<TI>Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals</TI>
<SO>Clinical Epidemiology</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>57-66</PG>
<IDENTIFIERS MODIFIED="2012-08-31 13:46:06 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="20865104"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2011" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Thorlund 2011" TYPE="OTHER">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>User manual for Trial Sequential Analysis (TSA)</TI>
<SO>http://ctu.dk/tsa/files/tsa_manual.pdf</SO>
<YR>2011 (accessed 30 April 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tzoulaki-2016" MODIFIED="2017-01-10 12:00:23 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Tzoulaki 2016" TYPE="JOURNAL_ARTICLE">
<AU>Tzoulaki I, Elliott P, Kontis V, Ezzati M</AU>
<TI>Worldwide exposures to cardiovascular risk factors and associated health effects: current knowledge and data gaps</TI>
<SO>Circulation</SO>
<YR>2016</YR>
<VL>133</VL>
<NO>23</NO>
<PG>2314-33</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="27267538"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vianna-2007" MODIFIED="2014-08-18 14:20:44 -0500" MODIFIED_BY="[Empty name]" NAME="Vianna 2007" TYPE="JOURNAL_ARTICLE">
<AU>Vianna AC, Mocelin AJ, Matsuo T, Morais-Filho D, Largura A, Delfino VA, et al</AU>
<TI>Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events</TI>
<SO>Hemodialysis International</SO>
<YR>2007</YR>
<VL>11</VL>
<PG>210-6</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:20:44 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-08-18 14:20:44 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 17403173"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vollset-2013" MODIFIED="2014-07-09 11:54:23 -0500" MODIFIED_BY="[Empty name]" NAME="Vollset 2013" TYPE="JOURNAL_ARTICLE">
<AU>Vollset SE, Clarke R, Lewington S, Ebbing M, Halsey J, Lonn E; B-Vitamin Treatment Trialists' Collaboration</AU>
<TI>Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals</TI>
<SO>Lancet</SO>
<YR>2013</YR>
<VL>381</VL>
<NO>9871</NO>
<PG>1029-36</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE=" 23352552"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wald-2002" MODIFIED="2014-08-18 14:25:15 -0500" MODIFIED_BY="[Empty name]" NAME="Wald 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wald DS, Law M, Morris JK</AU>
<TI>Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis</TI>
<SO>BMJ</SO>
<YR>2002</YR>
<VL>325</VL>
<PG>1202-6</PG>
<IDENTIFIERS MODIFIED="2014-08-18 14:25:15 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-08-18 14:25:15 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12446535"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Walsh-2014" MODIFIED="2017-07-31 08:53:10 -0500" MODIFIED_BY="Heather Maxwell" NAME="Walsh 2014" TYPE="JOURNAL_ARTICLE">
<AU>Walsh M, Srinathan SK, McAuley DF, Mrkobrada M, Levine O, Ribic C, et al</AU>
<TI>The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2014</YR>
<VL>67</VL>
<NO>6</NO>
<PG>622-8</PG>
<IDENTIFIERS MODIFIED="2017-01-08 16:51:31 -0600" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="24508144"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-2005" NAME="Wang 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wang H, Tan H, Yang F</AU>
<TI>Mechanisms in homocysteine-induced vascular disease</TI>
<SO>Drug Discovery Today: Disease Mechanisms</SO>
<YR>2005</YR>
<VL>2</VL>
<PG>25-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2012-08-31 13:40:00 -0500" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>1</NO>
<PG>64-75</PG>
<IDENTIFIERS MODIFIED="2012-08-31 13:33:39 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="18083463"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2012-08-31 13:41:01 -0500" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in random-effects model meta-analyses</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS MODIFIED="2012-08-31 13:34:03 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="20042080"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2017" MODIFIED="2017-03-21 13:18:47 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Wetterslev 2017" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Jakobsen JC, Gluud C</AU>
<TI>Trial sequential analysis in systematic reviews with meta-analysis</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2017</YR>
<VL>17</VL>
<NO>1</NO>
<PG>39</PG>
<IDENTIFIERS MODIFIED="2017-03-21 13:17:50 -0500" MODIFIED_BY="Arturo J Martí-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="28264661"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Williams-2010" MODIFIED="2012-03-04 06:19:34 -0600" MODIFIED_BY="[Empty name]" NAME="Williams 2010" TYPE="JOURNAL_ARTICLE">
<AU>Williams KT, Schalinske KL</AU>
<TI>Homocysteine metabolism and its relation to health and disease</TI>
<SO>Bifactors</SO>
<YR>2010</YR>
<VL>36</VL>
<NO>1</NO>
<PG>19-24</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="20091801"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wirakartakusumah-1998" MODIFIED="2009-04-07 04:01:27 -0500" MODIFIED_BY="[Empty name]" NAME="Wirakartakusumah 1998" TYPE="BOOK_SECTION">
<AU>Wirakartakusumah MA, Hariyadi P</AU>
<TI>Technical aspects of food fortification</TI>
<SO>Food and Nutrition Bulletin</SO>
<YR>1998</YR>
<VL>19</VL>
<PB>United Nations University Press, Tokyo, Japan</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2013" MODIFIED="2014-07-09 12:47:06 -0500" MODIFIED_BY="[Empty name]" NAME="Wu 2013" TYPE="JOURNAL_ARTICLE">
<AU>Wu Y, Huang Y, Hu Y, Zhong J, He Z, Li W, et al</AU>
<TI>Hyperhomocysteinemia is an independent risk factor in young patients with coronary artery disease in southern China</TI>
<SO>Herz</SO>
<YR>2013</YR>
<VL>38</VL>
<NO>7</NO>
<PG>779-84</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="23430091"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yeates-2015" MODIFIED="2017-01-10 12:05:04 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NAME="Yeates 2015" TYPE="JOURNAL_ARTICLE">
<AU>Yeates K, Lohfeld L, Sleeth J, Morales F, Rajkotia Y, Ogedegbe O</AU>
<TI>A global perspective on cardiovascular disease in vulnerable populations</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>2015</YR>
<VL>31</VL>
<NO>9</NO>
<PG>1081-93</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="26321432"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yetley-2011" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Yetley 2011" TYPE="JOURNAL_ARTICLE">
<AU>Yetley EA, Johnson CL</AU>
<TI>Folate and vitamin B-12 biomarkers in NHANES: history of their measurement and use</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2011</YR>
<VL>94</VL>
<NO>1</NO>
<PG>322S-31S</PG>
<IDENTIFIERS MODIFIED="2012-09-04 11:58:25 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21593508"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yusuf-2000" MODIFIED="2012-11-21 04:22:40 -0600" MODIFIED_BY="[Empty name]" NAME="Yusuf 2000" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G</AU>
<TI>Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<NO>3</NO>
<PG>145-53</PG>
<IDENTIFIERS MODIFIED="2012-02-09 05:49:55 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="10639539"/></IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-07-31 07:00:52 -0500" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2007" MODIFIED="2017-07-31 07:00:52 -0500" MODIFIED_BY="Heather Maxwell" NAME="Martí-Carvajal 2007" TYPE="COCHRANE_PROTOCOL">
<AU>Martí-Carvajal AJ, Salanti G, Hidalgo R, Ciapponi A</AU>
<TI>Homocysteine lowering interventions for preventing cardiovascular events</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2017-07-31 06:59:04 -0500" MODIFIED_BY="Heather Maxwell"><IDENTIFIER MODIFIED="2017-07-31 06:59:04 -0500" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD006612"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2009" MODIFIED="2017-07-31 06:56:08 -0500" MODIFIED_BY="Heather Maxwell" NAME="Martí-Carvajal 2009" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal AJ, Sola I, Lathyris D, Salanti G</AU>
<TI>Homocysteine lowering interventions for preventing cardiovascular events</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-07-19 14:20:58 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-07-19 14:20:58 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006612.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2013" MODIFIED="2017-07-31 06:54:59 -0500" MODIFIED_BY="Heather Maxwell" NAME="Martí-Carvajal 2013" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal AJ, Solà I, Lathyris D, Karakitsiou DE, Simancas-Racines D</AU>
<TI>Homocysteine-lowering interventions for preventing cardiovascular events</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-07-09 09:45:00 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-07-09 09:45:00 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006612.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2015" MODIFIED="2017-07-31 06:51:30 -0500" MODIFIED_BY="Heather Maxwell" NAME="Martí-Carvajal 2015" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal AJ, Sola I, Lathyris D</AU>
<TI>Homocysteine-lowering interventions for preventing cardiovascular events</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2017-07-31 06:51:09 -0500" MODIFIED_BY="Heather Maxwell"><IDENTIFIER MODIFIED="2017-07-31 06:50:38 -0500" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD006612.pub4"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2017-06-01 12:50:28 -0500" MODIFIED_BY="Arturo J Martí-Carvajal"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-08-07 11:14:39 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-08-07 11:13:04 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-08-02 10:05:57 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-B_x002d_PROOF-2015">
<CHAR_METHODS MODIFIED="2016-03-28 12:32:21 -0500" MODIFIED_BY="[Empty name]">
<P>Parallel design (2 arms</P>
<P>Multicentre study: yes (3 centres)<BR/>Country: The Netherlands<BR/>
</P>
<P>Follow-up period (years): 2</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-02 10:05:44 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Randomised:</B> 2919 (Original group of 'B-vitamins for the PRevention Of Osteoporotic Fractures')</P>
<OL>
<LI>Intervention: 1458</LI>
<LI>Placebo: 1461</LI>
</OL>
<P>The following data belong to subgroup analysis on cardiovascular events (named as 'Vascular subgroup' by trial authors).</P>
<P>
<B>Randomised:</B> 569</P>
<OL>
<LI>Intervention: 274</LI>
<LI>Placebo: 295</LI>
</OL>
<P>
<B>Age (Mean SD):</B>
</P>
<OL>
<LI>Intervention: 72.5 (5.8)</LI>
<LI>Placebo: 72.5 (5.3)</LI>
</OL>
<P>
<B>Gender (male %):</B>
</P>
<OL>
<LI>Intervention: 55.9</LI>
<LI>Placebo: 55.5</LI>
</OL>
<P>
<B>Homocysteine levels at baseline (median interquartile range ) (&#956;mol/L):</B>
</P>
<OL>
<LI>Intervention: 14.2 (13.0 to 16.3)</LI>
<LI>Placebo: 14.3 (13.0 to 16.6)</LI>
</OL>
<P>
<B>Self-reported cardiovascular medical history (intervention versus placebo):</B>
</P>
<OL>
<LI>MI: 6.1% vs 10.2%</LI>
<LI>Any type CVD: 21.0% vs 21.9%</LI>
<LI>Cerebrovascular event: 7.5% vs 8.4%</LI>
<LI>Hypercholesterolaemia: 25.1% vs 28.1%</LI>
<LI>Diabetes: 10.8% vs 12.0%</LI>
</OL>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Age &#8805; 65 years</LI>
<LI>Plasma Hcy level between 12.0 &#956;g/mol/L and 50.0 &#956;g/mol/L</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Serum creatinine level &gt;150 &#956;g mol/L</LI>
<LI>Cancer in the past 5 years (excluding non-melanoma skin cancer),</LI>
<LI>High doses of B-vitamins use (intramuscular injections of vitamin B12 and/or folic acid intake &gt; 300 &#956;g/day)</LI>
<LI>Permanent use of a wheel chair</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-02 08:29:14 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Experimental: 400 &#956;g folic acid and 500 &#956;g vitamin B12</LI>
<LI>Control: placebo</LI>
<LI>Co-intervention: 600 IU (15 &#956;g) of vitamin D3 daily</LI>
</OL>
<P>Treatment duration: two years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-02 10:05:57 -0500" MODIFIED_BY="Heather Maxwell">
<P>Outcomes related to vascular subgroup analysis:</P>
<OL>
<LI>Any type of CVD: MI, angina pectoris, heart failure, cardiac valvular disease, or arrhythmia.</LI>
<LI>Adverse events</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-02 08:29:55 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Identifier: Netherlands Trial Register NTR 1333 and NCT00696514</LI>
<LI>Conducted between August 2008 and March 2011</LI>
<LI>A priori sample estimation: yes</LI>
<LI>Financial disclosures: Two authors declared to have received an unconditional grant of Merck and Co for vitamin D assessment in Longitudinal Aging Study Amsterdam and one of them received personal fees from Merck and Co and Bristol-Myers Squibb.</LI>
<LI>Other disclosures: none</LI>
<LI>Funding/support: "supported and funded by The Netherlands Organization for Health Research and Development (ZonMw, Grant 6130.0031), the Hague; unrestricted grant from NZO (Dutch Dairy Association), Zoetermeer; Orthica, Almere; NCHA (Netherlands Consortium Healthy Ageing) Leiden/Rotterdam; Ministry of Economic Affairs, Agriculture, and Innovation (Project KB15-004-003), the Hague; Wageningen University, Wageningen; VU University Medical Center, Amsterdam; Erasmus Medical Center, Rotterdam." (Page 408).</LI>
<LI>Rol of sponsor: "The sponsors do not have any role in the design or implementation of the study, data collection, data management, data analysis, data interpretation, or in the preparation, review, or approval of the manuscript" (Page 408).</LI>
</OL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-02 10:07:26 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-BVAIT-2009">
<CHAR_METHODS MODIFIED="2016-03-28 12:32:47 -0500" MODIFIED_BY="[Empty name]">
<P>Parallel design</P>
<P>Multicentre study: yes<BR/>Country: USA<BR/>
</P>
<P>Follow-up period (years): B vitamins group (3.14 (0.48 to 4.56) versus placebo group (3.07 (0.46 to 5.0))<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-02 10:07:09 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Eligibility:</B> 5309</P>
<P>
<B>Randomised:</B> 506 (254 vitamins versus 252 placebo)<BR/>
<B>Age (years):</B>
</P>
<OL>
<LI>Overall: 61.4</LI>
<LI>B vitamins group: 61.7 (10.1)</LI>
<LI>Placebo group: 61.1 (9.6)</LI>
</OL>
<P>
<B>Gender (men):</B>
</P>
<OL>
<LI>Overall: 61%</LI>
<LI>B vitamins group: 61%</LI>
<LI>Placebo group: 61%</LI>
</OL>
<P>
<BR/>
</P>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Men and postmenopausal women 40 years old</LI>
<LI>Fasting tHcy 8.5 mol/L</LI>
<LI>No clinical signs/symptoms of CVD</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Fasting triglycerides &gt; 5.64 mmol/L (500 mg/dL)</LI>
<LI>Diabetes mellitus or fasting serum glucose &gt; 6.99 mmol/L (126 mg/dL)</LI>
<LI>Systolic blood pressure &#8805; 160 mm Hg and/or diastolic blood pressure &#8805; 100 mm Hg</LI>
<LI>Untreated thyroid disease</LI>
<LI>Creatinine clearance &lt; 70 mL/min</LI>
<LI>Life-threatening illness with prognosis 5 years</LI>
<LI>Five alcoholic drinks daily</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-02 10:07:26 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>HLI-intervention: folic acid (5 mg), vitamin B12 (0.4 mg) and vitamin B6 (50 mg, daily supplementation</LI>
<LI>Control: placebo</LI>
<LI>Treatment duration: initial 2.5-year treatment period was extended on average 1 to 2 years</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-02 08:41:00 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Primary:</B>
</P>
<P>Rate of change in the right distal carotid artery intima media thickness</P>
<P>
<BR/>
<B>Secondary:</B>
</P>
<P>Changes in calcium in the coronary arteries and abdominal aorta</P>
<P>
<BR/>
<B>Safety:</B>
</P>
<OL>
<LI>Deaths</LI>
<LI>Cardiovascular events</LI>
<LI>Cerebrovascular events</LI>
<LI>Arterial revascularisation procedures</LI>
<LI>Cancers</LI>
<LI>Occurrence of white blood cell count below the laboratory normal limit (4000 cells/&#956;L)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-02 08:44:31 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Identifier: NCT00114400</LI>
<LI>Conducted between 6 November 2000 and 1 June 2006</LI>
<LI>A priori sample estimation: yes</LI>
</OL>
<OL>
<LI>Quote: "Sample size based on carotid artery intima media thickness progression required 176 subjects/arm to detect a moderate effect size of 0.30 at 0.05 significance (2-sided) with 0.80 power. A total of 506 subjects were recruited to accommodate anticipated dropouts and initiation of lipid-lowering medications on-trial." (page 731)</LI>
</OL>
<OL>
<LI>Financial disclosures: not reported</LI>
<LI>Other disclosures: none</LI>
<LI>Funding/support: Grant R01AG-17160 from the National Institute on Aging, National Institutes of Health. Leiner Health Products provided the B vitamin supplements and placebo</LI>
</OL>
<P>We sent an email to the main author of this trial in order to get the type cardiovascular event data by comparison group (4 March 2012)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-04 09:47:27 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CHAOS-2002">
<CHAR_METHODS MODIFIED="2015-04-17 09:05:52 -0500" MODIFIED_BY="[Empty name]">
<P>Parallel design</P>
<P>Multicentre study<BR/>Follow-up period: mean of 1.7 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-04 09:47:27 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised: </B>1882 participants randomised (folic acid: 942 versus placebo: 940 participants)<BR/>
<BR/>
</P>
<P>
<B>Gender:</B> not reported<BR/>
<BR/>
</P>
<P>
<B>Age: </B>not reported<BR/>
<BR/>
</P>
<P>
<B>Homocysteine levels at baseline:</B> (treatment group) (&#956;mol/L): 11.2 (6.9 &#956;mol/L)<BR/>
<BR/>
</P>
<P>
<B>Inclusion criteria:</B> (1 of the following):</P>
<OL>
<LI>Positive coronary angiogram</LI>
<LI>Admission with MI or unstable angina</LI>
</OL>
<P>
<B>Exclusion criteria:</B> not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-02 08:49:42 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Intervention: folic acid 5 mg per day</LI>
<LI>Control: placebo in addition to usual drugs</LI>
</OL>
<P>Treatment duration: 2 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Composite outcome: MI, revascularisation, death from cardiovascular cause</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-02 08:50:40 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Sponsors: not available</LI>
<LI>Other: data not yet fully published. Results in the table correspond to conference proceedings</LI>
</OL>
<P>Homocysteine levels were only collected in 2 participating centres</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-02 10:09:29 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-CSPPT-2015">
<CHAR_METHODS MODIFIED="2016-03-29 09:24:30 -0500" MODIFIED_BY="[Empty name]">
<P>Parallel design</P>
<P>Multicentre study (32 communities in Jiangsu and Anhui provinces in China)</P>
<P>Country: China</P>
<P>Run-in treatment: three weeks taken enalapril (10 mg) oral daily.<BR/>Follow-up period: 5 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-02 10:08:57 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Randomised: </B>20,702 adults with hypertension without history of stroke or MI</P>
<OL>
<LI>Enalapril plus folic acid: 10348</LI>
<LI>Enalapril: 10354</LI>
</OL>
<P>
<B>Age, mean (SD) years:</B>
</P>
<OL>
<LI>Enalapril plus folic acid: 60.0 (7.5)</LI>
<LI>Enalapril: 60.0 (7.6)</LI>
</OL>
<P>
<B>Gender (male):</B>
</P>
<OL>
<LI>Enalapril plus folic acid: 41.0</LI>
<LI>Enalapril: 41.1</LI>
</OL>
<P>
<B>Homocysteine, median (IQR), &#956;mol/L:</B>
</P>
<OL>
<LI>Enalapril plus folic acid: 12.5 (10.5-15.5)</LI>
<LI>Enalapril: 12.5 (10.5-15.5)</LI>
</OL>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Men and women aged 45 to 75 years</LI>
<LI>Hypertension (&#8805;140 mm Hg/&#8805; 90 mm Hg)</LI>
<LI>Taking an antihypertensive medication</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>History of physician diagnosed stroke, MI, heart failure, coronary revascularisation, or congenital heart disease</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-29 09:23:24 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>Experimental: enalapril, 10 mg and folic acid (0.8 mg) single-pill fixed combination</LI>
<LI>Control: enalapril maleate (10 mg) (Lameiya,Yabao Pharmaceutical)</LI>
</OL>
<P>Treatment duration (median 4.5 years)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-02 10:09:13 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Primary:</B>
</P>
<OL>
<LI>First stroke</LI>
</OL>
<P>
<B>Secondary:</B>
</P>
<OL>
<LI>First ischaemic stroke</LI>
<LI>First haemorrhagic stroke</LI>
<LI>MI</LI>
<LI>Composite of cardiovascular events: of cardiovascular death, MI, and stroke</LI>
<LI>All-cause death</LI>
</OL>
<P>
<B>Other outcome measures (Source:</B> <A HREF="http://clinicaltrials.gov/show/NCT00794885">NCT00794885</A>)</P>
<OL>
<LI>Malignant tumours (Neoplasms benign, malignant and unspecified)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-02 10:09:29 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Sample size estimation a priori: yes</LI>
<LI>Clinicaltrials.gov Identifier: <A HREF="http://clinicaltrials.gov/show/NCT00794885">NCT00794885</A>
</LI>
<LI>Trial conduction date: 19 May, 2008, to 24 August, 2013</LI>
<LI>Goverments and academic centres sponsor: yes</LI>
<LI>Drug company sponsor: yes (Shenzhen AUSA Pharmed Co Ltd)</LI>
<LI>Role of sponsor: "The funding organizations/sponsor participated in the study design but had no role in the conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication." (Page E10).</LI>
</OL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-02 10:10:07 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-FOLARDA-2004">
<CHAR_METHODS MODIFIED="2015-04-17 09:06:08 -0500" MODIFIED_BY="[Empty name]">
<P>Parallel design</P>
<P>Multicentre study</P>
<P>Country: The Netherlands<BR/>Follow-up period: 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-02 10:10:07 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Randomised: </B>283 randomised participants (folic acid: 140 versus standard care: 143)</P>
<P>
<BR/>
<B>Gender (% men): folic acid:</B> 69% versus standard care: 70%</P>
<P>
<BR/>
<B>Age (mean): </B>folic acid: 59 years versus standard care: 59</P>
<P>
<BR/>
<B>Homocysteine levels at baseline:</B> not reported</P>
<P>
<BR/>
<B>Inclusion criteria (1 of the following):</B>
</P>
<OL>
<LI>MI</LI>
<LI>Total cholesterol value at admission or within 24 hours after onset of symptoms: &gt; 6.5 &#956;mol/L (251 mg/dL)</LI>
<LI>Elevation of CK-MB at least 2 times upper the limit of normal function</LI>
<LI>Markedly increased chest pain lasting more than 30 minutes or classical ECG changes</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Age under 18 years,</LI>
<LI>Use of lipid-lowering agents within the previous 3 months</LI>
<LI>High triglyceride levels &gt; 4.5 &#956;mol/L</LI>
<LI>Known familial dyslipidaemia</LI>
<LI>Low vitamin B12 levels</LI>
<LI>Hyperhomocysteinaemia (total plasma homocysteine &gt; 18 &#956;mol/L) or a known disturbed methionine loading test (total plasma homocysteine &gt; 47 &#956;mol/L)</LI>
<LI>Severe renal failure (serum creatinine &gt; 180 &#956;mol/L)</LI>
<LI>Hepatic disease</LI>
<LI>Severe heart failure (New York Heart Association class IV)</LI>
<LI>Scheduled percutaneous coronary intervention or coronary artery bypass graft operation</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-02 08:57:44 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Intervention:</B>
</P>
<P>Folic acid: 5 mg per day<BR/>Treatment was initiated at least 1 day prior to hospital discharge, and no later of 14 days after the MI. The treatment continued for 1 year. participants in this group also received statin therapy (fluvastatin, 40 mg per day). The clinician had at their discretion the prescription of additional prophylactic medication (aspirin, beta-blocking agents and/or ACE inhibitors)</P>
<P>
<BR/>
<B>Control:</B>
</P>
<P>Standard care: statin therapy (fluvastatin, 40 mg per day). The clinician had at their discretion the prescription of additional prophylactic medication (aspirin, beta-blocking agents and/or ACE inhibitors)</P>
<P>
<BR/>
<B>Treatment duration:</B> 1 year</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<OL>
<LI>Cardiovascular death (sudden death, fatal recurrent MI, fatal stroke and other cardiovascular deaths)</LI>
<LI>Non-cardiovascular death</LI>
<LI>Recurrent MI</LI>
<LI>Recurrent ischaemia requiring hospitalisation or revascularisation</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-02 08:57:57 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Study phase: III</LI>
<LI>A priori sample estimation: sample size calculation to detect (80% power and 5% significance level) a 50% reduction in clinical events in that kind of participants, assuming a 1-year event rate of 30%. These numbers resulted in an estimation of 120 participants per group. Analyses conducted on ITT basis</LI>
<LI>Sponsors: AstraZeneca, The Netherlands, Working Group on Cardiovascular research, The Netherlands. One author is an Established Investigator of the Netherlands Heart Foundation</LI>
<LI>Other: author did not perform homocysteine-level measures during the study</LI>
</OL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-02 10:10:38 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-GOES-2003">
<CHAR_METHODS MODIFIED="2015-04-17 09:06:17 -0500" MODIFIED_BY="[Empty name]">
<P>Parallel design</P>
<P>Single-centre study</P>
<P>Country: The Netherlands<BR/>Follow-up period: 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-02 10:10:38 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Rndomised: </B>593 randomised participants (folic acid: 300 versus standard care: 293)</P>
<P>
<BR/>
<B>Gender (% men): </B>folic acid: 76% versus standard care: 80%</P>
<P>
<BR/>
<B>Age (mean SD): </B>folic acid: 64.9 (9.9) versus standard care: 65.5 (9.7)</P>
<P>
<BR/>
<B>Homocysteine levels at baseline: </B>not reported</P>
<P>
<BR/>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>MI</LI>
<LI>Coronary artery lesions (&gt; 60%) on coronary angiography</LI>
<LI>Percutaneous coronary intervention</LI>
<LI>Coronary artery bypass graft surgery</LI>
<LI>Participants had to be stable, with no invasive vascular procedures scheduled</LI>
<LI>Statin therapy for at least 3 months</LI>
<LI>Taking any form of vitamin B-containing medication, regularly or sporadically</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Age &lt; 18 years</LI>
<LI>History of low vitamin B12 levels</LI>
<LI>Therapy for hyperhomocysteinaemia</LI>
<LI>Severe renal failure, or any other treatment for renal disease</LI>
<LI>Hepatic disease</LI>
<LI>Severe heart failure (New York Heart Association functional class IV)</LI>
<LI>Serious illness that would exclude follow-up time of at least 3 years</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-02 09:01:31 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Intervention: folic acid: 0.5 mg per day</LI>
<LI>Control group: standard care</LI>
<LI>Intensive follow-up and treatment of risk factors, with counselling provided by a qualified nurse. Statin dosage was increased when necessary. Dietary counselling was provided and smoking discouraged</LI>
<LI>Treatment duration: not reported</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-02 09:00:56 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Primary (composite):</B>
</P>
<OL>
<LI>Composite: vascular death (sudden death, fatal recurrent MI, fatal stroke and other cardiovascular deaths)</LI>
<LI>Non-cardiovascular death</LI>
<LI>Recurrent acute coronary syndromes</LI>
<LI>Invasive coronary procedures</LI>
<LI>Cerebrovascular accident or transient ischaemic attack</LI>
<LI>Any other vascular surgery (carotid endarterectomy, abdominal aneurysmectomy, or peripheral vascular surgery including limb amputation for vascular reasons)</LI>
</OL>
<P>
<B>Secondary:</B>
</P>
<OL>
<LI>Hospitalisation for unstable angina</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-02 09:02:11 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Study phase: III</LI>
<LI>A priori sample size estimation: (80% power and 5% significance level) to detect a 50% reduction in clinical events in that type of patients, assuming a 2-year event rate of 15%. These numbers resulted in an estimation of 300 patients per group. Analyses conducted on ITT basis</LI>
<LI>Sponsors: trial with public funding (Stichting Paracard)</LI>
<LI>Other: the trial allowed the entry of patients taking vitamin B supplementation. These patients showed higher levels of serum folate and lower levels of homocysteine</LI>
</OL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-02 10:11:09 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-HOPE_x002d_2-2006">
<CHAR_METHODS MODIFIED="2015-04-17 09:06:26 -0500" MODIFIED_BY="[Empty name]">
<P>Parallel design</P>
<P>Multicentre international study (13 countries; 145 centres)<BR/>Follow-up period: 5 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-02 10:11:00 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Randomised: </B>5522 patients randomised (vitamin: 2758 versus placebo group: 2764 patients)<BR/>
<BR/>
</P>
<P>
<B>Gender (% men): </B>vitamin: 71.1% versus placebo: 72.4%</P>
<P>
<BR/>
<B>Age (mean SD):</B> vitamin: 68.8 (7.1) versus placebo: 68.9 ( 6.8)</P>
<P>
<BR/>
<B>Homocysteine level at baseline:</B> 12.2 &#956;mol/L (1.6 mg/L)</P>
<P>
<BR/>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Men and women aged &gt; 55 years</LI>
<LI>History of vascular disease (coronary, cerebrovascular or peripheral vascular) or diabetes and additional risk factors for atherosclerosis, irrespective of their homocysteine levels, from countries with mandatory folate fortification of food (Canada and the USA) and countries without mandatory folate fortification (Brazil, western Europe and Slovakia)</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Patients taking vitamin supplements containing more than 0.2 mg of folic acid per day</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-02 09:04:45 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Intervention:</B>
</P>
<OL>
<LI>Multivitamin therapy with 2.5 mg of folic acid, 50 mg of vitamin B6 and 1 mg of vitamin B12 per day</LI>
</OL>
<P>
<B>Control:</B>
</P>
<OL>
<LI>Matching placebo daily</LI>
</OL>
<P>
<B>Treatment duration:</B> 5 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-02 10:11:09 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Primary outcome (composite):</B>
</P>
<OL>
<LI>Death from cardiovascular causes, MI, stroke</LI>
<LI>Secondary outcomes:</LI>
<LI>Total ischaemic events (composite of death from cardiovascular causes, MI, stroke, hospitalisation for unstable angina and revascularisation)</LI>
<LI>Death from any cause</LI>
<LI>Hospitalisation for unstable angina or congestive heart failure</LI>
<LI>Revascularisation</LI>
<LI>Incidence and death for cancer</LI>
<LI>Other outcomes: transient ischaemic attacks, venous thromboembolic events, fractures</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-02 09:05:09 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Study phase: III, registered (ClinicalTrials.gov number NCT00106886)</LI>
<LI>Sample calculation a priori: yes. Sample size calculation to detect between a 17% and a 20% reduction (80% and 90% power, respectively) in the risk rate of the primary endpoint over 5 years of follow-up (assuming an annual event rate of 4% in the placebo group). These numbers resulted in an estimation of 5000 patients. Analyses conducted on ITT basis</LI>
<LI>Sponsors: public funding (Canadian Institutes of Health Research). The study medication was provide by Jamieson Laboratories. They were not involved in the design, execution, analysis or reporting of the trial results</LI>
</OL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-07 11:13:04 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" STUDY_ID="STD-Li-2015a">
<CHAR_METHODS MODIFIED="2016-02-19 14:00:13 -0600" MODIFIED_BY="[Empty name]">
<P>Parallel design</P>
<P>Multicentre study: not stated</P>
<P>Country: China<BR/>Follow-up period: 5 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-07 11:13:04 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<OL>
<LI>Elderly females with hypertensive emergencies and homocysteine (Hcy) (&gt;10 mol/L)</LI>
<LI>Randomised: 319</LI>
</OL>
<OL>
<LI>High-dose folic acid: 144</LI>
<LI>Low-dose folic acid: 136</LI>
</OL>
<P>
<B>Age: </B>&#8805; 65 year<BR/>
</P>
<P>
<BR/>
<B>Gender: </B>only female.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-02 10:23:10 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Intervention: high-dose folic acid: 0.8 mg/day</LI>
<LI>Control: low-dose folic acid: 0.4 mg/day</LI>
<LI>Co-intervention: salt restriction (&#8804;5 g/day) and vitamin B12 500 &#956;g/day.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-02 09:08:43 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Ischaemic stroke</LI>
<LI>Orthostatic hypotension</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-02 09:08:50 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Trial conduction date: June 2006 to June 2009</LI>
<LI>Sponsors: not available</LI>
<LI>Other: data not yet fully published. Results in the table correspond to conference proceedings</LI>
</OL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-04 09:47:32 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NORVIT-2006">
<CHAR_METHODS MODIFIED="2015-04-17 09:06:34 -0500" MODIFIED_BY="[Empty name]">
<P>Parallel design</P>
<P>Multicentre study</P>
<P>Country: Norway</P>
<P>Follow-up period: 3.5 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-04 09:47:32 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised: </B>3749 patients randomised (folic acid, vitamins B6 and B12: 937 versus folic acid, vitamin B12: 935 versus vitamin B6: 934 versus placebo: 943)</P>
<P>
<B>Gender (% men):</B>
</P>
<P>
<BR/>Folic acid, vitamins B6 and B12: 73%<BR/>Folic acid, vitamin B12: 74%<BR/>Vitamin B6: 73%<BR/>Placebo: 75%</P>
<P>
<BR/>
<B>Age (mean SD, years):</B>
</P>
<P>Folic acid, vitamins B6 and B12: 63.6 (11.9)<BR/>Folic acid, vitamin B12: 63.2 (11.6)<BR/>Vitamin B6: 62.5 (11.7)<BR/>Placebo: 62.6 (11.4)</P>
<P>
<BR/>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Men and women aged 30 to 85 years,</LI>
<LI>History of acute MI within 7 days before randomisation</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Co-existing disease associated with a life expectancy &lt; 4 years</LI>
<LI>Prescribed treatment with B vitamins or untreated vitamin B deficiency</LI>
<LI>Inability to follow the protocol, as judged by the investigator</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-02 09:11:26 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Intervention:</B>
</P>
<OL>
<LI>Folic acid (group 1): 0.8 mg; vitamin B12: 0.4 mg; vitamin B6: 40 mg per day</LI>
<LI>Folic acid (group 2): 0.8 mg; vitamin B12: 0.4 mg per day</LI>
<LI>Vitamin B6 (group 3): 40 mg per day</LI>
</OL>
<P>
<B>Control:</B> placebo</P>
<P>Medication was delivered in single capsules taken once per day. For the first 2 weeks after study entry patients in groups 1 and 2 received an additional folic acid dose (5 mg) per day, whereas the other 2 groups received placebo</P>
<P>
<BR/>
<B>Treatment duration:</B> not clearly described</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-02 10:13:56 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Primary outcome (composite):</B>
</P>
<OL>
<LI>Recurrent MI, stroke and sudden death attributed to CAD</LI>
</OL>
<P>
<B>Secondary outcomes:</B>
</P>
<OL>
<LI>MI</LI>
<LI>Unstable angina pectoris requiring hospitalisation</LI>
<LI>Coronary revascularisation with percutaneous coronary intervention or coronary artery bypass grafting</LI>
<LI>Stroke</LI>
<LI>Death from any cause</LI>
</OL>
<P>Incident cases of cancer</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-02 09:12:05 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Study phase: III, registered (ClinicalTrials.gov number NCT00266487)</LI>
<LI>A priori sample size estimation: yes. Sample size calculation to detect a 20% relative reduction in the rate of primary endpoint (assuming 25% of endpoints in the placebo group). These numbers resulted in an estimation of 3500 patients assuming 750 primary events</LI>
</OL>
<P>The calculation of the sample size was based on data from previous Scandinavian trials, assuming the 3-year rate of the primary endpoint would be 25% in the placebo group. The planned enrolment of 3500 patients, with an average follow-up of 3.0 years, was expected to result in 750 primary events and give the study statistical power of more than 90% to detect a 20% relative reduction in the rate of the primary endpoint, given a 2-sided alpha value of 0.05</P>
<OL>
<LI>Sponsors: public and governmental funding. Supported by the Norwegian Research Council, the Council on Health and Rehabilitation, the University of Tromso, the Norwegian Council on Cardiovascular Disease, the Northern Norway Regional Health Authority, the Norwegian Red Cross, the Foundation to Promote Research into Functional Vitamin B12 Deficiency and an unrestricted private donation. The study medication was provide by Alpharma. The sponsors had no role in the design, conduct or reporting of the study</LI>
</OL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-02 10:14:53 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-SEARCH-2010">
<CHAR_METHODS MODIFIED="2017-08-02 10:14:21 -0500" MODIFIED_BY="Heather Maxwell">
<P>Parallel design</P>
<P>Multicentre study (88 sites)<BR/>Country: UK<BR/>
</P>
<P>Follow-up period: 6.7 ± 1.5 person-years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-02 10:14:45 -0500" MODIFIED_BY="Heather Maxwell">
<P>Clinical condition: survivors of MI in secondary care hospitals</P>
<OL>
<LI>Potential participants invited by mail: 83,237</LI>
<LI>Attended screening visit: 34,780</LI>
<LI>Entered pre-randomisation run-in-phase: 19,190. Quote: "Run-in treatment involved placebo vitamin tablets (and 20 mg simvastatin daily, which allowed baseline lipid levels to be assessed after all participants had received the same statin therapy)" (page 2487)</LI>
<LI>Randomised: 12,064 (folic acid and B12: 6033 versus placebo: 6031)</LI>
</OL>
<P>
<B>Gender (% men):</B>
</P>
<P>Men: 10,012<BR/>Women: 2052</P>
<OL>
<LI>Folic acid and B12: 83%</LI>
<LI>Placebo: 83%</LI>
</OL>
<P>
<B>Age (at randomisation):</B>
</P>
<P>Mean (SD) age of 64.2 (8.9) years</P>
<P>Folic acid and vitamin B12:</P>
<OL>
<LI>&lt; 60 years: 31%</LI>
<LI>&#8805; 60 years to &lt; 70 years: 40%</LI>
<LI>&#8805; 70 years: 29%</LI>
</OL>
<P>
<B>Placebo:</B>
</P>
<OL>
<LI>&lt; 60 years: 31%</LI>
<LI>&#8805; 60 years to &lt; 70 years: 40%</LI>
<LI>&#8805; 70 years: 29%</LI>
</OL>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Men and women</LI>
<LI>Aged 18 to 80 years</LI>
<LI>History of MI</LI>
<LI>Had no clear indication for folic acid</LI>
<LI>Blood cholesterol levels of at least 135 mg/dL if already taking a statin medication or 174 mg/dL if not (to convert cholesterol to mmol/L, multiply by 0.0259)</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Chronic liver, renal or muscle disease</LI>
<LI>History of any cancer (except non-melanoma skin cancer)</LI>
<LI>Use of potentially interacting medications</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-02 09:13:36 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Intervention: 1 tablet daily containing 2 mg folic acid plus 1 mg vitamin B12</LI>
<LI>Control: placebo</LI>
</OL>
<P>Both medications were supplied in specially prepared calendar packs (and, separately, using a 2 x 2 factorial design, either 80 mg or 20 mg simvastatin daily)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-02 10:14:53 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Primary outcome (composite):</B>
</P>
<OL>
<LI>Incidence of first major vascular event, defined as non-fatal MI or death from CHD, fatal or non-fatal stroke, or any arterial revascularisation</LI>
</OL>
<P>
<B>Secondary outcomes:</B>
</P>
<OL>
<LI>Major vascular events in the first year after randomisation (when little difference was anticipated) and, separately, in the later years of the treatment period</LI>
<LI>Major vascular events among participants subdivided into 3 similar-sized groups with respect to blood homocysteine levels at the end of the pre-randomisation run-in period (before any study vitamin treatment had been taken)</LI>
<LI>Major vascular events in the presence of one or other of the allocated study simvastatin regimens</LI>
<LI>Major coronary events, defined as non-fatal MI, death from coronary disease, or coronary revascularisation</LI>
<LI>Any type of stroke (excluding transient ischaemic attacks)</LI>
</OL>
<P>
<B>Tertiary outcomes:</B>
</P>
<OL>
<LI>Total and cause-specific mortality (considering vascular and non-vascular causes separately)</LI>
<LI>Vascular mortality excluding the first year after randomisation</LI>
<LI>Coronary and non-coronary revascularisation separately</LI>
<LI>Confirmed haemorrhagic and other strokes separately</LI>
<LI>Pulmonary embolus</LI>
<LI>Total and site-specific cancers</LI>
<LI>Hospitalisations for various other causes</LI>
<LI>Adverse effects of treatment</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-02 09:15:18 -0500" MODIFIED_BY="Heather Maxwell">
<P>Identifier: ISRCTN 74348595</P>
<P>Reason for a pre-randomisation run-in phase: to limit subsequent randomisation to those likely to take the randomly allocated study treatment for several years (page 2487)</P>
<P>Conducted between September 1998 and June 2008</P>
<P>
<B>A priori sample estimation: </B>yes</P>
<OL>
<LI>Quote: "It was prespecified in the protocol that the steering committee could modify the study plans while still blinded to the event rates in each treatment group." (page 2488)</LI>
<LI>Quote: "in 2004, blind to interim results for clinical outcomes, the steering committee decided to change the primary outcome from major coronary events to major vascular events and to continue until at least 2800 patients had had a confirmed major vascular event in order to have 90% power at P.05 to detect a 10% reduction in risk." (page 2489)</LI>
<LI>Comment: assumptions for sample size estimation were based on Boushey 1995; <LINK REF="REF-Bowman-2007" TYPE="REFERENCE">Bowman 2007</LINK>; <LINK REF="REF-HSC-2002" TYPE="REFERENCE">HSC 2002</LINK> and <LINK REF="REF-SSSS-1994" TYPE="REFERENCE">SSSS 1994</LINK>
</LI>
</OL>
<OL>
<LI>Financial disclosures: reported</LI>
<LI>Funding/support: Quote: "The study was funded by Merck (manufacturers of simvastatin and suppliers of the vitamins). The CTSU also receives core support from the UK Medical Research Council and the British Heart Foundation." (page 2493)</LI>
<LI>Role of sponsors: Quote: "The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript. The University of Oxford acted as the sponsor of the study." (page 2493)</LI>
<LI>Additional information: http://www.searchinfo.org/SEARCH_protocol.pdf</LI>
</OL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-02 10:15:22 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-SU.FOL.OM3-2010">
<CHAR_METHODS MODIFIED="2016-03-28 12:33:53 -0500" MODIFIED_BY="[Empty name]">
<P>Parallel design</P>
<P>Multicentre study (257 sites)<BR/>Country: France<BR/>
</P>
<P>Follow-up period: median: 4.7 years; mean 4.2 (1.0) years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-02 10:15:11 -0500" MODIFIED_BY="Heather Maxwell">
<P>Clinical condition: patients with a history of ischaemic heart disease or stroke</P>
<OL>
<LI>Patients assessed for eligibility: 3374</LI>
<LI>Randomised: 2501 (B vitamins plus omega 3 fatty acids: 620, omega 3 fatty acids: 633, B vitamins: 622, and placebo: 626)</LI>
<LI>Complete follow-up: 2222 (89%)</LI>
</OL>
<P>
<B>Gender (% men):</B>
</P>
<P>Men: 1987<BR/>Women: 514</P>
<OL>
<LI>B vitamins plus omega 3 fatty acids: 79.5%</LI>
<LI>Omega 3 fatty acids: 79.2%</LI>
<LI>B vitamins: 79.9%</LI>
<LI>Placebo: 79.2%</LI>
</OL>
<P>
<B>Age:</B>
</P>
<P>Mean (SD) age of 60.9 (8.8) years.</P>
<OL>
<LI>B vitamins plus omega 3 fatty acids: 60.5 (53.9 to 68.9)</LI>
<LI>Omega 3 fatty acids: 60.41 (5.7 to 68.7)</LI>
<LI>B vitamins: 60.7 (54.7 to 68.3)</LI>
<LI>Placebo: 60.9 (54.5 to 68.1)</LI>
</OL>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Men and women</LI>
<LI>Aged 45 to 80 years</LI>
<LI>History of acute coronary or cerebral ischaemic event within the 12 months before randomisation</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Age (&lt; 45 years or &gt; 80 years)</LI>
<LI>Ill-defined diagnosis of CVD</LI>
<LI>Inability or unwillingness to comply with study treatment</LI>
<LI>Disease or treatment that might interfere with metabolism of homocysteine or omega 3 fatty acids, in particular methotrexate for treating cancer or rheumatoid arthritis and chronic renal failure (plasma creatinine concentration &gt; 200 mol/L or creatinine clearance &lt; 40 mL/min)</LI>
<LI>Individuals with transient ischaemic attacks</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-02 09:16:47 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Intervention: 1 tablet daily containing 5-methyltetrahydrofolate (560 &#956;g), vitamin B6 (3 mg) and B12 (20 &#956;g)</LI>
<LI>Control: placebo</LI>
</OL>
<P>Furthermore: supplement containing omega 3 polyunsaturated fatty acids (600 mg of eicosapentaenoic acid and docosahexaenoic acid at a ratio of 2:1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-02 10:15:22 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Primary outcome (composite):</B>
</P>
<OL>
<LI>First major cardiovascular event: non-fatal MI, ischaemic stroke or death from CVD (including fatal MI, stroke, sudden death (within 1 hour of onset of acute symptoms in the absence of violence or accident), aortic dissection, cardiac failure or other fatal event defined by the medical committee as having a cardiovascular cause)</LI>
</OL>
<P>
<B>Secondary outcomes:</B>
</P>
<OL>
<LI>Acute coronary syndrome without MI</LI>
<LI>Resuscitation from sudden death</LI>
<LI>Coronary artery bypass surgery</LI>
<LI>Coronary angioplasty</LI>
<LI>Cardiac failure</LI>
<LI>Ventricular arrhythmia</LI>
<LI>Supraventricular arrhythmia</LI>
<LI>Cardiac surgery of any kind, transient ischaemic attack</LI>
<LI>Deep vein thrombosis</LI>
<LI>Pulmonary embolism</LI>
<LI>Carotid surgery or carotid artery angioplasty</LI>
<LI>Peripheral arterial surgery or angioplasty</LI>
<LI>Any vascular procedure</LI>
<LI>Death from all causes</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-02 09:17:44 -0500" MODIFIED_BY="Heather Maxwell">
<P>Identifier: ISRCTN 41926726</P>
<P>Conducted between 1 February 2003 and 1 June 2007</P>
<P>
<B>A priori sample estimation: yes</B>
</P>
<OL>
<LI>Quote: "The sample size was calculated for the estimated eventrate of 0.087 in the placebo group, based on the event rates observed in previous trials in similar populations and in epidemiological studies. No interaction between B vitamins and omega 3 fatty acids was anticipated. The planned enrolment of 2500 participants with an average follow-up of five years was expected to have more than 90% power to detect a 10% reduction in the relative risk of major vascular events associated with B vitamins or omega 3 fatty acids and a 19% reduction for the combination of omega 3 fatty acids and B vitamins, given a two sided &#945; value of 0.05." (page 3)</LI>
</OL>
<P>Comment: assumptions were based on Galan et al (<LINK REF="REF-HSC-2002" TYPE="REFERENCE">HSC 2002</LINK>; <LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>; <LINK REF="REF-Yusuf-2000" TYPE="REFERENCE">Yusuf 2000</LINK>)</P>
<OL>
<LI>Competing interest: reported</LI>
<LI>Funding/support: Quote: "The SU.FOL.OM3 trial was supported by the French Ministry of Research (R02010JJ), Ministry of Health (DGS), Sodexo, Candia, Unilever, Danone, Roche Laboratory, Merck EPROVA GS, and Pierre Fabre Laboratory." (page 8)</LI>
<LI>The supplements were provided without charge by Merck Eprova AG (5-methyltetrahydrofolate), Roche Laboratory (vitamins B6 and B12), and Pierre Fabre (omega 3 fatty acids). The gelatin capsules were manufactured by Catalent Pharma Solutions (Beinheim, France) (page 2)</LI>
</OL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-04 09:47:33 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-VISP-2004">
<CHAR_METHODS MODIFIED="2016-03-28 09:57:15 -0500" MODIFIED_BY="[Empty name]">
<P>Parallel design</P>
<P>Country: USA, Canada and Scotland<BR/>Multicentre international<BR/>study Follow-up period: 2 years<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-02 09:18:43 -0500" MODIFIED_BY="Heather Maxwell">
<P>3680 randomised (high-dose: 1827 versus low-dose: 1853)</P>
<P>
<B>Age (mean SD):</B> high-dose: 66.4 (10.8) versus low-dose: 66.2 (10.8)</P>
<P>
<BR/>
<B>Gender (% men):</B> high-dose: 62.3% versus low-dose: 62.8%</P>
<P>
<BR/>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Non-disabling ischaemic stroke (Modified Rankin Stroke Scale 3): onset 120 days before randomisation. Focal neurological deficit of likely atherothrombotic origin, classified as ischaemic stroke by questionnaire/algorithm or confirmed as new cerebral infarction consistent with symptoms by cranial computed tomography or brain magnetic resonance imaging</LI>
<LI>Total homocysteine level 25th percentile for North American stroke population</LI>
<LI>Age: &#8805; 35 years</LI>
<LI>Accessibility for follow-up</LI>
<LI>Agreement to take study medication and not take other multivitamins or pills containing folic acid or vitamin B6</LI>
<LI>Written informed consent</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Potential sources of emboli (atrial fibrillation within 30 days of stroke, prosthetic cardiac valve, intracardiac thrombus or neoplasm, or valvular vegetation)</LI>
<LI>Other major neurological illness that would obscure evaluation of recurrent stroke</LI>
<LI>Life expectancy 2 years</LI>
<LI>Renal failure requiring dialysis</LI>
<LI>Untreated anaemia or untreated vitamin B12 deficiency</LI>
<LI>Systolic blood pressure 185 mm Hg or diastolic blood pressure 105 mm Hg on 2 readings 5 minutes apart at time of eligibility determination</LI>
<LI>Refractory depression, severe cognitive impairment, or alcoholism or other substance abuse</LI>
<LI>Use within the last 30 days of medications that affect total homocysteine level (methotrexate, tamoxifen, levodopa, niacin or phenytoin) or bile acid sequestrants that can decrease folate levels</LI>
<LI>Childbearing potential</LI>
<LI>Participation in another trial with active intervention</LI>
<LI>General anaesthesia or hospital stay of 3 days, any type of invasive cardiac instrumentation or endarterectomy, stent placement, thrombectomy or any other endovascular treatment of carotid artery within 30 days prior to randomisation or scheduled to be performed within 30 days after randomisation</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-04 09:47:33 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>High-dose multivitamin therapy</B>
</P>
<P>2.5 mg folic acid; 0.4 mg vitamin B12; 25 mg vitamin B6 per day</P>
<P>
<BR/>
<B>Low-dose multivitamin therapy</B>
</P>
<P>20 micrograms folic acid; 6 micrograms vitamin B12; 200 micrograms vitamin B6 per day</P>
<P>
<BR/>
<B>Co-interventions: </B>1. Risk factor control education 2. Aspirin (325 mg/day)</P>
<P>
<BR/>
<B>Duration of treatment:</B> not described</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-02 10:15:57 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Primary outcome:</B>
</P>
<OL>
<LI>Recurrent cerebral infarction</LI>
</OL>
<P>
<B>Secondary outcomes:</B>
</P>
<OL>
<LI>CHD, including: MI requiring hospitalisation; coronary revascularisation; and fatal CHD</LI>
<LI>Death</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-02 09:20:29 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Study phase: III</LI>
<LI>A priori sample size estimation: yes. Sample size calculation (80% power at 0.05 significance level for a 2-sided test) to detect a 30% reduction in the rate of primary endpoint over 2 years of follow-up (assuming 8% of events in the first year and 4% in the second year, with 20% losses to follow-up). These numbers resulted in an estimation of 1800 patients per group. Trialists planned up to 6 interim analyses</LI>
<LI>Sponsors: supported by the National Institute of Neurological Disorders and Stroke (grant RO1 NS34447). The study medication was provided by Roche Inc. They had no role in the design and conduct of the study; the collection, analysis and interpretation of the data; or the preparation, review or approval of the manuscript</LI>
</OL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-02 10:16:30 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-VITATOPS-2010">
<CHAR_METHODS MODIFIED="2016-03-28 12:34:12 -0500" MODIFIED_BY="[Empty name]">
<P>Parallel design</P>
<P>Multicentre study: 123 medical centres (20 countries) from 4 continents<BR/>Follow-up period (median and interquartile range, years): 3.4 (2.0 to 5.5)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-02 09:21:33 -0500" MODIFIED_BY="Heather Maxwell">
<P>8164 randomised<BR/>4089 received folic acid and vitamins B (B6 and B12)<BR/>4075 received placebo</P>
<P>
<BR/>
<B>Age (mean SD years):</B>
</P>
<OL>
<LI>Overall: 62.6 (12.5)</LI>
<LI>Vitamin: 62.5 (12.6)</LI>
<LI>Placebo:  62.6 (12.4)</LI>
</OL>
<P>
<B>Gender (men):</B>
</P>
<OL>
<LI>Overall: 64%</LI>
<LI>Vitamin: 64% (2614/4089)</LI>
<LI>Placebo: 64% (2604/4075)</LI>
</OL>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Stroke (ischaemic or haemorrhagic) or transient ischaemic attack (eye or brain), as defined by standard criteria, within the past 7 months</LI>
<LI>Patients with haemorrhagic stroke</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Taking folic acid, vitamin B6, vitamin B12 or a folate antagonist (e.g. methotrexate)</LI>
<LI>Pregnant or women of childbearing potential</LI>
<LI>Patients with limited life expectancy (e.g. because of ill health)</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-02 10:16:13 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Intervention:</B>
</P>
<OL>
<LI>Folic acid: 2 mg/day</LI>
<LI>Vitamin B<SUB>6</SUB>: 25 mg/day</LI>
<LI>Vitamin B<SUB>12</SUB>: 0.5 mg/day</LI>
</OL>
<P>
<B>Control:</B> placebo</P>
<P>
<BR/>
<B>Co-interventions:</B> not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-02 10:16:30 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Primary outcome (composite):</B> whichever occurred first</P>
<OL>
<LI>Non-fatal stroke</LI>
<LI>Non-fatal MI</LI>
<LI>Death from any vascular causes</LI>
</OL>
<P>
<B>Secondary outcomes:</B>
</P>
<OL>
<LI>Stroke (non-fatal or fatal)</LI>
<LI>MI (non-fatal or fatal)</LI>
<LI>Death from any vascular cause</LI>
<LI>Death from any cause</LI>
<LI>Revascularisation procedures</LI>
<LI>The composite of non-fatal stroke, non-fatal MI and death from any vascular cause</LI>
<LI>Revascularisation procedures of the coronary, cerebral or peripheral circulation</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-02 09:23:49 -0500" MODIFIED_BY="Heather Maxwell">
<P>Identifier numbers: NCT00097669 and ISRCTN74743444</P>
<P>Date of study: 19 November 1998 to 31 December 2008</P>
<OL>
<LI>A priori sample size estimation: yes. Quote: "equally sized intervention and placebo groups, a minimum follow-up of 6 months for the last patient to be randomly allocated, an annual primary outcome event rate of 8% in the placebo group, and a 15% decrease in the relative risk of the primary outcome among patients assigned to B vitamins (i.e., 6.8% per year) compared with placebo. For a type 1 error of 5% and type 2 error of 20%, and assuming a mean follow-up of 2 years, a sample size of 3982 patients was required in each treatment group." (page 857). Comment: assumption for estimating annual primary outcome event rate in the placebo groups was based on <LINK REF="REF-CAPRIE-1996" TYPE="REFERENCE">CAPRIE 1996</LINK>
</LI>
<LI>Sponsor: Australia National Health and Medical Research Council, UK Medical Research Council, Singapore Biomedical Research Council, Singapore National Medical Research Council, Australia National Heart Foundation, Royal Perth Hospital Medical Research Foundation and Health Department of Western Australia</LI>
<LI>Rol of Sponsor: "The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, the writing of the report, or in the decision to submit the paper for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication." (page 858)</LI>
<LI>Conflicts of interest: reported</LI>
<LI>Vitamin tablets and matching placebo tablets were supplied by Blackmores, Australia (page 864)</LI>
<LI>All investigator-reported outcomes and adverse events were audited by a masked adjudication committee (page 857)</LI>
</OL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-02 10:17:02 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-WAFACS-2008">
<CHAR_METHODS MODIFIED="2015-04-17 09:07:23 -0500" MODIFIED_BY="[Empty name]">
<P>Parallel design</P>
<P>Multicentre study</P>
<P>Country: USA<BR/>Follow-up period: 7.3 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-02 10:16:46 -0500" MODIFIED_BY="Heather Maxwell">
<P>N: 5442 randomised patients (vitamin group: 2721 patients; placebo group: 2721 patients)</P>
<P>
<BR/>
<B>Gender: </B>women health professionals</P>
<P>
<BR/>
<B>Age (mean (SD)) years:</B>
</P>
<P>Active group: 62.8 (8.8)<BR/>Control group: 62.8 (8.8)</P>
<P>
<BR/>
<B>Inclusion criteria</B>
</P>
<OL>
<LI>Women</LI>
<LI>Age: 40 years or older</LI>
<LI>Postmenopausal or had no intention of becoming pregnant</LI>
<LI>History of CVD or had at least 3 cardiac risk factors</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Cancer (excluding non-melanoma skin cancer) within the past 10 years</LI>
<LI>Serious non-CVD</LI>
<LI>Warfarin or other anticoagulants use</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-02 09:26:09 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Intervention:</B>
</P>
<P>Folic acid: 2.5 mg; vitamin B12: 1 mg; vitamin B6: 50 mg per day</P>
<P>
<BR/>
<B>Control:</B>
</P>
<P>Matching placebo per day</P>
<P>
<BR/>
<B>Co-interventions:</B> vitamin C, vitamin E, ß-carotene</P>
<P>
<BR/>
<B>Treatment duration:</B> not clearly reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-02 10:17:02 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Primary (composite):</B>
</P>
<OL>
<LI>Incident MI, stroke, coronary revascularisation procedures (coronary artery bypass grafting or percutaneous coronary intervention) and cardiovascular mortality</LI>
</OL>
<P>
<B>Secondary:</B>
</P>
<OL>
<LI>MI rate</LI>
<LI>Stroke rate</LI>
<LI>Total CHD events (MI, coronary revascularisation and death from CHD)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-02 09:27:17 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Study phase: III, registered (ClinicalTrials.gov number NCT00000541)</LI>
<LI>The information in this table was kindly supplied by Dr. Nancy Cook who was the statistician for the WACS and WAFACS studies (23 June 2008)</LI>
</OL>
<P>The WACS study was a 2 x 2 x 2 factorial trial of 3 antioxidants, vitamins C, E and beta-carotene. Randomisation of the 8171 participants into the 8 treatment groups took place from June 1995 to October 1996, and was conducted using blocks of size 16 within 5-year age groups. The folate/B6/B12 arm was added in April 1998, and the 5442 participants who were willing and eligible were randomised (at one time) using blocks of size 8 within strata defined by age and the other treatment arms. Participants were sent yearly supplies of calendar packs containing the study medications or matching placebo pills that were identical in appearance. All medical records were reviewed by an Endpoints Committee that was blinded to treatment assignment</P>
<OL>
<LI>A priori sample size estimation: sample size with 91.5% power to detect a 20% reduction in the primary endpoint (major vascular events). For the endpoints of total CHD (defined as non-fatal MI, CHD death or revascularisation), MI and stroke, the minimum detectable risk reduction with 80% power ranges from 19% to 32%. A 2-sided significance level of 0.05 was used</LI>
<LI>Sponsor: public funding and from several industry sources. Grant HL47959 from the National Heart, Lung, and Blood Institute of the National Institutes of Health. Vitamin E and its placebo were supplied by Cognis Corporation (La-Grange, Illinois)</LI>
<LI>All other agents and their placebos were supplied by BASF Corporation (Mount Olive,New Jersey). Pill packaging was provided by Cognis and BASF. They did not participate in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript</LI>
<LI>Other: the analyses of the endpoints were done only for these confirmed outcomes. However, there were an additional 43 recorded deaths for total mortality</LI>
</OL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-02 10:17:31 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-WENBIT-2008">
<CHAR_METHODS MODIFIED="2015-04-17 09:07:32 -0500" MODIFIED_BY="[Empty name]">
<P>Parallel design</P>
<P>Multicentre study</P>
<P>Country: Norway</P>
<P>Follow-up period: 4 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-02 10:17:19 -0500" MODIFIED_BY="Heather Maxwell">
<P>3096 patients randomised (folic acid, vitamins B6 and B12: 772 versus folic acid, vitamin B12: 772 versus vitamin B6: 772 versus placebo: 780)</P>
<P>
<BR/>
<B>Gender (% men):</B>
</P>
<OL>
<LI>Folic acid, vitamins B6 and B12: 81.2%</LI>
<LI>Folic acid, vitamin B12: 80.4%</LI>
<LI>Vitamin B6: 80.2%</LI>
<LI>Placebo: 76.5%</LI>
</OL>
<P>
<B>Age (mean SD, years):</B>
</P>
<OL>
<LI>Folic acid, vitamins B6 and B12: 61.7 (10.3)</LI>
<LI>Folic acid, vitamin B12: 61.3 (10.0)</LI>
<LI>Vitamin B6: 61.4 ( 9.7)</LI>
<LI>Placebo: 62.0 (9.9)</LI>
</OL>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Age: 18 years or older</LI>
<LI>Undergoing coronary angiography for suspected CAD and/or aortic valve stenosis at the 2 university hospitals in western Norway</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Unavailability for follow-up</LI>
<LI>Participation in other trials</LI>
<LI>History of alcohol abuse, serious mental illness or cancer</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-02 09:28:53 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Intervention:</B>
</P>
<OL>
<LI>Folic acid (group 1): 0.8 mg; vitamin B12: 0.4 mg; vitamin B6: 40 mg per day</LI>
<LI>Folic acid (group 2): 0.8 mg; vitamin B12: 0.4 mg per day</LI>
<LI>Vitamin B6 (group 3): 40 mg per day</LI>
</OL>
<P>
<B>Control: placebo</B>
</P>
<P>
<BR/>
<B>Co-interventions: </B>statins, insulin, aspirin, clopidogrel, beta-blockers, ACE inhibitors/ARBs, calcium channel blockers, loop diuretics, oral antidiabetics, medication for chronic obstructive pulmonary disease</P>
<P>
<BR/>
<B>Duration of treatment:</B> not described</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-02 10:17:31 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Primary outcome (composite):</B>
</P>
<OL>
<LI>All-cause death, non-fatal acute MI, acute hospitalisation for unstable angina pectoris and non-fatal thromboembolic stroke</LI>
</OL>
<P>
<B>Secondary outcomes:</B>
</P>
<OL>
<LI>Acute MI</LI>
<LI>Acute hospitalisation for angina pectoris</LI>
<LI>Stable angina pectoris with angiographically verified progression</LI>
<LI>Myocardial revascularisation procedures</LI>
<LI>Stroke</LI>
<LI>Incident cases of cancer</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-02 09:29:27 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Study phase: III, registered (ClinicalTrials.gov number NCT00354081)</LI>
<LI>A priori sample size estimation: sample of 3088 participants to detect a 20% reduction in the primary endpoint during 4 years of follow-up with a statistical power of 80% at a 2-sided significance level of 0.05</LI>
<LI>Sponsors: the Advanced Research Program and Research Council of Norway, the Norwegian Foundation for Health and Rehabilitation, the Norwegian Heart and Lung Patient Organisation, the Norwegian Ministry of Health and Care Services, the Western Norway Regional Health Authority, the Department of Heart Disease at Haukeland University Hospital, Locus for Homocysteine and Related Vitamins at the University of Bergen, Locus for Cardiac Research at the University of Bergen, the Foundation to Promote Research Into Functional Vitamin B12 Deficiency, Bergen, Norway, and Alpharma Inc, Copenhagen, Denmark</LI>
<LI>The study medication was provide by Alpharma, which had no access to study data and did not participate in data analysis or interpretation, or in the preparation, review or approval of the manuscript</LI>
<LI>Other: the first 90 participants were randomised before undergoing angiography in order to ensure no effects on blood indexes from the invasive procedure. Subsequent participants were randomised after baseline angiography</LI>
<LI>This trial was stopped due to no beneficial effects and a suggested increased risk of cancer from B vitamin treatment</LI>
</OL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACE: angiotensin-converting enzyme<BR/>ARB: angiotensin receptor blockers<BR/>CAD: coronary artery disease<BR/>CHD: coronary heart disease<BR/>CK-MB: creatine kinase-MB<BR/>CVD: cardiovascular disease<BR/>ECG: electrocardiogram<BR/>HLI: homocysteine-lowering interventions<BR/>IQR: interquartile range<BR/>ITT: intention-to-treat<BR/>IU: international units<BR/>MI: myocardial infarction<BR/>RCT: randomised controlled trial<BR/>SD: standard deviation<BR/>t-Hcy: total homocysteine</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-08-02 05:07:34 -0500" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2017-08-02 05:02:15 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Bahmani-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-02 05:02:15 -0500" MODIFIED_BY="Heather Maxwell">
<P>Randomised clinical trial that did not assess patient-oriented outcomes and excluded the pre-defined outcomes for this Cochrane review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-16 16:01:37 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bailey-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-16 16:01:37 -0600" MODIFIED_BY="[Empty name]">
<P>Observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-16 16:14:44 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baszczuk-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-16 16:14:44 -0600" MODIFIED_BY="[Empty name]">
<P>Narrative review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-16 16:18:04 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baszczuk-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-16 16:18:04 -0600" MODIFIED_BY="[Empty name]">
<P>Non randomised clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bazzano-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-16 16:11:08 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bobak-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-16 16:11:08 -0600" MODIFIED_BY="[Empty name]">
<P>Observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clarke-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cui-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-19 12:32:35 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Debreceni-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-19 12:32:35 -0600" MODIFIED_BY="[Empty name]">
<P>Narrative review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-19 12:37:16 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dell_x0027_edera-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-19 12:37:16 -0600" MODIFIED_BY="[Empty name]">
<P>Non randomised clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-02 05:03:41 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Deshmukh-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-02 05:03:41 -0500" MODIFIED_BY="Heather Maxwell">
<P>Randomised clinical trial that did not assess patient-oriented outcomes and excluded the pre-defined outcomes for this Cochrane review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-16 16:35:14 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dong-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-16 16:35:14 -0600" MODIFIED_BY="[Empty name]">
<P>Network meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-02 05:03:56 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Durga-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-02 05:03:56 -0500" MODIFIED_BY="Heather Maxwell">
<P>Randomised clinical trial that did not assess patient-oriented outcomes and excluded the pre-defined outcomes for this Cochrane review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Earnest-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with follow-up of less than 1 year</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ebbing-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Combined analyses of <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK> and <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ebbing-2009a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Combined analyses of <LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006 </LINK>and <LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-FINEST-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with follow-up of less than 1 year</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-18 14:21:55 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goel-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-18 14:21:55 -0600" MODIFIED_BY="[Empty name]">
<P>Comment on <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-02 05:04:20 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Green-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-02 05:04:20 -0500" MODIFIED_BY="Heather Maxwell">
<P>Randomised clinical trial that did not assess patient-oriented outcomes and excluded the pre-defined outcomes for this Cochrane review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Holmes-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Meta-analysis of genetic studies and randomised trials</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-02 05:04:37 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Huang-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-02 05:04:37 -0500" MODIFIED_BY="Heather Maxwell">
<P>Randomised clinical trial that did not assess patient-oriented outcomes and excluded the pre-defined outcomes for this Cochrane review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huo-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Imasa-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with follow-up of less than 1 year</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jardine-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review in people with kidney disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ji-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review of randomised clinical trials</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lange-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with follow-up of less than 1 year</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-18 14:47:50 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-18 14:47:50 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-18 14:53:12 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-18 14:53:12 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-18 15:22:17 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-18 15:22:17 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lonn-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Narrative review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mager-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manolescu-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Narrative review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mei-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review of randomised clinical trials including pre-existing cardio-cerebrovascular or renal disease patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-18 15:55:43 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mishchenko-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-18 15:55:43 -0600" MODIFIED_BY="[Empty name]">
<P>Pharmacoeconomic study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moghaddasi-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Case-control study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-M_x00e9_ndez_x002d_Gonz_x00e1_lez-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Narrative review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ntaios-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Narrative review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-02 05:05:58 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Ntaios-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-02 05:05:58 -0500" MODIFIED_BY="Heather Maxwell">
<P>Randomised clinical trial that did not assess patient-oriented outcomes such as was pre-defined for this Cochrane review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PACIFIC-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with follow-up of less than 1 year</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pan-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-18 16:04:14 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Park-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-18 16:04:14 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-18 15:58:49 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qin-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-18 15:58:49 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rautiainen-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-02 05:06:15 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Sharifi-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-02 05:06:15 -0500" MODIFIED_BY="Heather Maxwell">
<P>Randomised clinical trial that did not assess patient-oriented outcomes and excluded the pre-defined outcomes for this Cochrane review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-02 05:06:41 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Shidfar-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-02 05:06:41 -0500" MODIFIED_BY="Heather Maxwell">
<P>Randomised clinical trial that evaluated the effects of folate supplementation on lowering homocysteine levels and changes in total antioxidant capacity in asymptomatic hypercholesteraemic adults under lovastatin treatment. It did not include the pre-defined outcomes for this Cochrane review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sudchada-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swiss-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with follow-up of less than 1 year</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-02 05:06:58 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Tighe-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-02 05:06:58 -0500" MODIFIED_BY="Heather Maxwell">
<P>Randomised clinical trial that evaluated the effects of folate supplementation on lowering homocysteine levels. It did not include the pre-defined outcomes for this Cochrane review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vesin-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Narrative review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-02 05:07:14 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Wang-2015a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-02 05:07:14 -0500" MODIFIED_BY="Heather Maxwell">
<P>Randomised clinical trial that did not assess patient-oriented outcomes and excluded the pre-defined outcomes for this Cochrane review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-19 13:37:39 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2015b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-19 13:37:39 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wierzbicki-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Narrative review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-18 16:46:35 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wise-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-18 16:46:35 -0600" MODIFIED_BY="[Empty name]">
<P>Comment on <LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-18 16:33:07 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yi-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-18 16:33:07 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-02 05:07:34 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Zappacosta-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-02 05:07:34 -0500" MODIFIED_BY="Heather Maxwell">
<P>Randomised clinical trial that did not assess patient-oriented outcomes and excluded the pre-defined outcomes for this Cochrane review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-18 16:24:32 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zeng-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-18 16:24:32 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-02-18 16:27:53 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-18 16:27:53 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2017-06-01 11:47:29 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-08-07 11:14:39 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2017-08-07 11:14:39 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" STUDY_ID="STD-NCT01956786">
<CHAR_STUDY_NAME MODIFIED="2017-07-31 08:55:25 -0500" MODIFIED_BY="Heather Maxwell">
<P>Efficacy of amlodipine-folic acid tablets on reduction of blood pressure and plasma homocysteine</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-08-02 10:18:22 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Allocation: randomised.</LI>
<LI>Endpoint classification: safety/efficacy study.</LI>
<LI>Intervention model: parallel assignment.</LI>
<LI>Masking: double-blind (participant, caregiver, investigator, outcomes assessor).</LI>
<LI>Primary purpose: treatment.</LI>
<LI>Study phase:</LI>
<OL>
<LI>Phase 2</LI>
<LI>Phase 3</LI>
</OL>
</OL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-07 11:14:39 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>Age: 18 years to 75 years.</P>
<P>Gender: both.<BR/>Inclusion criteria:</P>
<OL>
<LI>Aged 18-75 years.</LI>
<LI>Sedentary systolic blood pressure between 140 mmHg and 180 mmHg, and/or sedentary diastolic blood pressure between 90 mmHg and 110 mmHg.</LI>
<LI>Plasma homocysteine &#8805; 10 &#956;mol/L.</LI>
<LI>Angiotension-converting enzyme inhibitor Intolerance.</LI>
<LI>Signed the written informed consent.</LI>
</OL>
<P>Exclusion criteria:</P>
<OL>
<LI>Pregnant women or women within lactation period.</LI>
<LI>Hypersensitive to calcium channel blocker or folic acid.</LI>
<LI>Easily hypersensitiveness;</LI>
<LI>Diagnosed secondary hypertension or sceptical secondary hypertension.</LI>
<LI>Severe hypertension (sedentary systolic blood pressure greater than or equal to 180 mmHg and/or sedentary diastolic blood pressure greater than or equal to 110 mmHg).</LI>
<LI>Severe diseases: cardiovascular system, alimentary system, urinary system, endocrine system, respiratory system, neuropsychiatric system, and others such as malignant tumour, malnutrition, hematogenesis dysfunction.</LI>
<LI>Obviously abnormal laboratory examination or signs.</LI>
<LI>Taking other antihypertensive drugs and unwilling to stop.</LI>
<LI>Taking folic acid or other Vitamin B groups and unwilling to stop.</LI>
<LI>Participation in any drug trial not yet approved within 4 weeks before the first visit.</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-02 09:31:25 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Experimental (low-dose group): amlodipine-folic acid tablet: 5 mg amlodipine combined with 0.4 mg folic acid, once daily.</LI>
<LI>Experimental (high-dose group): amlodipine-folic acid tablet: 5 mg amlodipine combined with 0.8 mg folic acid,once daily.</LI>
<LI>Control: amlodipine: 5 mg, once daily.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-02 10:18:48 -0500" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Primary: combined effective rate of blood pressure and plasma homocysteine reduction.</LI>
<LI>Secondary:</LI>
<OL>
<LI>Blood pressure reduction</LI>
<LI>Plasma homocysteine reduction</LI>
</OL>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-04-22 15:04:21 -0500" MODIFIED_BY="[Empty name]">
<P>September 2013.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-04-22 15:03:49 -0500" MODIFIED_BY="[Empty name]">
<P>Wang Jiguang, MD. Ruijin Hospital, Shanghai Jiao Tong University.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-08-04 09:47:35 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>Official title: efficacy of amlodipine-folic acid tablets on reduction of blood pressure and plasma homocysteine in patients with mild to moderate hypertension, hyperhomocysteinaemia and angiotension-converting enzyme inhibitor Intolerance.</LI>
<LI>Sponsor: Shenzhen Ausa Pharmed Co.,Ltd.</LI>
<LI>Collaborators:</LI>
<OL>
<LI>Ruijin Hospital</LI>
<LI>Second Affiliated Hospital of Nanchang University</LI>
<LI>Xuzhou Medical College</LI>
</OL>
</OL>
<OL>
<LI>Information provided by (Responsible party):</LI>
<OL>
<LI>Shenzhen Ausa Pharmed Co.,Ltd</LI>
</OL>
</OL>
<OL>
<LI>Estimated enrolled: 540.</LI>
<LI>Listed location countries: China.</LI>
</OL>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-08-04 09:47:34 -0500" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-03-28 10:20:41 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-28 10:20:41 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-B_x002d_PROOF-2015">
<DESCRIPTION>
<P>Quote "The random allocation sequence and randomization were generated and performed using SAS 9.2 by an independent research dietician." (Page 402)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BVAIT-2009">
<DESCRIPTION>
<P>Quote: "Computer-generated random numbers were used to assign participants" (page 731)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CHAOS-2002">
<DESCRIPTION>
<P>Described as randomised</P>
<P>Insufficient information about the sequence generation process to permit judgement of 'Low risk' or 'High risk' Data not yet fully published. Results in the table correspond to conference proceedings</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-17 10:00:01 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CSPPT-2015">
<DESCRIPTION>
<P>Quote "Randomization was performed centrally by means of 4 randomization tables: 1was a randomization of drug code and treatment allocation, and the other 3 were MTHFR C677T genotype&#8211;specific randomized sequences with a fixed block size of 4."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-FOLARDA-2004">
<DESCRIPTION>
<P>Quote: "patients were randomised..."</P>
<P>Insufficient information about the sequence generation process to permit judgement of 'Low risk' or 'High risk'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GOES-2003">
<DESCRIPTION>
<P>Quote: "A computer program randomly allocated patients [...] to treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HOPE_x002d_2-2006">
<DESCRIPTION>
<P>Quote: "The study used central telephone randomization"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-19 13:44:26 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2015a">
<DESCRIPTION>
<P>Described as randomised</P>
<P>Insufficient information about the random sequence generation to permit judgement of 'Low risk' or 'High risk' Data not yet fully published. Results in the table correspond to conference proceedings</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NORVIT-2006">
<DESCRIPTION>
<P>No information reported about this domain</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SEARCH-2010">
<DESCRIPTION>
<P>Quote: "The central telephone randomization system used a minimization algorithm to balance the treatment groups with respect to major prognostic factors." (page 2487)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SU.FOL.OM3-2010">
<DESCRIPTION>
<P>Quote: "Randomisation was performed by means of a computerised block sequence stratified by three age groups (44 &#8211; 54, 55 &#8211; 64, and 65 &#8211; 80 years), sex, prior disease at enrolment (myocardial infarction, acute coronary syndrome, or ischaemic stroke) and recruitment centre. Permuted block randomisation (with block size randomly selected as 8) was used." (page 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-28 09:42:27 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VISP-2004">
<DESCRIPTION>
<P>The allocation of participants was programmed by the statistical co-ordinating centre, encrypted and entered into a data entry program installed on a study computer at each site<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:47:36 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VITATOPS-2010">
<DESCRIPTION>
<P>Quote: "Random allocation was done by use of a central 24 hrs telephone service or an interactive website by use of random permuted blocks stratified by hospital" (page 856)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WAFACS-2008">
<DESCRIPTION>
<P>Block randomisation with a block size of 8 generated by computer, stratified by age</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-WENBIT-2008">
<DESCRIPTION>
<P>2 x 2 factorial design with block randomisation, with a block size of 20</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-08-02 10:14:03 -0500" MODIFIED_BY="Heather Maxwell" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-28 10:20:55 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-B_x002d_PROOF-2015">
<DESCRIPTION>
<P>Quote "The random allocation sequence and randomization were generated and performed using SAS 9.2 by an independent research dietician." (Page 402)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BVAIT-2009">
<DESCRIPTION>
<P>Quote: "Computer-generated random numbers were used to assign participants" (page 731)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CHAOS-2002">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of 'Low risk' or 'High risk' Data not yet fully published. Results in the table correspond to conference proceedings</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-17 10:00:08 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CSPPT-2015">
<DESCRIPTION>
<P>Quote "All study investigators and participants were blinded to the randomization procedure and the treatment assignments."</P>
<P>Insufficient information to permit judgement of 'Low risk' or 'High risk'</P>
<P>Trial authors did not describe procedure to guarantee an adequate allocation concealment. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-FOLARDA-2004">
<DESCRIPTION>
<P>Insufficient information to permit judgement of 'Low risk' or 'High risk'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GOES-2003">
<DESCRIPTION>
<P>No information reported about this domain</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HOPE_x002d_2-2006">
<DESCRIPTION>
<P>Centralised telephone randomisation (accessible 24 hours a day)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-19 13:44:50 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2015a">
<DESCRIPTION>
<P>Described as randomised</P>
<P>Insufficient information about the allocation concealment to permit judgement of 'Low risk' or 'High risk' Data not yet fully published. Results in the table correspond to conference proceedings</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-02 10:14:03 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-NORVIT-2006">
<DESCRIPTION>
<P>The manufacturer provided central study sites with blocks of medication assigned in numerical order</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SEARCH-2010">
<DESCRIPTION>
<P>Quote: "The central telephone randomization system used a minimization algorithm to balance the treatment groups with respect to major prognostic factors." (page 2487)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SU.FOL.OM3-2010">
<DESCRIPTION>
<P>Quote: "Randomisation was performed by means of a computerised block sequence stratified by three age groups (44 &#8211; 54, 55 &#8211; 64, and 65 &#8211; 80 years), sex, prior disease at enrolment (myocardial infarction, acute coronary syndrome, or ischaemic stroke) and recruitment centre. Permuted block randomisation (with block size randomly selected as 8) was used." (page 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-28 09:41:18 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VISP-2004">
<DESCRIPTION>
<P>Allocation programmed by the statistical co-ordinating centre. All the information on assignment were encrypted an entered in computers in study sites After verification of eligibility participants were assigned in 1 of 20 medication codes<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VITATOPS-2010">
<DESCRIPTION>
<P>Quote: "Random allocation was done by use of a central 24 hrs telephone service or an interactive website by use of random permuted blocks stratified by hospital" (page 856)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WAFACS-2008">
<DESCRIPTION>
<P>Central randomisation. Patients were sent yearly supplies of calendar packs containing their medication or matching placebos identical in appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WENBIT-2008">
<DESCRIPTION>
<P>Centralised independently by the manufacturer (Alpharma)</P>
<P>Study nurses received coded boxes provided to participants in numerical order. The codes were kept by the manufacturer until eligibility data were complete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-03-28 09:53:47 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-03-28 12:50:14 -0500" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-28 10:22:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-B_x002d_PROOF-2015">
<DESCRIPTION>
<P>Quote "Intervention and placebo tablets were indistinguishable in taste, smell, and appearance. Both the participants and all researchers and research assistants were blinded to the study treatment" (Page 402)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BVAIT-2009">
<DESCRIPTION>
<P>Quote: "Participants, clinical staff, imaging specialists, and data monitors were masked to treatment assignment." (page 731)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CHAOS-2002">
<DESCRIPTION>
<P>Described as double-blinded. However, the information was obtained from the final report (abstract)</P>
<P>Insufficient information to permit judgement of 'Low risk' or 'High risk'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-04-17 09:55:53 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CSPPT-2015">
<DESCRIPTION>
<P>Quote "Both types of tablets were concealed in a single capsule formulation and were identical in appearance, size, color, and taste" </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-12-18 08:09:15 -0600" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-FOLARDA-2004">
<DESCRIPTION>
<P>Quote: "... treatment with open label folic acid [...] or not"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-GOES-2003">
<DESCRIPTION>
<P>Quote: "... treatment with open label folic acid [...] or standard care."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HOPE_x002d_2-2006">
<DESCRIPTION>
<P>Quote: "All study investigators, personnel, and participants were unaware of the randomization procedure and the treatment assignments."</P>
<P>Vitamins manufactured to be indistinguishable in colour, weight or ability to be dissolved in water</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-02-19 13:47:59 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2015a">
<DESCRIPTION>
<P>Insufficient information to permit judgement of 'Low risk' or 'High risk'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NORVIT-2006">
<DESCRIPTION>
<P>All study personnel and participants were unaware of the treatment assignments</P>
<P>Vitamins were manufactured to be indistinguishable in colour, weight or ability to be dissolved in water</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SEARCH-2010">
<DESCRIPTION>
<P>Quote: " All such information was reviewed by coordinating center clinicians who were unaware of the study treatment allocation and events coded according to prespecified criteria" (page 2487)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SU.FOL.OM3-2010">
<DESCRIPTION>
<P>Quote: "Patients, clinicians, trial coordinators, and outcome investigators were blinded to treatment allocation." (page 2)<BR/>Quote: "treatment capsules for one year (and repeated yearly) in an appropriately labelled package." (page 2)<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-28 09:42:20 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VISP-2004">
<DESCRIPTION>
<P>The drug distributor centre bottled and distributed the vitamins, which were manufactured to be indistinguishable in colour, weight or ability to be dissolved in water<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VITATOPS-2010">
<DESCRIPTION>
<P>Quote: "Patients, clinicians, trial coordinators, and outcome investigators were masked to treatment allocation" (page 856)</P>
<P>Quote: "had the same colour and coating" (page 856)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WAFACS-2008">
<DESCRIPTION>
<P>All study investigators, personnel and participants were unaware of the participants' treatment assignments<BR/>Patients were sent packs containing medication or matching placebos identical in appearance</P>
<P>An independent committee monitored the "safety and overall quality and scientific integrity" of the trial, which was blinded to treatment assignment<BR/>All the information was supplied by Nancy Cook (WACS statistician, 23 June 2008)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WENBIT-2008">
<DESCRIPTION>
<P>Vitamins were manufactured to be indistinguishable in colour, weight or ability to be dissolved in water. Endpoints adjudicated by an independent committee unaware of patient's assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2017-08-02 10:06:40 -0500" MODIFIED_BY="Heather Maxwell" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-08-02 10:06:40 -0500" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-B_x002d_PROOF-2015">
<DESCRIPTION>
<P>Insufficient information on blinding of outcome assessment to judge as 'high' or 'low' risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BVAIT-2009">
<DESCRIPTION>
<P>Quote: "...imaging specialists, ... were masked to treatment assignment." (page 731). &amp; "Scans were analyzed without knowledge of treatment assignment using validated calcium scoring software" (for secondary outcome)" (page 731)</P>
<P>Comments: the main outcomes were to assess the impact of the HLI on reduction of subclinical atherosclerosis progression</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CHAOS-2002">
<DESCRIPTION>
<P>Described as double-blinded. However, the information was obtained from the final report (abstract)</P>
<P>Insufficient information to permit judgement of 'Low risk' or 'High risk'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-04-17 10:45:13 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CSPPT-2015">
<DESCRIPTION>
<P>Quote "Both types of tablets were concealed in a single capsule formulation and were identical in appearance, size, color, and taste"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-18 08:09:16 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FOLARDA-2004">
<DESCRIPTION>
<P>Quote: "An Independent Data and Safety Monitoring Committee adjudicated all major clinical events."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-18 08:09:18 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GOES-2003">
<DESCRIPTION>
<P>Quote: "Adjudication of all clinical events was performed by an independent end point monitoring committee unaware of treatment arm."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HOPE_x002d_2-2006">
<DESCRIPTION>
<P>This trial assessed objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-19 13:48:14 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2015a">
<DESCRIPTION>
<P>Insufficient information to permit judgement of 'Low risk' or 'High risk'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-18 08:09:23 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NORVIT-2006">
<DESCRIPTION>
<P>Quote: "All end points were adjudicated by members of the end-points committee, who were unaware of patients&#8217; treatment assignments."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SEARCH-2010">
<DESCRIPTION>
<P>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SU.FOL.OM3-2010">
<DESCRIPTION>
<P>Quote: "... and outcome investigators were blinded to treatment allocation." (page 2)</P>
<P>Quote: "All events were adjudicated by two independent committees of cardiologists or neurologists who were blinded to treatment allocation." (page 3)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-28 09:44:05 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VISP-2004">
<DESCRIPTION>
<P>The primary endpoint was reviewed by a local neurologist and 2 external independent review neurologists<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VITATOPS-2010">
<DESCRIPTION>
<P>Quote: "...and outcome investigators were masked to treatment allocation" (page 856)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WAFACS-2008">
<DESCRIPTION>
<P>An independent committee monitored the "safety and overall quality and scientific integrity" of the trial, which was blinded to treatment assignment<BR/>All the information was supplied by Nancy Cook (WACS statistician, 23 June 2008)</P>
<P>Comments: this trial had objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WENBIT-2008">
<DESCRIPTION>
<P>Quote: "end-points committees were unaware of the treatment allocation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-08-04 09:47:34 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-02 10:06:45 -0500" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-B_x002d_PROOF-2015">
<DESCRIPTION>
<P>Follow-up:</P>
<P>Experimental group: 94.8% (260/274)<BR/>Control: 80.3% (237/295)</P>
<P>Imbalance between comparison groups: 14.5%<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-02 08:46:37 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-BVAIT-2009">
<DESCRIPTION>
<P>
<B>B vitamins group</B>
</P>
<OL>
<LI>Lost to follow-up (n = 27): brain tumour (n = 1), medical problems (n = 2), refused methionine test (n = 1), active military duty (n = 1), too busy (n = 22)</LI>
<LI>Discontinued intervention (n = 8): attributed intervention to a medical problem (n = 1), medical problem (n = 2), wanted to take vitamins (n = 1), too busy (n = 4)</LI>
</OL>
<P>
<B>Placebo group</B>
</P>
<OL>
<LI>Lost to follow-up (n = 27): died (n = 2), medical problems (n = 4), refused methionine test (n = 1), active military duty (n = 1), too busy (n = 19)</LI>
<LI>Discontinued Intervention (n = 7): attributed intervention to a medical problem (n = 1), medical problem (n = 3), wanted to take vitamins (n = 2), too busy (n = 1)</LI>
</OL>
<P>
<B>Evaluable included in analysis:</B>
</P>
<OL>
<LI>B vitamins group: 97.6% (248/254)</LI>
<LI>Placebo group: 96% (242/252)</LI>
</OL>
<P>Completed the initially planned (2.5-year trial period): 8.1% (446/506): (88% (223/446) B vitamin; 88% (223/446) placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CHAOS-2002">
<DESCRIPTION>
<P>Flow of participants during trial was not reported. Data not yet fully published. Results in the table correspond to conference proceedings</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-02 10:09:39 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-CSPPT-2015">
<DESCRIPTION>
<P>
<B>Lost to follow-up:</B>
</P>
<OL>
<LI>Overall: 0.32% (67/20702)</LI>
<LI>Experimental: 0.30% (32/10348)</LI>
<LI>Control: 0.33% (35/10354)</LI>
</OL>
<P>Trial authors described reasons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-29 15:01:11 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-FOLARDA-2004">
<DESCRIPTION>
<P>23 participants discontinued treatment and no information is given<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GOES-2003">
<DESCRIPTION>
<P>After randomisation, 12 patients per group withdrew from the study but were followed up and included in the final analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HOPE_x002d_2-2006">
<DESCRIPTION>
<P>21 patients in the treatment group and 16 in the placebo group did not complete the study<BR/>Vital status known for 99.3% of the sample</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-19 13:48:20 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2015a">
<DESCRIPTION>
<P>Insufficient information to permit judgement of 'Low risk' or 'High risk'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NORVIT-2006">
<DESCRIPTION>
<P>11% of patients stopped the medication<BR/>94% attended the final visit, but data on mortality were available for the entire sample. Incomplete outcome data for 20 patients<BR/>Patients that had not completed the planned follow-up were followed up by phone or consulted for vital status</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SEARCH-2010">
<DESCRIPTION>
<P>Vitamin group: 98.9% (5970/6033) completed follow-up<BR/>Placebo group: 99.1% (5975/6031) completed follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SU.FOL.OM3-2010">
<DESCRIPTION>
<OL>
<LI>B vitamins plus omega 3 fatty acids: 11.8% (547/620)</LI>
<LI>Omega 3 fatty acids: 9.6% (572/633)</LI>
<LI>B vitamins: 12.6% (542/622)</LI>
<LI>Placebo: 10.4% (561/626)</LI>
</OL>
<P>Comments: reasons for losses were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-28 09:47:41 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-VISP-2004">
<DESCRIPTION>
<P>132 patients in the low-dose group and 133 in the high-dose group were lost to follow-up. Of these 18 and 13 patients respectively had no contact after randomisation, and were not included in the analysis. 186 patients in the low-dose group and 179 in the high-dose group discontinued the assigned treatment </P>
<P>Patients who had not completed the planned follow-up were invited to an exit visit<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VITATOPS-2010">
<DESCRIPTION>
<P>Loss to final follow-up:<BR/>Global: 8.6% (702/8164)<BR/>B vitamins group: 8.5% (348/4089)<BR/>Placebo group: 8.7% (354/4075)</P>
<P>Comment: reasons for losses were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-WAFACS-2008">
<DESCRIPTION>
<P>Unknown vital status for 194 patients in the folic acid group and 207 patients in the placebo group. All the patients were included in the primary analysis, but how was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-04 09:47:34 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-WENBIT-2008">
<DESCRIPTION>
<P>6 patients (0.2% from the sample) withdrew consent to participate in the trial and were excluded from the analysis. Due to the media impact of the NORVIT interim results 692 patients were asked to stop the medication; outcome data available for 86% of patients at the final visit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-08-02 10:13:41 -0500" MODIFIED_BY="Heather Maxwell" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-28 12:39:20 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-B_x002d_PROOF-2015">
<DESCRIPTION>
<P>It is clear that the published reports relevant clinical outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BVAIT-2009">
<DESCRIPTION>
<P>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified. We also checked www.clinicaltrials.gov and the ID number was: NCT00114400</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CHAOS-2002">
<DESCRIPTION>
<P>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-13 15:23:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CSPPT-2015">
<DESCRIPTION>
<P>No bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FOLARDA-2004">
<DESCRIPTION>
<P>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GOES-2003">
<DESCRIPTION>
<P>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HOPE_x002d_2-2006">
<DESCRIPTION>
<P>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-02 10:13:41 -0500" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Li-2015a">
<DESCRIPTION>
<P>Trial reported no information clinical relevant outcomes such as MI, mortality or harms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NORVIT-2006">
<DESCRIPTION>
<P>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SEARCH-2010">
<DESCRIPTION>
<P>The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SU.FOL.OM3-2010">
<DESCRIPTION>
<P>The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have reported in the pre-specified way. "This study is registered with Current Controlled Trials (No ISRCTN41926726" (page 3)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-28 09:48:19 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VISP-2004">
<DESCRIPTION>
<P>The study protocol is not available but it is clear that the published reports include all expected outcomes,including those that were pre-specified<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VITATOPS-2010">
<DESCRIPTION>
<P>The study protocol is not available but it is clear that published reports include all expect outcomes, including those that were pre-specified. This trial is registered with ClinicalTrials.gov, NCT00097669 and Current Controlled Trials, ISRCTN74743444." (page 858)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WAFACS-2008">
<DESCRIPTION>
<P>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WENBIT-2008">
<DESCRIPTION>
<P>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-07-13 15:24:09 -0500" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-13 15:22:15 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-B_x002d_PROOF-2015">
<DESCRIPTION>
<P>Other sources of bias not identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-13 15:22:28 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BVAIT-2009">
<DESCRIPTION>
<P>Other sources of bias not identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CHAOS-2002">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-17 10:44:59 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-CSPPT-2015">
<DESCRIPTION>
<P>Industry bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-FOLARDA-2004">
<DESCRIPTION>
<P>Insufficient information to permit judgement of 'Low risk' or 'High risk'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-19 05:03:51 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-GOES-2003">
<DESCRIPTION>
<P>Insufficient information to permit judgement of 'Low risk' or 'High risk'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-13 15:23:19 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HOPE_x002d_2-2006">
<DESCRIPTION>
<P>Other sources of bias not identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-19 13:50:29 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2015a">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-13 15:23:30 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NORVIT-2006">
<DESCRIPTION>
<P>Other sources of bias not identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-13 15:23:36 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SEARCH-2010">
<DESCRIPTION>
<P>Other sources of bias not identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-13 15:23:44 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SU.FOL.OM3-2010">
<DESCRIPTION>
<P>Other sources of bias not identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-13 15:23:50 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VISP-2004">
<DESCRIPTION>
<P>Other sources of bias not identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-13 15:23:56 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VITATOPS-2010">
<DESCRIPTION>
<P>Other sources of bias not identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-13 15:24:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WAFACS-2008">
<DESCRIPTION>
<P>Other sources of bias not identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-13 15:24:09 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-WENBIT-2008">
<DESCRIPTION>
<P>Other sources of bias not identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-08-07 13:09:23 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-08-07 13:06:25 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="1" READONLY="YES">
<TITLE MODIFIED="2017-08-01 11:14:46 -0500" MODIFIED_BY="Heather Maxwell">Homocysteine-lowering interventions (Vitamin B6 (pyridoxine; pyridoxal); B9 (folic acid) or B12 (cyanocobalamin) compared with placebo or standard care for preventing cardiovascular events</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Homocysteine-lowering interventions (vitamins B6 (pyridoxine; pyridoxal); B9 (folic acid) or B12 (cyanocobalamin) compared with placebo or standard care for preventing cardiovascular events</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> adults at risk of or with established cardiovascular disease<BR/>
<B>Settings: </B>outpatients<BR/>
<B>Intervention:</B> homocysteine-lowering interventions (vitamins B6 (pyridoxine; pyridoxal), B9 (folic acid) or B12 (cyanocobalamin).<BR/>
<B>Comparison: </B>placebo or standard care</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo or standard care</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Homocysteine-lowering interventions </B>
<BR/>
<B>(vitamins B6 (pyridoxine; pyridoxal); B9 (folic acid) or B12 (cyanocobalamin)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Myocardial infarction</B>
<BR/>Follow-up: 1 to 7.3 years</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>60 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>61 per 1000</B>
<BR/>(57 to 66)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.02 </B>
<BR/>(0.95 to 1.10)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>46,699<BR/>(12 trials)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Stroke</B>
<BR/>Follow-up: 1 to 7.3 years</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>51 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>46 per 1000</B>
<BR/>(42 to 50)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.90 </B>
<BR/>(0.82 to 0.99)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>44,224<BR/>(10 trials)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Death by any cause</B>
<BR/>Follow-up: 1 to 7.3 years</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>123 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>124 per 1000</B>
<BR/>(118 to 130)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.01 </B>
<BR/>(0.96 to 1.06)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>44,817<BR/>(11 trials)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events</B>
<BR/>Follow-up: 3.4 to 7.3 years</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>85 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>91 per 1000</B>
<BR/>(85 to 97)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.07 </B>
<BR/>(1.00 to 1.14)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>35,788<BR/>(8 trials)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Cancer is the only reported adverse event.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is the outcomes of the study control arms. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2017-08-07 13:09:23 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="2" READONLY="YES">
<TITLE MODIFIED="2017-08-02 09:36:40 -0500" MODIFIED_BY="Heather Maxwell">Homocysteine-lowering interventions (high dose) compared with homocysteine-lowering interventions (low dose) for preventing cardiovascular events</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Homocysteine-lowering interventions (high dose) compared with homocysteine lowering interventions (low dose) </B>f<B>or preventing cardiovascular events</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> adults at risk of or with established cardiovascular disease<BR/>
<B>Settings:</B> outpatients<BR/>
<B>Intervention:</B> homocysteine-lowering interventions (high dose) either (folic acid; vitamin B12 (cyanocobalamin) and vitamin B6 (pyridoxine; pyridoxal) or folic acid<BR/>
<B>Comparison: </B>homocysteine-lowering interventions (low dose) either (folic acid; vitamin B12; vitamin B6 per day) or folic acid</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Homocysteine-lowering interventions (low-dose)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Homocysteine-lowering interventions (high-dose)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Myocardial infarction</B>
<BR/>Follow-up: 2 years</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>44 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>40 per 1000</B>
<BR/>(29 to 54)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.90 </B>
<BR/>(0.66 to 1.23)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>3649<BR/>(1 trial)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>:</P>
<UL>
<LI>High dose (2.5 mg folic acid; 0.4 mg vitamin B12 (cyanocobalamin) and 25 mg vitamin B6 (pyridoxine; pyridoxal)</LI>
<LI>Low dose (20 micrograms folic acid; 6 micrograms vitamin B12; 200 micrograms vitamin B6 per day).</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Stroke</B>
<BR/>Follow-up: 2 to 5 years</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>112 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>101 per 1000</B>
<BR/>(74 to 137)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.90 </B>
<BR/>(0.66 to 1.22)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>3929<BR/>(2 trials)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1, 2, 3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1. <LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK> was conducted including only Chinese elderly females.Trial used only folic acid as homocysteine-lowering intervention.</P>
<UL>
<LI>High-dose folic acid (0.8 mg/d)</LI>
<LI>Low-dose folic acid (0.4 mg/d))</LI>
</UL>
<P>2. <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>:</P>
<UL>
<LI>High dose (2.5 mg folic acid; 0.4 mg vitamin B12 (cyanocobalamin) and 25 mg vitamin B6 (pyridoxine; pyridoxal)</LI>
<LI>Low dose (20 micrograms folic acid; 6 micrograms vitamin B12; 200 micrograms vitamin B6 per day).</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Death by any cause</B>
<BR/>Follow-up: 2 years</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>64 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>55 per 1000</B>
<BR/>(42 to 71)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.86 </B>
<BR/>(0.66 to 1.11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>3649<BR/>(1 trial)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>:</P>
<UL>
<LI>High dose (2.5 mg folic acid; 0.4 mg vitamin B12 (cyanocobalamin) and 25 mg vitamin B6 (pyridoxine; pyridoxal)</LI>
<LI>Low dose (20 micrograms folic acid; 6 micrograms vitamin B12; 200 micrograms vitamin B6 per day).</LI>
</UL>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Cancer</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK> and <LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK> reported no information on this outcome.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is the outcomes of the study control arms. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1 </SUP>Downgraded one level for imprecision due to low number of events<BR/>
<SUP>2</SUP> Dowgraded one level for risk of bias as one trial (<LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>) was rated as having unclear risk of selection, conduction and detection biases<BR/>
<SUP>3 </SUP>Downgraded one level for heterogeneity (I-squared: 72%).<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2017-08-07 11:10:23 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="3" READONLY="YES">
<TITLE MODIFIED="2016-10-03 15:11:42 -0500" MODIFIED_BY="[Empty name]">Enalapril plus folic acid compared with enalapril for adults with hypertension</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Enalapril plus folic acid compared with folic acid for adults with hypertension</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> adults with hypertension<BR/>
<B>Settings:</B> Chinese outpatients<BR/>
<B>Intervention:</B> enalapril (10 mg) plus folic acid (0.8 mg)<BR/>
<B>Comparison: </B>enalapril (10 mg)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Folic acid</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Enalapril plus folic acid</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Myocardial infarction</B>
<BR/>Follow-up: median 4.5 years</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>2 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>2 per 1000</B>
<BR/>(1 to 4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.04 </B>
<BR/>(0.60 to 1.82)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>20,702<BR/>(1 trial)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Stroke</B>
<BR/>Follow-up: median 4.5 years</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>34 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>27 per 1000</B>
<BR/>(23 to 32)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.79 </B>
<BR/>(0.68 to 0.93)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>20,702<BR/>(1 trial)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>First unstable angina pectoris episode requiring hospitalisation</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK> did not assess this outcome.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Death from any cause</B>
<BR/>Follow-up: median 4.5 years</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>31 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>29 per 1000</B>
<BR/>(25 to 34)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.94 </B>
<BR/>(0.81 to 1.10)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>20,702<BR/>(1 trial)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Serious adverse event (cancer)</B>
<BR/>Follow-up: median 4.5 years</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>8 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>8 per 1000</B>
<BR/>(6 to 11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.96 </B>
<BR/>(0.71 to 1.31)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>20,243<BR/>(1 trial)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK> included either neoplasms benign, malignant or unspecified</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is the outcomes of the study control arms. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Downgraded one level for imprecision due to low number of events.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-03-07 04:14:46 -0600" MODIFIED_BY="Joey Kwong"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-08-07 13:00:17 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">
<COMPARISON ID="CMP-001" MODIFIED="2017-08-07 13:00:17 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="1">
<NAME>Homocysteine-lowering treatment versus other (any comparisons)</NAME>
<DICH_OUTCOME CHI2="6.900096475452704" CI_END="1.0868012312203057" CI_START="0.9484808562935975" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0152882164236772" ESTIMABLE="YES" EVENTS_1="1885" EVENTS_2="1395" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.03615012175163333" LOG_CI_START="-0.02297143028924198" LOG_EFFECT_SIZE="0.006589345731195671" METHOD="MH" MODIFIED="2017-03-21 13:21:37 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="1" P_CHI2="0.9072262733718016" P_Q="0.7329624336151104" P_Z="0.6621893377091577" Q="0.6213217724590533" RANDOM="YES" SCALE="25.313435632334937" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="37213" TOTAL_2="33837" WEIGHT="300.0" Z="0.4368924654040611">
<NAME>Myocardial infarction</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.2785779694449815" CI_END="1.0955801634276772" CI_START="0.9518632783350354" DF="11" EFFECT_SIZE="1.0211966147804754" ESTIMABLE="YES" EVENTS_1="1788" EVENTS_2="1290" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.03964416031805921" LOG_CI_START="-0.02142542738108458" LOG_EFFECT_SIZE="0.00910936646848733" MODIFIED="2016-09-19 12:44:36 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="1" P_CHI2="0.854145150740506" P_Z="0.5587420515527548" STUDIES="12" TAU2="0.0" TOTAL_1="25051" TOTAL_2="21648" WEIGHT="100.00000000000001" Z="0.5847110115813753">
<NAME>Homocysteine-lowering versus placebo</NAME>
<DICH_DATA CI_END="1.5762289505204619" CI_START="0.6919638917567603" EFFECT_SIZE="1.0443627333938208" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="43" LOG_CI_END="0.1976192999085921" LOG_CI_START="-0.15991656742175966" LOG_EFFECT_SIZE="0.01885136624341623" MODIFIED="2016-09-19 12:44:32 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="82" O_E="0.0" SE="0.2100183383009354" STUDY_ID="STD-B_x002d_PROOF-2015" TOTAL_1="1461" TOTAL_2="1458" VAR="0.04410770242268615" WEIGHT="2.9174991891430904"/>
<DICH_DATA CI_END="6.872002261275224" CI_START="0.13856197870817752" EFFECT_SIZE="0.9758064516129032" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8370832937305186" LOG_CI_START="-0.8583559234220886" LOG_EFFECT_SIZE="-0.01063631484578498" MODIFIED="2016-09-19 12:44:33 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="68" O_E="0.0" SE="0.9959093887149197" STUDY_ID="STD-BVAIT-2009" TOTAL_1="248" TOTAL_2="242" VAR="0.9918355105305252" WEIGHT="0.12974347529089716"/>
<DICH_DATA CI_END="3.821120562510988" CI_START="0.9573182559938257" EFFECT_SIZE="1.9125973106864826" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.5821907405952977" LOG_CI_START="-0.018943659041719105" LOG_EFFECT_SIZE="0.28162354077678936" ORDER="37" O_E="0.0" SE="0.35310932201005274" STUDY_ID="STD-CHAOS-2002" TOTAL_1="942" TOTAL_2="940" VAR="0.12468619329039912" WEIGHT="1.0320644383892685"/>
<DICH_DATA CI_END="2.0098760271954488" CI_START="0.33222071408619264" EFFECT_SIZE="0.8171428571428572" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.3031692701740288" LOG_CI_START="-0.478573292616494" LOG_EFFECT_SIZE="-0.08770201122123261" MODIFIED="2016-09-19 12:44:34 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="38" O_E="0.0" SE="0.4591994510712484" STUDY_ID="STD-FOLARDA-2004" TOTAL_1="140" TOTAL_2="143" VAR="0.21086413586413585" WEIGHT="0.6102706158436799"/>
<DICH_DATA CI_END="3.244541168646203" CI_START="0.16537199625791166" EFFECT_SIZE="0.7325" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.511153289113494" LOG_CI_START="-0.7815380310611997" LOG_EFFECT_SIZE="-0.13519237097385292" ORDER="39" O_E="0.0" SE="0.7593332803958506" STUDY_ID="STD-GOES-2003" TOTAL_1="300" TOTAL_2="293" VAR="0.5765870307167235" WEIGHT="0.22318258857330067"/>
<DICH_DATA CI_END="1.1259071344730907" CI_START="0.8516141849657619" EFFECT_SIZE="0.9792029854281683" ESTIMABLE="YES" EVENTS_1="341" EVENTS_2="349" LOG_CI_END="0.05150257111114221" LOG_CI_START="-0.0697571133198469" LOG_EFFECT_SIZE="-0.009127271104352342" ORDER="40" O_E="0.0" SE="0.07122853887988154" STUDY_ID="STD-HOPE_x002d_2-2006" TOTAL_1="2758" TOTAL_2="2764" VAR="0.005073504750962796" WEIGHT="25.363962855998363"/>
<DICH_DATA CI_END="1.2908667841046046" CI_START="0.9390180305015682" EFFECT_SIZE="1.100975560695967" ESTIMABLE="YES" EVENTS_1="534" EVENTS_2="163" LOG_CI_END="0.11088142591208357" LOG_CI_START="-0.027326068572911845" LOG_EFFECT_SIZE="0.04177767866958588" ORDER="41" O_E="0.0" SE="0.08118376639861764" STUDY_ID="STD-NORVIT-2006" TOTAL_1="2806" TOTAL_2="943" VAR="0.006590803926665318" WEIGHT="19.52480873122569"/>
<DICH_DATA CI_END="1.142405312184526" CI_START="0.8829411307067917" EFFECT_SIZE="1.0043289491325293" ESTIMABLE="YES" EVENTS_1="431" EVENTS_2="429" LOG_CI_END="0.057820213906068486" LOG_CI_START="-0.05406825164495704" LOG_EFFECT_SIZE="0.00187598113055574" MODIFIED="2010-06-27 06:14:35 -0500" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.06572383852150938" STUDY_ID="STD-SEARCH-2010" TOTAL_1="6033" TOTAL_2="6031" VAR="0.004319622950001441" WEIGHT="29.79060615767602"/>
<DICH_DATA CI_END="1.4639797230697291" CI_START="0.5373896688919942" EFFECT_SIZE="0.8869766505636071" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="32" LOG_CI_END="0.16553506154483796" LOG_CI_START="-0.269710686965609" LOG_EFFECT_SIZE="-0.052087812710385546" MODIFIED="2016-09-19 12:44:36 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="64" O_E="0.0" SE="0.2556655071762391" STUDY_ID="STD-SU.FOL.OM3-2010" TOTAL_1="1242" TOTAL_2="1259" VAR="0.06536485155968355" WEIGHT="1.968706162143613"/>
<DICH_DATA CI_END="1.3294537093043652" CI_START="0.8003908163147914" EFFECT_SIZE="1.0315437652580952" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="114" LOG_CI_END="0.12367322008528125" LOG_CI_START="-0.09669790310265673" LOG_EFFECT_SIZE="0.013487658491312267" MODIFIED="2016-03-23 16:47:59 -0500" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.12944708861524762" STUDY_ID="STD-VITATOPS-2010" TOTAL_1="4089" TOTAL_2="4075" VAR="0.016756548750963766" WEIGHT="7.679635464656778"/>
<DICH_DATA CI_END="1.2204757235062305" CI_START="0.6321703584452255" EFFECT_SIZE="0.8783783783783784" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="74" LOG_CI_END="0.08652914528361275" LOG_CI_START="-0.19916587145985398" LOG_EFFECT_SIZE="-0.056318363088120604" ORDER="43" O_E="0.0" SE="0.1678186670482534" STUDY_ID="STD-WAFACS-2008" TOTAL_1="2721" TOTAL_2="2721" VAR="0.02816310500985253" WEIGHT="4.569247105677195"/>
<DICH_DATA CI_END="1.4648397272808813" CI_START="0.8324077776262513" EFFECT_SIZE="1.1042390963756548" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="58" LOG_CI_END="0.16579010976503922" LOG_CI_START="-0.07966387059834557" LOG_EFFECT_SIZE="0.043063119583346854" MODIFIED="2015-04-22 07:42:46 -0500" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.14418088308225055" STUDY_ID="STD-WENBIT-2008" TOTAL_1="2311" TOTAL_2="779" VAR="0.020788127046377607" WEIGHT="6.190273215382104"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.205673094458136E-31" CI_END="1.2268879695051964" CI_START="0.6590033448489941" DF="0" EFFECT_SIZE="0.8991792233247581" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="81" I2="100.0" ID="CMP-001.01.02" LOG_CI_END="0.08880490792096865" LOG_CI_START="-0.18111238108766783" LOG_EFFECT_SIZE="-0.046153736583349585" MODIFIED="2016-03-28 13:07:36 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.5026812962354595" STUDIES="1" TAU2="0.0" TOTAL_1="1814" TOTAL_2="1835" WEIGHT="100.0" Z="0.6702768969528256">
<NAME>Homocysteine-lowering treatment at high dose versus low dose</NAME>
<DICH_DATA CI_END="1.2268879695051964" CI_START="0.6590033448489941" EFFECT_SIZE="0.8991792233247581" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="81" LOG_CI_END="0.08880490792096865" LOG_CI_START="-0.18111238108766783" LOG_EFFECT_SIZE="-0.046153736583349585" MODIFIED="2016-03-28 13:07:36 -0500" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.15855075167580218" STUDY_ID="STD-VISP-2004" TOTAL_1="1814" TOTAL_2="1835" VAR="0.025138340856961892" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8236591976310033" CI_START="0.5956859183600369" DF="0" EFFECT_SIZE="1.0422706481123567" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.2609436813513822" LOG_CI_START="-0.22498266622785623" LOG_EFFECT_SIZE="0.017980507561762952" MODIFIED="2016-03-28 16:06:23 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.8846735432953376" STUDIES="1" TAU2="0.0" TOTAL_1="10348" TOTAL_2="10354" WEIGHT="100.0" Z="0.1450472789564424">
<NAME>Homocysteine-lowering treatment (folic acid) plus antihypertensive therapy (enalapril) versus antihypertensive therapy (enalapril)</NAME>
<DICH_DATA CI_END="1.8236591976310033" CI_START="0.5956859183600369" EFFECT_SIZE="1.0422706481123567" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" LOG_CI_END="0.2609436813513822" LOG_CI_START="-0.22498266622785623" LOG_EFFECT_SIZE="0.017980507561762952" MODIFIED="2016-03-28 14:00:57 -0500" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.28543554194225856" STUDY_ID="STD-CSPPT-2015" TOTAL_1="10348" TOTAL_2="10354" VAR="0.08147344860387086" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.385548764386025" CI_END="0.9415514560669617" CI_START="0.8050226364347757" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8706148606025671" ESTIMABLE="YES" EVENTS_1="1506" EVENTS_2="1609" I2="22.00473194835133" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.02615594067621354" LOG_CI_START="-0.09419190753213834" LOG_EFFECT_SIZE="-0.06017392410417594" METHOD="MH" MODIFIED="2017-08-07 13:00:17 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="2" P_CHI2="0.22102606985118334" P_Q="0.3994350136535998" P_Z="5.263953995004684E-4" Q="1.8354086470079858" RANDOM="YES" SCALE="2.8159736770166806" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.004780436590453943" TOTALS="SUB" TOTAL_1="36115" TOTAL_2="32740" WEIGHT="300.0" Z="3.466952246078386">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.807041484512714" CI_END="0.988802155011113" CI_START="0.8175573834367365" DF="9" EFFECT_SIZE="0.8991120634200678" ESTIMABLE="YES" EVENTS_1="1014" EVENTS_2="1034" I2="8.229204350641268" ID="CMP-001.02.01" LOG_CI_END="-0.004890595745940051" LOG_CI_START="-0.08748175495476206" LOG_EFFECT_SIZE="-0.046186175350351015" MODIFIED="2016-03-28 13:39:29 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3663312245185638" P_Z="0.028373684925769888" STUDIES="10" TAU2="0.002024193406766882" TOTAL_1="23809" TOTAL_2="20415" WEIGHT="100.0" Z="2.1920806327820705">
<NAME>Homocysteine-lowering treatment versus placebo</NAME>
<DICH_DATA CI_END="1.1156403737194664" CI_START="0.5246909291716162" EFFECT_SIZE="0.7650924024640657" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="60" LOG_CI_END="0.04752422248743765" LOG_CI_START="-0.2800964437962586" LOG_EFFECT_SIZE="-0.1162861106544105" MODIFIED="2016-03-28 13:39:04 -0500" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.19244600112349652" STUDY_ID="STD-B_x002d_PROOF-2015" TOTAL_1="1461" TOTAL_2="1458" VAR="0.03703546334842482" WEIGHT="6.025788786812665"/>
<DICH_DATA CI_END="4.0446125554663945" CI_START="0.009418829137784123" EFFECT_SIZE="0.19518072289156627" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6068769256807967" LOG_CI_START="-2.0260030813476826" LOG_EFFECT_SIZE="-0.709563077833443" MODIFIED="2016-03-28 13:39:29 -0500" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="1.5465667490947563" STUDY_ID="STD-BVAIT-2009" TOTAL_1="248" TOTAL_2="242" VAR="2.3918687094055233" WEIGHT="0.09831903566599996"/>
<DICH_DATA CI_END="74.57749473307939" CI_START="0.12586978147683617" EFFECT_SIZE="3.0638297872340425" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8726077901023332" LOG_CI_START="-0.9000785217832687" LOG_EFFECT_SIZE="0.4862646341595322" MODIFIED="2016-03-28 13:39:28 -0500" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="1.6286896646202007" STUDY_ID="STD-FOLARDA-2004" TOTAL_1="140" TOTAL_2="143" VAR="2.6526300236406617" WEIGHT="0.08866135566008469"/>
<DICH_DATA CI_END="0.9627266837866402" CI_START="0.5948340660393838" EFFECT_SIZE="0.7567447573663257" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="147" LOG_CI_END="-0.016496990726962545" LOG_CI_START="-0.2256041674714151" LOG_EFFECT_SIZE="-0.12105057909918886" MODIFIED="2016-03-28 13:39:28 -0500" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.12283059071691017" STUDY_ID="STD-HOPE_x002d_2-2006" TOTAL_1="2758" TOTAL_2="2764" VAR="0.0150873540158651" WEIGHT="13.754760798598976"/>
<DICH_DATA CI_END="1.3680129519728332" CI_START="0.5708828704344923" EFFECT_SIZE="0.8837279902853673" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="27" LOG_CI_END="0.13609020918505013" LOG_CI_START="-0.2434529879748997" LOG_EFFECT_SIZE="-0.053681389394924776" MODIFIED="2016-03-28 13:39:28 -0500" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.22294555278088088" STUDY_ID="STD-NORVIT-2006" TOTAL_1="2806" TOTAL_2="943" VAR="0.04970471950477254" WEIGHT="4.54997463593869"/>
<DICH_DATA CI_END="1.1377129737401066" CI_START="0.823961211812356" EFFECT_SIZE="0.9682103906370441" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="286" LOG_CI_END="0.05603271052691064" LOG_CI_START="-0.08409323234700268" LOG_EFFECT_SIZE="-0.014030260910046017" MODIFIED="2013-04-06 11:40:55 -0500" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.08231067247874067" STUDY_ID="STD-SEARCH-2010" TOTAL_1="6033" TOTAL_2="6031" VAR="0.0067750468039025164" WEIGHT="26.748359637551072"/>
<DICH_DATA CI_END="1.0070605309453127" CI_START="0.3472052482205792" EFFECT_SIZE="0.5913177670424047" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="36" LOG_CI_END="0.0030555752859611376" LOG_CI_START="-0.4594137188180948" LOG_EFFECT_SIZE="-0.2281790717660668" MODIFIED="2013-04-06 11:39:01 -0500" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.271656752616649" STUDY_ID="STD-SU.FOL.OM3-2010" TOTAL_1="1242" TOTAL_2="1259" VAR="0.07379739124222323" WEIGHT="3.1041983991997806"/>
<DICH_DATA CI_END="1.06011519231317" CI_START="0.8065095179482671" EFFECT_SIZE="0.924658311335668" ESTIMABLE="YES" EVENTS_1="360" EVENTS_2="388" LOG_CI_END="0.02535305834767253" LOG_CI_START="-0.0933905029581936" LOG_EFFECT_SIZE="-0.03401872230526054" MODIFIED="2013-04-06 11:40:55 -0500" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.06975055570117394" STUDY_ID="STD-VITATOPS-2010" TOTAL_1="4089" TOTAL_2="4075" VAR="0.004865140020622568" WEIGHT="34.16371760386285"/>
<DICH_DATA CI_END="1.5744311510392066" CI_START="0.8325921793130026" EFFECT_SIZE="1.144927536231884" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="69" LOG_CI_END="0.19712367394206512" LOG_CI_START="-0.07956767283569291" LOG_EFFECT_SIZE="0.058778000553186105" MODIFIED="2013-04-06 11:39:03 -0500" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.16252986674151093" STUDY_ID="STD-WAFACS-2008" TOTAL_1="2721" TOTAL_2="2721" VAR="0.0264159575830133" WEIGHT="8.275808443378624"/>
<DICH_DATA CI_END="1.4395515958890144" CI_START="0.5037592827095392" EFFECT_SIZE="0.8515794028559065" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="19" LOG_CI_END="0.15822723531921837" LOG_CI_START="-0.2977769380867916" LOG_EFFECT_SIZE="-0.06977485138378663" MODIFIED="2013-04-06 11:39:04 -0500" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.2678591087157532" STUDY_ID="STD-WENBIT-2008" TOTAL_1="2311" TOTAL_2="779" VAR="0.0717485021219977" WEIGHT="3.1904113033312567"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.530681873656885" CI_END="1.223139633280935" CI_START="0.6565417366360222" DF="1" EFFECT_SIZE="0.8961262293798862" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="221" I2="71.67685915116857" ID="CMP-001.02.02" LOG_CI_END="0.0874760388039335" LOG_CI_START="-0.1827376604129375" LOG_EFFECT_SIZE="-0.04763081080450202" MODIFIED="2016-12-21 11:58:23 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NO="2" P_CHI2="0.06024314801510344" P_Z="0.48958489258903826" STUDIES="2" TAU2="0.03617593812729148" TOTAL_1="1958" TOTAL_2="1971" WEIGHT="100.0" Z="0.6909692143797614">
<NAME>Homocysteine-lowering treatment at high dose versus low dose</NAME>
<DICH_DATA CI_END="0.9807257492849167" CI_START="0.5941054790278697" EFFECT_SIZE="0.7633181126331812" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="73" LOG_CI_END="-0.008452422002357391" LOG_CI_START="-0.22613644240433023" LOG_EFFECT_SIZE="-0.11729443220334383" MODIFIED="2016-12-21 11:58:23 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="80" O_E="0.0" SE="0.12786867113739842" STUDY_ID="STD-Li-2015a" TOTAL_1="144" TOTAL_2="136" VAR="0.016350397058444148" WEIGHT="47.963716717069076"/>
<DICH_DATA CI_END="1.2904789725355523" CI_START="0.8363929903448912" EFFECT_SIZE="1.0389165350576597" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="148" LOG_CI_END="0.11075093240861424" LOG_CI_START="-0.07758961558092052" LOG_EFFECT_SIZE="0.016580658413846868" MODIFIED="2016-03-30 11:05:28 -0500" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.1106321701898012" STUDY_ID="STD-VISP-2004" TOTAL_1="1814" TOTAL_2="1835" VAR="0.012239477080905139" WEIGHT="52.03628328293093"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9266726531632203" CI_START="0.6807431032739176" DF="0" EFFECT_SIZE="0.7942455650700263" ESTIMABLE="YES" EVENTS_1="281" EVENTS_2="354" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="-0.03307365316055606" LOG_CI_START="-0.1670167498781972" LOG_EFFECT_SIZE="-0.10004520151937661" MODIFIED="2016-03-30 14:38:08 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.00341276248658239" STUDIES="1" TAU2="0.0" TOTAL_1="10348" TOTAL_2="10354" WEIGHT="100.0" Z="2.927884999066241">
<NAME>Homocysteine-lowering treatment (folic acid) plus antihypertensive therapy (enalapril) versus antihypertensive therapy (enalapril)</NAME>
<DICH_DATA CI_END="0.9266726531632203" CI_START="0.6807431032739176" EFFECT_SIZE="0.7942455650700263" ESTIMABLE="YES" EVENTS_1="281" EVENTS_2="354" LOG_CI_END="-0.03307365316055606" LOG_CI_START="-0.1670167498781972" LOG_EFFECT_SIZE="-0.10004520151937661" MODIFIED="2016-03-28 14:01:07 -0500" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.07867883804096434" STUDY_ID="STD-CSPPT-2015" TOTAL_1="10348" TOTAL_2="10354" VAR="0.006190359555476297" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.716329063792779" CI_END="1.2089241455265045" CI_START="0.800054852471098" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9834661300207322" ESTIMABLE="YES" EVENTS_1="910" EVENTS_2="468" I2="65.58184095570853" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.08239905171870221" LOG_CI_START="-0.09688023637197528" LOG_EFFECT_SIZE="-0.00724059232663652" METHOD="MH" MODIFIED="2017-08-07 12:42:33 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="3" P_CHI2="0.03331025136524579" P_Q="1.0" P_Z="0.8742085894899644" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.025402195973341878" TOTALS="YES" TOTAL_1="8015" TOTAL_2="4629" WEIGHT="100.0" Z="0.1583149993296145">
<NAME>First unstable angina pectoris episode requiring hospitalisation</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.151257449682013" CI_START="0.2728011162774668" EFFECT_SIZE="0.7660714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3326923872752742" LOG_CI_START="-0.5641538569182265" LOG_EFFECT_SIZE="-0.11573073482147614" ORDER="50" O_E="0.0" SE="0.5268119232997698" STUDY_ID="STD-FOLARDA-2004" TOTAL_1="140" TOTAL_2="143" VAR="0.27753080253080253" WEIGHT="3.6609083650587952"/>
<DICH_DATA CI_END="1.4544855883469692" CI_START="1.0340927413317813" EFFECT_SIZE="1.2264065350776985" ESTIMABLE="YES" EVENTS_1="268" EVENTS_2="219" LOG_CI_END="0.16270942243258352" LOG_CI_START="0.014559489669417197" LOG_EFFECT_SIZE="0.08863445605100036" ORDER="51" O_E="0.0" SE="0.08702400385907849" STUDY_ID="STD-HOPE_x002d_2-2006" TOTAL_1="2758" TOTAL_2="2764" VAR="0.007573177247664909" WEIGHT="33.631460085178865"/>
<DICH_DATA CI_END="1.0912094613099388" CI_START="0.7528215850123303" EFFECT_SIZE="0.9063586686537506" ESTIMABLE="YES" EVENTS_1="356" EVENTS_2="132" LOG_CI_END="0.03790812287039899" LOG_CI_START="-0.12330793724637387" LOG_EFFECT_SIZE="-0.04269990718798745" ORDER="52" O_E="0.0" SE="0.09469911174496042" STUDY_ID="STD-NORVIT-2006" TOTAL_1="2806" TOTAL_2="943" VAR="0.008967921765284501" WEIGHT="32.26669040559673"/>
<DICH_DATA CI_END="1.0638067906581887" CI_START="0.7048153159848998" EFFECT_SIZE="0.8659026038213729" ESTIMABLE="YES" EVENTS_1="280" EVENTS_2="109" LOG_CI_END="0.026862758249993953" LOG_CI_START="-0.1519246670598925" LOG_EFFECT_SIZE="-0.06253095440494927" MODIFIED="2008-08-28 14:28:46 -0500" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.1050206186390559" STUDY_ID="STD-WENBIT-2008" TOTAL_1="2311" TOTAL_2="779" VAR="0.011029330339330016" WEIGHT="30.440941144165606"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.055121687997513" CI_END="1.0467607168380169" CI_START="0.9529591708758448" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9987593427965326" ESTIMABLE="YES" EVENTS_1="3222" EVENTS_2="2981" I2="0.4572470475548493" I2_Q="3.24690566587549" ID="CMP-001.04" LOG_CI_END="0.01984741593517034" LOG_CI_START="-0.02092570612261077" LOG_EFFECT_SIZE="-5.391450937201878E-4" METHOD="MH" MODIFIED="2017-03-21 13:22:42 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="4" P_CHI2="0.44126307016086896" P_Q="0.3557388970587009" P_Z="0.9586614343882622" Q="2.0671173503694407" RANDOM="YES" SCALE="3.78" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="3.9455790273946286E-5" TOTALS="SUB" TOTAL_1="36271" TOTAL_2="32897" WEIGHT="300.0" Z="0.051833409501267746">
<NAME>Death from any cause</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.98918161102987" CI_END="1.062446641797468" CI_START="0.9610139987241988" DF="10" EFFECT_SIZE="1.010458359193926" ESTIMABLE="YES" EVENTS_1="2821" EVENTS_2="2544" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.026307128129581355" LOG_CI_START="-0.01727028608338635" LOG_EFFECT_SIZE="0.00451842102309749" MODIFIED="2016-03-31 12:45:59 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.441443014719784" P_Z="0.6844146030194249" STUDIES="11" TAU2="0.0" TOTAL_1="24109" TOTAL_2="20708" WEIGHT="100.0" Z="0.4064464416809918">
<NAME>Homocysteine-lowering treatment versus placebo</NAME>
<DICH_DATA CI_END="1.3594883620134919" CI_START="0.5685176985818927" EFFECT_SIZE="0.8791434438251686" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="42" LOG_CI_END="0.13337549413392366" LOG_CI_START="-0.24525601070041653" LOG_EFFECT_SIZE="-0.05594025828324644" MODIFIED="2016-03-31 12:45:59 -0500" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="0.22241002019586795" STUDY_ID="STD-B_x002d_PROOF-2015" TOTAL_1="1461" TOTAL_2="1458" VAR="0.04946621708352639" WEIGHT="1.324614235834253"/>
<DICH_DATA CI_END="4.0446125554663945" CI_START="0.009418829137784123" EFFECT_SIZE="0.19518072289156627" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6068769256807967" LOG_CI_START="-2.0260030813476826" LOG_EFFECT_SIZE="-0.709563077833443" MODIFIED="2012-03-05 11:57:31 -0600" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="1.5465667490947563" STUDY_ID="STD-BVAIT-2009" TOTAL_1="248" TOTAL_2="242" VAR="2.3918687094055233" WEIGHT="0.027394336103837347"/>
<DICH_DATA CI_END="2.540305099599004" CI_START="0.3017425417018056" EFFECT_SIZE="0.8755102040816326" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.4048858800510077" LOG_CI_START="-0.5203634557385866" LOG_EFFECT_SIZE="-0.05773878784378944" ORDER="53" O_E="0.0" SE="0.543496039900886" STUDY_ID="STD-FOLARDA-2004" TOTAL_1="140" TOTAL_2="143" VAR="0.29538794538794544" WEIGHT="0.22182237415156392"/>
<DICH_DATA CI_END="1.7794287703714766" CI_START="0.3938388402695121" EFFECT_SIZE="0.8371428571428572" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.2502806081006086" LOG_CI_START="-0.4046814560929408" LOG_EFFECT_SIZE="-0.07720042399616615" ORDER="54" O_E="0.0" SE="0.3847279586217968" STUDY_ID="STD-GOES-2003" TOTAL_1="300" TOTAL_2="293" VAR="0.148015602145295" WEIGHT="0.4426807335985248"/>
<DICH_DATA CI_END="1.1136974734403262" CI_START="0.8829351689785808" EFFECT_SIZE="0.9916262738063433" ESTIMABLE="YES" EVENTS_1="470" EVENTS_2="475" LOG_CI_END="0.04676723441151702" LOG_CI_START="-0.05407118406515551" LOG_EFFECT_SIZE="-0.0036519748268192607" ORDER="55" O_E="0.0" SE="0.05923298617141922" STUDY_ID="STD-HOPE_x002d_2-2006" TOTAL_1="2758" TOTAL_2="2764" VAR="0.0035085466507835403" WEIGHT="18.67544082022498"/>
<DICH_DATA CI_END="1.3080738753695722" CI_START="0.8303361209494794" EFFECT_SIZE="1.042180880456806" ESTIMABLE="YES" EVENTS_1="276" EVENTS_2="89" LOG_CI_END="0.11663227209172777" LOG_CI_START="-0.08074606916114345" LOG_EFFECT_SIZE="0.017943101465292176" ORDER="56" O_E="0.0" SE="0.11594101469048328" STUDY_ID="STD-NORVIT-2006" TOTAL_1="2806" TOTAL_2="943" VAR="0.013442318887458858" WEIGHT="4.874430958696977"/>
<DICH_DATA CI_END="1.121262774838215" CI_START="0.9522491726205677" EFFECT_SIZE="1.0333061258068357" ESTIMABLE="YES" EVENTS_1="983" EVENTS_2="951" LOG_CI_END="0.04970740411024319" LOG_CI_START="-0.02124939601170293" LOG_EFFECT_SIZE="0.014229004049270138" MODIFIED="2012-02-15 10:26:25 -0600" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.04168037563345654" STUDY_ID="STD-SEARCH-2010" TOTAL_1="6033" TOTAL_2="6031" VAR="0.0017372537129460382" WEIGHT="37.716802591022486"/>
<DICH_DATA CI_END="2.3342885526878177" CI_START="1.1269215750221253" EFFECT_SIZE="1.6219001610305959" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="45" LOG_CI_END="0.3681545402672898" LOG_CI_START="0.05189369357916221" LOG_EFFECT_SIZE="0.210024116923226" MODIFIED="2012-02-09 07:20:46 -0600" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.18577318686104555" STUDY_ID="STD-SU.FOL.OM3-2010" TOTAL_1="1242" TOTAL_2="1259" VAR="0.034511676956508947" WEIGHT="1.8985937839032976"/>
<DICH_DATA CI_END="1.0706710204910543" CI_START="0.8727588861712986" EFFECT_SIZE="0.9666631508957296" ESTIMABLE="YES" EVENTS_1="614" EVENTS_2="633" LOG_CI_END="0.029656047925021585" LOG_CI_START="-0.0591057206340775" LOG_EFFECT_SIZE="-0.014724836354527971" MODIFIED="2012-02-15 10:44:14 -0600" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.05213910222945536" STUDY_ID="STD-VITATOPS-2010" TOTAL_1="4089" TOTAL_2="4075" VAR="0.0027184859812935964" WEIGHT="24.10299548814558"/>
<DICH_DATA CI_END="1.1528755322864253" CI_START="0.8272135973905942" EFFECT_SIZE="0.9765625" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="256" LOG_CI_END="0.06178242216106865" LOG_CI_START="-0.08238233544069258" LOG_EFFECT_SIZE="-0.010299956639811952" ORDER="58" O_E="0.0" SE="0.08468309224233389" STUDY_ID="STD-WAFACS-2008" TOTAL_1="2721" TOTAL_2="2721" VAR="0.007171226111723631" WEIGHT="9.13702264032471"/>
<DICH_DATA CI_END="1.6919128510200008" CI_START="0.7611973599672892" EFFECT_SIZE="1.1348478292225588" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="30" LOG_CI_END="0.22837798914279922" LOG_CI_START="-0.11850272662992863" LOG_EFFECT_SIZE="0.054937631256435276" MODIFIED="2011-02-02 17:56:48 -0600" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.20375944953213623" STUDY_ID="STD-WENBIT-2008" TOTAL_1="2311" TOTAL_2="779" VAR="0.04151791327363918" WEIGHT="1.578202037993785"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.109731724314752" CI_START="0.6602041286118115" DF="0" EFFECT_SIZE="0.8559494529726063" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="117" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.045218001550874326" LOG_CI_START="-0.18032176412003434" LOG_EFFECT_SIZE="-0.06755188128458" MODIFIED="2016-03-28 14:07:30 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.24036872087997696" STUDIES="1" TAU2="0.0" TOTAL_1="1814" TOTAL_2="1835" WEIGHT="100.0" Z="1.174065726386269">
<NAME>Homocysteine-lowering treatments at high dose versus low dose</NAME>
<DICH_DATA CI_END="1.109731724314752" CI_START="0.6602041286118115" EFFECT_SIZE="0.8559494529726063" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="117" LOG_CI_END="0.045218001550874326" LOG_CI_START="-0.18032176412003434" LOG_EFFECT_SIZE="-0.06755188128458" MODIFIED="2016-03-28 14:07:30 -0500" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.13248317479493754" STUDY_ID="STD-VISP-2004" TOTAL_1="1814" TOTAL_2="1835" VAR="0.017551791603745974" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2288569940627782E-30" CI_END="1.1024645096015568" CI_START="0.8088216969711944" DF="0" EFFECT_SIZE="0.9442972071897952" ESTIMABLE="YES" EVENTS_1="302" EVENTS_2="320" I2="100.0" ID="CMP-001.04.03" LOG_CI_END="0.04236461761171923" LOG_CI_START="-0.09214720713456721" LOG_EFFECT_SIZE="-0.024891294761423988" MODIFIED="2016-03-28 16:08:18 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.4682194230795298" STUDIES="1" TAU2="0.0" TOTAL_1="10348" TOTAL_2="10354" WEIGHT="100.0" Z="0.7253792200496991">
<NAME>Homocysteine-lowering treatment (folic acid) plus antihypertensive therapy (enalapril) versus antihypertensive therapy (enalapril)</NAME>
<DICH_DATA CI_END="1.1024645096015568" CI_START="0.8088216969711944" EFFECT_SIZE="0.9442972071897952" ESTIMABLE="YES" EVENTS_1="302" EVENTS_2="320" LOG_CI_END="0.04236461761171923" LOG_CI_START="-0.09214720713456721" LOG_EFFECT_SIZE="-0.024891294761423988" MODIFIED="2016-03-28 14:01:14 -0500" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.07901291170023975" STUDY_ID="STD-CSPPT-2015" TOTAL_1="10348" TOTAL_2="10354" VAR="0.006243040215349882" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.429637425449321" CI_END="1.1364246324967722" CI_START="0.9923460016276401" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0619446502569387" ESTIMABLE="YES" EVENTS_1="1700" EVENTS_2="1458" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.05554063867416782" LOG_CI_START="-0.0033368758318950966" LOG_EFFECT_SIZE="0.02610188142113632" METHOD="MH" MODIFIED="2017-03-21 13:22:53 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="5" P_CHI2="0.4910647223684268" P_Q="0.5270516732816117" P_Z="0.08224561066321417" Q="0.4000735926471935" RANDOM="YES" SCALE="2.28" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="29710" TOTAL_2="26321" WEIGHT="200.0" Z="1.7378025530916168">
<NAME>Serious adverse events (cancer)</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.031653559351557" CI_END="1.1440025556451099" CI_START="0.9955593792686558" DF="7" EFFECT_SIZE="1.0672031082131468" ESTIMABLE="YES" EVENTS_1="1621" EVENTS_2="1376" I2="0.45015811834841846" ID="CMP-001.05.01" LOG_CI_END="0.05842699465047497" LOG_CI_START="-0.0019328317494321492" LOG_EFFECT_SIZE="0.02824708145052142" MODIFIED="2016-09-14 13:30:04 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="1" P_CHI2="0.42559165214912886" P_Z="0.06658859677230257" STUDIES="8" TAU2="5.5624010296542917E-5" TOTAL_1="19591" TOTAL_2="16197" WEIGHT="99.99999999999999" Z="1.8344407402562237">
<NAME>Homocysteine-lowering versus placebo</NAME>
<DICH_DATA CI_END="2.196891129626527" CI_START="1.0199728199004212" EFFECT_SIZE="1.4969199178644763" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="42" LOG_CI_END="0.34180853531196026" LOG_CI_START="0.008588598894720318" LOG_EFFECT_SIZE="0.17519856710334028" MODIFIED="2016-03-29 14:27:31 -0500" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.19573504011677426" STUDY_ID="STD-B_x002d_PROOF-2015" TOTAL_1="1461" TOTAL_2="1458" VAR="0.03831220592951523" WEIGHT="3.2764529181799533"/>
<DICH_DATA CI_END="2.058192499780468" CI_START="0.5263793291430824" EFFECT_SIZE="1.0408602150537634" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.31348599126350585" LOG_CI_START="-0.2787011737545888" LOG_EFFECT_SIZE="0.017392408754458518" MODIFIED="2016-03-30 13:45:33 -0500" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.34785367210537227" STUDY_ID="STD-BVAIT-2009" TOTAL_1="248" TOTAL_2="242" VAR="0.12100217719719185" WEIGHT="1.0384327743989479"/>
<DICH_DATA CI_END="1.212265271620601" CI_START="0.9185400753085686" EFFECT_SIZE="1.0552318389284647" ESTIMABLE="YES" EVENTS_1="358" EVENTS_2="340" LOG_CI_END="0.08359766388575178" LOG_CI_START="-0.03690189095785367" LOG_EFFECT_SIZE="0.02334788646394906" ORDER="60" O_E="0.0" SE="0.07078203499755026" STUDY_ID="STD-HOPE_x002d_2-2006" TOTAL_1="2758" TOTAL_2="2764" VAR="0.0050100964783944294" WEIGHT="24.81589512314628"/>
<DICH_DATA CI_END="1.248792589723576" CI_START="0.6113704378363911" EFFECT_SIZE="0.8737704918032787" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="40" LOG_CI_END="0.09649031297900178" LOG_CI_START="-0.21369556494739136" LOG_EFFECT_SIZE="-0.058602625984194766" ORDER="61" O_E="0.0" SE="0.1822047201388224" STUDY_ID="STD-NORVIT-2006" TOTAL_1="2806" TOTAL_2="943" VAR="0.0331985600408666" WEIGHT="3.780287863239016"/>
<DICH_DATA CI_END="1.1745798658338824" CI_START="0.9578271114455168" EFFECT_SIZE="1.0606811208151723" ESTIMABLE="YES" EVENTS_1="678" EVENTS_2="639" LOG_CI_END="0.06988255207292966" LOG_CI_START="-0.01871287434650635" LOG_EFFECT_SIZE="0.025584838863211633" MODIFIED="2012-02-09 07:36:53 -0600" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.052041392033210405" STUDY_ID="STD-SEARCH-2010" TOTAL_1="6033" TOTAL_2="6031" VAR="0.0027083064847542955" WEIGHT="45.482470921619985"/>
<DICH_DATA CI_END="1.6083524378363674" CI_START="0.896112016135888" EFFECT_SIZE="1.2005265285392979" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="77" LOG_CI_END="0.20638122167370537" LOG_CI_START="-0.0476376991001334" LOG_EFFECT_SIZE="0.07937176128678598" MODIFIED="2012-02-09 07:36:56 -0600" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.14921197147649004" STUDY_ID="STD-SU.FOL.OM3-2010" TOTAL_1="1253" TOTAL_2="1259" VAR="0.022264212431900875" WEIGHT="5.632227131058319"/>
<DICH_DATA CI_END="1.1827551569194699" CI_START="0.8020213055253932" EFFECT_SIZE="0.9739583333333334" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="192" LOG_CI_END="0.07289485028795603" LOG_CI_START="-0.09581409462205728" LOG_EFFECT_SIZE="-0.011459622167050623" MODIFIED="2012-03-04 06:33:28 -0600" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.0991004693628878" STUDY_ID="STD-WAFACS-2008" TOTAL_1="2721" TOTAL_2="2721" VAR="0.009820903027944663" WEIGHT="12.728197663387833"/>
<DICH_DATA CI_END="1.9663952835336027" CI_START="0.9096850044678861" EFFECT_SIZE="1.3374603927918371" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="31" LOG_CI_END="0.29367082387344734" LOG_CI_START="-0.04110896427628645" LOG_EFFECT_SIZE="0.1262809297985804" MODIFIED="2008-08-28 14:33:45 -0500" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.19665130474583173" STUDY_ID="STD-WENBIT-2008" TOTAL_1="2311" TOTAL_2="779" VAR="0.038671735658237984" WEIGHT="3.246035604969644"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.643650466881677E-31" CI_END="1.311247642288054" CI_START="0.7085505486481569" DF="0" EFFECT_SIZE="0.9638906765587075" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="82" I2="99.99999999999999" ID="CMP-001.05.02" LOG_CI_END="0.11768472031146468" LOG_CI_START="-0.14962916134330975" LOG_EFFECT_SIZE="-0.01597222051592251" MODIFIED="2016-03-28 16:08:44 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.8148150704331347" STUDIES="1" TAU2="0.0" TOTAL_1="10119" TOTAL_2="10124" WEIGHT="100.0" Z="0.2342188648831119">
<NAME>Homocysteine-lowering treatment (folic acid) plus antihypertensive therapy (enalapril) versus antihypertensive therapy (enalapril)</NAME>
<DICH_DATA CI_END="1.311247642288054" CI_START="0.708550548648157" EFFECT_SIZE="0.9638906765587075" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="82" LOG_CI_END="0.11768472031146468" LOG_CI_START="-0.14962916134330967" LOG_EFFECT_SIZE="-0.01597222051592251" MODIFIED="2016-03-28 14:03:37 -0500" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.15702149730906934" STUDY_ID="STD-CSPPT-2015" TOTAL_1="10119" TOTAL_2="10124" VAR="0.02465575061718207" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5886140193443739" CI_END="1.1867128264400169" CI_START="0.8808170771858711" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0223878536269293" ESTIMABLE="YES" EVENTS_1="322" EVENTS_2="312" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.07434563640907985" LOG_CI_START="-0.05511427390041184" LOG_EFFECT_SIZE="0.009615681254333963" METHOD="MH" MODIFIED="2017-08-07 12:41:33 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="6" P_CHI2="0.7450477488185692" P_Q="1.0" P_Z="0.7709334999320001" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6903" TOTAL_2="6899" WEIGHT="100.00000000000001" Z="0.29115405534047856">
<NAME>Adverse events (serious and non-serious) excluding cancer</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5886140193443739" CI_END="1.1867128264400169" CI_START="0.8808170771858711" DF="2" EFFECT_SIZE="1.0223878536269293" ESTIMABLE="YES" EVENTS_1="322" EVENTS_2="312" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.07434563640907985" LOG_CI_START="-0.05511427390041184" LOG_EFFECT_SIZE="0.009615681254333963" MODIFIED="2017-01-10 08:34:03 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NO="1" P_CHI2="0.7450477488185692" P_Z="0.7709334999320001" STUDIES="3" TAU2="0.0" TOTAL_1="6903" TOTAL_2="6899" WEIGHT="100.00000000000001" Z="0.29115405534047856">
<NAME>Homocysteine-lowering versus placebo</NAME>
<DICH_DATA CI_END="1.2719231562833309" CI_START="0.6756374386618393" EFFECT_SIZE="0.927016129032258" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="60" LOG_CI_END="0.10446087404021484" LOG_CI_START="-0.17028629315408933" LOG_EFFECT_SIZE="-0.03291270955693723" MODIFIED="2017-01-10 08:13:17 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="122" O_E="0.0" SE="0.16138784603034598" STUDY_ID="STD-BVAIT-2009" TOTAL_1="248" TOTAL_2="242" VAR="0.026046036846314662" WEIGHT="22.20261647396904"/>
<DICH_DATA CI_END="1.241971264103781" CI_START="0.8794492222277276" EFFECT_SIZE="1.0451079667887226" ESTIMABLE="YES" EVENTS_1="253" EVENTS_2="242" LOG_CI_END="0.09411154754302964" LOG_CI_START="-0.05578923084315947" LOG_EFFECT_SIZE="0.019161158349935075" MODIFIED="2017-01-10 08:23:55 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="123" O_E="0.0" SE="0.08805245924486763" STUDY_ID="STD-SEARCH-2010" TOTAL_1="6033" TOTAL_2="6031" VAR="0.007753235579069074" WEIGHT="74.58694642618165"/>
<DICH_DATA CI_END="2.774776308284195" CI_START="0.52565695068862" EFFECT_SIZE="1.207717041800643" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4432279777312835" LOG_CI_START="-0.2792975885968119" LOG_EFFECT_SIZE="0.0819651945672358" MODIFIED="2017-01-10 08:34:03 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="124" O_E="0.0" SE="0.42441509422035856" STUDY_ID="STD-SU.FOL.OM3-2010" TOTAL_1="622" TOTAL_2="626" VAR="0.18012817220207583" WEIGHT="3.210437099849316"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2017-07-12 15:41:21 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="2">
<NAME>Homocysteine-lowering treatment versus placebo or standard care (Sensitivity analysis)</NAME>
<DICH_OUTCOME CHI2="2.303926048393363" CI_END="1.0881850896636003" CI_START="0.9374144298157789" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0099902996370986" ESTIMABLE="YES" EVENTS_1="1517" EVENTS_2="1161" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.03670277089796416" LOG_CI_START="-0.028068365578839977" LOG_EFFECT_SIZE="0.004317202659562119" METHOD="MH" MODIFIED="2017-07-12 15:24:43 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="1" P_CHI2="0.805690197816231" P_Q="1.0" P_Z="0.7938799115385368" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19649" TOTAL_2="17793" WEIGHT="99.99999999999999" Z="0.2612756912095419">
<NAME>Myocardial infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.303926048393363" CI_END="1.0881850896636003" CI_START="0.9374144298157789" DF="5" EFFECT_SIZE="1.0099902996370986" ESTIMABLE="YES" EVENTS_1="1517" EVENTS_2="1161" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.03670277089796416" LOG_CI_START="-0.028068365578839977" LOG_EFFECT_SIZE="0.004317202659562119" MODIFIED="2017-07-12 15:24:43 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="1" P_CHI2="0.805690197816231" P_Z="0.7938799115385368" STUDIES="6" TAU2="0.0" TOTAL_1="19649" TOTAL_2="17793" WEIGHT="99.99999999999999" Z="0.2612756912095419">
<NAME>Trials with low risk of bias</NAME>
<DICH_DATA CI_END="1.1259071344730907" CI_START="0.8516141849657619" EFFECT_SIZE="0.9792029854281683" ESTIMABLE="YES" EVENTS_1="341" EVENTS_2="349" LOG_CI_END="0.05150257111114221" LOG_CI_START="-0.0697571133198469" LOG_EFFECT_SIZE="-0.009127271104352342" ORDER="62" O_E="0.0" SE="0.07122853887988154" STUDY_ID="STD-HOPE_x002d_2-2006" TOTAL_1="2758" TOTAL_2="2764" VAR="0.005073504750962796" WEIGHT="28.531865440484896"/>
<DICH_DATA CI_END="1.2908667841046046" CI_START="0.9390180305015682" EFFECT_SIZE="1.100975560695967" ESTIMABLE="YES" EVENTS_1="534" EVENTS_2="163" LOG_CI_END="0.11088142591208357" LOG_CI_START="-0.027326068572911845" LOG_EFFECT_SIZE="0.04177767866958588" MODIFIED="2008-09-03 13:14:27 -0500" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.08118376639861764" STUDY_ID="STD-NORVIT-2006" TOTAL_1="2806" TOTAL_2="943" VAR="0.006590803926665318" WEIGHT="21.963413944157843"/>
<DICH_DATA CI_END="1.142405312184526" CI_START="0.8829411307067917" EFFECT_SIZE="1.0043289491325293" ESTIMABLE="YES" EVENTS_1="431" EVENTS_2="429" LOG_CI_END="0.057820213906068486" LOG_CI_START="-0.05406825164495704" LOG_EFFECT_SIZE="0.00187598113055574" MODIFIED="2012-02-15 10:00:52 -0600" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.06572383852150938" STUDY_ID="STD-SEARCH-2010" TOTAL_1="6033" TOTAL_2="6031" VAR="0.004319622950001441" WEIGHT="33.511386651486106"/>
<DICH_DATA CI_END="1.4639797230697291" CI_START="0.5373896688919942" EFFECT_SIZE="0.8869766505636071" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="32" LOG_CI_END="0.16553506154483796" LOG_CI_START="-0.269710686965609" LOG_EFFECT_SIZE="-0.052087812710385546" MODIFIED="2012-02-09 07:39:19 -0600" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.2556655071762391" STUDY_ID="STD-SU.FOL.OM3-2010" TOTAL_1="1242" TOTAL_2="1259" VAR="0.06536485155968355" WEIGHT="2.2145931859717685"/>
<DICH_DATA CI_END="1.3294537093043652" CI_START="0.8003908163147914" EFFECT_SIZE="1.0315437652580952" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="114" LOG_CI_END="0.12367322008528125" LOG_CI_START="-0.09669790310265673" LOG_EFFECT_SIZE="0.013487658491312267" MODIFIED="2010-11-02 10:32:49 -0500" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.12944708861524762" STUDY_ID="STD-VITATOPS-2010" TOTAL_1="4089" TOTAL_2="4075" VAR="0.016756548750963766" WEIGHT="8.638804864743136"/>
<DICH_DATA CI_END="1.2204757235062305" CI_START="0.6321703584452255" EFFECT_SIZE="0.8783783783783784" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="74" LOG_CI_END="0.08652914528361275" LOG_CI_START="-0.19916587145985398" LOG_EFFECT_SIZE="-0.056318363088120604" MODIFIED="2017-01-04 13:19:52 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="64" O_E="0.0" SE="0.1678186670482534" STUDY_ID="STD-WAFACS-2008" TOTAL_1="2721" TOTAL_2="2721" VAR="0.02816310500985253" WEIGHT="5.139935913156236"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.394166422206444" CI_END="1.0210415118004859" CI_START="0.8021095585620148" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9049790916390168" ESTIMABLE="YES" EVENTS_1="919" EVENTS_2="953" I2="32.37912545511813" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.00904339926555542" LOG_CI_START="-0.09576630823790033" LOG_EFFECT_SIZE="-0.04336145448617246" METHOD="MH" MODIFIED="2017-07-12 15:24:55 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="2" P_CHI2="0.1929370305429302" P_Q="1.0" P_Z="0.10485967777530984" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.006890566290983719" TOTALS="YES" TOTAL_1="19649" TOTAL_2="17793" WEIGHT="100.0" Z="1.6217369771281653">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.394166422206444" CI_END="1.0210415118004859" CI_START="0.8021095585620148" DF="5" EFFECT_SIZE="0.9049790916390168" ESTIMABLE="YES" EVENTS_1="919" EVENTS_2="953" I2="32.37912545511813" ID="CMP-002.02.01" LOG_CI_END="0.00904339926555542" LOG_CI_START="-0.09576630823790033" LOG_EFFECT_SIZE="-0.04336145448617246" MODIFIED="2017-07-12 15:24:55 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="1" P_CHI2="0.1929370305429302" P_Z="0.10485967777530984" STUDIES="6" TAU2="0.006890566290983719" TOTAL_1="19649" TOTAL_2="17793" WEIGHT="100.0" Z="1.6217369771281653">
<NAME>Trials with low risk of bias</NAME>
<DICH_DATA CI_END="0.9627266837866402" CI_START="0.5948340660393838" EFFECT_SIZE="0.7567447573663257" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="147" LOG_CI_END="-0.016496990726962545" LOG_CI_START="-0.2256041674714151" LOG_EFFECT_SIZE="-0.12105057909918886" ORDER="65" O_E="0.0" SE="0.12283059071691017" STUDY_ID="STD-HOPE_x002d_2-2006" TOTAL_1="2758" TOTAL_2="2764" VAR="0.0150873540158651" WEIGHT="17.246128898666658"/>
<DICH_DATA CI_END="1.3680129519728332" CI_START="0.5708828704344923" EFFECT_SIZE="0.8837279902853673" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="27" LOG_CI_END="0.13609020918505013" LOG_CI_START="-0.2434529879748997" LOG_EFFECT_SIZE="-0.053681389394924776" ORDER="66" O_E="0.0" SE="0.22294555278088088" STUDY_ID="STD-NORVIT-2006" TOTAL_1="2806" TOTAL_2="943" VAR="0.04970471950477254" WEIGHT="6.697272417784304"/>
<DICH_DATA CI_END="1.1377129737401066" CI_START="0.823961211812356" EFFECT_SIZE="0.9682103906370441" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="286" LOG_CI_END="0.05603271052691064" LOG_CI_START="-0.08409323234700268" LOG_EFFECT_SIZE="-0.014030260910046017" MODIFIED="2012-02-15 10:01:16 -0600" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.08231067247874067" STUDY_ID="STD-SEARCH-2010" TOTAL_1="6033" TOTAL_2="6031" VAR="0.0067750468039025164" WEIGHT="27.736336738406223"/>
<DICH_DATA CI_END="1.0070605309453127" CI_START="0.3472052482205792" EFFECT_SIZE="0.5913177670424047" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="36" LOG_CI_END="0.0030555752859611376" LOG_CI_START="-0.4594137188180948" LOG_EFFECT_SIZE="-0.2281790717660668" MODIFIED="2012-02-09 07:40:04 -0600" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.271656752616649" STUDY_ID="STD-SU.FOL.OM3-2010" TOTAL_1="1242" TOTAL_2="1259" VAR="0.07379739124222323" WEIGHT="4.697529323140291"/>
<DICH_DATA CI_END="1.06011519231317" CI_START="0.8065095179482671" EFFECT_SIZE="0.924658311335668" ESTIMABLE="YES" EVENTS_1="360" EVENTS_2="388" LOG_CI_END="0.02535305834767253" LOG_CI_START="-0.0933905029581936" LOG_EFFECT_SIZE="-0.03401872230526054" MODIFIED="2010-11-02 10:33:27 -0500" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.06975055570117394" STUDY_ID="STD-VITATOPS-2010" TOTAL_1="4089" TOTAL_2="4075" VAR="0.004865140020622568" WEIGHT="32.24255833631381"/>
<DICH_DATA CI_END="1.5744311510392066" CI_START="0.8325921793130026" EFFECT_SIZE="1.144927536231884" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="69" LOG_CI_END="0.19712367394206512" LOG_CI_START="-0.07956767283569291" LOG_EFFECT_SIZE="0.058778000553186105" MODIFIED="2017-01-04 13:19:10 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="67" O_E="0.0" SE="0.16252986674151093" STUDY_ID="STD-WAFACS-2008" TOTAL_1="2721" TOTAL_2="2721" VAR="0.0264159575830133" WEIGHT="11.380174285688717"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.140996879164835" CI_END="1.1229351777732561" CI_START="0.9473176598517785" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0313953290438163" ESTIMABLE="YES" EVENTS_1="2145" EVENTS_2="1923" I2="40.83421904677549" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.05035468702912556" LOG_CI_START="-0.0235043665218023" LOG_EFFECT_SIZE="0.013425160253661651" METHOD="MH" MODIFIED="2017-07-12 15:41:21 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="3" P_CHI2="0.11883864262984234" P_Q="1.0" P_Z="0.47614611891198777" Q="0.0" RANDOM="YES" SCALE="1.5575671558700295" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.004754975214485965" TOTALS="YES" TOTAL_1="19897" TOTAL_2="18035" WEIGHT="100.00000000000001" Z="0.7125146970834657">
<NAME>Death from any cause</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.140996879164835" CI_END="1.1229351777732561" CI_START="0.9473176598517785" DF="6" EFFECT_SIZE="1.0313953290438163" ESTIMABLE="YES" EVENTS_1="2145" EVENTS_2="1923" I2="40.83421904677549" ID="CMP-002.03.01" LOG_CI_END="0.05035468702912556" LOG_CI_START="-0.0235043665218023" LOG_EFFECT_SIZE="0.013425160253661651" MODIFIED="2017-07-12 15:41:21 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="1" P_CHI2="0.11883864262984234" P_Z="0.47614611891198777" STUDIES="7" TAU2="0.004754975214485965" TOTAL_1="19897" TOTAL_2="18035" WEIGHT="100.00000000000001" Z="0.7125146970834657">
<NAME>Trials with low risk of bias</NAME>
<DICH_DATA CI_END="4.0446125554663945" CI_START="0.009418829137784123" EFFECT_SIZE="0.19518072289156627" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6068769256807967" LOG_CI_START="-2.0260030813476826" LOG_EFFECT_SIZE="-0.709563077833443" MODIFIED="2017-07-12 15:41:21 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="67" O_E="0.0" SE="1.5465667490947563" STUDY_ID="STD-BVAIT-2009" TOTAL_1="248" TOTAL_2="242" VAR="2.3918687094055233" WEIGHT="0.0785385417801286"/>
<DICH_DATA CI_END="1.1136974734403262" CI_START="0.8829351689785808" EFFECT_SIZE="0.9916262738063433" ESTIMABLE="YES" EVENTS_1="470" EVENTS_2="475" LOG_CI_END="0.04676723441151702" LOG_CI_START="-0.05407118406515551" LOG_EFFECT_SIZE="-0.0036519748268192607" ORDER="70" O_E="0.0" SE="0.05923298617141922" STUDY_ID="STD-HOPE_x002d_2-2006" TOTAL_1="2758" TOTAL_2="2764" VAR="0.0035085466507835403" WEIGHT="22.778100240391336"/>
<DICH_DATA CI_END="1.3080738753695722" CI_START="0.8303361209494794" EFFECT_SIZE="1.042180880456806" ESTIMABLE="YES" EVENTS_1="276" EVENTS_2="89" LOG_CI_END="0.11663227209172777" LOG_CI_START="-0.08074606916114345" LOG_EFFECT_SIZE="0.017943101465292176" ORDER="71" O_E="0.0" SE="0.11594101469048328" STUDY_ID="STD-NORVIT-2006" TOTAL_1="2806" TOTAL_2="943" VAR="0.013442318887458858" WEIGHT="10.343698812102932"/>
<DICH_DATA CI_END="1.2422539548437819" CI_START="0.9637909979260662" EFFECT_SIZE="1.094199789259937" ESTIMABLE="YES" EVENTS_1="463" EVENTS_2="423" LOG_CI_END="0.09421038804111416" LOG_CI_START="-0.016017134446195735" LOG_EFFECT_SIZE="0.0390966267974592" MODIFIED="2012-02-15 10:01:32 -0600" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.06474819234408204" STUDY_ID="STD-SEARCH-2010" TOTAL_1="6033" TOTAL_2="6031" VAR="0.0041923284118262445" WEIGHT="21.037324455184002"/>
<DICH_DATA CI_END="2.3342885526878177" CI_START="1.1269215750221253" EFFECT_SIZE="1.6219001610305959" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="45" LOG_CI_END="0.3681545402672898" LOG_CI_START="0.05189369357916221" LOG_EFFECT_SIZE="0.210024116923226" MODIFIED="2012-02-09 07:43:25 -0600" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.18577318686104555" STUDY_ID="STD-SU.FOL.OM3-2010" TOTAL_1="1242" TOTAL_2="1259" VAR="0.034511676956508947" WEIGHT="4.793567034085279"/>
<DICH_DATA CI_END="1.0706710204910543" CI_START="0.8727588861712986" EFFECT_SIZE="0.9666631508957296" ESTIMABLE="YES" EVENTS_1="614" EVENTS_2="633" LOG_CI_END="0.029656047925021585" LOG_CI_START="-0.0591057206340775" LOG_EFFECT_SIZE="-0.014724836354527971" MODIFIED="2010-11-02 10:31:38 -0500" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.05213910222945536" STUDY_ID="STD-VITATOPS-2010" TOTAL_1="4089" TOTAL_2="4075" VAR="0.0027184859812935964" WEIGHT="25.186098442856803"/>
<DICH_DATA CI_END="1.1528755322864253" CI_START="0.8272135973905942" EFFECT_SIZE="0.9765625" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="256" LOG_CI_END="0.06178242216106865" LOG_CI_START="-0.08238233544069258" LOG_EFFECT_SIZE="-0.010299956639811952" MODIFIED="2017-01-04 13:19:32 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="72" O_E="0.0" SE="0.08468309224233389" STUDY_ID="STD-WAFACS-2008" TOTAL_1="2721" TOTAL_2="2721" VAR="0.007171226111723631" WEIGHT="15.782672473599524"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2017-08-07 12:40:52 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="3">
<NAME>Homocysteine-lowering treatment versus placebo (Subgoup analysis)</NAME>
<DICH_OUTCOME CHI2="6.2785779694449815" CI_END="1.0955801634276772" CI_START="0.9518632783350354" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0211966147804754" ESTIMABLE="YES" EVENTS_1="1788" EVENTS_2="1290" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.03964416031805921" LOG_CI_START="-0.02142542738108458" LOG_EFFECT_SIZE="0.00910936646848733" METHOD="MH" MODIFIED="2017-01-04 12:46:12 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NO="1" P_CHI2="0.854145150740506" P_Q="0.963563319449883" P_Z="0.5587420515527548" Q="0.0020868911900390275" RANDOM="YES" SCALE="15.387254376721632" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25051" TOTAL_2="21648" WEIGHT="99.99999999999999" Z="0.5847110115813753">
<NAME>Myocardial Infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.872002261275224" CI_START="0.13856197870817752" DF="0" EFFECT_SIZE="0.9758064516129032" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.8370832937305186" LOG_CI_START="-0.8583559234220886" LOG_EFFECT_SIZE="-0.01063631484578498" MODIFIED="2017-01-04 12:36:02 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NO="1" P_CHI2="1.0" P_Z="0.9803807077408117" STUDIES="1" TAU2="0.0" TOTAL_1="248" TOTAL_2="242" WEIGHT="0.12974347529089716" Z="0.02459161474509037">
<NAME>Without history of cardiovascular disease</NAME>
<DICH_DATA CI_END="6.872002261275224" CI_START="0.13856197870817752" EFFECT_SIZE="0.9758064516129032" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8370832937305186" LOG_CI_START="-0.8583559234220886" LOG_EFFECT_SIZE="-0.01063631484578498" MODIFIED="2017-01-04 12:13:15 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="68" O_E="0.0" SE="0.9959093887149197" STUDY_ID="STD-BVAIT-2009" TOTAL_1="248" TOTAL_2="242" VAR="0.9918355105305252" WEIGHT="0.12974347529089716"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.2764886945425635" CI_END="1.0956948997104505" CI_START="0.951876043737034" DF="10" EFFECT_SIZE="1.0212569345072913" ESTIMABLE="YES" EVENTS_1="1786" EVENTS_2="1288" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.03968964008038237" LOG_CI_START="-0.021419603113462315" LOG_EFFECT_SIZE="0.00913501848346" MODIFIED="2017-01-04 12:36:11 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NO="2" P_CHI2="0.7915235980446289" P_Z="0.5578909360530198" STUDIES="11" TAU2="0.0" TOTAL_1="24803" TOTAL_2="21406" WEIGHT="99.87025652470909" Z="0.5859770564952038">
<NAME>With history of cardiovascular disease</NAME>
<DICH_DATA CI_END="1.5762289505204619" CI_START="0.6919638917567603" EFFECT_SIZE="1.0443627333938208" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="43" LOG_CI_END="0.1976192999085921" LOG_CI_START="-0.15991656742175966" LOG_EFFECT_SIZE="0.01885136624341623" MODIFIED="2017-01-04 12:31:19 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="82" O_E="0.0" SE="0.2100183383009354" STUDY_ID="STD-B_x002d_PROOF-2015" TOTAL_1="1461" TOTAL_2="1458" VAR="0.04410770242268615" WEIGHT="2.9174991891430904"/>
<DICH_DATA CI_END="3.821120562510988" CI_START="0.9573182559938257" EFFECT_SIZE="1.9125973106864826" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.5821907405952977" LOG_CI_START="-0.018943659041719105" LOG_EFFECT_SIZE="0.28162354077678936" MODIFIED="2017-01-04 12:32:30 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="37" O_E="0.0" SE="0.35310932201005274" STUDY_ID="STD-CHAOS-2002" TOTAL_1="942" TOTAL_2="940" VAR="0.12468619329039912" WEIGHT="1.0320644383892685"/>
<DICH_DATA CI_END="2.0098760271954488" CI_START="0.33222071408619264" EFFECT_SIZE="0.8171428571428572" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.3031692701740288" LOG_CI_START="-0.478573292616494" LOG_EFFECT_SIZE="-0.08770201122123261" MODIFIED="2017-01-04 12:16:41 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="38" O_E="0.0" SE="0.4591994510712484" STUDY_ID="STD-FOLARDA-2004" TOTAL_1="140" TOTAL_2="143" VAR="0.21086413586413585" WEIGHT="0.6102706158436799"/>
<DICH_DATA CI_END="3.244541168646203" CI_START="0.16537199625791166" EFFECT_SIZE="0.7325" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.511153289113494" LOG_CI_START="-0.7815380310611997" LOG_EFFECT_SIZE="-0.13519237097385292" MODIFIED="2017-01-04 12:17:50 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="39" O_E="0.0" SE="0.7593332803958506" STUDY_ID="STD-GOES-2003" TOTAL_1="300" TOTAL_2="293" VAR="0.5765870307167235" WEIGHT="0.22318258857330067"/>
<DICH_DATA CI_END="1.1259071344730907" CI_START="0.8516141849657619" EFFECT_SIZE="0.9792029854281683" ESTIMABLE="YES" EVENTS_1="341" EVENTS_2="349" LOG_CI_END="0.05150257111114221" LOG_CI_START="-0.0697571133198469" LOG_EFFECT_SIZE="-0.009127271104352342" MODIFIED="2017-01-04 12:18:57 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="40" O_E="0.0" SE="0.07122853887988154" STUDY_ID="STD-HOPE_x002d_2-2006" TOTAL_1="2758" TOTAL_2="2764" VAR="0.005073504750962796" WEIGHT="25.363962855998363"/>
<DICH_DATA CI_END="1.2908667841046046" CI_START="0.9390180305015682" EFFECT_SIZE="1.100975560695967" ESTIMABLE="YES" EVENTS_1="534" EVENTS_2="163" LOG_CI_END="0.11088142591208357" LOG_CI_START="-0.027326068572911845" LOG_EFFECT_SIZE="0.04177767866958588" MODIFIED="2017-01-04 12:21:58 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="41" O_E="0.0" SE="0.08118376639861764" STUDY_ID="STD-NORVIT-2006" TOTAL_1="2806" TOTAL_2="943" VAR="0.006590803926665318" WEIGHT="19.52480873122569"/>
<DICH_DATA CI_END="1.142405312184526" CI_START="0.8829411307067917" EFFECT_SIZE="1.0043289491325293" ESTIMABLE="YES" EVENTS_1="431" EVENTS_2="429" LOG_CI_END="0.057820213906068486" LOG_CI_START="-0.05406825164495704" LOG_EFFECT_SIZE="0.00187598113055574" MODIFIED="2017-01-04 12:23:55 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="44" O_E="0.0" SE="0.06572383852150938" STUDY_ID="STD-SEARCH-2010" TOTAL_1="6033" TOTAL_2="6031" VAR="0.004319622950001441" WEIGHT="29.79060615767602"/>
<DICH_DATA CI_END="1.4639797230697291" CI_START="0.5373896688919942" EFFECT_SIZE="0.8869766505636071" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="32" LOG_CI_END="0.16553506154483796" LOG_CI_START="-0.269710686965609" LOG_EFFECT_SIZE="-0.052087812710385546" MODIFIED="2017-01-04 12:25:06 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="64" O_E="0.0" SE="0.2556655071762391" STUDY_ID="STD-SU.FOL.OM3-2010" TOTAL_1="1242" TOTAL_2="1259" VAR="0.06536485155968355" WEIGHT="1.968706162143613"/>
<DICH_DATA CI_END="1.3294537093043652" CI_START="0.8003908163147914" EFFECT_SIZE="1.0315437652580952" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="114" LOG_CI_END="0.12367322008528125" LOG_CI_START="-0.09669790310265673" LOG_EFFECT_SIZE="0.013487658491312267" MODIFIED="2017-01-04 12:27:06 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="50" O_E="0.0" SE="0.12944708861524762" STUDY_ID="STD-VITATOPS-2010" TOTAL_1="4089" TOTAL_2="4075" VAR="0.016756548750963766" WEIGHT="7.679635464656778"/>
<DICH_DATA CI_END="1.2204757235062305" CI_START="0.6321703584452255" EFFECT_SIZE="0.8783783783783784" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="74" LOG_CI_END="0.08652914528361275" LOG_CI_START="-0.19916587145985398" LOG_EFFECT_SIZE="-0.056318363088120604" MODIFIED="2017-01-04 12:28:19 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="43" O_E="0.0" SE="0.1678186670482534" STUDY_ID="STD-WAFACS-2008" TOTAL_1="2721" TOTAL_2="2721" VAR="0.02816310500985253" WEIGHT="4.569247105677195"/>
<DICH_DATA CI_END="1.4648397272808813" CI_START="0.8324077776262513" EFFECT_SIZE="1.1042390963756548" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="58" LOG_CI_END="0.16579010976503922" LOG_CI_START="-0.07966387059834557" LOG_EFFECT_SIZE="0.043063119583346854" MODIFIED="2017-01-04 12:29:42 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="37" O_E="0.0" SE="0.14418088308225055" STUDY_ID="STD-WENBIT-2008" TOTAL_1="2311" TOTAL_2="779" VAR="0.020788127046377607" WEIGHT="6.190273215382104"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.807041484512716" CI_END="0.988802155011113" CI_START="0.8175573834367365" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8991120634200677" ESTIMABLE="YES" EVENTS_1="1014" EVENTS_2="1034" I2="8.229204350641284" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.004890595745940051" LOG_CI_START="-0.08748175495476206" LOG_EFFECT_SIZE="-0.04618617535035107" METHOD="MH" MODIFIED="2017-08-07 12:40:29 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="2" P_CHI2="0.3663312245185636" P_Q="0.32311347943387214" P_Z="0.028373684925769815" Q="0.9763029115099009" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0020241934067668876" TOTALS="YES" TOTAL_1="23809" TOTAL_2="20415" WEIGHT="100.0" Z="2.1920806327820714">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.044612555466395" CI_START="0.009418829137784123" DF="0" EFFECT_SIZE="0.19518072289156632" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.6068769256807968" LOG_CI_START="-2.0260030813476826" LOG_EFFECT_SIZE="-0.7095630778334429" MODIFIED="2017-01-04 12:36:33 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NO="1" P_CHI2="1.0" P_Z="0.2907748171163401" STUDIES="1" TAU2="0.0" TOTAL_1="248" TOTAL_2="242" WEIGHT="0.098319035666" Z="1.0564234401874861">
<NAME>Without history of cardiovascular disease</NAME>
<DICH_DATA CI_END="4.0446125554663945" CI_START="0.009418829137784123" EFFECT_SIZE="0.19518072289156627" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6068769256807967" LOG_CI_START="-2.0260030813476826" LOG_EFFECT_SIZE="-0.709563077833443" MODIFIED="2017-01-04 12:14:21 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="69" O_E="0.0" SE="1.5465667490947563" STUDY_ID="STD-BVAIT-2009" TOTAL_1="248" TOTAL_2="242" VAR="2.3918687094055233" WEIGHT="0.098319035666"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.822460460620617" CI_END="0.9904230521125353" CI_START="0.818517664599141" DF="8" EFFECT_SIZE="0.900377011912402" ESTIMABLE="YES" EVENTS_1="1014" EVENTS_2="1032" I2="9.322347935609345" ID="CMP-003.02.02" LOG_CI_END="-0.004179259995239959" LOG_CI_START="-0.08697194355179569" LOG_EFFECT_SIZE="-0.04557560177351781" MODIFIED="2017-01-04 12:48:33 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NO="2" P_CHI2="0.3574940066440333" P_Z="0.030940544463024817" STUDIES="9" TAU2="0.0020655762986701736" TOTAL_1="23561" TOTAL_2="20173" WEIGHT="99.901680964334" Z="2.157836519185073">
<NAME>With history of cardiovascular disease</NAME>
<DICH_DATA CI_END="1.1156403737194664" CI_START="0.5246909291716162" EFFECT_SIZE="0.7650924024640657" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="60" LOG_CI_END="0.04752422248743765" LOG_CI_START="-0.2800964437962586" LOG_EFFECT_SIZE="-0.1162861106544105" MODIFIED="2017-01-04 12:31:35 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="83" O_E="0.0" SE="0.19244600112349652" STUDY_ID="STD-B_x002d_PROOF-2015" TOTAL_1="1461" TOTAL_2="1458" VAR="0.03703546334842482" WEIGHT="6.025788786812668"/>
<DICH_DATA CI_END="74.57749473307939" CI_START="0.12586978147683617" EFFECT_SIZE="3.0638297872340425" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8726077901023332" LOG_CI_START="-0.9000785217832687" LOG_EFFECT_SIZE="0.4862646341595322" MODIFIED="2017-01-04 12:48:33 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="45" O_E="0.0" SE="1.6286896646202007" STUDY_ID="STD-FOLARDA-2004" TOTAL_1="140" TOTAL_2="143" VAR="2.6526300236406617" WEIGHT="0.08866135566008473"/>
<DICH_DATA CI_END="0.9627266837866402" CI_START="0.5948340660393838" EFFECT_SIZE="0.7567447573663257" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="147" LOG_CI_END="-0.016496990726962545" LOG_CI_START="-0.2256041674714151" LOG_EFFECT_SIZE="-0.12105057909918886" MODIFIED="2017-01-04 12:19:18 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="46" O_E="0.0" SE="0.12283059071691017" STUDY_ID="STD-HOPE_x002d_2-2006" TOTAL_1="2758" TOTAL_2="2764" VAR="0.0150873540158651" WEIGHT="13.75476079859898"/>
<DICH_DATA CI_END="1.3680129519728332" CI_START="0.5708828704344923" EFFECT_SIZE="0.8837279902853673" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="27" LOG_CI_END="0.13609020918505013" LOG_CI_START="-0.2434529879748997" LOG_EFFECT_SIZE="-0.053681389394924776" MODIFIED="2017-01-04 12:22:12 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="47" O_E="0.0" SE="0.22294555278088088" STUDY_ID="STD-NORVIT-2006" TOTAL_1="2806" TOTAL_2="943" VAR="0.04970471950477254" WEIGHT="4.549974635938692"/>
<DICH_DATA CI_END="1.1377129737401066" CI_START="0.823961211812356" EFFECT_SIZE="0.9682103906370441" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="286" LOG_CI_END="0.05603271052691064" LOG_CI_START="-0.08409323234700268" LOG_EFFECT_SIZE="-0.014030260910046017" MODIFIED="2017-01-04 12:24:12 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="45" O_E="0.0" SE="0.08231067247874067" STUDY_ID="STD-SEARCH-2010" TOTAL_1="6033" TOTAL_2="6031" VAR="0.0067750468039025164" WEIGHT="26.748359637551072"/>
<DICH_DATA CI_END="1.0070605309453127" CI_START="0.3472052482205792" EFFECT_SIZE="0.5913177670424047" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="36" LOG_CI_END="0.0030555752859611376" LOG_CI_START="-0.4594137188180948" LOG_EFFECT_SIZE="-0.2281790717660668" MODIFIED="2017-01-04 12:25:23 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="65" O_E="0.0" SE="0.271656752616649" STUDY_ID="STD-SU.FOL.OM3-2010" TOTAL_1="1242" TOTAL_2="1259" VAR="0.07379739124222323" WEIGHT="3.1041983991997815"/>
<DICH_DATA CI_END="1.06011519231317" CI_START="0.8065095179482671" EFFECT_SIZE="0.924658311335668" ESTIMABLE="YES" EVENTS_1="360" EVENTS_2="388" LOG_CI_END="0.02535305834767253" LOG_CI_START="-0.0933905029581936" LOG_EFFECT_SIZE="-0.03401872230526054" MODIFIED="2017-01-04 12:27:22 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="51" O_E="0.0" SE="0.06975055570117394" STUDY_ID="STD-VITATOPS-2010" TOTAL_1="4089" TOTAL_2="4075" VAR="0.004865140020622568" WEIGHT="34.16371760386284"/>
<DICH_DATA CI_END="1.5744311510392066" CI_START="0.8325921793130026" EFFECT_SIZE="1.144927536231884" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="69" LOG_CI_END="0.19712367394206512" LOG_CI_START="-0.07956767283569291" LOG_EFFECT_SIZE="0.058778000553186105" MODIFIED="2017-01-04 12:28:35 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="48" O_E="0.0" SE="0.16252986674151093" STUDY_ID="STD-WAFACS-2008" TOTAL_1="2721" TOTAL_2="2721" VAR="0.0264159575830133" WEIGHT="8.275808443378626"/>
<DICH_DATA CI_END="1.4395515958890144" CI_START="0.5037592827095392" EFFECT_SIZE="0.8515794028559065" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="19" LOG_CI_END="0.15822723531921837" LOG_CI_START="-0.2977769380867916" LOG_EFFECT_SIZE="-0.06977485138378663" MODIFIED="2017-01-04 12:29:56 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="38" O_E="0.0" SE="0.2678591087157532" STUDY_ID="STD-WENBIT-2008" TOTAL_1="2311" TOTAL_2="779" VAR="0.0717485021219977" WEIGHT="3.190411303331258"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.98918161102987" CI_END="1.062446641797468" CI_START="0.9610139987241988" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.010458359193926" ESTIMABLE="YES" EVENTS_1="2821" EVENTS_2="2544" I2="0.0" I2_Q="11.5513091029243" ID="CMP-003.03" LOG_CI_END="0.026307128129581355" LOG_CI_START="-0.01727028608338635" LOG_EFFECT_SIZE="0.00451842102309749" METHOD="MH" MODIFIED="2017-08-07 12:40:52 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="3" P_CHI2="0.441443014719784" P_Q="0.2876476504408343" P_Z="0.6844146030194249" Q="1.1305989832723031" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24109" TOTAL_2="20708" WEIGHT="100.00000000000004" Z="0.40644644168099187">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.044612555466395" CI_START="0.009418829137784123" DF="0" EFFECT_SIZE="0.19518072289156632" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.6068769256807968" LOG_CI_START="-2.0260030813476826" LOG_EFFECT_SIZE="-0.7095630778334429" MODIFIED="2017-01-04 12:36:54 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NO="1" P_CHI2="1.0" P_Z="0.2907748171163401" STUDIES="1" TAU2="0.0" TOTAL_1="248" TOTAL_2="242" WEIGHT="0.027394336103837354" Z="1.0564234401874861">
<NAME>Without history of cardiovascular disease</NAME>
<DICH_DATA CI_END="4.0446125554663945" CI_START="0.009418829137784123" EFFECT_SIZE="0.19518072289156627" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6068769256807967" LOG_CI_START="-2.0260030813476826" LOG_EFFECT_SIZE="-0.709563077833443" MODIFIED="2017-01-04 12:15:20 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="65" O_E="0.0" SE="1.5465667490947563" STUDY_ID="STD-BVAIT-2009" TOTAL_1="248" TOTAL_2="242" VAR="2.3918687094055233" WEIGHT="0.027394336103837354"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.85972505784911" CI_END="1.0629327411150589" CI_START="0.9614404730599857" DF="9" EFFECT_SIZE="1.0109137240381147" ESTIMABLE="YES" EVENTS_1="2821" EVENTS_2="2542" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.0265057846674822" LOG_CI_START="-0.017077599643772506" LOG_EFFECT_SIZE="0.004714092511854868" MODIFIED="2017-01-04 12:37:01 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NO="2" P_CHI2="0.4503225162309301" P_Z="0.6715733755929099" STUDIES="10" TAU2="0.0" TOTAL_1="23861" TOTAL_2="20466" WEIGHT="99.9726056638962" Z="0.4239896322433839">
<NAME>With history of cardiovascular disease</NAME>
<DICH_DATA CI_END="1.3594883620134919" CI_START="0.5685176985818927" EFFECT_SIZE="0.8791434438251686" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="42" LOG_CI_END="0.13337549413392366" LOG_CI_START="-0.24525601070041653" LOG_EFFECT_SIZE="-0.05594025828324644" MODIFIED="2017-01-04 12:31:48 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="86" O_E="0.0" SE="0.22241002019586795" STUDY_ID="STD-B_x002d_PROOF-2015" TOTAL_1="1461" TOTAL_2="1458" VAR="0.04946621708352639" WEIGHT="1.3246142358342532"/>
<DICH_DATA CI_END="2.540305099599004" CI_START="0.3017425417018056" EFFECT_SIZE="0.8755102040816326" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.4048858800510077" LOG_CI_START="-0.5203634557385866" LOG_EFFECT_SIZE="-0.05773878784378944" MODIFIED="2017-01-04 12:16:51 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="53" O_E="0.0" SE="0.543496039900886" STUDY_ID="STD-FOLARDA-2004" TOTAL_1="140" TOTAL_2="143" VAR="0.29538794538794544" WEIGHT="0.22182237415156397"/>
<DICH_DATA CI_END="1.7794287703714766" CI_START="0.3938388402695121" EFFECT_SIZE="0.8371428571428572" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.2502806081006086" LOG_CI_START="-0.4046814560929408" LOG_EFFECT_SIZE="-0.07720042399616615" MODIFIED="2017-01-04 12:18:05 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="54" O_E="0.0" SE="0.3847279586217968" STUDY_ID="STD-GOES-2003" TOTAL_1="300" TOTAL_2="293" VAR="0.148015602145295" WEIGHT="0.4426807335985249"/>
<DICH_DATA CI_END="1.1136974734403262" CI_START="0.8829351689785808" EFFECT_SIZE="0.9916262738063433" ESTIMABLE="YES" EVENTS_1="470" EVENTS_2="475" LOG_CI_END="0.04676723441151702" LOG_CI_START="-0.05407118406515551" LOG_EFFECT_SIZE="-0.0036519748268192607" MODIFIED="2017-01-04 12:19:06 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="55" O_E="0.0" SE="0.05923298617141922" STUDY_ID="STD-HOPE_x002d_2-2006" TOTAL_1="2758" TOTAL_2="2764" VAR="0.0035085466507835403" WEIGHT="18.675440820224985"/>
<DICH_DATA CI_END="1.3080738753695722" CI_START="0.8303361209494794" EFFECT_SIZE="1.042180880456806" ESTIMABLE="YES" EVENTS_1="276" EVENTS_2="89" LOG_CI_END="0.11663227209172777" LOG_CI_START="-0.08074606916114345" LOG_EFFECT_SIZE="0.017943101465292176" MODIFIED="2017-01-04 12:22:28 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="56" O_E="0.0" SE="0.11594101469048328" STUDY_ID="STD-NORVIT-2006" TOTAL_1="2806" TOTAL_2="943" VAR="0.013442318887458858" WEIGHT="4.874430958696978"/>
<DICH_DATA CI_END="1.121262774838215" CI_START="0.9522491726205677" EFFECT_SIZE="1.0333061258068357" ESTIMABLE="YES" EVENTS_1="983" EVENTS_2="951" LOG_CI_END="0.04970740411024319" LOG_CI_START="-0.02124939601170293" LOG_EFFECT_SIZE="0.014229004049270138" MODIFIED="2017-01-04 12:24:27 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="46" O_E="0.0" SE="0.04168037563345654" STUDY_ID="STD-SEARCH-2010" TOTAL_1="6033" TOTAL_2="6031" VAR="0.0017372537129460382" WEIGHT="37.71680259102249"/>
<DICH_DATA CI_END="2.3342885526878177" CI_START="1.1269215750221253" EFFECT_SIZE="1.6219001610305959" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="45" LOG_CI_END="0.3681545402672898" LOG_CI_START="0.05189369357916221" LOG_EFFECT_SIZE="0.210024116923226" MODIFIED="2017-01-04 12:25:35 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="66" O_E="0.0" SE="0.18577318686104555" STUDY_ID="STD-SU.FOL.OM3-2010" TOTAL_1="1242" TOTAL_2="1259" VAR="0.034511676956508947" WEIGHT="1.898593783903298"/>
<DICH_DATA CI_END="1.0706710204910543" CI_START="0.8727588861712986" EFFECT_SIZE="0.9666631508957296" ESTIMABLE="YES" EVENTS_1="614" EVENTS_2="633" LOG_CI_END="0.029656047925021585" LOG_CI_START="-0.0591057206340775" LOG_EFFECT_SIZE="-0.014724836354527971" MODIFIED="2017-01-04 12:27:34 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="52" O_E="0.0" SE="0.05213910222945536" STUDY_ID="STD-VITATOPS-2010" TOTAL_1="4089" TOTAL_2="4075" VAR="0.0027184859812935964" WEIGHT="24.102995488145588"/>
<DICH_DATA CI_END="1.1528755322864253" CI_START="0.8272135973905942" EFFECT_SIZE="0.9765625" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="256" LOG_CI_END="0.06178242216106865" LOG_CI_START="-0.08238233544069258" LOG_EFFECT_SIZE="-0.010299956639811952" MODIFIED="2017-01-04 12:28:47 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="58" O_E="0.0" SE="0.08468309224233389" STUDY_ID="STD-WAFACS-2008" TOTAL_1="2721" TOTAL_2="2721" VAR="0.007171226111723631" WEIGHT="9.137022640324712"/>
<DICH_DATA CI_END="1.6919128510200008" CI_START="0.7611973599672892" EFFECT_SIZE="1.1348478292225588" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="30" LOG_CI_END="0.22837798914279922" LOG_CI_START="-0.11850272662992863" LOG_EFFECT_SIZE="0.054937631256435276" MODIFIED="2017-01-04 12:30:08 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" ORDER="40" O_E="0.0" SE="0.20375944953213623" STUDY_ID="STD-WENBIT-2008" TOTAL_1="2311" TOTAL_2="779" VAR="0.04151791327363918" WEIGHT="1.5782020379937853"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2017-01-04 14:12:00 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NO="4">
<NAME>Homocysteine-lowering treatment (folic acid) plus antihypertensive therapy (enalapril) versus antihypertensive therapy (enalapril) (Sensitivity analysis)</NAME>
<DICH_OUTCOME CHI2="25.68886231928136" CI_END="1.3330938000604462" CI_START="0.7518121602336401" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.001117440472154" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="107" I2="92.21452481957968" I2_Q="92.21451965287224" ID="CMP-004.01" LOG_CI_END="0.12486070861524204" LOG_CI_START="-0.12389065404165518" LOG_EFFECT_SIZE="4.850272867934901E-4" METHOD="MH" MODIFIED="2015-04-17 11:37:47 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.6408224744756126E-6" P_Q="2.6408449845805038E-6" P_Z="0.9939016180245794" Q="25.68884527128563" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.7675437739633912" TOTALS="SUB" TOTAL_1="31012" TOTAL_2="31027" WEIGHT="300.0" Z="0.007643262762307679">
<NAME>Myocardial infarction</NAME>
<GROUP_LABEL_1>Enalapril plus folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Enalapril</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours enalapril plus folic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours enalapri</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8231285172387977" CI_START="0.5955151405310718" DF="0" EFFECT_SIZE="1.0419695941579423" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.2608172843216477" LOG_CI_START="-0.22510719242552124" LOG_EFFECT_SIZE="0.017855045948063194" MODIFIED="2015-04-17 11:31:32 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8854722435695009" STUDIES="1" TAU2="0.0" TOTAL_1="10316" TOTAL_2="10319" WEIGHT="100.0" Z="0.14403574495680344">
<NAME>Per protocol analysis</NAME>
<DICH_DATA CI_END="1.8231285172387977" CI_START="0.5955151405310718" EFFECT_SIZE="1.0419695941579423" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" LOG_CI_END="0.2608172843216477" LOG_CI_START="-0.22510719242552124" LOG_EFFECT_SIZE="0.017855045948063194" MODIFIED="2015-04-17 11:31:32 -0500" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.28543444300624016" STUDY_ID="STD-CSPPT-2015" TOTAL_1="10316" TOTAL_2="10319" VAR="0.08147282125428255" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6762787973673159" CI_START="0.2657992208777139" DF="0" EFFECT_SIZE="0.42397450092706035" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="59" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="-0.16987422832317442" LOG_CI_START="-0.575446296414376" LOG_EFFECT_SIZE="-0.3726602623687752" MODIFIED="2015-04-17 11:31:57 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="3.1598575061305437E-4" STUDIES="1" TAU2="0.0" TOTAL_1="10348" TOTAL_2="10354" WEIGHT="100.0" Z="3.6018293673409505">
<NAME>Best-worst scenario</NAME>
<DICH_DATA CI_END="0.6762787973673159" CI_START="0.2657992208777139" EFFECT_SIZE="0.42397450092706035" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="59" LOG_CI_END="-0.16987422832317442" LOG_CI_START="-0.575446296414376" LOG_EFFECT_SIZE="-0.3726602623687752" MODIFIED="2015-04-17 11:31:57 -0500" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.23823504041088722" STUDY_ID="STD-CSPPT-2015" TOTAL_1="10348" TOTAL_2="10354" VAR="0.05675593447957707" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.825619881776519" CI_START="1.4761445700081959" DF="0" EFFECT_SIZE="2.3763770776961732" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="24" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.5827018158093918" LOG_CI_START="0.16912889331504163" LOG_EFFECT_SIZE="0.37591535456221675" MODIFIED="2015-04-17 11:32:13 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="3.6663801218204435E-4" STUDIES="1" TAU2="0.0" TOTAL_1="10348" TOTAL_2="10354" WEIGHT="100.0" Z="3.563001908992796">
<NAME>Worst-best scenario</NAME>
<DICH_DATA CI_END="3.825619881776519" CI_START="1.4761445700081959" EFFECT_SIZE="2.3763770776961732" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="24" LOG_CI_END="0.5827018158093918" LOG_CI_START="0.16912889331504163" LOG_EFFECT_SIZE="0.37591535456221675" MODIFIED="2015-04-17 11:32:13 -0500" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.24293478189216475" STUDY_ID="STD-CSPPT-2015" TOTAL_1="10348" TOTAL_2="10354" VAR="0.05901730825299366" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4805406857108374" CI_END="0.8713514629997511" CI_START="0.7314497499083161" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.798341912775105" ESTIMABLE="YES" EVENTS_1="875" EVENTS_2="1097" I2="42.537663524207986" I2_Q="42.53630096930643" ID="CMP-004.02" LOG_CI_END="-0.05980663528672143" LOG_CI_START="-0.13581550424426211" LOG_EFFECT_SIZE="-0.09781106976549174" METHOD="MH" MODIFIED="2015-04-17 11:58:08 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.17547328216540137" P_Q="0.17548052304758044" P_Z="4.5515928125438045E-7" Q="3.480458156603742" RANDOM="YES" SCALE="2.26" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0044284592198313676" TOTALS="SUB" TOTAL_1="31012" TOTAL_2="31027" WEIGHT="300.0" Z="5.044310661609434">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>Enalapril plus folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Enalapril</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours enalapril plus folic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours enalapri</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9263977500096282" CI_START="0.6805517923977884" DF="0" EFFECT_SIZE="0.7940161517515438" ESTIMABLE="YES" EVENTS_1="281" EVENTS_2="354" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-0.03320250840894196" LOG_CI_START="-0.16713881785721063" LOG_EFFECT_SIZE="-0.10017066313307633" MODIFIED="2015-04-17 11:55:35 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0033710650433958164" STUDIES="1" TAU2="0.0" TOTAL_1="10316" TOTAL_2="10319" WEIGHT="100.0" Z="2.9317052688263634">
<NAME>Per protocol analysis</NAME>
<DICH_DATA CI_END="0.9263977500096282" CI_START="0.6805517923977883" EFFECT_SIZE="0.7940161517515438" ESTIMABLE="YES" EVENTS_1="281" EVENTS_2="354" LOG_CI_END="-0.03320250840894196" LOG_CI_START="-0.16713881785721071" LOG_EFFECT_SIZE="-0.10017066313307633" MODIFIED="2015-04-17 11:55:35 -0500" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.07867485116533747" STUDY_ID="STD-CSPPT-2015" TOTAL_1="10316" TOTAL_2="10319" VAR="0.006189732205888002" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8406026099998701" CI_START="0.6214786078812826" DF="0" EFFECT_SIZE="0.7227838818375047" ESTIMABLE="YES" EVENTS_1="281" EVENTS_2="389" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="-0.07540926588092481" LOG_CI_START="-0.20657381575766814" LOG_EFFECT_SIZE="-0.14099154081929646" MODIFIED="2015-04-17 11:56:36 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="2.5131749071529553E-5" STUDIES="1" TAU2="0.0" TOTAL_1="10348" TOTAL_2="10354" WEIGHT="100.0" Z="4.213613242149772">
<NAME>Best-worst scenario</NAME>
<DICH_DATA CI_END="0.8406026099998701" CI_START="0.6214786078812826" EFFECT_SIZE="0.7227838818375047" ESTIMABLE="YES" EVENTS_1="281" EVENTS_2="389" LOG_CI_END="-0.07540926588092481" LOG_CI_START="-0.20657381575766814" LOG_EFFECT_SIZE="-0.14099154081929646" MODIFIED="2015-04-17 11:56:36 -0500" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.07704670587259231" STUDY_ID="STD-CSPPT-2015" TOTAL_1="10348" TOTAL_2="10354" VAR="0.0059361948858177496" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0274636814022335" CI_START="0.7617617341213131" DF="0" EFFECT_SIZE="0.8846934586011326" ESTIMABLE="YES" EVENTS_1="313" EVENTS_2="354" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="0.011766479457725193" LOG_CI_START="-0.11818084721374122" LOG_EFFECT_SIZE="-0.053207183878007984" MODIFIED="2015-04-17 11:57:15 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.1084889460973289" STUDIES="1" TAU2="0.0" TOTAL_1="10348" TOTAL_2="10354" WEIGHT="100.0" Z="1.6050220776507034">
<NAME>Worst-best scenario</NAME>
<DICH_DATA CI_END="1.0274636814022335" CI_START="0.7617617341213131" EFFECT_SIZE="0.8846934586011326" ESTIMABLE="YES" EVENTS_1="313" EVENTS_2="354" LOG_CI_END="0.011766479457725193" LOG_CI_START="-0.11818084721374122" LOG_EFFECT_SIZE="-0.053207183878007984" MODIFIED="2015-04-17 11:57:15 -0500" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.07633170293646062" STUDY_ID="STD-CSPPT-2015" TOTAL_1="10348" TOTAL_2="10354" VAR="0.005826528873180071" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5264673757324387" CI_END="1.0299172260132916" CI_START="0.8639190123118083" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9432735937469681" ESTIMABLE="YES" EVENTS_1="938" EVENTS_2="995" I2="43.2860200618018" I2_Q="43.28592815051059" ID="CMP-004.03" LOG_CI_END="0.01280232205448511" LOG_CI_START="-0.06352696834824488" LOG_EFFECT_SIZE="-0.02536232314687994" METHOD="MH" MODIFIED="2015-04-17 14:11:21 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.17148947308309925" P_Q="0.17148996311579023" P_Z="0.1927474017119727" Q="3.526461660710411" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.004604274945101187" TOTALS="SUB" TOTAL_1="31012" TOTAL_2="31027" WEIGHT="300.0" Z="1.30249448592734">
<NAME>Death from any cause</NAME>
<GROUP_LABEL_1>Enalapril plus folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Enalapril</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours enalapril plus folic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours enalapri</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.2290809895830462E-30" CI_END="1.1021374931255472" CI_START="0.8085943651426033" DF="0" EFFECT_SIZE="0.9440244523070958" ESTIMABLE="YES" EVENTS_1="302" EVENTS_2="320" I2="100.0" ID="CMP-004.03.01" LOG_CI_END="0.042235776712646854" LOG_CI_START="-0.0922692894628943" LOG_EFFECT_SIZE="-0.025016756375123735" MODIFIED="2015-04-17 12:14:46 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.46595760214153026" STUDIES="1" TAU2="0.0" TOTAL_1="10316" TOTAL_2="10319" WEIGHT="100.0" Z="0.7290720401752636">
<NAME>Per protocol analysis</NAME>
<DICH_DATA CI_END="1.1021374931255472" CI_START="0.8085943651426033" EFFECT_SIZE="0.9440244523070958" ESTIMABLE="YES" EVENTS_1="302" EVENTS_2="320" LOG_CI_END="0.042235776712646854" LOG_CI_START="-0.0922692894628943" LOG_EFFECT_SIZE="-0.025016756375123735" MODIFIED="2015-04-17 12:14:46 -0500" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.0790089416823285" STUDY_ID="STD-CSPPT-2015" TOTAL_1="10316" TOTAL_2="10319" VAR="0.006242412865761587" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9899327268950848" CI_START="0.7319054462926058" DF="0" EFFECT_SIZE="0.8511974825372801" ESTIMABLE="YES" EVENTS_1="302" EVENTS_2="355" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="-0.0043943178579588325" LOG_CI_START="-0.1355450211352654" LOG_EFFECT_SIZE="-0.06996966949661211" MODIFIED="2015-04-17 12:15:20 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0365007708855217" STUDIES="1" TAU2="0.0" TOTAL_1="10348" TOTAL_2="10354" WEIGHT="100.0" Z="2.0913045648495587">
<NAME>Best-worst scenario</NAME>
<DICH_DATA CI_END="0.9899327268950848" CI_START="0.7319054462926058" EFFECT_SIZE="0.8511974825372801" ESTIMABLE="YES" EVENTS_1="302" EVENTS_2="355" LOG_CI_END="-0.0043943178579588325" LOG_CI_START="-0.1355450211352654" LOG_EFFECT_SIZE="-0.06996966949661211" MODIFIED="2015-04-17 12:15:20 -0500" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.07703857231154135" STUDY_ID="STD-CSPPT-2015" TOTAL_1="10348" TOTAL_2="10354" VAR="0.005934941623800586" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.214431503135854" CI_START="0.8980973886368492" DF="0" EFFECT_SIZE="1.0443551894085814" ESTIMABLE="YES" EVENTS_1="334" EVENTS_2="320" I2="0.0" ID="CMP-004.03.03" LOG_CI_END="0.08437302457627932" LOG_CI_START="-0.046676566390299615" LOG_EFFECT_SIZE="0.01884822909298986" MODIFIED="2015-04-17 12:15:47 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5729009483860361" STUDIES="1" TAU2="0.0" TOTAL_1="10348" TOTAL_2="10354" WEIGHT="100.0" Z="0.5637842884079098">
<NAME>Worst-best scenario</NAME>
<DICH_DATA CI_END="1.214431503135854" CI_START="0.8980973886368492" EFFECT_SIZE="1.0443551894085814" ESTIMABLE="YES" EVENTS_1="334" EVENTS_2="320" LOG_CI_END="0.08437302457627932" LOG_CI_START="-0.046676566390299615" LOG_EFFECT_SIZE="0.01884822909298986" MODIFIED="2015-04-17 12:15:47 -0500" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.07697917843970596" STUDY_ID="STD-CSPPT-2015" TOTAL_1="10348" TOTAL_2="10354" VAR="0.005925793913252091" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2017-08-02 09:41:13 -0500" MODIFIED_BY="Heather Maxwell" NO="5">
<NAME>Homocysteine-lowering treatment at high dose versus low dose (Subgoup analysis)</NAME>
<DICH_OUTCOME CHI2="3.530681873656885" CI_END="1.223139633280935" CI_START="0.6565417366360222" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8961262293798862" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="221" I2="71.67685915116857" I2_Q="69.91283203976303" ID="CMP-005.01" LOG_CI_END="0.0874760388039335" LOG_CI_START="-0.1827376604129375" LOG_EFFECT_SIZE="-0.04763081080450202" METHOD="MH" MODIFIED="2017-03-21 13:56:57 -0500" MODIFIED_BY="Arturo J Martí-Carvajal" NO="1" P_CHI2="0.06024314801510344" P_Q="0.06828904755866683" P_Z="0.48958489258903826" Q="3.323676064565447" RANDOM="YES" SCALE="13.05" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03617593812729148" TOTALS="YES" TOTAL_1="1958" TOTAL_2="1971" WEIGHT="100.0" Z="0.6909692143797614">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2904789725355523" CI_START="0.8363929903448912" DF="0" EFFECT_SIZE="1.0389165350576597" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="148" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.11075093240861424" LOG_CI_START="-0.07758961558092052" LOG_EFFECT_SIZE="0.016580658413846868" MODIFIED="2016-03-30 14:19:59 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7300245285091802" STUDIES="1" TAU2="0.0" TOTAL_1="1814" TOTAL_2="1835" WEIGHT="52.03628328293093" Z="0.34509290408252">
<NAME>Combined (folic acid, vitamin B6 and vitamin B12)</NAME>
<DICH_DATA CI_END="1.2904789725355523" CI_START="0.8363929903448912" EFFECT_SIZE="1.0389165350576597" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="148" LOG_CI_END="0.11075093240861424" LOG_CI_START="-0.07758961558092052" LOG_EFFECT_SIZE="0.016580658413846868" MODIFIED="2016-03-30 14:19:59 -0500" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.1106321701898012" STUDY_ID="STD-VISP-2004" TOTAL_1="1814" TOTAL_2="1835" VAR="0.012239477080905139" WEIGHT="52.03628328293093"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9807257492849167" CI_START="0.5941054790278697" DF="0" EFFECT_SIZE="0.7633181126331812" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="73" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-0.008452422002357391" LOG_CI_START="-0.22613644240433023" LOG_EFFECT_SIZE="-0.11729443220334383" MODIFIED="2016-03-30 14:19:51 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.034671843885646196" STUDIES="1" TAU2="0.0" TOTAL_1="144" TOTAL_2="136" WEIGHT="47.963716717069076" Z="2.112170312557729">
<NAME>Folic acid alone</NAME>
<DICH_DATA CI_END="0.9807257492849167" CI_START="0.5941054790278697" EFFECT_SIZE="0.7633181126331812" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="73" LOG_CI_END="-0.008452422002357391" LOG_CI_START="-0.22613644240433023" LOG_EFFECT_SIZE="-0.11729443220334383" MODIFIED="2016-03-30 14:19:51 -0500" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.12786867113739842" STUDY_ID="STD-Li-2015a" TOTAL_1="144" TOTAL_2="136" VAR="0.016350397058444148" WEIGHT="47.963716717069076"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2017-01-04 13:14:59 -0600" MODIFIED_BY="Arturo J Martí-Carvajal" NO="6">
<NAME>Homocysteine-lowering treatment (high dose) versus Homocysteine-lowering treatment (low dose) (Sensitivity analysis)</NAME>
<DICH_OUTCOME CHI2="3.530681873656885" CI_END="1.223139633280935" CI_START="0.6565417366360222" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8961262293798862" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="221" I2="71.67685915116857" I2_Q="69.91283203976303" ID="CMP-006.01" LOG_CI_END="0.0874760388039335" LOG_CI_START="-0.1827376604129375" LOG_EFFECT_SIZE="-0.04763081080450202" METHOD="MH" MODIFIED="2016-03-31 12:14:16 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06024314801510344" P_Q="0.06828904755866683" P_Z="0.48958489258903826" Q="3.323676064565447" RANDOM="YES" SCALE="1.8390721937593888" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03617593812729148" TOTALS="YES" TOTAL_1="1958" TOTAL_2="1971" WEIGHT="100.0" Z="0.6909692143797614">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>High-dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low-dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high-dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours low-dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2904789725355523" CI_START="0.8363929903448912" DF="0" EFFECT_SIZE="1.0389165350576597" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="148" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.11075093240861424" LOG_CI_START="-0.07758961558092052" LOG_EFFECT_SIZE="0.016580658413846868" MODIFIED="2016-03-31 12:12:12 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7300245285091802" STUDIES="1" TAU2="0.0" TOTAL_1="1814" TOTAL_2="1835" WEIGHT="52.03628328293093" Z="0.34509290408252">
<NAME>Trials with low risk of bias</NAME>
<DICH_DATA CI_END="1.2904789725355523" CI_START="0.8363929903448912" EFFECT_SIZE="1.0389165350576597" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="148" LOG_CI_END="0.11075093240861424" LOG_CI_START="-0.07758961558092052" LOG_EFFECT_SIZE="0.016580658413846868" MODIFIED="2016-03-31 12:09:33 -0500" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.1106321701898012" STUDY_ID="STD-VISP-2004" TOTAL_1="1814" TOTAL_2="1835" VAR="0.012239477080905139" WEIGHT="52.03628328293093"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9807257492849167" CI_START="0.5941054790278697" DF="0" EFFECT_SIZE="0.7633181126331812" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="73" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="-0.008452422002357391" LOG_CI_START="-0.22613644240433023" LOG_EFFECT_SIZE="-0.11729443220334383" MODIFIED="2016-03-31 12:12:20 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.034671843885646196" STUDIES="1" TAU2="0.0" TOTAL_1="144" TOTAL_2="136" WEIGHT="47.963716717069076" Z="2.112170312557729">
<NAME>Trials with high risk of bias</NAME>
<DICH_DATA CI_END="0.9807257492849167" CI_START="0.5941054790278697" EFFECT_SIZE="0.7633181126331812" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="73" LOG_CI_END="-0.008452422002357391" LOG_CI_START="-0.22613644240433023" LOG_EFFECT_SIZE="-0.11729443220334383" MODIFIED="2016-03-31 12:09:42 -0500" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.12786867113739842" STUDY_ID="STD-Li-2015a" TOTAL_1="144" TOTAL_2="136" VAR="0.016350397058444148" WEIGHT="47.963716717069076"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-08-08 10:43:11 -0500" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-08-08 09:41:41 -0500" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAr4AAATBCAYAAADdI5dbAACAAElEQVR42uydf4RXS/z/PyRJkkiu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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-08-08 09:41:52 -0500" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-08-08 09:42:02 -0500" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVEAAAMXCAIAAAAMivFNAAApYUlEQVR42u3dvW4Uyfv28ZGQEIED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</FILE>
</FIGURE>
<FIGURE FILENAME="IAM correcto.JPG" FILE_TYPE="JPG" ID="FIG-04" MODIFIED="2017-08-08 10:41:57 -0500" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial Sequential Analysis for homocysteine-lowering interventions versus placebo on myocardial infarction. The diversity-adjusted required information size (DARIS) was calculated based on an expected relative risk reduction (RRR) of 10% from proportion event in control (Pc) group of 5.95% with an alpha of 5% and beta of 20%. Cumulative Z-curve (blue line) reached futility area which means that no more trials are needed.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a
HBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIy
MjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCAKYA1ADASIA
AhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQA
AAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3
ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWm
p6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEA
AwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSEx
BhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElK
U1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3
uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3+iii
gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorK1HU7XRrM3t67rAHRMpE0rMz
sFVVVAWYlmAAAPWqcHifS7y6itQ97byzNti+2afcWwdsZ2q0iKCcA8A5oA6GiiszUtUtdJtTeXjS
LCHVAIomlZmZgqhVQFmJJHABoA06KydM1a31Zpfs0V9H5QXd9qsZ7bOc42+ai7unOM44z1FQ33iH
TbG9FpcSyiUKHfy7eSRYlOcNIyqVReDyxA4PpQBuUVg6l4gsNLnht7lrt55kZ0jtbKa4bapALERI
xAywGTjOeKZceJtMtbW3uZ2vUFwJDHD/AGfcGYqhwzGIJvVRkZYqB8y88jIB0NFZNvq1ldzW0UFy
krXFuLqIxgsrRHADZHAB3DGTzzjODjWoAKK5258Wabb31xZFdRlntnCTC2025nVGKhgC0cbLnayn
Ge4pJPFmjx2FvfLcTSw3M5t4lt7WWWRpQrMyGNFLhgEYkFRjHNAHR0VhWHiXTtRvFs42uobpkLrD
d2c1szqMZKiVV3YyM4ziqEfjrRZLSO8VtRFo6CQXL6TdLDsIyG8xowoXBzuJxigDrKKrxyJKiujB
kYAhgcgg9CDVGLUrS41O5sIbhHurVY3uIlOTGr7tue2TtbjrjB7jIBrUVz0fibS59RXT47l/PaRo
VY28ixPIudyrIV2Mw2tlQSeD6UQeJ9LuNXOmxTubnzJIgTbyCN3QEsiyFdjMuGyqsSNrccHAB0NF
Z9pew6lEtxauZIGLKH2kBsMVJGRyMg4PQjkZBBrQoAKKyItYtJtYn0qO6DXtuiyyxbTwrdDnGD24
ByMjPUZnt72O5uL2GGXc9pIIZV2kbHKK4HI5+V0ORkc46g0AaFFZt1fQ6fEstzLsVpI4g20tl5HV
FHA7syjPQZycCtKgAoorB1PX7DSriK3uTdvPMjOkdrZTXDbVIBYiJGIGWAycZzxQBvUVz1x4m0y1
tbe5na9QXAkMcP8AZ9wZiqHDMYgm9VGRlioHzLzyM27fVrK7mtooLlJWuLcXURjBZWiOAGyOADuG
MnnnGcHABrUUVztz4s023vriyK6jLPbOEmFtptzOqMVDAFo42XO1lOM9xQB0VFZdjqNrqlmt1Zyl
4yxU5QqVYHBDKwBUg9QQDU11PDaxrJcSrFG0iRBieC7sEUfUsyge5oAvUUVGzBFLEgKBkkngUASU
ViWXiLS9RvhaW9xJ5rqXjEkEkayqMZaNmUBwMjlSRzUMfibS59RXT47l/PaRoVY28ixPIudyrIV2
Mw2tlQSeD6UAdDRXPQeJ9LuNXOmxTubnzJIgTbyCN3QEsiyFdjMuGyqsSNrccHGjaXsOpRLcWrmS
Biyh9pAbDFSRkcjIOD0I5GQQaANCis/UL6DTbCfULqXy7W2jaaZ9pO1FBZjgAk4APAGayk8XaY88
cb/2hbGVljWS7025t49xOApeSNVBJ4GSMkgDk0AdLRVGOUGWSHEm9VDkmNghBLAYbGCflOQDkcEg
bhm9QAUUUUAFFUZJQJY4cSb2UuCI2KAAqDlsYB+YYBOTyQDtOFtLiG+tILu2lWW3njWWKRDw6MMg
j2IINAF2imkgAknAHU1iab4l0rVrsW9nPI0jIZI/Mt5I1lQEAtGzKA68jlSRyPWgDdornNP8W6Nq
UkiWl4x2xNPvkgkiR4lOGkRmUK6gkZZSRyOeRWnaXEd3aw3ERbypUDoWUoSpGRkEAg4xwQCKANCi
qcUwllmVfMBicIS0bKCdob5SQAwww5GRnIzkEC5QAUUVnXt5HYWUly6TtGhG4QQSTuckDhEBY9ew
OBz0FAGjRXLWvjHTLy6NrbpqhlWUQuDpN2ojchSA7NEAnDKcsQAGBPHNdTQAUUUUAFFFVIJhNGXQ
SAB3TDoyElWKnhgDjIOD0IwQSCDQBborNS9V9Rls1kzPBEk0i7Twjl1U5xg5MbcA5G3nqM6VABRW
fcXsdtcWUM0u17uQwxLtJ3uEZyOBx8qOcnA4x1IrQoAKKKKACiis171U1GKzaTE88TzRrtPKIUVj
nGBgyLwTk7uOhwAaVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU
UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHJ+MmmTw/G0EaSTDUrAxrI5RWb7ZDgMwBKg
nqQDj0PSi4s9f1poLfUrXTbG2iuIrljb3clw7mN1dVG6JAvzKuT83GRjnNbV1Yw6hEsVzFvVZI5Q
u4rh43V1PB7MqnHQ4wcitKgDjdFtJdXuZ9Wn1HUY7mLUbiFYo7lhEscUzRhDF9whlUMWK7vm4YcY
0fEGnnUE06FNS/s51vFkRgis8rBHO1Q3y7v4uQ33Tx3D5PDOlyan/aLWrtOZFmKiaQRGRcbXMW7Y
XGBhiuRgc8VbvtOttVtTBcxlk3BgVYoysOjKykMrDsQQRQBS0q4vIdXvdIubmW9+zwQTpdSoquwk
MilW2KqkgxZyAOHHHGTmzTXmlalrsltYDUI7uVZ2lWaNUtmECIVmDMGC4QN8oY4c8dM7UGj2dpZS
WcSzqk4PmyNcyNM2RtyZSxfcBgBt2RgYIwKZqPh7TtVuBPexSu20IypPIiSqCSFkVWCuvJ4YEcn1
oA5nw3pN1f6fod0PEE9pdJodmktvBHEZRkElmMivhWII4UHKH5uMC8kGp6zFaa1bajBY31l9ssXk
mtjLFIgmCs+0OpUkwIwO4gAkEGtm/wBFsdQmieWOZJYl2pJbXEkDheu0tGykrkfdJx7VLLplnLpb
aY0CiyaIwtEpKjYRgrkEEDHFAHn+iarceGtJnmttN+229npUF3NNPc+TIlgiukCooVtzlYZJCpKA
M5GeePSYoRFLMy+YTK4chpGYA7QvygkhRhRwMDOTjJJOXqfhfSNZuPtF7avI5jEL7J5I1kjBJCSK
rAOoJPysCOTxya0LS2eC6vpHkZ1mnEkal2YIojRdoB4UZVjgcZJPUmgDj1vtesNZ8Wy6VotpqMKa
hG7K960Mpb7JbZCqImDcYP3gTyMdM09t4i6Bqtm9nf3up6216FEjQQc2EyBQ21mGEQZJXJbOQueO
8t7KO2uL2aGLa93IJpW3E73CKgPJ4+VEGBgcZ6k1XTRdPS4ikW3CtDdPeRgMwVZnRkZgM45V3yOm
WJxk5oAwrKbVda8UQpqtta6c+jyNcJbQzNO1xvjaNZA5VBsw7jGCdwGcY5w9D1jxHZeA/Daf2dpk
NlPY20Cag948iwBolVGki8pepIGAxAJwWxzXfS2ME13b3ckeZ4NwjkBIIDDDDjqDgHByMgHqAQ2D
S7G20aPSI7dDYRQC2WB8sPKA2hTuySMDHOc0ASaRYJpGjWWmxu0kdnbxwKzfeYIoUE+5xWBoem2u
l+LdUtLONkiXTLLOWLMSZrslmJyWYnJJJJJPNdBbxLbwrCm7bGoVd7FmwBgZJJJPuTk01LJU1GW8
WPE88SQyNuPKIXZRjOBgyNyBk7uegwActbrI3w38Lgj/AEsS6YW6bt4mi838ceZn8arat4e1Gzur
O3t9WXZNqdxNZRJa4liknEpldpNxBVFmnZRtHzbASe/TW/hvTbfU1v0t5PPEjSgGeRo0kbO51jLb
FY7mywUE7j6mrrWUL30d86f6TFG0SMWPyqxUsAOnJVecZ4oA5bw5rbanbafp0mkjT9O1DS2nsDb3
rFxbr5a7W2qpjYLKhG1mxz8wI57ZmVFLMwCgZJJwAK5tPCOnWNndppSTW1xNayW0Mhu5mFurc4iy
x8pchThNv3V9BjYvLWO9tpbSdS8M6NHIoYqSpGCMggjg9RzQB57puoXqXmmeIJdD1CBLy/kee9ke
DyzbXG1IhtEhcYCWucqMbDnHabUUmn8R3NnDqVzYpdeKI4ppLeUxs6f2WrFMj+8VA9QcEYIBruLq
wt73T5bO4iVraWMxtGCV+UjGARgj2IwR2rG1zwjaa1dWjNCvk/2n9vvQZXVpGW2aFShU5VgfKIwV
xtJ69QDB123lig1LQIr69a2S70iWGeWdpZYGlvQrKHYljt8tWG4kjf6Yq1du+hXOu2NvqOoi3W1s
ZId8zXUwlmmmiZY2lbIZ9iKMttVjnHXPRxeHNLhsjaLbs0ZnjuWaSZ3d5UdXRndiWYgon3ieFA6c
VJe6Hp16921zaiVruGOCYlm+ZEZ2QDn5SrOxBGDkjngYAOe0Wa+svGUFg8F7a2t1p89wYL3UWu33
pJCA3zM2wYkYYViD6DbzoXeky33iN7m38QzWUqWiI1vbxwtIFLsdxMivhWxjhRyh54wLeneGdJsN
R+320EzXvlNAbme6lnkMbFWKlpGYkZVSM9OcYycz6hotnqUqSXCTLKg2iW3uZIH25ztLRspK5GcE
49qAMVINT1mK01q21GCxvrL7ZYvJNbGWKRBMFZ9odSpJgRgdxABIINc7omq3HhrSZ5rbTfttvZ6V
BdzTT3PkyJYIrpAqKFbc5WGSQqSgDORnnj0CXTLOXS20xoFFk0RhaJSVGwjBXIIIGOKqan4X0jWb
j7Re2ryOYxC+yeSNZIwSQkiqwDqCT8rAjk8cmgDUihEUszL5hMrhyGkZgDtC/KCSFGFHAwM5OMkk
8nY2+ty+IPEzaZf6dbQ/2lGGS6sHnbd9jtskMsyADGOMHoeecDqLS2eC6vpHkZ1mnEkal2YIojRd
oB4UZVjgcZJPUms248J6bc31xeltRinuXDzfZtSuYFdgoUErHIq52qozjsKAOYuLm/sraWzH2m6v
7vWxb6hLp7LC8n+jCQeUXZVTKLGn3sj5sMX5NS/guLq1utPvYtWtLSLUNKkt4rvUg9wpkulRgXim
ZyuBlS7ZDEleUBHdnQNLOkHSzZj7GW3FN5yW3bt+7O7fu+bdndnnOahTw1pcdjcaebeR4bh1kleS
4keV3UgqxlZi+5SqlTuyMDGMUAc5qEE9zql/Z2v9sXUdgscCSJqbWkVqwiVsO+8vMxDB2ZlYYKjB
O7PReHZ31vwZpFzqCpcPfadDJcBlBWQvGpYFemDk8dKguPB+jXD7pLedw0aRSr9tmCzqo2jzQHxK
ccZcMT3NaUGl2lro8ekQRNFYxW4tkVJGBSMLtADZ3Agd8575zQBnSFNY12ylhI+z6XM8jSjo8xje
PYD3Cq7lvRto6hsZVusjfDfwuCP9LEumFum7eJovN/HHmZ/GtjTvC2m6S1ubFtRAgGxIpNTuZI1X
G3HlvIVIAPAI44I5AqW38N6bb6mt+lvJ54kaUAzyNGkjZ3OsZbYrHc2WCgncfU0Aczq3h7UbO6s7
e31Zdk2p3E1lElriWKScSmV2k3EFUWadlG0fNsBJ72vDmttqdtp+nSaSNP07UNLaewNvesXFuvlr
tbaqmNgsqEbWbHPzAjnqWsoXvo750/0mKNokYsflVipYAdOSq84zxWQnhHTrGzu00pJra4mtZLaG
Q3czC3VucRZY+UuQpwm37q+gwAWPHf8AyT3xL/2Crr/0U1X9W/s/+ybv+1fI/s/ym+0faMeXsx82
7PGMUuoWMGpWE+n3UXmWtzG0MybiNyMCrDIIIyCeQc1lJ4R0tJ45H/tC58plkWO71K5uI9wOQxSS
RlJB5GQcEAjkUAczoK6ze6UbMXd1HqEfhvS54lkkZStzm4J3An+JkVXz94DBqXUPE93qWmXms6Wb
pbdIrW0iSMqriSd4zK2HIXciugBYgKwcEjmu0SyVNRlvFjxPPEkMjbjyiF2UYzgYMjcgZO7noMEe
j6fHp0+nraxfZLhpGlhIyrmRiz5HuWP50Aef6jd6rpmmeII4Ita0+3/sO7uEOo6hFNMk6KNrxMs0
jgEMc9FUquMFq19c0LUbZ7F7T+2NTtEeVry2h1R4J5XYLtdX3rhV2t+7DKuXyBxWzF4Z0dLO9tTb
yyR3sBt5zLcSyu0RBBQOzFlXDHABAGeKtapotlq3ltdJMHh3eXLbzSQSLuxkB42VgDgZGcHAz0oA
5vTbj7fqWkWsd5qbWk+naikyTzFJldJ7dCrMhHzoS6BgSw5IYkljR8KTQeFvC+gX1zeTrpt5o0Uk
n2i5eRIpo4RJ8gdiFDJ5h2rhR5YwK66y0TTbB7V7S38s20UsMRLsxCyMryZJJ3FmRWLNkk5OeTnG
1PwdDcaXa6HawImk/aluJhNPJI0YRlKxxK24KrbdpAKqoJwp3HAA69j1CP4XagJGlbVZNKnlYMxZ
lmaNmKgnsrHaB2AArQ1ZVOreFjbbdgvXPy/88vss36btn6V0RGRg1had4c0rSbz7RZwSLJsMaeZc
SSLEhIO1FZiEXIHCgDgegoA4jV9Hm8PWdpb3uoC+sdN0qdPJhtvKcWEXlvIHYuwdn8mGPgIMM5x6
djo+s317e3Wm6pp8dleW0MM+ILkzoySFwvzFEIYNE4IxjpgnPF6XS7O5lvGntlkN3CLecOSRJGN3
ykHjHzt0655qvpXh+z0XzfsUcu+cKJJJ7iSdyFBCrukZm2jJwM4GTxyaAMWdNW1G18W2ljdSi4i1
KFYVE5QiMW9q7xo38G4FwGGMM5bg81b8KSqst5ZvHq1pdQrFI9lqV19pKK24B0k3MWVirDBbgp91
e+rNomnzpfxyWodL+VZrgFm+Z1VFVgc/KQI0wVxgqD15pNO0Gy0l5pLRJzLPt82a4uZJ5GC52gvI
zNgZbAzgbjxyaAOb1f7VqWualDANVuVtNqB4NQNjBaMY1baxVt0jYYOSVZQGUY4Oei8KX0+p+E9G
v7tg1xc2EE0rAYyzRqxOO3JNM1DwvpGpXUlzdW0rPKoWdY7iREnAGAJEVgsnHHzA8cdKvafYwabY
QafaxeXa20awwpuJ2ooCqMkknAA5JzQBz9jbPd3HjO1imeGaa/EaSoxVkY2NsAwI5BBOcjpWJZ+K
L28udO8QvctHpFvHb2l9EThPNnQM7MOmUdrcZ/hBkHrXd29lHbXF7NDFte7kE0rbid7hFQHk8fKi
DAwOM9SaoDwzpI0e60f7Eo0678wzwbm+YyMWc5zkEknoeOMYwKAOa0JbzxBJb22o6hqEUf8AZkWo
hILp4neS4llYgspDYjCqoXO0bsEEAVpaDr4NlaWl8b+5ujPNbrcx2E0iSqk7wq7yIhRSwQMckAZz
wCDWtf8Ah/TtS8hriGUPboUikhnkhdVOMruRlYqcDKk4OBxWja2sFjaRWtrEkNvCoSONFwFUcAAU
AcQY77S/ELTat/bSpNqAEOpW99utdskgWKF4C2FHzLGWCZJ+bcCch8F7eT6PY2r3lwi32vX1pLOs
hDpEk1yyqrdVyIkjGMEBhtwQK3n8KaQ+oi+ME3mCcXHli6lEJlB3BzCG8stu+bO3OeevNWH0PTn0
+bTmtQ1pLM87JvbPmPIZGYHOVO8lgQRg9MYFAHD3yXPh3VvE32C7vrmRrTS0i8ycTTW6yXE8ZCvK
3JAZnBdsAnk7anXUdV0E6pJBZarDDFpNxdpBq9/Fcu88W3aU2zSPtbcQw4UELjBaunsvCuj2H28R
WRkN/GsV41xPJO06ru2hy7MWwHYZPOMDoBibTfD+n6VLLJbRSs8qhHkuLiSd9ozhQ0jMQoyeAcc9
KAOZutGXT/EXhO5XWL66aW9kEonuWkSZvsc581VJKpjkYQBcN04Fbeth7/XtL0dri5t7SeG4uJmt
5miaQxmNVj3qQyg+YzfKQTs9M0WvhDRbXUbW/htHFxasxti9zK6wblZSI1ZiqKVYjaAB0OMgYXxJ
pV5qMdsltbWl0sTl2We6ltZFbGFaOaIFkIBYEBeQ3Uc5AOYgiu/7S/sf+3NSltx4ma38w3T+Z5H9
mmXytwOcBu+c5G7O7mrt/BPPql9Z2x1i7SwWOFZU1N7SK2YRK2HcOXlchg7MysMMowTnOn4d8I2u
kwB54Yhcm+a/VIZXZIpWh8kkMx3OSm7LN95mLYBxjQ1DwvpGpXUlzdW0rPKoWdY7iREnAGAJEVgs
nHHzA8cdKAOP0X7V4q1Kxm1DVtQVH8N6fdvbWt28AeaUzbpPkIPG0AgcHIyDgYktYJdf17QY76+v
P3NpqsTy287QPcJFdQRKxZCCAwVXO0jJ9uK1B4G05ddFyYXSzt9NtrCzWC7mikjSNpSyllYFlIaM
YLHO05HAz0EOlWNvcW9zDapG9rA9tbqmVWONihZQo4xmNO3G3jqcgGf4Sknk0PM08s5gvLy3V5WL
OUiuZY13MeWIVVGTycZOTXTVm2tjDp8TRW0WxWkklK7i2XkdnY8nuzMcdBnAwK0qACiiigAooooA
KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5zxHc3UKafYWcxt5tQuxbLOoBMai
N5GKggjdtjYDIIBIODjFRx6BJYzQ3Gm6jfiVZV89Ly8luEmTow2uxCnuCu3kAHjIq3rmmy6naxG2
nFteW0yz20rR71VxkYYZGVZWZTgg4Y4INVYF8R3U8S3yafZW8bh3NpcPM82OQvzIgQE4z94kZHfN
AD/+EkP9jf2l9kP/ACFf7O8vzP8Ap9+y784/4HjHtnvWRJ4x1RLae9Hh4SafFqL6duW8HmyOLgwK
yoVClWfaDlwQSeCBkpJ4d8Q+X/ZsbacNPXV11Hz2mfzXQ3YuWTZs2qwJIDbjnaOF3EjQ/wCEfu/+
Ee/s/wAyDzP7Z/tDOW2+X/aH2nHTO7ZxjGN3Gcc0AQf8JTfWs1xbalpkUN3DNYrtguzKjR3U/kq2
4opDKVclduDgYPOQviXWpkuptNiEkL29xpUxnSQgus175bJgdBtjIPPzByMertb0G9v9Q1G8t5Lc
ebFp5gWUsAZLW5knIYgHarblXcMkfMccDNSbw9ruoX95e332CJ530sxwwSu4jW2ummcFii7iQ3B2
jk4IAG4gE2teMLnR47q+n0+3i0y0dg73V75M8iqcM0cRQhxkHbllLY46jNYa3qsep64t/axSWEOt
WdtAYr91kTzDaKo2hB8v70uw3ckshBU7jS1fwbrF1aa7aWNrohm1P7RjVLgsbgLLuxGyhDwFbYGD
8KAdpIwdW90PVJtQ1FI0szaXup2WpCVpXEitC1sGTYEIIKwMQ27qwBAHNAGhL4g8iz1KQ2v+mWl3
9kW28z/WuxXycNjgMHQk4O3LDnbUFz4puYftl9HpqvotlM0VzeG42yDY22Rkj2kMiEMGJZT8jYBw
MzXHhz7T4rtNYE2IIo8zQf8APSVAyxN6cLLLn3Cf3Rjn77wGr3t6kei+H54b25ec6jc2qvdQ723O
NrRssh3FtpZgACAQQvIB6NRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU
UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRR
RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFF
ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVC4aSGF5EiaZlUssaEAsQOAM
kDJ6ckCgDlLy01mLV7PTrPxVq01zIwlmEkNmVigU/MzbYAcsflUZHJJ5Cmt3xDe3WnaHcXdlGXmT
b0QuUUuA77By21SzbRyduB1rE0e/1i1Sa4u/CGtPqF03mXDpPZlQeiopM4OxRwOBnliMsa1hZaxp
1jcm21WfU7slDCmorEiDByygwxoQWGRk7sEA4xkEAz9KuJ7x4brSPGEesxNIvnQz+QVKZ+bYYUVl
YDJAbdnGDjO4Xx4gjk1NrWDTtRnhSb7PJexRK0KSdCp+beQCcFgpVTnJGDjIubGTXb6xnl8MPpl5
a3UU/wDaEzQFlCuGdUaN2dtygqQwUYYk9MVe0pNV0i5m0xdJkmt5L6e4W+89FjEc0rSsGGd+9S7A
AKQcD5hk4AJLjxbbQXM6/ZL2Sztpvs9xqCIpghfIBDZYMQCQGZVKrzkjBw9fEsDavf2P2S78vT32
Xd2QiwRfullBJLbiCrAcA4I5wCCce70rWf7H1fw1Dp7SW2pTXWzUBKgjiiuHZ3LqW37l8xwoVSDh
ckZOL7aBPfW3jCym/cw6tMywyAg4RrOGItgHjDK4wcHj0INAFvTvEsN/dwW8lhf2f2lDJaSXUaqt
woGTt2sSpwc7XCtjJxwcdHXAaPotymrWN1eabf2v2AvJLPfaxNdRbzGyZhVpmGMO3zOqkLkYycjo
dO8S6Rqd4tvZ3LtIyGSMPA8azIMZaNmUB1GRypI5oA3qKKKACiiigAooooAKKKKACiiigAooooAK
KKKACiiigAoopNw9RQAtFFFABRSZHqKWgAopMj1oyPUUALRSZHrRmgBaKKTIHegBaKTcPUUZA7ig
BaKTI9aTcvqKAHUUUUAFFFJketAC0UmR60tABRRSZHrQAtFJmloAKKKKACiikyB3oAWikyPWloAK
KKTIHegBaKTI9RS0AFFFFABRRSZHrQAtFJkDqaM0ALRRkUUAFFJmk3A9xQA6iiigAooooAKKKTIo
AWiiigAopMj1ozQAtFFFABRRRQAUUUmR60ALRRRQAUUmaMj1oAWiiigAooooAKKKKACiiigAoooo
AKKKKACiiigAooooAKKKxrrxDpFnfx6fd6tYW97LtCW8tyiSNuOFwpOTk8DjmgC1c3MFray3NxMk
MEKl5JJGAVFAySSeAAOc1xnhH4raB4w8QXek2jSQzRsfshm+UXaAfMyjqCME7Tzt59Qtzxd4QvvG
OqWFpd6gIfDUQ826tIcrLdSg/KrN2QdeOc577WXzrw74J0zxPrfjqwAFhNY6op066tVCtZuu8Lsx
j5flXKgj7oxggEAHvdFYugxavHolrFr09vcakibZ5bcEI5B4bBA5IwTwBnOABW1QBm6rp8eqaRe6
fI7JHdwPA7L1UMpUke/NcJ4TstW1DxVeSalcW5j0q9MiiHd+8kMLRjAPCJtcnaM845+Xn0jOTisH
Q9J/s7U9ZuPPSX7VciTao5T5QMH3qGndG1OUVCae7St96OjoooqzEKKKKACiiigAooooAKKKKACi
iigAooooAKKKKAOc8USy2/hfVJo5GjlS1lZXU4ZSEJBBHQg9683We3tvDcWqReNb86kLdZfs7Xgk
BlKg7CmM9eMHp36V6b4jtJ7/AMO6jaW0fmTzW8iRrkDLFSByeBye9Z/hzwtp9hpNgbjSLNb+OCPz
X8lC4kCjPzAcnOec1nJNy07HRRqRhC8t77abFOfxbfWkOnWcWlPfavcW4nltlkEQjGBuyTnHJIA9
q39Jv31DTIruW1ntXlBJhnQq6kEggj8OPUYNc9r2mava+JYNd0izS+f7K1rLA0ojIG7cGBPHXqP8
jodFbUn02FtVSFL4gmVYM7AcnAGSe2M89aUW+Zp3+7QdaMOSMoJa766/d0R5nqOo/avEuq3F5qfi
CC0hufJzpxYRQqqgMXOCBznpz1OOa9XSeOSATROGjZQVYcggjIIri9btfFdw2p6VHaxXtne71iu3
lWP7OjLgqVC5bGTg8n1J6Vv2outJTS9LtbQ3FmsXlTXJkC+SEQBTt6tuIxx0ohdN3LrOMlFqydtk
1skjzg+IriLT31+XX7ldYS5KyaWZB5aqJNpUx4yPl5z/AFrQ8Tag9x4uuIpbvXEgt4Ih5WlFsgtk
lmxwAARyeenpVu90TWNav5LG/wBG0+BJpVNxqMDAGWNWDBQvLZOB1OM1s6ofEtpqtwdPs49Tsp0R
URpViNswGCSSMsDwcZJ9MVmubre2nRnRzUrqyV2n1Vkna1nt3M3W9ScWnhx7TUrj+x5VYXF55zJI
2I/3e5xggswOemTxWfo3iK+vLjSIdX1BrRLOPz7ySSTyvMZiRCjcjqvzEHrXYeHtJk8P+FLfT2Uz
zwRsSqkfMxJYgE47kgE4rl08L6tbz6brE1sbi88+a4vbYSKCWkTaoBY7SFGBjPriqkp3Uu+6+4zp
ypNSg7WV0n1e5295d3UaWj6fZi8SaZVkYTKgjjOcyZP3sccDk5rG+IdxcWngm+ntZ5IJlMW2SNyr
DMig4I5HBIqLSV1Hwp4c0bTpbf7ZcPcLBJtl2+UHLEkZzu2jsOwJ4Aq3440291jwneWVjB51xIY9
ibgM4dSeSQOgPetJXcX3sc0FGFRXacU9+6PPrjU9KhtmbRfFniC61IAmGFjI6u/YEFACCff8+lXN
e1GZPEdlBr2tajpULaYkki2crKBMXIIwoPbdzjsOa6/xR4fkv7OG60xQurWJ8yBum71Q+zDjnj8M
1XstN1a78aQ6xeWRghOliFt0iNsl8zJXgnPHOen41laV7enR2/M6/a0WlJed7tXv0tpsYXhvUJH8
Qxw6Pq2pappjRSG7e9yREQPlwSAck8Y9PXtgaRqmky6VHPqvi7XbfUDu3xRTylRyQv8ACeoweveu
8j0bU9G8UPLplv5ml34LXKB1XyZR/GATyD3A/oBTfDvhR28BRaLq1uIpsSb1DKxQl2ZSGBIyMg0c
k2/v728rD9pRSu9nbZq9tb30LvgS51O80EvqDzOBO628s67ZJIQRtZh6nmqPxGv9bstCmlsJPstr
GiGSdXIldmcLtXH3QMgk5yeg7mtbwsup22kGy1eHFxbMY0nDgidB91+CSDjrnnv3pnjrTb3WPCN5
Y2EJluZDGUTcBnDqTySB0B71bTcGle9vmcalFVU2ly3+Vih4rubu61XQ9Etr2azOoNI0s0Bw+2NN
xAPbORzWK2o63pmn+JNItru4vLrTzEbeeQ7pAkgBOT3IGTmt/wAT6TqUl9pWr6Vbpc3WnM/7h5An
mI67SATwDwOtS+FNN1CK/wBU1bVrdLa7v5EPko4fYiLtUEjgnr0qLNya19fK3+Z0qUIwT0dltpe9
/vtY5GTXbxRf6VZX0r2t3PFDZXbzMzIuzdM4cnJC+ueCfavQILyOXRml0qVNSMURWILcBvNZRwC/
IyTgEn1ya5LXvCup+IZ9YuWXyHCLb6erODuUEM7HBONxGOcHHWtDRoNR0hvEGr3FoIlnVJIrSSVV
2+XHg5YEqMkdc8AZNVDmTaa0JrKnOmpQaut156HUWjzyWkM1xbm3ndA0kO8N5bEZK5HBweMjrXnO
p65fL4rn1mC9ddM067itJIQ5CMpBEjFc4JBYAf8A1hXoEN3cT6Cl4tky3UtuJBaluQ5XOwk45zxk
4/CuNs/hpp1xoP8AxM4H/tmaNnlm81vllbJ6A7TgkDpg4706ilJLl9SMNKnBydTS+miT333/ADJ9
W12fTfHN3MrSyW1vobXH2bzCEZlkPOOQCQMZxnFSWHjm4ubnTzd6TLaWd+AsF0ZQwMhGdpGAQM8A
nr1xisK70nWora71HU7Vogvh+W1kcyIcyAk9ieoAOenOOvFT6Lpmt65Y+Hobq0ih02xEV0tysoJl
wnyKF6gjODng9R6VPPK/X7jZU6XK27O2l7+XQTT/ABdqmnNr8i2F1qMEGozs8rTgCCIYwBuyeME7
QMAc966PUvF81vZ2k+m6VPem5gE4LOIY0U4PzO3APPTrVKy0TUoPDviy1ks8TX9xdvbLvU71dcKc
5wMn1xjvisa98L6yF0V5dITU4bawSB7N51QQygDL5zg9McZ6fSk3NR0v/XyJjGjOaukree+nqdp4
Z8RxeI7CS6WEwSRStDJGXDAMMZww4I5HNcZ4pvprjxZewNea4sFrDEvlaWWyC2SWbHAwCOTz09K3
vAej3ui6ffwahapbyy3rypHGwKbSFA24PA4IAODgdKk1U+KLLV7h9OtI9RsrhVVI2mWI27AYJJIy
wPBxkn0xVe84q979dCY+zjWko2t0u9Pk2Zms6k4s/Dr2uo3A0eVWFxeecySNiP8Ad7nGCCzA56ZP
FUNG8RX13PpEOr6g1olnH595JJJ5XmMxIhRuR1X5iD1rsPD2lS+H/Clvp7KZp4I2JVSPmYksQCcd
yQCcVy8fhfVoJtO1ia2NxeefNcXtsJFBLSJtUAsdpCjAxn1xSkp3Uu+6+4uEqTUou1ldJ9XudveX
l1Glo+n2YvUmmVZGEyoI4znMmT97HHA5Oax/iJc3Fn4JvprWaSCVWixJG5VhmRQcEcjgkVFpK6h4
U8O6Np0tv9suHuFgk2y7fKDliSM53bR2HYE8AVa8c6be6x4TvLKxgM1xIY9ibgM4dSeSQOgPetJN
uD72OanGMKsbtOKe/dXOBTVoIZ4T4e8U6te6g8iKlvdszROCwyDuUADGec5rt9Y8WXFjq8mnafpU
moTQIslwVlVBEDyBz1JAzgVj6nB4n8S2y6XL4fj0uAyIz3TXaSFApByoAzu4qr4l8HXE/iKbUI9H
XVYrmNBta6aBoXUbc8EbgQBx147d8FzpPl8ujX53O6UaMpJSts9Lp9rXasWr3xRe3vinws+mRSPY
XiyOV80Lv+XDBh6xjnHQk4HIzV7WfHN1pdxOU0KeSztmKyXE0yw5x1KK3Lj0I69qqL4Y1LTrnwrN
ZWcMiWDSrcRwylVjEoALDeSSFyx6knHGM8Y2r+E9duNT1XOiwX0t07vDdyzqDEhGFRVPcDgHgA98
U25qLte9/wBPQinClOcU7cqT3dnu99dz0+xvI9T06C+hJ8qaNZFyMHBGR/OuD1my1/SLVdYm1yZt
UlulSKwikzbsC+AiqVBJ28k+x+tdh4ftprLw3p1rcJsnhtY43XIOGCgEZHB5HauNgPi5NZk1O98M
m8kDMtuWvYkWBD2VeeT3bOT04FaT2V738r/oc9JKMpOLVk9m1r5K5auYr7xR4l1S0h1a8sYtMhi8
tbd9m6SRS2W9QMAYrOXX7/UdE8OTXV1LBZzmZL64SQxHcgITLDBGWB9MmtTUNO8QaX4kvtR0TT47
uLUYo1fdMqGN0BUE56jB6D9K3PDulSaB4VtbEwieeCIkqhHzOSSQCcDqSMnFSoty6rf89DaU4Rin
o9rLS601v8zkNG8Q317NpEWq3zWaWMfn3ckkvleYzEiFG5HVRuIPWvQLq8uY47R7CzF6ssyrIwmV
BHGc5kyfvY44HJzXCJ4X1q3l07V5LYz3nnzXF7brIoJaRNqgFjghRgYz64rb0kah4S8N6Pp81t9r
nedYJdsuPLDsxJGc7to7DsCeAKIuSTUr+pniI05WlBq/ZeruSfEG6uLTwRqE1rNLBMpi2yRuVYZk
UHBHI4JFZF/oN/oWmTaxp3iPU5ZrVDM0V7KJI3UDJBGBjgHn/wDXXQ+OdPu9X8H3tlYQmW4kMZRM
gZw6k8kgdAe9YWoyeLfEFg+lSaDFpkM42S3Ml2suEPDAKozkjI/H8aVS/M7p7K1u46P8NWaWrvdr
ay6Pcgu/F80OuJf28FzcA6Mt0bf7VtiKmQZOzafnAJ+bPQYx3ro7/wASJavpS2kIum1FwEAfbiPG
5pOhyAOce9Z1n4du7Xxmk622dNTShaK5ZTlg+dpGc9O+MVX8MeGdTsNTmk1HBt7JGt9O5B/dsxJY
8nBxtXtwPxNrnT9fwCUaL100Xfe/+RKPHzNdeb/Zcv8AZHn+R/aHmrjdu252ddu7jOf14qyPFVzP
4ovNGt9KaaK1aLzLgThQqMu4sQR1GQAASTyeMVxkXw8u4bw2LaJb3CibI1GS7cDyic4MasDuA44w
Pr1rttE0q8tPFXiC9ntylveC38iTcDv2xkNwDkYPqBURdRtc2mv6Fzhh4pta6aa+a137FTSfHVxq
uoRiLRZzp0spiS7jcOQckZeMDKDjqa5q/wDEWo283/EtF5If+EgeJzJdg7yCCsIyBtRsnA5AxyTm
rcfh7Xz4otbg6Va2EkcxM99ayAJcRZJKmLk5PHJ7/hSTeFtdjhmlg0/zJo9fOoRxmdR5sQ6EHOBn
0PI9Kbcmtb/d/wAAfLSjJONrNbX0+budbaeJ1eTWI76H7M+mktIN+7fHt3BwcDqAeO2OtXtE1aTV
tCg1KS2+ztNH5gjD7toPI5wM5GD071xnxC0159S01rOXZc6ifsUyL954yQ2cei4OT6GvQoIEgtEg
QARooVQPTGKqLk20+hjVp04xjNby6drb/eeXPd6q3hw+NRrN5xc7vse4eV5Xm7Nu3HX3/rzVnxFq
mqxa5qKpcTLcRfZv7NgSRlWfJ/e5UcPjkHOcD0po8OeI00o+FTp8J0o3O77Z54/1fmb8bOuc/wCH
vXZeJoL640SS30uPdeT4i8zcAIlJwznJHQZ6c5xUKMmnutF9/U3nUpxlHZpt220Wlr/iYvhvXI9T
1q9vbvUFijmb7NZWrzAB1Q4aQKTyS2QDjOBiutvJpoLWeaCA3EsaExxbwvmMBkDJ4GTxk9K87vfB
GoQy3tlpySNbXSWqQ3HmAfZhERuJBOcnGeAcknNejXVpDd2M1pOu+GWNo5FyRlSMEZHPT0rSDla0
lqc2IjTU1KDun07aI5ceKfFjSbR4NH/gyi/wrq7i5S2tpJ5nVI41LMzHAUAck1zS/DLwmD/yDWP/
AG8y/wDxVamu6PHrmlT6bNLLFFMFDNEwDYBB4JBHOMHjpmiKkk76smrKlKUVFWXXR/5s5LQPEOo6
r49LzySR2E2ntJbQFiAU8wBXK9NxwTn0IFZGuavdxatqSX+u31pqcUpGnWts37qRMDZuABGSeu4j
Fatl4Cu7LxnBcC+1J7GGAEXD3ILs4kB8o8ZKEDJGMe9MvNC8QQjWdPttNhvIdTmkkF3JOFMIdQMM
pGTjtj/61ZWly2d93/Wh2qVHnvG1rLsvz/E1/EWoa9D4U86ARQXAs2lu585MTKgJCAdSTuAOcDGe
avaRc6jJ4H0+a2C3N61nEQZ5CAzFVyWbknqSe5x71Ne6XcjwPcaUhM9x9ga3UkgGRtm0cngZPr61
Z8O2s9j4b0+1uV2Tw20cbrkHDBQCMjg8jtWqTv1OSU48tklo/vOX8M6nqX9g+I5553vb6zvLhI92
cFkQYVV7DPQD1rE0vXJLW40S9j8QXF9c6hPHFd2ckqukYcc4UD5CCR9fpXV+HdL1TTINe8yFI5rn
UJ7i23kMpVgNpIU5xkcjg/Ssmx0HVtS1iwk1LRLLTYbS4+0zS2zqftMoBCkKBkDJJ+Yk1LWite/z
NYSg3Ju1vVdtkj0scgUtFFbHCFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnWuQyvZeNXil
C2HP26FosySEWsRfy33ALmLYo3K2GBPSvRaxbrw9pF7fJf3ek2FxexkbLia2R5F2nK4YjIweRzxQ
Bg+KNP8AiBd6oJPDWu6ZZWOwDyri33Nu7nO1sj8q5f4OxajD4j8cx6rPFcXy38YnkiXajP8AvNzA
YGAfpXsFeX/DH/kePiJ/2FV/m9AHqFFFFAGVq0d5No19Hp8gjvXt5Ft3PRJCpCk/Q4ryXSbLVtA8
RHUNK0G+a0LF71Gikjl2lCNjF/lmYMQ25S2dp5G417b+NRMMe1S1fqaUqns7ppNPe5h6J4l03X1k
W0lYTx/62CVSkkf1B/8A1Vu7hnA5qlLYQSpOAgjeZCjSxja+OR94c8Z49K5U2Hivw6xawnGs2S9L
a6bbOB6CTofxpXcVqr+g1ThNvlduyb/U7ugCsKw1uG4sLe4u4pNPeZzGIbshH3gkYAJ5zgkeo5rc
DhuAc1aehDhKL1H0UUUEhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUmBS0UAJgUtFFABRRR
QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ17Zw31nNazrvhmRo5FyRkEYIyOelJY2kNjZw
2sK7IYkWONck4AGAMnk8etaB4ozmi3UfM7cvQdRRRQIKKKKACiiigAooooAKKKKACiiigAooooAK
KKKACiiigAooooAKKKKACiiigAooooA55PDumJrj6stqv2+QANMSScABeATgcADgVuEgUo+tOoSS
HKTla7vYdRRRQIibk89K81+ITtZ38Nzfad/aGnlYYYUeEzRRSGRvMJjH8TKUCtg42sAQTz6UePpX
M+NLC71LSII7OIyut3C5AxwA3J59Kmpe2hVFRc0pbX67FrwvBeW/h+2ivRKsgaQokz7njiLsY1Zs
nLKhRScnkHk10FMj+4PpT6pEy3FooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuS8Y6u
2j2mnvLq6aRbXN+sFxeny90aFHI27wy5LKiklTgFjwBkdbXN+Jr64tILGG3uEtPtt2tq95IoYWyl
XYNg/LuZlVF3cbnXIb7pAM3RdS0y61OCK3+IP9qzNu22P2ixbzflJPEUSucD5uCOnPGRXbVx6Tah
o/iLTLF9bn1VL8yK8N3HEssKrGz+apiRPk3BUO5Ty64I6N2FABRRRQAUUUUAFeX/AAx/5Hj4if8A
YVX+b16hXl/wx/5Hj4if9hVf5vQB6hRRRQAUUUUAFFFFAGJquj2Gs2pt7+1S4i6gMOh9QRyD7iue
Ph3XdElU6Dqnn2m4Zs7/ACwVf9lx8wx2H867jqORRt46VLim79TSFWUFyp3XZ6o5q/8AFel6bqw0
6+me2lZQUklUrG+ewY8ZHvW/FKsyBkYMpGQQcg1Fe2FpqFs1veW8c8TdUdQQfzrE0jwnBoV88un3
d1HaspH2NpN0QJ7jOSPzpe8n3Q7UpRum1JfNP/I6P7uBS8niuJXxvLp1x9m8RabNp2Thbhf3sLen
zAcH2I+uK661u4L22W4tpkmhcZV0YEH6EVSmnsTOlOCTa0fXdP5l6iiimQFFFFABRRRQAUUUUAFF
FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU
UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEP8Xt
XNeNL+707SIJbOUxO13EhIxyC3I59a6TqfasHxXpNzrGlwwWuzelzFKd5wMK2T+lTUvyuxVFxUk3
tfW50MZyin2p9MQYQD2p9UiZC0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXNa7cXKQ
pZfY9Pujf3BtYbe8uHVJl8lnbdiFwD8j/KQQQud2Ttrpa4bxvoemXdzpdxJo+jzXtxfLb/bdQtBK
sSmKTG8AqXBICKpYDc6nqBQA7S4ZPD2p2lt/wjnh3SI9QlMW7Trli8jrG7gbRboDwjHLMAOepwD2
9cXovg+TRtUjvEg8MxAblc2Gh/ZpcEHgSec2BnGflOQMcdR2lABRRRQAVwHibwh4beFLVNF043+r
3pRrh7ZXly7NJO+9gWBCCQqc/KdoGBgV39ZclhDLewXbR7p4VdY2LH5Q23dx0ydo56jnHU5AOZ8U
+Mda0LUhaaf4L1TV4mQMbm3bC5PbhScj3xXNfBy9n1HxD45u7iylsppr9JHt5T88THzMqeByPpXr
9eX/AAx/5Hj4if8AYVX+b0AeoUUUUAFFFFABRRRQAUUUUAFFFFAFCW2juITHLEkikY2sM5HuDWNJ
oP2LTJ7bw88elyyP5u5Igy54z8p4wQAOOldL3FBpNJlRnKOz07dDzC/8X+JNGvhY6la2cDRIkkt+
Imni2uzKuUDIVyVbJ3HHHynIrtPD+qNq+jw3skSxSM8kUio25Q8cjRsVPdSykg9wRUGs+HLDxFb7
L+3LMEaNZI5WjcK2MruUglSQDg5BwMisvwPcSWttP4cuVC3OlMIlIGA8J5Rh+HH4e9Qm4ys3dM0m
o1IOcVZrdLa3dHc0UUVoYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU
UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRR
RQAUUUUAFFFFABRRRQAUUUUAFFFFAEZrlPH00sGiW7RSPGTewAlGIJG8ccV1O/58VheJdN/tjToo
PtCQbbmKTc44O1gcfU9qiabi7FUpRU05bJ6nQR/cX6U+mLwoHtT6slhRRRQAUUUUAFFFFABRRRQA
UUUUAFFFFABRRRQAUUUUAFcx4p+zXVpYWFxpdlfy3l55Nul/EJIYnEbuZGBBzhUfAGCSQuVySOnr
D1/TpdQ0s20MVrMd4doroMA+MkbXU7o2DbSHAYrjgZwQAch4ct7LT9U0m4bQPDsc9ze3mnpcWGnr
byRywtON68sdjRwkEZypPVg2F9Lrz7wm+gwazPZ22mzx6pE0iSS/bG1BEZmLyAS7nMW5skhxGWPY
mvQaACiiigAooooAK8v+GP8AyPHxE/7Cq/zevUK8v+GP/I8fET/sKr/N6APUKKKKACiiigAooooA
KKKKACiiigAooooAj7dK5nxVqd1odpHqVrEkkUUym7XbljF0JHuMg10xxjk1Unt4rqJ4ZlDo6lWV
hwQRgik02rLQunNRmm1ddV5Dre5iuoI54XDxSKGVlPBB6YqxnrxXMeFdLu9Cs59PupUe3jmYWbbs
sYjyA3uCSK6nHvSi21d6BUiozai7rox9FFFUQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABR
RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFF
FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBEORXI/EPP9iW3/X7B/6HXW9DWD4ntLK90yJL
65+zRLcxMr5HLBhtHPqeKmavFoui0pJvZM6GP7i/SnU1fuD6U6qIkLRRRQAUUUUAFFFFABRRRQAU
UUUAFFFFABRRRQAUUUUAFcr4ss7m8s7ERafcalDFeK9zYwyRqJ4tjqVbe6qVDFW2nOSoGP4l6quc
8Swyz2dsBFLc2SXIa/toCd80G1wQACCwDlGZR95VZcNnaQBuk6jcedBYx+FtR020UbQ7taiKIAEg
bY5mIHGBhT1HQc10tea+ErFvtdidP0m809LS8v8A7RJJaPao1o8s7QwhGCluXjdcAhAGGVLYPpVA
BRRRQAVxuteJDZ3UlvFq+k6ZHDIElutV+ZXcqr7ETzEJwrqxbdgZAAPO3sq4tdL1zStf1S9sLPS7
9b+ZZRLd3ckEkShFXy8LE4KgpuByPvHjjNAEmpeP/DOgyxWeta7apdtErtsjfDAjO4AbsKeoBJ47
muS+EGo2up+KPHl7ZTCa3n1FJYpFBAZWMmDg813sHhvTZNNsodT02wvLi3gSIyS26vkqoBwWBOOK
4n4WQQ23i/x/FBFHFEmqKqpGoVVAL4AA4AoA9WooooAKKKKACiiigAooooAKKKKACiiigAooooA4
vxtYXAtrbXLHm80tjMq54eMj94p+oH6Vv6ZqMOp6fBe253QzIHU/X1q++GXBHBrlrCTTfDmqQeHY
BPEZ1e5h3nKHLEsinPUdcY6d+ai3LK/RmylzwUbXa29Op19FFFWYhRRRQAUUUUAFFFFABRRRQAUU
UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRR
QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQAZ4rlPiGR/Ydsv8A0+wf
+hiur7dfmrC8Tf2V/Z0X9rb/ACPtEW3ZnO/eNvTtnrU1FeLLpS5ZJ2vZ7I34v9Wv0qSkXoKWqREh
aKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAriPF9lO1/pN7Hq+rJKt3i1sbGG1ZnkMEw
JVpVAU7C7EuxXCkAbipHb1yfilLW7toWlutZtJLO9R0m06xeaUSBCRgeU+UKsQWA29VJ5ZSAUdLt
NTuNasX1KDxPItu7SxPftpwhicxsm4iAhydrMoGCMtkjjI7quM0e9MuqwJ/bvim6zu/c32i+RC3y
n7z/AGVNuOo+YZIA5zg9nQAUUUUAFFFFABXl/wAMf+R4+In/AGFV/m9eoV5f8Mf+R4+In/YVX+b0
AeoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMx0rlfGWkTahpqXVl8uoWLie2I6kjqvuCOMe
uK6vFBAxSaUlZlQm4SUl0MXRdRXVtHtr9EaMTRhtrA5U9x+f51r7BmuQn1q50vxnHZXpX+zL6ILa
ttA2Sr1UnvuHIz9B3rsc/lSi9Ldh1INNStZPVD6KKKogKKKKACiiigAooooAKKKKACiiigAooooA
KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAo
oooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAI65L4iZ/sO2P/T7B/6GK6rIP41heJ7uysdN
ia/tftMTXMSqmBwxcbTz6HmpmrxdyqMnGSaV2nsb8X+rX6VJTV+4PpTqpEyFooooAKKKKACiiigA
ooooAKKKKACiiigAooooAKKKpXE8dugeWRI1ZlQF2CgszBQBnuSQAO5IFAF2sHXNc/sK3tpWsLy+
kubhbaK3tFRpGdgxzhmUYAUk4PAyTwCRYXWdNk1WTS0v7RtQjXc9oJ1MqrgHJTO4DBBzjuKz/FD2
UNtaXNzdy29xDcq9k8UDTuZyrrtESgs4KNIGUDO0kgqRuABTuPGktpqFtaXfhjXYHuQxjYi3dTtG
5hlJjlgoLbRliFOAcGumtZ4L21hureRZYJkWSN16MrDII9iDXGWdzdaxqcH2u+u2u4RI1gR4du7S
CKUxuvmSGXO4hWYAb0B3EYJII67SdOi0jRrLTYGdorOBIELnLFVUKM++BQBo0UUUAFc7H4hkm1q5
0+30XUZ1trhLee7RoFiR2RJOjShyAsik4U98Zroq858TJbRvrM2n2PiW38QTBmtjbG78iacIEidv
LYwbfkTO/Hyj5h1oA9Gry/4Y/wDI8fET/sKr/N62PE/w00bxbqIv7+61OKYKExb3W1cD/ZIIB+lc
z8HtLg0vxJ45sbdpWhtr9IUMrbmKr5gBJ7n3oA9eooooAKKKKACiiigAooooAKKKKACiiigAoooo
AKKKKAOZ8UaKNe0mW2RxHdIRLby/885F5Bz+h9jV6wd2t0jmkikuIkVJ/KOVD4Gfcdc4PYitOuCu
S3hjxrHeZI03V2EUvpHOPut7bhx+ZNQ7RfN3NaalUi4X2u0u/dHoVFIDkZpasyCiiigAooooAKKK
KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooo
AKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCLriuR+IYI0W2IH/L
7B/6HXWtzx61geJ9T/sfTYp/s6T7rmKPa54G5gM/UdqmaTi7lUm1NOKu77HRR/cX6U6mLyoPtT6o
mQtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXKeKY5XuNEkt2tzexahvt4Lkusc7+RMCpZVY
rhS7glSMpjjOa6uub8T6XNqunwwRWa3TRzrKFfUprIDAOGDwqzEgkcEY75yBQBQ07w1dWjaIZZ7d
zaXt3qNxKiEM80wlGxQf4R575JOfkXjk7X+LZ7U29pcDxDpmkT6fqCuLi9CuiyGJsxFTIgDNHITg
nO1sgZwwz9Ptb7SvE2lJfWEkUV28kSTjxNe3ahxEzhTFIoViVViCeBtJzu2g7niUahHa2t7YS2yN
Z3H2iUXd21vC0QRwwdlRsgbg2CAAVDEnbggFDR/Ef27V4Lb/AITTwtqO/d/othDtmkwpPyn7Q/TG
T8p4B6dR2dcno+v32rXUQCaFJaMhkaWw1hrlwuWUMq+QoYb1K53DkHqRiusoAKKKKACiiigAry/4
Y/8AI8fET/sKr/N69Qry/wCGP/I8fET/ALCq/wA3oA9QooooAKKKKACiiigAooooAKKKKACiiigA
ooooAKKKKAIs4aszVtKs9YsHs7yISxMQSpJHIORyORyK1O1ONDV9AjJpprRo5/R9cg1g3UKxyQz2
czQTRSfeBHQ/QjkGtzofpXn3iVz4a8XWGtWsEtz9vBgurS3ALyKMbZBkhRtJUFmIABAzzXXaTqkO
sWxnhWWN43MU0Ew2vE4wSrAEjOCCCCQQQQSCDURb1TNqtNK047Nfc+qNmiiirMQooooAKKKKACii
igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKK
ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCLd82K5Lx1FLc6LbpFE8hF
5ASEUkgbxzxXWcA5rA8XatcaRpUM1sE3vcxRneMjazYP6VM7cruXRclJOKu76HQx/cX6U+mIcoPp
T6pES3FooooAKKKKACiiigAooooAKKKKACiiigAooooAK5vxI0b2ltbPHdy3Fzc+Vaw217JaM8ux
2+aRGUhAqux68LwrNgV0lc94hspb+xjMFtJNLDMJUeC5EM8RAYbomIKl+du1iqsGYMcZBAMXTLA6
Z4hsP7W02aO4md0sZzrlzqEayeWzMu2bbsYor4YKeAwJGQG0PFwhS30y5kktStvfpKLS7mWJLtgj
gRqW+UuCQ6g8boxyv3hU0d7GfVok1HVdUm1iIN9mtdXjSExnBDtEsaIkp25BdS+ASAwDHOv4gOqD
SZF0uxtb2dmCtFckbdhByQpIDt0+UsgOT8w7gHPaFpmqyXVlNd6U2miy1C+vDLNLG8kqTyTMsSiN
mG3EqM2WHzIoAb7w9ArzbwppuhWGvxiWaew1mRWK6ebRdPiYgHdsjjG2faCTkvLt6gjrXpNABRRR
QAVnT3MNmqNcTxxK8ixoZHCgsxwqjPUkkADqSa0a808bS6idQjluNDvp7a01Kw+xSRSW/lkm4hLN
hpVbexzGMrgDPIDMQAel15f8Mf8AkePiJ/2FV/m9bHijT/iBd6oJPDWu6ZZWOwDyri33Nu7nO1sj
8q5j4NxahD4j8cx6pPFcXy36CeSJdqNJ+8ywGBgH6UAev0UUUAFFFFABRRRQAUUUUAFFFFABRRRQ
AUUUUAFFFFABRRRQBy+v6D/bYhmimSO5iSSIGaHzYnjfG9HTcpIJRTwykFRz1BwNP8DX+gxM+ia9
PDcSOZJo5Y90DtwOEJJUABVByTgDk9a9EHNBz6VLinuXTqzhpHbs9V9zOYudbvNC0q2m1i0luJ2O
2ZtPiLonX5iCchcY/GrOleJdL1tC2nXkMpxkpuww+oPI/KtsgMKwNR8IaJqV0tzPZItwpDebCTG+
c55K4z+NDTWxUZU5Jqaafdf5HQ0mfSuX1lPE9vfC50ia0uLbaAbOdSp467XHc+/AqLRvE73l+mm6
jpN3p184JCuu+NsDJ2yLwf0o5knZi9jJx5otNdddV8jsc0tVEnjkB2OrYJU4OcEdR9at1RnZrcKK
KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooo
oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIG5PtXNeM7C71LSIIrOIy
ut3E5AxwA3J59K6VuD7VzXjO/u9M0m3ls5TE7XcKEjHILcjn1qZ25Xcuhzc65d76X2OoiGEUe1Pp
kRyin2p9URLcWiiigAooooAKKKKACiiigAooooAKKKKACiiigArlfFE04trG0tzcG5vbsQRxw3P2
cSERu7B5QrOi7UY5QbsgAHBNdVXPXKWviJ7y3DXNvcaVeKq3EZCvHL5KOGQnII2zbSGGDlgQR1AO
b8L6jNaXOlxjwzYadbauZFe6iv3mmM6KzGOXdCGeT5XyWYj5G+YnAbe8WfvrWwsTH5s19eCCEPNJ
FEG8t3Jk2EF1Co/yHhjtBx94V9I0PTriWz1yyv7yewkZr+ytmYCKJ5wxaRRtD5YSPw7ELvbAHGJd
cg1bU2ns10TTryxJUo1xqUsEm4YIYBYG2MrdGVsjAOQeAAVNKsH8Lara2kljogi1KQwrNpmnm0dZ
FjeT51LvuUqj/NuBBwMHdkdrXD+HtMurbWnlfTbAtDmCa4bX7m/mt8qH2Ks0Xy7soSAy5BU84Fdx
QAUUUUAFZGp6FpOtNF/aul2N/wCUG8v7VbrLs3Yzt3A4zgZx6CteigAry/4Y/wDI8fET/sKr/N69
Qry/4Y/8jx8RP+wqv83oA9QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA
KKKKACm7R6CnUUAcXeeCbJrh7zSbq50u8clme3c7XP8AtIeCPYYqxp7a7pNjdyau8V+IlzAbOMrL
IADkFTxnpgD3rqBmlqVBJ3Rp7WTjyy1Xnv8AeczpvjLR9UlFulybe6HBtrpfLkB9MHqfpmuiU5Ss
jVNA0vW4RHqNlFMMcFl+YfQjkfga4Xxb4dmtLi2ht7aS406C3CwRy2b3yLJuYuHRQzAsDHtfacbG
GVzyryW+voNwpSa5W030eq+89SXmgtgE5rzjQr/xlpWlWkGoeHzeKqkgxXI8yNSSVUhiSSFIXqen
JJrpr3xRYaXZWlxqjS2JuVyEkjYlDgEhtoIB570e0Wt9LdxyoTi0lZ32s0/wR0n5UnX3rH0/xBpW
qDNnqFvMfRJAT+XWtgEY7VaaauZShKLtJNMkooooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFF
FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUU
AQ8E4rA8XaTcavpUMNsU3pcxSHecDarZP6V0G35s1yXjqWW20W3eKV4ybyAEoxBI3jjipnbldy6K
k5JRdnfQ65BhB9KfTI/uL9KfVIiW4tFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXJLbeItN1
jWZ7Gw0u5tb+7W4Rp7+SF1xBFEQVEDjrETnPQ11tFAHI+FrTxHpGl6Vo9/Y6WLa0to7d7m3vpHc7
EChghhUclRxu4B74519V1U6bFbrHbtc3d3L5FtCGCh5NrPyx4VQqMxPJwpwGOAdeuY8TyW8djZpN
b3s1zLdBbEWJVZxOEdtyM5VVwiuTuO0ruUgg4IBm6BrDrqTSXOntbtrWoTxs0dx5yJdQBoWQZRDs
aO13hsHncDt+XPc1wXhvSprPU4WutJ8QyFZZ5op9SmsjHbvKWeRgsD53MWYZ2sRuIG1Sa72gAooo
oAKKK4fxLLqumiS4TXrqG7lZhY28dkn2RnyNkczsjFdxKqWLpnJ246AA7ivL/hj/AMjx8RP+wqv8
3rW8U+Mda0LUhaaf4L1TV4mQMbm3bC5PbhScj3xXNfBy9n1HxD45u7iylsppr9JHt5T88THzMqeB
yPpQB6/RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA
UUUUAFRPGkilXUMpGCCMg1LRQBzN54K8OXjiSbSrcPnO6NfLJPuVxn8aj1rQr+9uEutP1y5sJFQJ
5agPEcEnJQ9+euewrpAMjmn4pOEWXGtUTTve219V9zPJPEU/ijS9Qt4NU1qA2Hlb0l+0PYLJJuII
MiEfMAFIUthtx4OOMSLxH4o+VpZrmTWNwW0t5LtoZJFyPL/0fCrIpGCzFSfmb5kxge5FQadjjpUc
nmzX6wvtRTfpb8jkrfxbefaYre/8M6nbu7BN8arLGpJxksp4Hvir954w0HT782V5qEcFwFDFZFYA
A9OcY/Wt7H0/Kq1xZWt2m24gilX0dAf507SS0f3k89OUryi0vJ/53K9nrGn6lxZ3tvcAjIMUqt/I
1oBgMDIzWDB4U0O0vo7620y3huEJKPGu3bkYPA46E1n3vg1p76W8s9c1S0kkYvsjmzGCTk/KR+ma
d5JaoXLSlKyk0vNdfkdfmm5x1rntG0vXLCeQ32t/2hblMIj26xsrZHOR1GM/nWb/AGr40sji50G1
vh/etLrZj3w/Wlz2V2mNUOaTUJJ287X+87RnPanHpXM2GuvPp91dahpV5YLajcyyLuLjGcrt+90q
O18f+GrlvLGqxxsOCJwYsH3LACnzx013I9jPWybtvbVL5o62lqla3ttdwCa3uIpoj0eNwyn8RxVs
MD0IqiGmtx1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFF
FFABRRRQAUUUUAFFFFAELcc+lYHifTP7Y02KD7QkG25ik3OODtYHH1Paug6YrkfiGSdFtgD/AMvs
H/odTNpRdyqSbklF2d9zr14UD2p9Nj+4v0p1UTIWiiigAooooAKKKKACiiigAooooAKKKKACiiig
AooooAK5PxSlrd20LS3Ws2klneo6TadYvNKJAhIwPKfKFWILAbeqk8sp6yuc8SzzW1pbbZJ4LFrl
Vv7m3B3wwbXJYEAlQXCKzDlVZmyuNwAM/R70y6rAn9u+KbrO79zfaL5ELfKfvP8AZU246j5hkgDn
OD2deaeFtSF5dacml6rc6iEvb+K8H2p7mNLRZpzCzMxbD58oKc7mUn7wUFfS6ACiiigArlNc0PWt
Xtr3Thq9vHpt6jRSo9gXmVHBDBZBIqjgkAlGI4JzXV0UAFeX/DH/AJHj4if9hVf5vXqFeX/DH/ke
PiJ/2FV/m9AHqFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUU
AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA3GRis660WwvVIurOCYHtJErfzFaVNz70
WQ1Jx2djDuPDGk3Ok/2abRIbXfv8uAmMBs5yNuO9ZI8ES2uTp3iHVrf0RpRKg/Bh/Wuw6H29ab1p
OEXuONScVZPTe25z9/b+I4dPtY9NurSa5jXEz3cZAlOBzhenOaz11nxjZkLc+HILpc4MlrdAfo3N
dkBSFCe9S4t6p2LjWSVnFP1v+hz2r+KLXRLlIby3vMMgfzordnjXJIwWHfjp9KjsPGuganMkVtqc
PmyEKsb5RmJ6AAgEn2rpdoZfmANUX02xmlWaS0gaVCGR2jBZT2IOMg0WlffQalScbSi+bunp91v1
LAmjyVDqSOozzU4YEcVy+peCdF1S+e9lgkjvHwTPDMyNwAOxx0A7U/SPCz6PfefFrOpTRFSPIuZR
IvPpkZGKLyva2guSny3Unfs1+p0pNICcVxt1beNLW4kezudNuoWcsqTxMjBc8DK9wOMmtLStQ1uV
J/7U0hIBEu5HgnEnmnnIA4IPHf1oUr7qwSo2XMmn8/0Oi5B4Io+bvXGN8RtOtI5H1PT9T09UBLG4
tWxwM8EZzVHTPidpl1cxR3wtrOO4B8mQXW9kIGdsqlV2MRn7pZcgjdnGXzR7k+xnvZnoPQcUbqyL
HxJo+ozeTZ6nbTS4J8tJATgdTjrTW8T6HG7xnV7Hepwy/aEyp9CM8U+ZWuL2cr2adzaoz71jprWm
S201xHqFs8UCGSZklDBFAyScHgYBrM0rxnp+qXkdqIbi2aZS1u8+wCbA3EAKzMrbfm2uFbAJxwcH
Mg9nLXR6HXUUwOp6MD+NLkeopk2HUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEHQ/Ss
LxNaWV9pkS6hdfZoluYmV8jlg42jn1PFdBiuR+ImTodsP+n2D/0MVM3aLuVSi5TUU7Nvc7Bfuj6U
6o4v9Wv0qSqJYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXH+KF1uPUdJms9asbK1+
1hBDLaSyPKzRyKFOyVd4ywbbhQu3eWwmD2Fcv4ttrmS0sLu0adLqyu/PjkithcBMxSIxeLerOu12
GEJbJU4IBoAyrTVLq48S2lld+ILeVoJ5QIrLS57eO4kWN1aMzNI8b7dzMUGSGTJxtNd7XBaHDpcl
xpFjDrm+50+a4vWtbiPyLmWeXeGdo3AZU/fS4G3ncpz8vzd7QAUUUUAFFFche+INctba/wBQXw9D
/Z1m8ufMvWS5lSNiGZIvKKndtJUFxuBByM0AdfXl/wAMf+R4+In/AGFV/m9dPrnxA8L+HL77Fq+r
w2t1tDGJlZiAehO0HFcV8IdRs9S8UePb20mWW2n1FJY3AI3KxkwcHnmgD12imeYvqPzo8xfUfnU3
QrofRTPMX1H50eYvqPzouguh9FM8xfUfnR5i+o/Oi6C6H0UzzF9R+dHmL6j86LoLofRTPMX1H50e
YvqPzouguh9FM8xfUfnR5i+o/Oi6C6H0UzzF9R+dHmL6j86LoLofRTPMX1H50eYvqPzouguh9FM8
xfUfnR5i+o/Oi6C6H0UzzF9R+dHmL6j86LoLofRTPMX1H50eYvqPzouguh9FM8xfUfnR5i+o/Oi6
C6H0UzzF9R+dHmL6j86LoLofRTPMX1H50eYvqPzouguh9FM8xfUfnR5i+o/Oi6C6H0UzzF9R+dHm
L6j86LoLofRTPMX1H50eYvqPzouguh9FM8xfUfnR5i+o/Oi6C6H0UzzF9R+dHmL6j86LoLofRTPM
X1H50eYvqPzouguh9GKZ5i+o/OjzF9R+dF0F0PopnmL/AHh+dHmL/eH50cyC6H0UzzF9R+dHmL6j
86LoLofRTPMX1H50eYv94fnRzILofS1HvX+8Pzo3j1H50cyC4+im719R+dJvX+8PzouguU7i2gvI
JbeeJZIZUZJEYZDKRgg+xBrn7LwRplreJcTvPfGMFYEuhGwiyME8KCzY43OWbGeeTXWbh/eFIXX+
8Pzobi9ylUktnYow6Rp1tKZYLG3jlxjekQDY9MjmqU3hLQJ3aSTR7BnYks32dMknqScc1teav95f
zo3q38Q/Oi8WCqyTupa+phjwvokdleWkOnwQx3sLQT+UgUsjAgjI9ia5m0+GOmC6R9TeG6hiBESQ
27QMxIxukYOdzAZ+6EHJOOmPQdyr/EKNyj+IUm4vR2CNecW3GTV99TA0vwbo+iXXn2EU0T7Suwzu
y4PsSfSqM/gy4NxJNbeJdYjLsX2tOHVSTnABHA9q6zzF/vClDp/eH50e5aw1XfNzOV356/mYGl6T
q9is63WvSXe9MQ+Zbqvltzzkde3B9KzmtPHducRalpdz/wBdoXT/ANBrsfMQ9x+dG5T/ABD86Wlr
J/iUsQ7ttJ38kYNpP4lj0meS9s7KW/U/uYoJSEccdWYcHrWf/wAJJ4ohk/0jwjLsH8UV5G+fw611
odG5BFIZVboQaG+0vyFGvBNuUU7+v4WZgnxHLBoialc6RfoWfabdIg8i8kZIB6cdfcVQHxG0VVzd
C8tv+uto4/kDXXM8Y4LCkYR4520OXZjjVpa80fudrfmY0/ifSLa1tbm4v4ooLpN0DyZXeMA55HHB
HX1qWDxRoVywEOrWTk9luFJ/LNW7mztLqPZcRRSr6OoYfrWZJ4R8OSctpNiSepEKj+Qoc/QIui1r
dP5G2ZFxzgUqsp6Mv51gav4S0bXp457+2Z5o02I6SshC9cfKQOpNVbbwVp1ldQ3FtfahEYnVwgu2
Ktg5wwPUHuKObX/gjSpOF3Jp9raffc3L3VtNsZoYL3ULW2ln4iSadUaQ+igkE/hV0OcV5j4n8J63
c+IdTu7M3VxBqMaIFikiCKoQIY5Q5B2Zy2VDfeb5c8nYsvC3iC0sLe3Txfch4olQkwIwOAB357dT
zQ6lnsONOm4puaTfdP8AQ7gcDBpSAw6Vzmr6ZrN0sBsvELWGxcP/AKMknmH1O7p9BWJBba3Z3sKX
Xjm2ctKq+S9rEhc5+6MHOT09aHUS/pf5jjQUo35l6Wf+R3hbA9BThwc96858UeI7608QyWmn6qyv
GqBrWPT2mYEjOd3TkEd68x0PWtattV03VriDUXuZb9FmmXTgGkG/98nmjDMdob5SSBg/KuAVSrRb
a7DeHfKpXWqul1PpNW454rB8TNpf2KJdW3+R9oi27M537ht6ds9ai0zxnomp3S2lve7bpjgQyxtG
2cZxhgM/hWH8Tdd0zT9Ls4Lq9hSaS8iKxjLNhWBY7VBPH9afOpRbjqZU4OMkpXXnt8z0JfujHTFP
qnZXcF9Yw3VrMk1vKgaORDlWB6EGrlaEMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigA
rn9evZ7U2ENrcCG4vLxLdP8AR/OLAqzNtG5QpVVZtzZACn5WJAPQVznir7D9ggN4bv7QLgGy+xf6
/wA/a23y+2du7O75du7d8u6gCheaHof9p6fBrsNxqt1d744Lm+AkUSKC+1VACRuVViGRVyEOTnGe
isLZrOwt7UzzXBhiWPzrht0km0AbmOBljjJOOprltIG7xBZjWx4g+3AObD+1vs3lltpD7Ps3yb9m
77/zbd23jdXc0AFFFFABXJX2s61DLdLB4V1O88osLYfaLVIpWXO1izTbgCQOq5A5wSK62igDE1Lw
/pGsFv7R0y1uWKlC8sKswBGOGIyPwNeSfDPwfpY8T+MbNDcImn3wt4CsuD5e58A+v3RzXuf8NeYf
DH/kePiJ/wBhVf5yVM4Ka5XsTJKSs1dHUf8ACEWP/Pxd/wDf3/61H/CEWP8Az8Xf/f3/AOtXUUVj
7GPYj2UOxy//AAhFj/z8Xf8A39/+tR/whFj/AM/F3/39/wDrV1FFHsY9g9lDscv/AMIRY/8APxd/
9/f/AK1H/CEWP/Pxd/8Af3/61dRRR7GPYPZQ7HL/APCEWP8Az8Xf/f3/AOtR/wAIRY/8/F3/AN/f
/rV1FFHsY9g9lDscv/whFj/z8Xf/AH9/+tR/whFj/wA/F3/39/8ArV1FFHsY9g9lDscv/wAIRY/8
/F3/AN/f/rUf8IRY/wDPxd/9/f8A61dRRR7GPYPZQ7HL/wDCEWP/AD8Xf/f3/wCtR/whFj/z8Xf/
AH9/+tXUUUexj2D2UOxy/wDwhFj/AM/F3/39/wDrUf8ACEWP/Pxd/wDf3/61dRRR7GPYPZQ7HL/8
IRY/8/F3/wB/f/rUf8IRY/8APxd/9/f/AK1dRRR7GPYPZQ7HL/8ACEWP/Pxd/wDf3/61H/CEWP8A
z8Xf/f3/AOtXUUUexj2D2UOxy/8AwhFj/wA/F3/39/8ArUf8IRY/8/F3/wB/f/rV1FFHsY9g9lDs
cv8A8IRY/wDPxd/9/f8A61H/AAhFj/z8Xf8A39/+tXUUUexj2D2UOxy//CEWP/Pxd/8Af3/61H/C
EWP/AD8Xf/f3/wCtXUUUexj2D2UOxy//AAhFj/z8Xf8A39/+tR/whFj/AM/F3/39/wDrV1FFHsY9
g9lDscv/AMIRY/8APxd/9/f/AK1H/CEWP/Pxd/8Af3/61dRRR7GPYPZQ7HL/APCEWP8Az8Xf/f3/
AOtR/wAIRY/8/F3/AN/f/rV1FFHsY9g9lDscv/whFj/z8Xf/AH9/+tR/whFj/wA/F3/39/8ArV1F
FHsY9g9lDscv/wAIRY/8/F3/AN/f/rUf8IRY/wDPxd/9/f8A61dRRR7GPYPZQ7HL/wDCEWP/AD8X
f/f3/wCtR/whFj/z8Xf/AH9/+tXUUUexj2D2UOxy/wDwhFj/AM/F3/39/wDrUf8ACEWP/Pxd/wDf
3/61dRRR7GPYPZQ7HL/8IRY/8/F3/wB/f/rUf8IRY/8APxd/9/f/AK1dRRR7GPYPZQ7HL/8ACEWP
/Pxd/wDf3/61H/CEWP8Az8Xf/f3/AOtXUUUexj2D2UOxy/8AwhFj/wA/F3/39/8ArUf8IRY/8/F3
/wB/f/rV1FFHsY9g9lDscv8A8IRY/wDPxd/9/f8A61H/AAhFj/z8Xf8A39/+tXUUUexj2D2UOxy/
/CEWP/Pxd/8Af3/61H/CEWP/AD8Xf/f3/wCtXUUU/YQ7D9lHscv/AMIRY/8APxd/9/f/AK1H/CEW
P/Pxd/8Af3/61dPRR7CPYXs4djmP+EIsf+fi7/7+/wD1qP8AhCLH/n4u/wDv7/8AWrqPxoxR7CHY
PZR7HL/8IRY/8/F3/wB/f/rUf8IRY/8APxd/9/f/AK1dRRzS9jDsHsodjl/+EIsf+fi7/wC/v/1q
P+EIsf8An4u/+/v/ANauooo9hDsHsodjl/8AhCLL/n4u/wDv7/8AWo/4Qix/5+Lv/v7/APWrp+aX
mn7CPYXsodjl/wDhCrH/AJ+Lv/v7/wDWpP8AhCLD/n4u/wDv7/8AWrqOoqncXtvapumnijUd3cAf
rS9jBdENYeLdkjD/AOEJ0/bn7ReZ/wCuv/1qT/hCbDb/AMfN2T/12/8ArVcn8SaVBpcmpNfwyWsT
BJJYT5gDEgY+XPPI/OshvH0M4xpuj6te56NHbFV/NiMVTo01ukaRwzkrqOi0v0LR8E2WP9dd5/66
/wD1qf8A8ITp+Obi8/7+/wD1qddX+uz6RbXGnaXHFdyt+8iu5ceWvPJ29T0496zv7P8AHN5jz9Ys
bAHr9ltzIf8Ax+pdKC2jcqGGi9W0vXy9C83gzTwObm6/7+1Wl8L6TAf3l9Om4hQGnHJ7AZq7qvho
awYTPqeoReUm1lt5vLWQ+rADr/jUFn4C8PWUyXC2XmTqwcSzSNIdw6H5iaToxvpFAqNHlvJu/ZL9
TD1WPwtotwYL/V7iKcAExq7MwzyOADUenpouq6hHaWdvrzq+f9JaMrEuATySO+MdO9egC1gV/M8p
N5GN+0Zx9amVAq5GBT9gr7KwclFRtytvu3p9x4Z4itb2012/tJmnsIxj7C82oFPNXH3kVRmVywPy
4YgbRt5yel03wL4ivbG2m1DVksZHjRpIYYizKSASCS2AQeOM16kBQVpujB7q5aqRikoxSt5X/M4u
5+HWmXhU3F3qLbRgqJwA3uRimwfDbw/bsrRQzqynIYvkg+uSK7YgYpgTHRaPYU7WsT7WaVlJpdls
c5/whFj/AM/F3/39/wDrVXX4eaItybpFlW5YYaYEBz9TjNdhRSVCmtkZ2Ryv/CDaaxVmmuiw6Ey8
j9K86+Ifw101Liz1eBZJFaZIbiCSUqX3NwQwVsdSDxnpgjv7SWycVyvxB50C1P8A0/Qf+hVXsIwX
NBWZrSalJRezdmafhnTDoWiW+nGRZDGzuxQELud2chQSSFBYgAknAFb9Rxf6tfpUlbEMKKKKACii
igAooooAKKKKACiiigAooooAKKKKACiiigArmfFTWkdnaXE97LZ3MFyGsZYbdrhzOUZcCJQTICjO
CoGdu4grjcOmrkfGf2gLoQtJ4be6/tRBFdzrvjtyY5ASy5G7cCYgMr80q4IOKAKWl3Mur69Yyane
3s72xZ7WNPD93YwrIUZS7tKGBOxmUDco+Y8EkY7uuesofEcd0r3upaZPbc744dOkiduDjDGdgOcH
7pyOOOo6GgAooooAKKKwrrWY7XU7PT2trpmu5mt0l8vbGHETy4JOM5WNuVDDPBxQBu15f8Mf+R4+
In/YVX+b16hXl/wx/wCR4+In/YVX+b0AeoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFA
BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAF
FFFABRRRQBGOnSlOfSqV1eW9tGXmmSNB1LMAP1qjZeIdJ1G6a0s7+C4nVC5SJw2FBAJ49yKG0hqn
Nq6Tt3NrtS54ri28bT3UpTTfD2q3XOA7Q+Uh/Fj/AErRsbnxBqFjdfadPt9NuSv+jhpvOGcdWxjo
cdKlTTdkaOhNLmlZfNX+7c32ZY1LMwCgZJPAArF0/wAS6Rqd2ILS7ZnZDJHvheNZUGMtGzKA6jI5
Ukc1iXPhHxBq1pcW2q+KJTFcRtG8VtbrGAGBBGepHNY9h8N5bm9t316VZ4LbcSyXksj3LEEAkFV8
tQCTgFiTj5sDmeaT2X3l+zpR0lO/om/zsekrcwu3liZC2M7dwzj6Vk3Xi3w/aMyTazZq4OComUkH
6A5qPTPCGiaNN59hYJDLtKh9zFsHqMkmrSeHNGWVpV0qyEjEsWEC5JPU5xT9+3S5NqSlu2vkn+pn
/wDCY6NLp2pXlpdC7Gn27zzJEDnaqlsDIwSdprl7L4l35vreKbT3v0u8rGlnaOhicLu27mY+YMBs
nCEYztIPHocVlBHEY44UVCMFQowR6EVn6b4a0jTLwXFnasrqhjj3zPIsSHGVjVmIRTgcKAOKVpaa
gp0k37ra6Xf52Kukazreo3ZW58PyWVrsJE0s6lifTYOR3qnLYeN7qWQNq+n2UZY7DbwGRgueM7uM
4rsetM8vb0p8l1ZtgqyjJyjFLytf8zn9L0K9t7a6i1HWbm+NymwkgR7BggldvQnPXPYVXg+HvhyK
UyS2RuZP71xK0hP4E4/Sus70mBnijkTST1t3J9rNNtO197afkUrPTbLT4PItLWGCLOdkSBVz64He
rwjUD7op9N7VSS2Ibb3Y+iiimIKKKKACiiigAooooAKKKKACiiigCHZhs1heJdS/sXTorj7Ok+65
ij2ueBuYDP1Hat9q5Tx9DLPolusUbyEXsBIRSSBvHPFTNtRdiqSjzJS2b1OsXlQfan0yP7i/Sn1R
LCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5XxasVxBYafNpdhqEt7eCC3S/iEkMTi
N3MjAg5wqPgDBJIGRkkdVXMeKpEawtLFtOi1CbULoQQxSzGBEdUeXeZFDMhURsQVBbdjGOoAMfTd
Ct/DfiDTBPpPh5pLySSK3u9P0sWksEgidzkFnJVkVgSGXBwMENx39cboei6jY6otxcaRarlGja5f
Xbm9mjQjO1BNEMAsFyAy9AecAV2VABRRRQAVxXiPVYo9d0RPsmqy/Yb8zXDQaVcyoqG1nUEMiFW+
aRBhSSCeehx2tFAHBa/8PdF8aXserXlzq8LyRLtSORoQBgYyjLlT6ggH1HFc98HtLg0vxJ45sbdp
Whtr9IUMrbmKr5gBJ7n3r16vL/hj/wAjx8RP+wqv83oA9QooooAKKKKACiiigAooooAKKKKACiii
gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopCQOpoAY
KM+1QNNGiks4AAyee1c1dePfDcEnlLfi5kP3UtkaQn6FRj9alyS30LjSnJ2Sb9Edb2ppPeubsdfu
NT0y5urHR70SR8Rw3aiAyn1BOePc1QZ/HV9JhY9N02P/AGi0zj8uKHPsrlRoSbak0rd3+h2QO3mo
Lm9traLzJ7iKJP70jhR+tYbaFeX2hxWOpazdtch9z3Vpi3Z+TxgZAGDj3wKrwfD3w+kvmzWbXc3e
S5laQn6gnH6Um5dF94RhTV+eT07K9/vaNHVfFOkaLHA95dhftAJhCIzmQDHTaD6j86yI/GlxfTrH
pvh7U7hcgGWSIRJjPUFjzXURW0MEaRxRoqRgKihQAoAwAPQcVb2gdAB+FDUn1HGdOMdY3fm9PuX+
ZzOrr4qnvgmkPp8FptGZJwzOG74A4/OodP0HXkvI7nU/EctwsZz9nht1jjPGMHHJFdWoOOtBUdqO
VN3uxKtJR5Ukvkr/AHnMXXgXQLzUJL+7tGuJ5GLEyysw57Bc4x7YrSsNI0/S1P2Kwt7ckYJijCkj
3I61rDpzS496pRinexMqtSSUXJtLpfQUAegp1FFMgKKKKACiiigAooooAKKKKACiiigAooooAKKK
KACiiigAooooAKKKKACiiigAooooAg6Nz0rB8WatdaPpcM9rs3vcxRHeMjDNg/pW8Dlvaub8aafd
6lpEEVnEZXW7icgY4Abk8+lTO/K7blUVFzSe19bnTocoD7U+mRjCKPan1SJluLRRRQAUUUUAFFFF
ABRRRQAUUUUAFFFFABRRRQAUUUUAFc5qvhPStauvOvzfyP5iyBU1K5jRWXG1lRJAqkYByAOeepzX
R0UAc9Y+HrKzmS6t59TeVM4E+qXUyHII5R5GU9e4ODz1FdDRRQAUUUUAFFFFABXl/wAMf+R4+In/
AGFV/m9eoV5d8Mf+R4+In/YVX+b0Aeo0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRR
RQAUUUUAFFFFABRRRQAUUUUAJRR2rndZ8SW+kTrbrbXF3P5fnPHAUXy484DMzsqgEggDOTg4BwaB
pNuyN4HinDAzXFj4ieGGtoZU1MP5oyqJGzOD6FQOCDxg1fv9dvPsFtc6Tpc9+bhdwXIjKDAI3bum
c1PPHW3Qv2NTS6sns3ovvZ0hpxNcQLnx1esPKsdN09O/nytK2P8AgPFX9Y8O3Wr3Cs2uX9pAqBTD
asI9zZJ3bsE9wMe1LmbWiG6KhK0pL5a/kTav4mttJuUtRDcXdyyeYYrcoCiZwGZnZVGSCAM5ODgH
BrK/4WRoh2zAXItMqr3TqqJExwCrKzBztJAYhSFOckYOKl78MdPkuo7m1uP9JCbJWvUe5WQZyCQH
Uhhzg5xycg1WT4U2KKbcXUUlpJ/rvNtA05z98K4YKgY5P3CV3HaRxhXn2RfJRX2m/l/wTeHjnw/P
fR2lveG4nlYIqwRs/JOMkgYx+NLqmuavaXzWmmeH5r3AB89plijOfQnrit+3tLa1Tbb28UI9EUAf
pVn607Sa1f3Ec9OMrxjddm+vfQ5jTZPF019HJqEWnW9lzujjZnk6HHPTriq934TuNRvZZbnxFqXl
s5ZbeBxEqrnheBkgdM12QFIeafKmrPUPbSUuaKS9EYGkeE9K0WWSa0gfz5V2ySySs5YZzg7ia0Lf
TbK0Xba2kES/3Y4wo/QVoYFM6e1NRSVkQ6s22222yUAAcCloopkhRRRQAUUUUAFFFFABRRRQAUUU
UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQAYb2rmvGt
/d6dpEEtnKYna7iQkY5Bbkc+tdL1bnpWD4s0m51jS4YLXZvS5ilO84GFbJ/SpnfldtyqLippva+t
zoYzlFPtT6YgwgHtT6pEy3FooooAKKKKACiiigAorm/EXi7TPC82nLqzSwQX0xhW52ExRNjI8xv4
c9voScAEjoFYOoZSCpGQQcgigCSiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAbivmzwH
rPjvT/EviO0sNP0++1m4mEt9FdSohV1ZlYrsZVPLDOOOmOtfSPevnHfdaJ4+8ReLbbcYtI1zy7tA
B80MxZWPXsQABg8sD2rSjGM3yydm1p69hSdtT0L+2/jF/wBCnof/AIF//bKP7b+MX/Qp6H/4F/8A
2yvSIZEniSWNgyOAysDkEHkGrFZ7DPL/AO2/jF/0Keh/+Bf/ANso/tv4xf8AQp6H/wCBf/2yvUKK
APL/AO2/jF/0Keh/+Bf/ANso/tv4xf8AQp6H/wCBf/2yvUKKAPL/AO2/jF/0Keh/+Bf/ANso/tv4
xf8AQp6H/wCBf/2yvUKKAPL/AO2/jF/0Keh/+Bf/ANso/tv4xf8AQp6H/wCBf/2yvUKKAPL/AO2/
jF/0Keh/+Bf/ANspP7c+MP8A0Keh/wDgX/8AbK9PyPWsu91Wy02PzL28t7aPn55pFQcAk8kjsCfw
NCTbslcDhP7c+MP/AEKeh/8AgV/9so/tz4w/9Cnof/gV/wDbKv8Aij4teFvDLWySXD6i05cY014p
vK27fv5cbc7uPofSut07WNN1aJpNPv7W8VThmgmVwp9DgnBpuEl0C6OE/tv4xf8AQp6H/wCBf/2y
j+2/jF/0Keh/+Bf/ANsr1CikB5f/AG38Yv8AoU9D/wDAv/7ZR/bfxi/6FPQ//Av/AO2V6hRQB5f/
AG38Yv8AoU9D/wDAv/7ZR/bfxi/6FPQ//Av/AO2V6hRQB5f/AG38Yv8AoU9D/wDAv/7ZR/bfxi/6
FPQ//Av/AO2V6hRQB5f/AG38Yv8AoU9D/wDAv/7ZR/bfxi/6FPQ//Av/AO2V6hRQB5f/AG38Yv8A
oU9D/wDAv/7ZWD4t174pwaPvv9HsdOszMiz3VncHeiE85YOSingFhjHqOte2ikPSgE7M+frPXvHU
tldnTZLq409JcLLFKboK2PmVJSZGdRwchjg5Ge1Y8eo+LfPvC9ha3QCRrdnVZyQcs3lZ3spBDeZt
28ctkGvpMDnGPlrD1nw3b6xMs/2i4s5/L8p5LfYfMjznayurKQCSQcZGTgjJrH2bTbvf1Op4qMoK
HJaz3WjPJ/B+r+N4tHjj0Tw14emRWkDSNcoJGfed5YBx/FnoAMYxxiupGtfF5Rx4U0L8Lr/7ZW7/
AMK58NLBDCmnhBEMK8cjK5PqSDySecmtC+0K5l0+1tdN1a4sDbrtDgCQuMADdu69P1q05LdfcTP2
c2rSeu91t9zZyn9t/F7/AKFTQ/8AwK/+2Un9t/GD/oVdD/8AAr/7ZW0bXx1ZSL5d/puoRjr50bQu
fptyK0Nb8QXWjzoraJf3cDIGM1qokw2SNu3IPYHPvT5tLtWIlRfMlGSd+3/BOW/tz4wf9Crof/gV
/wDbKP7b+MP/AEKmh/8AgV/9sq9e/E3Tkuo7W0g/0kpvlW9d7ZYxnABIRiWPOBjHByRVZfizYyr5
/wBmijtEP77zbsCYY++VQKVdVOR98Ftp2g8ZSnHuJ0Ki+yyL+3PjD/0Keh/+Bf8A9so/tz4w/wDQ
p6H/AOBf/wBsr0S2u7e6j3wTxyof4kcEfpVyrM2mnZnmH9t/GL/oU9D/APAv/wC2Uf238Yf+hT0P
/wAC/wD7ZXqFFAHl/wDbfxh/6FPQ/wDwL/8AtlH9t/GH/oU9D/8AAv8A+2V6hRQB5f8A238Yv+hT
0P8A8C//ALZR/bfxi/6FPQ//AAL/APtleoUUAeX/ANt/GL/oU9D/APAv/wC2Uf238Yv+hT0P/wAC
/wD7ZXqFFAHl/wDbfxi/6FPQ/wDwL/8AtlH9t/GL/oU9D/8AAv8A+2V6hRQB5f8A238Yv+hT0P8A
8C//ALZR/bfxi/6FPQ//AAL/APtleoUUAeX/ANt/GL/oU9D/APAv/wC2Uf238Yv+hT0P/wAC/wD7
ZXqFFAHl/wDbfxi/6FPQ/wDwL/8AtlH9t/GL/oU9D/8AAv8A+2V6hRQB5f8A238Yv+hT0P8A8C//
ALZR/bfxi/6FPQ//AAL/APtleoUUAeX/ANt/GL/oU9D/APAv/wC2Uf238Yv+hT0P/wAC/wD7ZXqF
FAHl/wDbfxi/6FPQ/wDwL/8AtlH9t/GL/oU9D/8AAv8A+2V6hRQB5f8A238Yv+hT0P8A8C//ALZR
/bfxi/6FPQ//AAL/APtleoUUAeX/ANt/GL/oU9D/APAv/wC2Uf238Yv+hT0P/wAC/wD7ZXqFFAHl
/wDbfxi/6FPQ/wDwL/8AtlH9t/GL/oU9D/8AAv8A+2V6hRQB5f8A238Yv+hT0P8A8C//ALZR/bfx
i/6FPQ//AAL/APtleoUUAeX/ANt/GL/oU9D/APAv/wC2Uf238Yv+hT0P/wAC/wD7ZXqFFAHl/wDb
fxi/6FPQ/wDwL/8AtlH9t/GL/oU9D/8AAv8A+2V6hRQB5f8A238Yv+hT0P8A8C//ALZR/bfxi/6F
PQ//AAL/APtleoUUAeX/ANt/GL/oU9D/APAv/wC2Uf238Yv+hT0P/wAC/wD7ZXqFUY7mCS8ltknj
aeJVaSIOC6Bs7Sw6gHacZ64PpQB57/bfxi/6FPQ//Av/AO2Vj23j34m3Pie78PReHNFbULSBZ5Yv
OICq2MHdvwfvDgV6tbatp17dz2trqFrcXNucTQxTKzxH/aUHI/GuX0/SbC2+LOr6wusWb3l3Yxw/
2esq+cm3bliuc4wo/WgDH/tz4w/9Cnof/gV/9srI17W/iSbCP+1dC06xg8+MpJbXOWZ93yqcOeCe
teqtq+npqaadJqFot643JatMolYeoXOSPwrH8XJYX1tZ6dc6pZ2VxJcxyRRzyqrS7WBIUEgk/Soq
JuLSNKTippy2T1OZXXPjBgbfCeh4/wCvr/7ZS/238Yf+hT0P/wAC/wD7ZXpqDCge1Pq0Zy3PMP7b
+MX/AEKeh/8AgX/9so/tv4xf9Cnof/gX/wDbK9QooA8v/tv4xf8AQp6H/wCBf/2yj+2/jF/0Keh/
+Bf/ANsr1CigDy/+2/jF/wBCnof/AIF//bKQ658Y8jHhLQ//AAKH/wAcr1GigDxvX7z4jajoV5aa
34R0BtOaMm48+9CoFHO4t5g24xnOQRjOaPgfqfiS80OeDUInl0O3Pl6fdSsd/BwY1yMsgHQnG0ja
M9F7nxh4STxjFY2V5qFxDpkU3m3dpD8ouwPuqzDkAEZwOvsQCN61toLG1htbaJIbeFAkcaDaqqBg
ADsABQBdooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEryLwRp0Oq+IviZYXKloLnUDFI
AcHawkBwex56167Xl/ww/wCR5+Iv/YVX+clJNp3W6AtfDDUrhdNvPDOok/2hoUxtTkEF4f8Almwy
B8uMgewU969ErzHxWy+DviDpHikfJYaiP7O1JuAATzHIfpjk9lTHevS+o4q6yTalFaNX+fVEx0Vu
xJ2rnPEXjTw/4R+zf25f/ZDdbvJ/cySbtuN33FOMbh1x1rovavKPiHpFp4v8e+FvD9xGj+WZbq5J
LArB8uVGCPvlCM9RgEY5yqMHUlyrom36JXKeiOvvPiH4Qsoy8viLT2GM/uZhKfyTJrDm+MfhCLAt
bq6vpD92O3tX3E+g3BR/+uukt/BPhiz2m38P6YjJ91vsqFh+JGf1rZjhihjCRxqijgKqgAfgK0Uq
Ufst/NL9Cde559J8T7ydFOl+CfENyzD5TNa+Uv8A30Nwx0p0viT4i3ar9h8EwWu7OHu79HA4OCVB
UjnHH/6x6KoHpTqFVgtoL5tv/ILPueaywfFW+QAXXh7Tg2cmFZHdeD2ZWB7fl+FPm8FeNL4L9t8f
3CjnctpZrFjgjhlYHv6fqAa9HAxRikq0o/Ckvkn+Y+VdTziX4T2d5j+0/EniG/4O5JrwFTkEdNvH
BPerkPwm8FxN5h0jzZMklpriVsk56gtjv6V3VLil7apayk0vJ2/IXKuxzK+BfCSxqh8M6OwHd7KN
j+ZGaxr/AOE/hTUJDNHYtY3GcrLZSGIqeeQvKjk56dh24rvqWohUnGTlGTTe+o2k1Znmf/CF+L9I
Eh0Lxrcyr/Db6pEJgeuAXOSB06L/AIU4+I/iHook/tXwrbanBGufO0y4wSeeiNlm7cAD+lekY+lL
2rT27fxRT+Vn96sLltszzu3+Lvh1blrfVY9R0edQD5d/aMrEnthd2PXnHUV2Gna9pWsKTpupWd3t
6iGZXI+oB4qxdWdre25hubeKeI4JjkQMpxyODxXIan8LPCOpMXOkpaTZBElkxhK4x0UfL29P1ovT
lumn96DVeZ3nbioyTXlGv/DjxYlglv4a8caog8xWaO9u3UhQpHEiDPX+HABznqObtr4K8etp1vbX
vj10ZI1VxBZqzcAD/WkqzHj7xGT3qVTi3bmSXdp/kF3bY9OyPWqlzfWtnH5lzcQwp03SuFH5muCH
woFxCqaj4u8TXeDkqb7Cn8CD/OrFt8HfBMCqG0t52H8UtzJk/UBgP0q1Ckt5N+i/zaC77GxcePvC
Vqm+TxFpxz2iuFkP5KSe9Ys/xh8GxgC31Ga6kJACQ2sm45I/vKB3rctvAnhW1VVi8PaZ8vIZ7ZXY
fiwJ/WtyC1gtohHBBHEg6LGoUD8BTTpR6N/NL9GHveR59/ws+W5iT+zfBviO5DkYZrTYnOP4gSOh
+n4c0/8A4Sn4gXsMbWfgRLfcR893qCcDIzlflYcZ/wAO1ej4oxSVaC2gvm2/ysFn3PNtnxWvYk3T
eHtOHylgiyO46E9dy+o6/j3rI8QfCfxH4xjsz4h8XxyyWoby1j01cKW27uQy5ztHUdu1ew03HrUy
rycXFRSXklf73qO3W55s9p8UNH8xrbUdJ1yEcqtzCYJW9gFwoPHUseTTn+IOuaU0g1/wTqkCxoG8
+xZblT1yTjAUcepxxntn0enbaftk9JRT81o/w0/AVn0ZxNh8UfCN+/lHVktZgcNHeI0JU88EsAO3
rXT2l9aX9uJrS5huIiSA8ThlJBwRkcdahv8AQdK1dQupabaXYHTz4VfHXpkcdT+dcjd/CLwxJJ51
il7pdwHLiaxumVgTnoG3AdSOAODRalLq19zX6B7y8zodY8NW2r3CXSzz2lyqeWZbcRsXTOQGV1ZT
gkkHGRk4Iyayf+FcaGCsQ+1Gz3Kz2rsjpKwwSSzKXGSAWAYBjnIOTnltd+G3jkrBFoXjm9aFCxK3
d1LE65xjLpuL9D1Ax26mk/4Qz4sf8JN/a3/CXWmz/nj58vlfc2/6nZs9/rz1qZUYOVlJNd9V+hpG
rNLRtHbp4F0GK/jvbez+zSRsGBgkZOQc4IBwRS6voWsXN813pviCeyBAHkNCssfHoD0zXPDw/wDE
8kbvGdkgPXbYIcfmtTJ4X+Ip+/47gA9tMiP9BVuhFL4kvS/+RSrT5lJu7Wmtnp8zb06Lxdb6hGmo
Tadc2XO6SIMkg4OOOh5xVa78Wz6feyx3Xh7U9iuVW4gQSqyg8NwcgHriqSeF/iBzv+IKj0xpEJ/w
pJPCPjdzub4huT7aTEB+Qaj2UVpzr8X+ge1i5XnG/pp+R0OkeK9J1uWWGyuH86Jd0kckTIyjOMnc
BWhbahaXqb7S7hnX+9G4YfpXBv4F8ZMGB+IEu1gQQNNQcHt9+slfgleiZZf+EtdGXvDZCMj6EPxV
KlTSV5p/J/5Bem23ZpdNmewgikOPWvLU+GOvLCY1+IGtDj5cMwA/8f6e3FZl38O/HcEmYfFupXkY
7LqEsTH88j9afsaf86+5/wCQqced2Wnroey8Clz9K8fbwfqljocd9qeueM1uC5V7azv/AD2Tk4PH
UYAPtmoIrTw7LIIp/HvjC2lxho7m+eMj67kx+tZSjTi7c34Maozd2ldLtqe0ZHrSb1/vV5qvw1sL
qJHHi/xNJG4DIf7RBVgRkEfLyMHrTj8INMkxv8S+I5AOga+U4/8AHKap0+sn93/BMmpJ7Hou9P7w
o3p/eFecf8Ka0M8y6prcp7F7sEj24Wl/4Up4VPLG/Zu7G55Pv0quSl/M/u/4Iry7fiej70/vCk3r
/eFefJ8FvBgILWFw2OzXL/0NTJ8G/BKnLaTI31u5v6MKTjSX2n93/BC8u34ncPcwxnDyop9GYCoG
1OxQ4e8t1PoZFB/nXJf8Kh8Df9AT/wAm5/8A4uj/AIVB4H/6An/k5P8A/F0JU+rf3L/MLy7L7zqX
17SEzv1SyXHXNwox+tc7p3xM8H6v5ptPENoBFt3faN1v1zjHmBc9D0zjjPUVEvwi8ELg/wBijj1u
Zj/7PRp/wt8EadIzQeHrYs+Mid3mHHs7MB1/GlJUk1yNtdbpL9WGvUs3fxL8G2WfN1+zYjr5LGX/
ANABz0rLn+MngyOM+TqM9y/ZIrSQMx9BuUDNdRb+EvDlq++30HTYX67o7SNT+YFascEcUYSONEUd
AowB+FNSpL7LfzS/QNe5wCfFa2uVZrHwr4mu8fdaOxBVvxDEgfhWFoPxI8c4uG13wNfMo2+V9jsp
oSOuch927t0xjnOcivYcCjGKh1Ic11HTs3+ug7O255wvxP1X/lp4C8RD/dtmb+gqVPidd7fn8D+K
AfQWJP8AhXoeDS4NW6kH9hfews+5wI+JjkDd4L8XA9wNMyP/AEKmN8VIU3b/AAj4qXb1zp4GP/Hq
9BwPSjaPSpU4dY/iFjzg/GCwUbn8NeJVHqbJQP8A0Oo/+FyaKv8ArdH12JezPZgA+3DV6VtHpSeW
n90VSqUusX9//AJtLueb/wDC6/C68Sx6jE3917XB+vWnr8avB5XLXV0p7g2zZH5V6JsT+4KTy0/u
Cjnpfyv7/wDgBaXf8DhF+MfglgM6pKufW1l4/Jak/wCFw+Bf+g03/gJP/wDEV2/lp/cFNaFHXDIr
D0IyKL0n0f3/APAHr3/A4v8A4XD4F/6DTf8AgJP/APEUD4weBz01r87WYf8Aslda9hZuMPaQMP8A
ajB/pUL6JpUhy+m2bH1aBT/SmnS6p/ev8he93RxF58bfCFtqltaRSXdyk+3NzFDiKLLFfm3ENxjJ
wp4Ixk8Vr/8AC1vBf/Qbi/79Sf8AxNakvhHw3cTLPN4f0qSZcYkezjZhjkYJXNT/APCKaB/0BdP/
APAZP8KUXSu7p26ar/Ib5uhzF/8AFvwnBaO1pqkE9wcLGhRwu4nALHbwB1PfAOATgHlG8c+HdKbx
NdafriT311pEQiuDGytPdqbkntxjfGAOgBUA4HHqf/CLaB/0BNP/APAVP8KpDwZ4eGoT3TaTZt58
KQtCbdPLUIXO4Dbwx8wgnPIC+lPmpdn96/yF7xwlj8QPDkF/pTXuo6U0EAZbdbKCeNrHKEbWYkiV
SPlPyr8207e65Xg74h2/iGWx027sk3W0kE0wEJR1naaOLzlmEpLFpZVJUoo2swLMBhvQ7H4faDZX
SzNbrdpGpWGG4hiKxA4HZAznAxucs3Xnk1DD8OtDsdRlu7ON7XduZEt4IU8tid24MI97bWwyqzMo
IXC/KMFR0nb2aa73af6Iav1OLafWtG0XxEt1d6hfXMUVzK0iWSi3nuQSVlWURgL5YVflL7ty7VA2
gG346u1stT1Kynsrm6lvLu0uEljjDRxwBVRY3Yn5cukxAPB3E+tdTB8PrNIobW61TU7ywhl84Wcx
hWJm2lfmCRqSDkkjOGJJYHJzX17wR4eCiQXB0e1kaKOWC0CRQzFXJUEBcg5ZhlSOvOamThJ3f+Rr
Sk1JPt82VvD/AI8hHgzTLu5stQuHGlNdSyqI/wB55DLFNjc4OQTu5xlTxz8tb58UhftQOl6gJYJ4
4BD+63yFzwyjf93HOTjgHjhsUbn4e2E8Dww6jqNpbPFcQ/Z7dotixzsrSooZGIBZc8HIyQDjAG8u
jwDUbe9kllluYYPJMjFR5nozAADcMtjAAG9uORhNwWxDvcq+HfFGmeJmuRp0u82xXcd6tuVs7W+V
jjO1vlbDDHIHFdJWHo+iRaJA0MF1cyQgKkUUzhlhRc7UQADgZxk5YgAEnAxuVnLd226AjgfDTtpg
nmZnNlf6xfxvk5EU/wBsmVT7K4AX2YLgZcmpvC2ozRX8WmYQwXFxrVw7EHcGjvwqgHOMYlbPHYdO
c7FlokNtpNzpty5uIbi4uZXGNvE0zy7Rg5BXfjIPbPHbLtPCWpafHYS2etRm+tWvA89zZ+YsyXMw
mbKK64YMq4YNjg/LzgMCKLxDr2oahZ2ViLCJ7h9UEk08buI1trpYUIUOu4kNyNw5OQQBtLLfX/Eb
WMOp3Q0pbZdUXTZoI4pC8h+1C2MquXwo3EsEKtwPvZPGpovhWTSLqzmk1FrqS3S+VmaIIZTc3CTF
jg4BXZjgc5zx0qb/AIRs/wBjf2b9rP8AyFf7R8zy/wDp9+1bMZ/4BnPvjtQBzWlalrekaNrGqlbA
6RY6lqMjQlHM0sS3UrSOH3YUr8+F2ndt6jPFjWfGgs9av7GHV/D9g9gFDw6nOEkuZGQPhPnXYu1l
G8huSRj5ebkXhHUEivdPk1sS6RfXk9xPbfZMSbZZGkaJZN+Ah3YbKknLYK5AF670TUTqFzc6Vqsd
iL0L9qR7XzjuChRJGdy7X2qoywZflX5euQCnp2vahruqwR6a1rFprafZaiWuImeVlmaXKDDAA7Yw
Q3OCDkNnjR1jUL9NRsNJ0v7NHd3ccsxmuEZ44o4ygY7FKliWkQAbl6k54wZLHSBZatPfC5kkD2Vt
ZhZSWceS0p3MxOWLebzn+7nJzwzVNLnvrm0v7C8W01C1DpHLJD5sbI+3ejoGUkEqh4YEFRz1BAOV
1uTU/EMuk6TcHTFkh1h7O9hntGnt52Fo88bbPMXK7SrbCThipz8nzekgYGO1ctb+GTDc2NzLfPNd
xag+oXMhj2id2geEKBn5FVWUDrwgByTmuqoAKKKKACiiigAooooAKKKKACqM8wt4ZJ2EhSNS7CNG
kYgDJ2qoJY+gAJPQCr1FAHPWXiKyvp0tbeDU0mfJDT6VdRIMAnl3jVR07kZPHU1W1kTxeIfDkqXl
1suNReJ4Q+2PZ9knbBUAbvmRW+bJBHGK6quX1bw5PqepW94Ne1a3+zS+dbxQJbbIn8toyRvhZjlX
fhiRluMYGADP8T/EvRvCWoiwv7XU5ZiofNva7lwf9okAn6VzHwe1SDVPEnjm+t1lWG5v0mQSrtYK
3mEAjsfavUoYnht0SS4kmZFCtJIFDOQMFm2gDJ6nAA9AK87+GP8AyPHxE/7Cq/zegDrPFuhReJfD
V7pMmF8+MhHIPyOOVbj0IBx3GR3rM+HOuy654XhS7JGo2LNZ3aN95ZE4yfUkYJI4ySO1dtXl7RL4
O+LSyDbHpniVNrdAEuk6dv4snHOSzn0rWl78JQ6rVfLdfcS9Gmenk4rxz4Prruu6vrXijxG5ubra
ljb3IZAjBSTIFCfKQCI/mAwecE812fxC14eH/Bt/dxyFbqRPItgDhmlfgbfUgZbjspqz4K0L/hHf
CenaYT+9ihBl5B/eN8zcgDIySB7AVMY8tNyvZt2Xot/0He7sdVRRRUDCiiigAooooAKKKKACiiig
AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAG
/WqVzY213Hsmt4pk/uyIGH5Gr9JQNSad0YOreF9I1qOBby0z9nBEJjdozHnHTaR6D8qyI/B91p9w
JNO8QalAm4ExSyCZMZ6AMOP1rssACmhT6VLim79So1ZxjZPTs9Uc1rB8VQXwfSI9PntNgzHOWWQn
vgjj061DYa9rz3aW2peHZbdZDj7RFOsqDjOTjBArqs+lPJPpS5Xe92UqseTlcU/PW5y0/jrw/bX0
tld3jW88bFWEsTKOO4bGMe+a1rDWNO1MH7DfW9xgZIikDEfUA8VYntobmMpPCkqHqrqCD+dVLPw7
pGnXZurPTre2mZCjNEgXKkgkce4FC5r67A3ScdE0/VNGju2jqKcHzXHnwPc2spfTPEWqWvOQjyCV
B+DD+taNla+INPsbn7VqFvqVyFzblovJBOOjYz1OOlCk76ocqULXjJPys0/8jofNFOrhrrxfr+k2
lxcar4Vl8mCNneW1nWQEAEk46gcd6yLD4lyW15bjXY0ggudwKpaTI1swXcASSwkU4IyApBx8uDkH
OuunqJ4efRX9Gn+R6f8AhQTjoK53TPF2ja1KIbHUI5JsFtgBBwOpwRVlPEOjSTNGmp2ZdSVZROuQ
R1BGaalFq6IdKd3Fxaa8jc60tUluoXQyLKhQDJYMCAPXNZeneJdI1W8W3s7p2dkMke+F41lQYy0b
MoDqMjlSRyKoTi1udDRRRQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCEfrXJ/EMj+
xbbP/P5B/wChiur7dfmrB8T/ANl/2dF/a2/yPtEW3ZnO/eNvTtnrU1FeLKpS5JKVr2eyOhi/1a/S
pKav3RTqolhRRRQAVxr+JNWfWdYtNP8AD/2mDS5EWWVrvY026JJNsa7DucB8bWKjp83OB2VcHZL4
h/4SbxUul/2f9mkv408y4dw8En2O3y4UKRIMFflLLyvXngA0rvxJPJFbS6TawXFvPbpdC6vLk20G
xuVAfY2WIBO0DgYJIyM5Vl4l1LWvEWhSaZb2zadc2d356ven78VxFE7LtRg+3nacgOHbJXAzPP4T
ns7vT2sLHTNRgtLCKxgi1N2X7NsJ/eIQj5LAqGGFzsX5qZo3hzWtIudLuHk0+6uInv0usO8S7Lm6
Wbeg2t8wCAbTgZON3GSAW7XxHJJ4f8PnTtPM97qdklxDbz3TERxhELNJMQzHbvRd21mZmHHJIWbx
VcxwWscWkl9Sk1BtOltWuQoikELzbt+05UqqtnAO1s4yNpz5fBLNoHhy3uLDS9Tu9HsltXt75N0E
oKIrlWKMVO6NSG2k4yMc8W9N8KS2T6VJHBptmLfUnvprayiEcSK1tLCFTai72y6EswBPPQBVoAqX
viPX5dR0u1ttOtYruHV5LK7ha/YRSH7G86AOISSpVlYkqCGQDBBLDQ0/xFqOoancRQaXBJaQXj2s
h+3AXC7W2GQwlAoTI3D5ySpBAJOKgvNE1RNVm1Kz+yyzDWBqEMM0jxqyfYhalWYIxVs7mGFYEAdM
nBqXhvUL/X4Lv+z9Fjkiu45l1aIst2IVYExbdhzuUFCTJghidv8ADQB21FFFABRRRQAUUUUAFFFF
ABRRRQAUUUUAFFFFABXl/wAMf+R4+In/AGFV/m9eoV5d8Mf+R4+In/YVX+b0AeoVx3xD8Py+IPCV
xHaFlv7Ui7s3QkMsqcgKQRgkZAOeCQe1df3o60oTcJKS6MTSejPFrfXx8R/EfhCyVSYLWA6pfqpA
XzUOxRg9g4/FXFe04rz34cfDT/hX0upMdVGoNeiIZ+zeV5YTdkfebOdw9OlehVVerGbSirJbL1dw
SaH0UUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRR
QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQuiupVlBUjBBGQRWJp3hj
SNOuhPaWrq6oY498zyLEhxlY1diEU4HCgDgV0OaTNA7speRAG3iJA+Mbtoz+dZN34R8P3ZaSXR7N
nY5ZhCASfUkDNdCPrSmk4p7jjUnF3i2n6nJr4O0WHTdSsrS3+yDUbd7eZ42JO0qVyMkgEbjXL2Pw
41Bb2CSbUWs1tctE9ldu5lcqV3bWUCMbSeMuTnG7A59ROf7tBzilyx7DjXmm3dtve+t/vOZ0nRtb
0+7LXPiCS9tNhAglt1Vg3GDvHJ71Sk1DxrZSuz6PYX8eTtFvcGJiO2d/Ga7TPqKXbS5dLJtFqu3J
ynFO/lb8rHNaZrt3dWt1NqGj3Vj9mTeQSJN4wSQu3qRjpjuKgh+IfhyeTy3vvs8ndbiNo8fiRj9a
6gEL96qtzp9tcpsnt4pF9GQEfrRaVtH94ozpNtzi0ntZ7ffcjsNQs9St/tNncw3EWcb4nDDPpkfW
ryup5DCsafw1o82mS6X9hhis5mDPFCPLDMCDn5cc8D8qxz4Ahhbdp2s6tYgdEjuSyfkwOad5LoKM
KUr3k12ur/idnTs1ztzYa7BpNvBpuqRSXkbfvJruLPmLzwQvQ9Ofas3+0fHFrxPo1hfkdTa3Bi/R
6Tl3THGlzfC183b8zss4pS3HFc5qfiUaP5H2nTNQkEqbma2h8xYz6MQev+FV7Tx34dvZkt1vxHOz
BBFNG0bbj0HIFNzinZkqlNxuk2u61OupapC6h8zy/NTeBnZuGQPpVsMG6EGqJcWtx1FFFAgooooA
KKKKAI+9cl8RM/2HbH/p9g/9DFdVkH8aw/Et5ZWOmRNf2v2mJrmJVTA4YuNrc+h5qZq8XcqjJxmm
ldp7G9F/q1+lSU1fuD6U6qRMjjfEOtahBb+K7myufKTSdMcxYRW/0nyml3HIP3V8vA6Hc2QeK7Ou
A1Sxubq18daRbxmS81G2NxAm4Lv8y2ECjJIA+aA9TxkZ61v2OsahcXkcE/h7VLOJs5nnktSi4BPI
SZm5xjhTyew5oAzoPFsSWehi3tNU1KfVbH7XbqqRCR1VYyxkO5UViJVPGFyCBjgG3/wlVrJptpc2
9lfT3F1LJDHYoiiYPGzLIG3MEG1lILFtucYJyM0vDeiajYDwl9qt/L+waDJZXPzqfLmP2XC8Hn/V
PyMj5evIznTeGb4Q2t5JZ3s0lte6lutrPUGtZXhuLlpVdXR0BOFQ7WYDDHPzKBQB0A8UWZ09br7P
dGdrg2gsgg8/zxkmPGduQAWzu27Ruzjmq7+Lre0tbqa9sNQtJ7aS3SW0kRHlxNII42XY7Kylt3Ri
flPGeDknQ9Rg0ImCwvES41L7TeWSak7XU0HleWFad5D8+VjYgOq7V256k1rbw3qTXuozw6F/Z1vP
NpLxo9wjyyCC7aSVpCGb5wpB+82QFAJOQADsZNXS20KbVr+2uLKK3iknmim2s8aICSTsZgeBkYJ6
iq1p4hE++S80rUdMjSA3HmXYjKGMdTvjd1BAOdrEHGSAcHGndo7Wc6pBHOWjYCKVsJIcH5WODgHo
Tg/Q1w9n4avriLU9MttO1HR9KvNLntpYr2+W4QzuFVGiAkcqqr5mfu53L8vHAB01n4liuIpri606
/wBPt0gNyJ7uNQjRAZLZVm2nHO1trY7cHDbTxILi9tbe40jUrFbzItpbpYwszBS+0BXZlbarNhwp
wp7jFRi58Ranpl7brpx0q8+yOsVzNOjr9oK4UoqliUB5y208D5Tk4wLLQ7s+INAuovDd3apZ3Ej3
d3f363E3zW8qAId7koWcZ+6c7TtxkgA09F8TzN4d0J5LW81PVLzTYbueO1SMMAyKWdtzKqgsTgA5
POAcHGk/iOzFjZ3VpDcXr32fs9tCgErbR82Q5ULtxg7iMHjqQK5W28M31hY6JPPp2pXMsejWthc2
+n6o1rJFJCCQSVlRHXLuCSxIwMA5Nadpo19okGkX9tp/2ia2S6jns4rku5W4kWVmWSZvncOi5LMA
25iMcLQBFb+Kb+7sdd1JPPt49L1VEa2uIUVkt1hgMyNjPQvI4YE5IGCV4rvq84uoNUbwt4u/tKw+
xTa5d+RbQ+ash2ywQ26klSRuyDkdiDyRgn0egAooooAKKKKACiiigAooqjNCLiGWFjIEkUoxjdo2
AIwdrKQVPoQQR1BoAvVyF74g1y1tr/UF8PQ/2dZvLnzL1kuZUjYhmSLyip3bSVBcbgQcjNXrLw7Z
WM6XVvPqbzJkBZ9VupUOQRyjyMp69wcHnqKpXus61FNdCHwrqd4YmYWy/aLRIpWXO1ixl3AEgdVy
BzgkUAaOqeIdK0dJDfahawyIhcQvMiuwAzhQSMk9q8i+F3jO3k8Q+LdQktLlE1G7FwgVNwQZf5WP
97BH616frfgDwv4jvPt2raTDdXW0L5rMynA6A7SM1xfwj02007xP47srOBYreDUUiijBJCqpkwMn
mpmpONouzJkm1ZOzO0/4TbT/APn3vP8Av1S/8Jtp/wDz73n/AH6rpfLT+6v5UeWn91fyrn9nX/mX
3GPJV/mX3f8ABOZ/4TjT/wDn3vP+/VL/AMJvp/8Az73n/fqul8tP7q/lR5af3V/Kj2db+ZfcHJW/
mX3f8E5r/hN9P/597z/v1R/wm+n/APPvef8Afqul2J/dX8qNif3V/Kj2db+dfd/wQ5K38y+7/gnN
f8Jvp/8Az73n/fqj/hN9P/597z/v1XS7E/ur+VGxP7q/lR7Ot/Ovu/4Iclb+Zfd/wTmv+E30/wD5
97z/AL9Uf8Jvp/8Az73n/fqul2J/dX8qNif3V/Kj2db+dfd/wQ5K38y+7/gnNf8ACb6f/wA+95/3
6o/4TfT/APn3vP8Av1XS7E/ur+VGxP7q/lR7Ot/Ovu/4Iclb+Zfd/wAE5r/hN9P/AOfe8/79Uf8A
Cb6f/wA+95/36rpdif3V/KjYn91fyo9nW/nX3f8ABDkrfzL7v+Cc1/wm+n/8+95/36o/4TfT/wDn
3vP+/VdLsT+6v5UbE/ur+VHs6386+7/ghyVv5l93/BOa/wCE30//AJ97z/v1R/wm+n/8+95/36rp
dif3V/KjYn91fyo9nW/nX3f8EOSt/Mvu/wCCc1/wm+n/APPvef8Afqj/AITfT/8An3vP+/VdLsT+
6v5UbE/ur+VHs6386+7/AIIclb+Zfd/wTmv+E30//n3vP+/VH/Cb6f8A8+95/wB+q6XYn91fyo2J
/dX8qPZ1v5193/BDkrfzL7v+Cc1/wm+n/wDPvef9+qP+E30//n3vP+/VdLsT+6v5UbE/ur+VHs63
86+7/ghyVv5l93/BOa/4TfT/APn3vP8Av1R/wm+n/wDPvef9+q6XYn91fyo2J/dX8qPZ1v5193/B
DkrfzL7v+Cc1/wAJvp//AD73n/fqj/hN9P8A+fe8/wC/VdLsT+6v5UbE/ur+VHs6386+7/ghyVv5
l93/AATmv+E30/8A597z/v1R/wAJvp//AD73n/fqul2J/dX8qNif3V/Kj2db+dfd/wAEOSt/Mvu/
4JzX/Cb6f/z73n/fqj/hN9P/AOfe8/79V0uxP7q/lRsT+6v5Uezrfzr7v+CHJW/mX3f8E5r/AITf
T/8An3vP+/VH/Cb6f/z73n/fqul2J/dX8qNif3V/Kj2db+dfd/wQ5K38y+7/AIJzX/Cb6f8A8+95
/wB+qP8AhN9P/wCfe8/79V0uxP7q/lRsT+6v5Uezrfzr7v8AghyVv5l93/BOa/4TfT/+fe8/79Uf
8Jvp/wDz73n/AH6rpdif3V/KjYn91fyo9nW/nX3f8EOSt/Mvu/4JzX/Cb6f/AM+95/36o/4TfT/+
fe8/79V0uxP7q/lRsT+6v5Uezrfzr7v+CHJW/mX3f8E5r/hN9P8A+fe8/wC/VH/Cb6f/AM+95/36
rpdif3V/KjYn91fyo9nW/nX3f8EOSt/Mvu/4JzX/AAm+n/8APvef9+qP+E30/wD597z/AL9V0uxP
7q/lRsT+6v5Uezrfzr7v+CHJW/mX3f8ABOa/4TfT/wDn3vP+/VH/AAm+n/8APvef9+q6XYn91fyo
2J/dX8qPZ1v5193/AAQ5K38y+7/gnM/8Jtp//Pvef9+qP+E20/8A597z/v1XTbE/ur+VGxP7q/lR
7Ot/MvuDkq/zL7v+Cc1/wm+n/wDPvef9+qP+E30//n3vP+/VdL5af3V/Kk8tP7q/lR7Ov/MvuDkr
fzL7v+Cc3/wm+n/8+95/36o/4TfT/wDn3vP+/VdL5af3V/Kk8tP7q/lR7Ov/ADL7g5K38y+7/gnN
/wDCcaf/AM+95/36o/4TjT/+fe8/79V0nlp/dX8qXy0/ur+VHs6/8y+4OSt/Mvu/4Jzf/Cb6f/z7
3n/fqj/hN9P/AOfe8/79V0mxP7q/lRsT+6v5Uclb+dfcHJW/mX3f8E5r/hONP/597z/v1R/wnGn/
APPvef8Afqul8pP7i/lR5af3V/Kj2df+ZfcHJW/mX3f8E5v/AITjT/8An3vP+/VH/Ccaf/z73n/f
quk8tP7i/lSeWv8AdX8qPZ1/5l9wclb+dfd/wTnP+E30/wD597z/AL9Un/Cbaf8A8+95/wB+q6Xy
0/ur+VHlp/dX8qPZ1/5l9wclb+Zfd/wTm/8AhN9P/wCfe8/79Un/AAnGn/8APvef9+q6XyY/7i/l
SeSn9xfyo9nX/mX3D5K38y+45z/hONP/AOfe8/79Un/Cb6f/AM8Lz/v1XSeWv91fypuIv9inyVf5
193/AAR+zrfzL7jnj4100/8ALtef9+f/AK9VpfE2jzEF7CdypBG6AZB7EZrpLi4s7RN9xLDEvq7A
D9azJfFvhyI4fV7EH0Eyk/oaThVW8l9xcaeIesX9yf8AmcvqUvhXWJjPf6RcyzkAGRUZWOOByCKh
06TRdJ1GO6s7rXljTP8AorSFojkEcgnPGcjntXU6v4s0TQ50g1C6CTOm9UWJmLDJGRtB9DVO38ba
Ze3UNva2d/MZXCBxaOFXJxlicYA7ml7OfNrJX9NfzLjTruGkm15rQ828R3t9d6/f3cqz38bEfYUm
08t5S4+6jKcxOGJ+bKkjad3GB0em+OPEVlZ20OoaUl66RIsk0UpVmIABJBXkk88Yp3ibxVrVr4g1
KzsxdW0OnRo4aKKIxspQOZJS4J2ZyuFK/db5s8DXsfFHiC4sraUeEbrdLErkeciAEgE9eR1780OF
RPSWvXS50Qp1JQTkk1Z72X63Jrv4i6ZaFBPa6goIyWEAKj2JzSxfEzw/cFUiknLscBSgBJ9OTWlq
2p6zaCD+z9Ba/EiZkxcJH5Z9Du6/UVhLNrt9fwSXXgi1jKyKfPe6icpg9RgZyOtN+0WnNr6McKMZ
Qu7J97pfgzZPjSw7293/AN+qrp8QNFe4a1RpWuVGWhABcfVc5rH8T+HL681yS707RmaWRU3XcepN
CxIGMbenAArzHRdG1i61fTtJuJtSjuor9GmhGoqWjG/98/lDLKSpb5iADk/M2QGziq92nL8CXhrQ
U+deasr/AJntJ8c6apCmG7DHoDHyf1rzX4mfE+MyWek6TZtJIJkmmkmQ/KVbhFUEZJI559vp6hpv
gvQ9LuluoLPddKcieWRpHzjGck8H6Vm+N9P0lbK1vb3TFuZluo0R0meF03OMnehDdgcZxkCtYRqp
N1GmvJGcIWmlGTb6aJam/wCGdVbW/D1tfyW7W8rl45Yic7XR2RgM9tynHtityqlnaW9jZQ21rCkN
vEgWONBhVUdABVuukgoeRD9qW5aNDMqFBJgbgpIJUHrgkA49hV+iigAooooAKKKKACiiigAooooA
KKKKAKUkEU7xmWJHaJ98ZZQSjYIyM9DgkZHqau0UUAFFFFABRRRQAUUUUAFFFFABRRRQAV5f8Mf+
R4+In/YVX+b16hXl/wAMf+R4+In/AGFV/m9AHqFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAB
RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFF
FFABRRRQA2lphdUHLAVnyanZQzJDJdQpI7BUVpACxPQAZyTSuNRb2RoHp0pAQO1c1qPjfRdMvZLG
a4ke8TGYYYWdhkZHQY6Ed6j0rxPNrF8beHSNSgh2k/aLmDy04+pyc0uZXt1K9lPlu1Zd2dRnNObO
OlcZc3PjW4uHjs7LTLSESMqyTStISueGwuOSOcVe0vT9dRLg6nqyTeam1EggEflHnkHkk89x2oU9
bWKdFRV3Jel7m3c3MFlBLcXEixwxI0kjscBVAySfYAVz9l440y7vEt5457LzVLQPdbFWXAyRwxKt
jna4VsZ44NVG+HWnXcbpqV/qeoK4IK3F22ORjgDGKo6Z8M9NtbmOS/NveQ24Pkxi1KM5IxulYs29
gM/dCrkk7c4xN59l95ahRS1k36L/AIJ2cGrafeuYYLyGSTGdiSAtj1wDmqkvivQYHaOXWbBWUkMp
uEyCOoIzxUlj4c0bTJvOstNtoJcEeZHGA2D1GetMbwxobyPIdIsS7HLH7MmWJ7k45p+9bpcz/dKT
3t+I3/hKtDayvLuHUbeeKyhaafyXDlEUEk4HsDXMWnxR0xrlE1NYbaGYExPFO0zKQM7ZFCDaxGfu
l14I3dM9dHommw2k9vFYWyQzoY5USMKHQjBU4HIwTWZpPg7TtLvUuhNcXJgBW3SfYVhyNpIKqGZt
vy7nLNgkZ5OT3+6HF0k3dN9tf+AT6V4y0fWrr7PYTzSNtLbzA6rge5AqhN40uFuJIbfw1rExRiu8
24RWwccEnpXXCJeygUFRjgUWlbcOempXUbrs3+qsc9pWsarqCzm40Gaz2JmLzJ1PmHnjA6dufes8
3vju5P7rTdMtv+u07P8A+g12XOOtN6ntRyaatjVaKbagtfV2/EwbOLxK+lTx3t5YxX7H9zLbxMUQ
cdQx571nnw94omkPn+LnC/3YLONP1yTXXbafzmh00+r+8Ua8oNuKWvkn+a0Odfw/NcaImnXOr37M
H3G4jkEcjck4JA6c4x7CqK/DvRXXF017c+vm3bn+RFdlig9abhF7olVZq9na/bQ5+bwxo11a21rP
YRSw2qbIUky2wYAxycngDr6VLB4W0K1YGLSbJG9RAufzxW0RQKORbi9rO1ru3qIY1PJUUgjUdFA/
CpKKqxPMzOvtI02/lhnvdOtLqWA5ieaBXaM+qkgkfhWlRRQAUUUUAFFFFAEW75sVyXjmOW40W3WK
N5MXkBIRSSBvHPFdZwDmsDxdq1xpGlQzWwTe9zFGd4yNrNg/pUytyu5VJyUk0ru+h0Uf3F+lPpiH
KD6U+qJYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZ8/nm3cW7rHM
VIjaRC6q2OCyggsAeoBGfUdaANCubu/F+jWMsqTXE+2Fik08VpNJDEwOCHlVSiYPXcwxznFSWkPi
OO4R7zU9Mnt+d8cGnSRO3BxhjO4HOD905HHHUYHjbXtMGl3VqNbiS5ijkV9GkKK2oAjHk7WXzDv5
VWQjO7PzCgDv68v+GP8AyPHxE/7Cq/zetbxT4O1rXdSF3YeM9U0mIIF+zW65TI78MDk++a5r4OWU
+neIfHNpcXst7NDfpG9xKPnlYeZljyeT9aAPX6KKKACiiigAooooAKKKKACiiigAooooAKKKKACi
iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApKSqtzeW9qu6aeOJfV3Cj9aN
hpNuyJzjBzSjHFYNv4o0K7vY7G21S2nuZCQqRuGzgEnpx0BrPvfGMlvfSWlroWqXUkblC8cGEJBx
94np70uaO5UaU5O1rPz00+Z12DQWA71zGj6rrmoTuL3QjYQbCUke5V2Y5GAVHTjPX0qmdK8aXh/0
jX7Ky9rW03/q5qebS6TZaoe84zklbzv+Vzse1UrjVrGxUm6vIYgOpkkC/wAzWXY+HpINPu7TUNUv
L8XQ2s0jbSgxjC7fu9arW3w+8NWzl/7PjlYnJM7NJk+4YmneVtEKMKSbU5N22st/vsXrjxPpNtpZ
1I3ay2u/Z5kAMgLZxgbc96yv+E2e5Zhp/h/VrkZwHMIjQ/ix/pXTWljbWMAgtoI4Yh0SNQqj8BVr
au3bgUWk+oozpxv7rfq+nojnr+58RzafbPplnaQ3Mi5mS7kJEXHTK9ec1QGjeMbvDXPiOG1GclLW
2B/Vua7LbilwSKTjfqyoV3BWjFfNJ/mc3q3hu11q5Sa9ub3CoE8qK4ZIzyTkqO/OM+lJp/gvw/pk
qTW+mQiRGDLI+XYEdCCSTmujVeKdjjpT5Y3vbUhVZqNk2l2voJ5SZLbBk98c08KB0FOoqiLhRRRQ
AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBA3J9q5rxnYX
epaRBFZxGV1u4nIGOAG5PPpXStwfaua8Z393pmk28tnKYna7hQkY5Bbkc+tTO3K7l0ObnXLvfS+x
1EQwij2p9MiOUU+1PqiJbi0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFct4rE/laNJHB9p8r
UUkazEyRPc4jkKqu9lVmV9kmCR/qyRyBXU1zHiyzuLuxtWtY9Ua4gulljbTTbLKhCsM5n+ULhiDj
k5x90tQBk6b4YvYtU0nVZrOCPVWu7u61G8DAuYnEgjty33nC74sD7oEHBHy52fFNvNcWdqfIuLmw
W4DX9tb5LzQbHG0KCCwDlGZRyyqVw2dpxtMvdUtvEVja6lJ4oX7R5mwX6ab5DlULbWaAb92BkKpy
dpOCqtifxh4t0nS7i006fxBaWfmXSQ36JcotxDCyMwIGdyhm8tSwGVVywK43AAi0q103+2rKXwzo
k2lwRs51B/7PexiljKMEQo6pvfeUYMFO0Kw3Ddhu7rzzTtc0ODxVpem+HvEf9om9aUXNu+qNeBY1
jZg6s7MVcMEG0NyrMSp25X0OgAooooAKKKKACvL/AIY/8jx8RP8AsKr/ADevUK8v+GP/ACPHxE/7
Cq/zegD1CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiii
gCPHNJjisrVdd0zR4PM1C+igUjgM3zH6Acn8K4Lxd4hnuZbO4triS30yeBWt5Zbx7JGk3MHLupVi
VUJtTcN29jhscJySNIUZzs7WT0u9F956ienrUJdVBZ2VQO5OK8/0LT/GesaVaXGoa+bNWVgBHbDz
ZFBIVmLAFSQFboOvIBrpLzwtp2q2VrbaqJb42y4V5JGBc4AJbaQCeO9TzN7L7y3Rpwa5pp97Jtr7
7IW98a+HbGQRz6rAXzgrE3mEH3C5Ipusa9faddLb2Oh3l/IyBxIpVIhkkYLk9eOmO4q/YeH9J0oA
WOnW8BHdEAP59a08bscUWk1q7ehLlSjJOCbXW/X7tjyfxFD4m1bULefVNGhWx8vZHF9ne/WOTcSW
MaA/MwIAYrhdp5GecaPw54p+QS291Fq5YG0uHtmlkjGR5f8ApGWWNVGAylgThvlfOT7pjikILCly
ebK+staRikvS/wCZyVt4VvzcxXF/4l1Kd42DlInESMQc4IUcj2zV+98IaFqWoG+vLBJ7gqFLOzEE
DpxnH6VvdqOOtVyxta1zN1p83MnZ+WmnyM+y0bTtO/487K3gxx+6iVf5CtPA9KQHPendqaSRLk5a
t3FooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiii
gAooooAKKKKACiiigAooooAKKKKAIeCcVgeLtJuNX0qGG2Kb0uYpDvOBtVsn9K6Db82a5Lx1LLba
LbvFK8ZN5ACUYgkbxxxUztyu5dFSckouzvodcgwg+lPpkf3F+lPqkRLcWiiigAooooAKKKKACiii
gAooooAKKKKACiiigArnPEc4t9PjxqF/a3DzKkK2EcUk07kNiNVkRl5ALE4GApJIUGujrmvEkEkl
nb3EK3a3FpcCeGe2iWYwtsdSzRkgupVmUqmWO/5cHkAGRpayS+IbAa7ceIVuYneSxh1RbQRPJ5bK
xVrZcFgjP8rN0LEA7SRseJtQuLW3sYoLhLQXt4ttJeSKGFspV2DYPy7iyqi7uNzrkN905+iH+3tT
hvbnXrPUZNPYulpaWrWxglZWQtKju7htrMAp2gZbIJwRp6/fCzi0+2kitmg1C8Wzla65iWNlZiCO
hLbfLUE43OvX7pAMPQ9Y1JL/AEy2uNSa+e5vb+0mikjjDrHBNOFn+RVx9yNG42kupG053d7XILHp
3hzXtK07SNK0y0j1N5VnjtYVikGyMusuFAygKlDkdZF5HRuvoAKKKpTSvDbu8dvJMyKWWOMqGcgZ
CruIGT0GSB6kUAXaK5+x1jULi8jgn8PapZxNnM88lqUXAJ5CTM3OMcKeT2HNcp401YSahFFcw6nH
Bp+pae0IjsLh453+0Qsz71QqwCkqq5yWLcE7KAPS68v+GP8AyPHxE/7Cq/zetjxRqHxAtNUEfhrQ
tMvbHYD5txcbW3dxjcuB+dcx8G5dQm8R+OZNUgit75r9DPHE25Fk/eZUHJyB9aAPX6KKKACiiigA
ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGZ4ph59KeSAuSRXN6j4v0TTZ1t571WuGIU
QwgyPk+oXOPxpNpK7HGnObtFNvyOkJqPeFBJPSuX1iXxPPdi20eC1t7YqC15cOWIJ6hUHce/FJpP
hSS0vE1LUtUu9QvkBCl22RJkYO2McDj60uZ3tY09lFQ5pSV+y1f/AACG78dWS3L2WlW1zqt4h2lL
dDtQ/wC054A9xmrWnrr2rWN4mrpFp/mriAWcpaWMEHJLHjPTBHvXQRQxxAiONVydxwMZJ6mp8YHp
SUW3dsJVIKNoRt5t3ZzmleC9G0yX7QLY3N0eTc3R8yQn1yeh+gFdGAEGAAKdikwe2KpJLRETqSlr
JtklFFFMkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK
KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCFuOfSsDxPpn9sabFB9oS
DbcxSbnHB2sDj6ntXQdMVyPxDJOi2wB/5fYP/Q6mbSi7lUk3NKLs77nXrwoHtT6bH9xfpTqomQtF
FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXMeKL6eysrZLSe4S5urlYI0toFkmlJVmIj3ssasF
UtufKgKeCSK6euev4otdYx2V35OoaReBllMRZYpjDnaynG5THNg4I+9wQRwAcz4b1LT59Z0qWbQt
cN3fxvJa6nqkkMuMKSwXEreUzDOURV7/ACgKSOh8R3Fx9lstOt47R5NTufspa8iMsKDy3kYsgI3g
iMqBuHLDnjBrWGgMb+yu4dXiudJhuJtQsooohuLzB8sZQxDoBM+0BV4Zcs2OV1+PU547iObS9Im0
uPbKLi61aW2dCoB35WFthU5wwfPGcjoADB8LfbtLvdHkWx8OWtpqks1pcrpmltbyJcRLISm7zSGU
GKT5sfwgAfNkemV534dNvqWvHU7W20GUK7tLLp+vS3YgdwSWWExCNGcg7mG0nLEk5IPolABRRRQA
Vg6xoFjrSwx3/wBrZIXDosF5NANwZWViI2XcQyqQTnaRkYreooAK8v8Ahj/yPHxE/wCwqv8AN69Q
ry/4Y/8AI8fET/sKr/N6APUKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5TxBr
40cQxwwRzXEyPKBNN5UUcabd7u+1iAC6DAUklhx1Iw9O8dX2t27JomhT3FxHIY5nkkCwIcA5DkAs
CCGA2g4I4HSn+I4j4m8WWOj2s01ubDM11dwMA8asBiMZBU7iFJVgQQAccV1OmaXDpFsYIXlkeRzL
PPMcvK5wCzEADOAAAAAAAAAABWd5SbSdkjdRjSinJXb1s9kumxnz6Pea5o9tDrFzLbzqS0yWEpRH
68E9SMY/Gr2keHNJ0SPbY2UUTEYLhcsfqTya1hwOBxTh/Or5Ve9tTN1ptOKdk9bLYlooopkBRRRQ
AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAB
RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQYA/CsLxPaWV9psS39
19miW5iZXyOWDjaOfU8V0Fcl8RM/2HbD/p9g/wDQxUzdou5VGLlJJOzb3OuX7g+lOqOL/Vr9Kkqk
TIWiiigAooooAKKKKACiiigAooooAKKKKACiiigArj7efVNJ1vXCvh3Ub6C8vUuIZraW2ClRbwxk
ESTKwIaNu3pXYUUAcb4Qn1Sx0LR9GvfD2o2zWtlFby3LS2zRBkjAJ+WZmIJXA+XuM45xN4ut9Qmg
0qaw0t9UNtqEc8tmJI1WRAjjJLso+Usrr1+ZF4H3h1lFAHA6hea5da/o99D4Q1ONLRpTPN9osxK6
NGyiIAT4KlijnLdY14PUdjDK81ujyW8kLOoZo5CpZCRkq20kZHQ4JHoTV2igAooooAKKK4VvFMv/
AAl17plx4i0Gwitb2KCOzuYz9pnVoonJVjMvJaRlGEI+XvyKAO6ry/4Y/wDI8fET/sKr/N62PE/x
L0bwlqIsL+11OWYqHzb2u5cH/aJAJ+lcz8HtUg1TxJ45vrdZVhub9JkEq7WCt5hAI7H2oA9eoooo
AKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIP4ves/VtUtNIsJLy8m8qJMAsQTyTgcDk8ntV/
gAZrhLwN4m8bR2QydO0lhJP6STn7q++0c/mDUydlpuzSlBSk29EldnR6NokGj/apkd5pryYzyyyf
eJPQfQDgCt6mINoxmn9qaVkRKTlJybuOooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAo
oooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACii
igAooooAKKKKACiiigAooooAKKKKAIO3T5qwfE39l/2dF/a2/wAj7RFt2Zzv3jb07Z61vA45rlPi
GB/Yds3/AE+wf+hipqO0WVSjzSSva73R2C9BS1HF/q1+lSVSJkLRRRQAUUUUAFFFFABRRRQAUUUU
AFFFFABRRRQAUUUUAFFFFABRRRQAVQuIYrq3lguIklglQpJHIoZXUjBDA8EEHBBq/RQBztj4T8P6
bdR3dhoWl2l1GTsmgs443XIIOGVQRkEj6GqWvWXiPVtM1LR4oNKe0voZLcXTXEkbxI4K58oIwZlB
/vqCR/DXX0UAFeX/AAx/5Hj4if8AYVX+b16hXl/wx/5Hj4if9hVf5vQB6hRRRQAUUUUAFFFFABRR
RQAUUUUAFFFFABRRRQAUUUUAcx4o1saDpUlyiCS5ciO2i5PmSHhRgdfU+wq/pcUiWqSTxxR3Mqq8
/lDCl8DPuemMnsBWHcaJc6n42hvLwJ/ZljHm1TdkvM3ViO20Dj8CO9dcowOTUK7bvt0NZ8kIKMdW
9W/yRNRRRVmQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA
UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABR
RRQAUUUUAQ9TWD4ou7Ky0yJ762+0xNcxKqYHDFhtPPoea3+i1yPxCz/Ylt/1+wf+h1M3aLZdGKck
ns2dgv3B9KdTY/uL9KdVESFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA
KKKKACiisG+1s2lytra6fd6jdY3vBaeXmJT0ZmkdFGT0GcnBwCASADery/4Y/wDI8fET/sKr/N67
OfxBplksa6je2thM6hjDdXMauuRnB+bGR7Ej0JrhvhZPDc+L/H8sEscsT6orK8bBlYEvggjgigD1
aiiigAooooAKKKKACiiigAooooAKKKKACiiigCLAPGK5XxjrM1hpyWlhzqV84t7YDqGPVvoBzn6V
0ztsGScDuK5vTY9M8QanD4kt2mkMCvbQ7+IxhiGdRjqemc9PpUSvayerNKNlLnkrpfn0TNLQtMXS
NHtrFHZxDGFLMSST3P55rX6Gnd89qM1aVlZESk5Scnux1FFFAgooooAKKKKACiiigAooooAKKKKA
CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK
KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAh2fNmsLxLqX9jadFP9nSfdcxR7XPA
3MBn6jtW+a5Tx9DLPolusUbyEXsBIRSSBvHPFRNtRdiqSjzJS2b1OsXlQfan0yP7i/Sn1ZLCiiig
AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqlNE81u6R3EkLOpVZIwpZCRgMu4
EZHUZBHqDV2igDn7HR9Qt7yOefxDql5EucwTx2oRsgjkpCrcZzww5HccVzlysceva2utx+IIoZLt
ZbVdLiu9kieTGm8vbDJbKEbWPGAcc5r0OigDh5fAvh7xLaWN94g0dLnUjaxpNJKzq+QoyGweoOet
c18INOtdM8UePLKyhENvBqKRRRqSQqqZMDJ5r12vL/hj/wAjx8RP+wqv83oA9QooooAKKKKACiii
gAooooAKKKKACiiigApM0GqdxcJawPNIwWNFLMxPAAGSTQCTbsjl/G17cCC20SwJF5qjmIMP4Ixz
I34A/rXRaVp8Gl6dBY2y7YoUCqPpWV4V1O71uzm1K6iSO3lmY2a7cN5Q4Bb3JBNdIpA4FTFXfMaV
JOMVTtaz182SUUUVRmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQ
AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAB
RRRQAUUUUAFFFFABRRRQBB0bnpWD4s1a60fS4Z7XZve5iiO8ZGGbB/St4HLe1c3400+71LSIIrOI
yut3E5AxwA3J59Kmd+V23KoqLmk9r63OnQ5QH2p9MjGEUe1PqkTLcWiiigAooooAKKKKACiiigAo
oooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5W58caHbrdSSNqJitXkSadNKuniQxsyv86xlS
FKsCQccHmgDqq8v+GP8AyPHxE/7Cq/zevUK8v+GP/I8fET/sKr/N6APUKKKKACiiigAooooAKKKK
ACiiigAooooAh3fNXPeKdNutZsI9NtJUjilmUXbZwwi6kL7nAFLr/iPS9ChzqMzoSjSCOONpXKrj
LYUEgAkDccAEjmszwJBJdWs/iG5YNPqzCVQDkJEOEUfhz+PtUy1901hFxi6l7WtbzZ1ltbR2lvHD
EipHGoVVUcAAYAFXKMUtUZNtu7CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACi
iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK
KACiiigAooooAKKKKACiiigAooooAKKKKAIAMN7VzXjW/u9O0iCWzlMTtdxISMcgtyOfWul6tz0r
B8WaTc6xpcMFrs3pcxSnecDCtk/pUzvyu25VFxU03tfW50MZyin2p9MQYQD2p9UiZbi0UUUAFFFF
ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZ8/nm3cW7rHMVIjaRC6q2OCyggsAeoB
GfUda0KKAOftIfEcdwj3mp6ZPb8744NOkiduDjDGdwOcH7pyOOOob4jH22fTdGU5+13Aln9oIiHb
8C3lofaSuiooA4XxT4O1rXdSF3YeM9U0mIIF+zW65TI78MDk++a5r4OWU+neIfHNpcXst7NDfpG9
xKPnlYeZljyeT9a9fry/4Y/8jx8RP+wqv83oA9QooooAKKKKACiiigAooooAgLADninr9Kp3dxFa
QtNcSJFGgyzuQAB7k1h6Z4qs9b1Caz09Z5VjQsboRHyQwwNu44yec8dh1pOSWjZUKU5JySdlu+h0
E9xFboWkdVXGSScVi3GuvLpb3mgwrq7CTywsMqqoPfLHjA46ev41jr4OvdWuVn8Uak16vazgzHAp
98ct9TiuwtLO1sbZLe0gjghQfKkagAfgKhOUull+JpKNOFrPmfXt6dzzm/8AB/iTXL4ajqE9nNvj
SKTT1leCLajMy5cKxbBZsrtGeORgV23h7Sm0fSIrOR1lkDySyMi7V3ySNIwUdlDMQB2AFbQx1pAm
KtRS1RFWrKoknolslsS0UUUyAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooo
oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiig
AooooAKKKKACiiigAooooAKKKKACiiigCNq5Tx9NLBolu0Ujxk3sAJRiCRvHHFdTv+bFYXiXTf7Y
06KD7QkG25ik3OODtYHH1Paomm4uxVKUVJOWyep0Ef3F+lPpi8KB7U+rJYUUUUAFFFFABRRRQAUU
UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5f8Mf+R4+In/YVX+b16hXl/wx/wCR
4+In/YVX+b0AeoUUUUAFFFFAELPt70u3jNVLq6htLWW5mfZFEhd2xnCgZJ49hXGnxPrmvuU8N6ds
tzx9uvAUT6qvU/X9KTkomlOjKpdrRLdt2R2l3eW1hbtc3c8cEK/eeRgAPxNcqvi+51S7WHw9pkt5
DuAe8nzDCBnnaSMsfoPzrXg0FLzTLaHXWj1SeFi/myxKoLHP8I44Bx+FbCRJGgVEAAHAAxUtSl1s
vxGpU4J3V3+H/BOb1HwlZaxqovdRkuLiNQNlo8n7lCBjO0dSfet22torWBYYIo4o0GFVBgAewFWz
9aaFA9KpRSuyJVZySi27LZdCeiiimSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU
UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQ
AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBH1rkfiHn+xLb/r9g/8AQ663+Jaw
fFNnZXumxJfXP2aJbmJlfI5YMNo59TxUzV4tFUmlNN7JnQR/cX6U6mr9wfSnVRMhaKKKACiiigAo
oooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqM8wt4ZJ2EhSNS7CNGkYgDJ2qoJY+gAJPQ
Cr1FAHPWXiKyvp0tbeDU0mfJDT6VdRIMAnl3jVR07kZPHU1zWtC5Nx4iuln1EPa7Ta3UF+8VvZfu
Ub99ErqG2sTI2VbKsAfSvRq5e/8AC6X9zfAapqFva3//AB+WkIhMc/yLGclo2dcoqqdrL0yMHJoA
zfFPjHWtC1IWmn+C9U1eJkDG5t2wuT24UnI98VlfCuw1VNU8U6xqekXGmf2perPFBcDDAfOT9cbs
dBXp9FABRRRQBlavdy2Gj315BAZ5re3klSEdZGVSQo+pGPxrzKz8S+JNR8QxaVpmrx3KXLMklzLH
EypiMv5kKIAwTgD5y3LrkgmvWhjdz96uV8OPp76zrcdrpNnZTw3Ajkmt4lVpsruyxABJyTUS1aV7
XNqOilPlvZLfprvbqW9D8NrpMslzPeXN5eTACWaZuCBzhVHCj2ro1UDoKfSVSSSsZznKbu2Oooop
khRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUA
FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU
UUUAFFFFABRRRQAUUUUAFFFFABRRRQBF3/rXnfjr+09V1KHRbSTyEiWG7yoUvN+9KsVLZGI9qs3G
fnXoAc+j9qztQ0nTtWhSLUrC1vI1bcqXEKyBT6gMDg0pLmVmVCTjJSW6KfhnUZ9U0O3vLgxvIzSI
JYlwsoWRkEijnCsFDDk8MK36jRFjQIihVAwABgAVJTJCiiigAooooAKKKKACiiigAooooAKKKKAC
iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAytVv00rTLvUZEZ47SCSdlXqwVSxA9+K4Tw
rdatZ+LbtdTtrcJql4UVoQ37uQQtIME8Om1CNwxzjj5uPSnRXUoygqRggjORWPp3hrSNMvBcWds6
uqGOPfM8iwocZWNWYhFOBwoA4pON2n2NIVOWMo23VjeooopmYUUUUAFFFFABRRRQAUUUUAFFFFAB
RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFF
FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU
UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQ
AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAB
RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFF
FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU
UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot myocardial infarction 3 Jan 2016.PNG" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2017-08-08 09:58:26 -0500" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of comparison: 1 Homocysteine-lowering interventions versus placebo, outcome: 1.1 Myocardial infarction.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA6sAAAKWCAYAAACvcQ9CAAA9aklEQVR42u3dz3GkSOI2YNmxdlSU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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Contour-enhanced funnel plots for meta-analysis of myocardial infarction 3 Jan 2016.PNG" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2017-08-08 09:58:54 -0500" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Contour-enhanced funnel plot of comparison: 1 Homocysteine-lowering interventions versus placebo, outcome: 1.1 Myocardial infarction.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA70AAAKqCAYAAAD2eTk7AAA7m0lEQVR42u3du3HkWIKG0bQKQloD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</FILE>
</FIGURE>
<FIGURE FILENAME="Stroke HLI versus placebo.JPG" FILE_TYPE="JPG" ID="FIG-07" MODIFIED="2017-08-08 09:48:40 -0500" MODIFIED_BY="[Empty name]" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial Sequential Analysis for homocysteine-lowering interventions versus placebo on stroke. The diversity-adjusted required information size (DARIS) was calculated based on an expected relative risk reduction (RRR) of 10% from proportion event in control (Pc) group of 5% with an alpha of 5% and beta of 20%.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot stroke 3 Jan 2016.PNG" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2017-08-08 09:59:53 -0500" MODIFIED_BY="[Empty name]" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of comparison: 1 Homocysteine-lowering interventions versus placebo, outcome: 1.2 Stroke.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7EAAAKkCAYAAADWT7jFAAA8LklEQVR42u3dO24ry4IlUI2jxkFw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</FILE>
</FIGURE>
<FIGURE FILENAME="Contour-enhanced funnel plots for meta-analysis of stroke 3 Jan 2016.PNG" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2017-08-08 10:00:10 -0500" MODIFIED_BY="[Empty name]" NO="9" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Contour-enhanced funnel plot of comparison: 1 Homocysteine-lowering interventions versus placebo, outcome: 1.2 Stroke.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7IAAAKfCAYAAABTxfSoAABFj0lEQVR42u3dyZHbapZA4bQKi7QG
q3ShTcA2o9zgPjdlQW3ggKJ2ZcDzAC0pkySIGSSGf/hOxImOlnISH8Xi0b348fbPP/80JEmSJEnG
4psHgSRJkiQpZEmSJEmSFLIkSZIkSQpZkiRJkqSQ5etemvLtrXnrWFS1x4YkSZKkkPUghOWl7Afs
o0VT1R4nkiRJkkKWAVhXxUzEXi2bi8eLJEmSpJDlqdZVU7Rjtaiauv37l/IxZsuLx4wkSZKkkGUg
K8VjkfoQu1aMSZIkSQpZnmb7cKfpteH2+rHDn0iSJEkKWZ6/Vjy3Mtz+2O76MUmSJEkKWR7huilr
3VSFQ59IkiRJClkGErLl5Z8VIes6WZIkSZJClifYPuhpPmTbHy9kSZIkSQpZnhqyy8J07ccvuzft
o//9739JkiRJMgiFbFIhu2yC+0zIilmS5Ku28XiQJLeMWSGbwUR29Zj+J2T/97//kST5lF3+/e9/
e1xIkk8pZIWskCVJ7u6faB1CzJIkhaxTi4UsSTKaiP3D//3f/4lZkqSQTcZLGdR9ZIUsSXLriBWy
JEkhm5p11RTXQ5bKy/KPLaqmFrIkyUAidi5kxSxJUsgm5aUp35ZNWdtryPPTWyFLkgwnYtshK2ZJ
kkI2qQOfJqay7WnsTtfHClmS5J4hK2ZJkkI21fXiobXh1nW0i1aQhSxJ8sCI/ROnaxCzJEkhm+Dp
xdPuc8iTkCVJHhGxQpYkKWRTXjEedL+VYiFLklwbsc+GrJhlai4bRpBsK2STPvzpbffDnYQsSfLZ
iP3zvxev0I5ZQUshSwpZIUshS5LcLWK7b0aELIXs28v/sAPkgpClkCVJHh6yY/+y3n6DsjZm//Of
/4hZCllAyApZClmS5P6T2ClNZilkAQhZClmSZJDrxFvEbHcqK2YpZAEhK2QpZEmSm64TD70heSVm
/4SsmKWQBYSskKWQJUmeHrFilkIWgJClkCVJnhqx7XvGDsXqKzHbDlmHP1HIAkJWyFLIkiQ3idhr
yD47pRWzFLIAhCyFLEkyqIjdOmbbK8aClkIWELJClkKWJLlLxL4as2NTWSFLIQsIWSFLIUuSnA3Z
a1T+61//euoAp61i1poxhSwgZIUshSxJcjBihyayW0XsmonuVMiKWQrZ8b9zgJClkPU/SiSZXcT+
8U80vnornTWHQYlZCtltosBUGEKWQlbIkmSyb7bnIvaPfwLy2ZjdImLFLIXscxErZiFkKWT9jxJJ
Jvcmu/saPxaxV9fG7JYROxayrpelkJ2/Bl3MQshSyJIkk4rY9ut8N2LbIfvn2ti5N8t7Ruwf/vwM
YpZCdvk/GolZCFkKWf+jRJLJRuzVuYhdMvnZK2K7U9mpFWNBy5xCdu7vVDAx+/Ux8Jrx3nz+Ouj7
//ps3v98z4+v6y80n++////3z+aXlhSyFLIkybjWibu/PrRS/Mwa4x4Ru3QqK2SZS8gu/Tt1dsx+
fcy8Vtzi8tqc779//aP5ErJCVshSyJKkN9VDr+lDt9iZmsY+e03elm+kp2LWmjFzCdm1f6dOi9nr
JHYoGK9x+dt2y36H794hCyFLIUuSjP5gp+7HXSN2KmSXXjO7xxvosRVjk1nmELLP/p06I2a/p6sT
K8Q/gfne+gAhK2SFLIUsSXozPRmx7etiux8/F7Fr14y3fOPcnsqKWeYUsq/+nTo6Zr9D9nHiOvHR
3+u+vbXjsTXgsV//aj66X2PxanH/Z3gfqfD+yvTG8S1khSyFLEmK2P/1QnZoLfeVN7ljhz3t9YZZ
zDK3kN3q79ShMdtaH36bnYhuELLd73f1/X0+ZMc+d+DnHr/u98ADrISskKWQJUkR+5/R+8WG/EZZ
zDLXkA0lip+K2Zmw7a8WLw3Zewg/TFHb3380ZEc+txWt9x/1Z+Lb/dl/rgd+V7JClkKWJLl9xA6F
bDsG/8ThlpOfPblex+vwJ5rIhrtePD/JfJxiPh2yU9fBXg+dGgvZyWtofz729nut1WWnHgtZClmS
5LYhuzRiu6cUX6+NDeH+k0u+r5ila2TjiNiBurwHYSsgXw3Z4Ylod4o6ErJTtr7/9drfJRNmCFkK
WZLkExPZGCN2zfdfE7Jilk4tPvjv9Z9AXHRd7D1cgw3Z3mFOnUOlTGmFLIUsSXK7mJ2K2KGQDS1i
536O688tZplLyD4Tpef8vb6G3tRpvitCdiwkN1wtfu361uuf14FPQpZCliS5SczGHrFLY3bq4Ccx
y5RCdk2chnFN7FDctU4p7q0WD1032w7N1ue2JqD9j1t/2FOvg7sRPBrM168hZIUshSxJcreY3euA
p63flC/5uZZOZV0vy5RCdsnfj/OviR24pc7MKu7D9afXWLzG5MPnfTQfC2+h8/7x8drtd0bC2nWy
QpZCliS5oddYm4rZGCJWzFLI7vuPQAeOZgejb7j5hk8Ffgjcv78+c+1sOyx7U9SFnztxzevQgU8a
VshSyJIkX4zY63WxQzEbU8Q+E7NrVowFLWMP2VfW8gEhSyFLkgwuYq9239ReIy+m04mXfPwzU1kh
yxRC9pmD0gAhSyFLkgwqZIfCLbSJzV63EFkTs9aMmVLIBrdODAhZClmS5DOT2KUxG9ub7aUxO7di
bDLL1EK2/XcEELIUsv5HiSSjiNgl94s9O2S3+t5TX+fZqayYZSohCwhZClkhS5LRrhMvDdmzTljd
M4rFLIUsIGQpZEmSCUdsSPe93PLrrFkxFrMUsoCQpZAlSQZyXezcCcUxxuzSz187lXX4E4UsIGQp
ZEmSJ0fsNWTnwi+mmF3zee2QFbMUsoCQpZAlSSYSsTHF7DM/41DIrlkxFrQUsoCQpZAlSZ4YsX9i
7ojrV/eI2Wd/tlenskKWQhYQshSyJMkDDncaumfsNeT2vn51j5h99Wd6NmatGfPIkL2+QQ9JQMhS
yJIkg4/YNeG4deTueRjVFiErZilkASFLIUuS3GmleCxi14Ts3mG59Htu+b3ELGMJ2RD+DEIWQpZC
liR5WMR2Q/bZiF0alkfG7BY8c/CTmKWQBYQshSxJcseIfeaAp1cj9oiY3YpXprKul6WQBYQshSxJ
cuPrYq8hu+aWO6+u+O59MNQeX1PMUsgKWQhZClmSZACT2HbEXgPt2chcO3k945TjUFaMBS2FLCBk
KWRJkp2IXbNS3A3ZZ2L22fXh2GJ2q6mskKWQBYQshSxJ8ol14qFpbPuAp2dj9NUIjilkn4lZa8YU
soCQpZAlSQH7xDrxXMQujcytDnKKOWbXrhibzFLIAkKWQpYkRewL18V2Q3ZNZG59GnEsMbv1VFbM
UsjGwFfz8fu/zcfXyO9+tF6/3j+bX72P+NV8vv/+vbEvACFLIUuS1om3mcaumbxuFaFilkJWyIYa
sW8jIfvr8/337703n79aH9v9wK+P1sdAyFLIkqSI3Sxi5+4bOxWtW8ZnrDH7zIqxmKWQDZxfn817
6/WoH7I/k9bWFPY7bD+ar87HvKtYIUshS5Ii9rXrYtdMY59ZM+5+Tg7Xyj47lXX4E4XsGXHaDs3p
KezfSernx0jI9iewjxPa6zR27vtByFLIkmTmEfvn9XfraezQG4i168cpRayYpZDdN2S/rzn9jr+H
609fCcKvjxVf5ztQb1PUr4/FE9n2z24aK2QpZEmSMxHbDcG9IvaZ9ePU7ie794qxoBWyQvY7Bj8+
hl5L1l1r+tX5Gk9F5WjITl8j218zhpClkCVJETsasd2YfXWleM+YjTli95rKClkhK2SHo/X267On
//5MSt+WfvzzIduL5dsHdaa6ELIUsiTpcKf5iG3H7BHT2CURu+ba2lxj1pqxkBWy1zAcmrxeA3Vq
yjlycvCOITt8KW57Gtu+5lbcClkKWZIUsYMT2O6vhxSxW9+yR8hSyKZ9jez0Km8YE9mxmP7++M51
tE9EMYQshSxJJrNSPHdNbPf3j7w29tkJbUohK2YpZM8M2eOukR2dxl7D9ecWPvfv+xO2SlbIUsiS
pIgdPqF4Kmb3jthnr5lNcSr76vWyglbIWi1es1o8HaNPnX68KmTb09h7yN4/t3/SMYQshSxJitjO
4U5DMXtUxOYUs3tOZYWskM0zZPvBufywp8lx6YL7yD4fsn9/xnakmsgKWQpZksz9utglETt0uNMe
4fjqfWLFrDVjCtm5iez7+9DrxQm3s1kasr3pq2tkhSyFLEmaxD4VsXvE7CtfK8VTi/dcMTaZFbJ5
XyPbObTprHXchfHZm8Z21o2dWixkKWRJMvmIbYfs2ogdO6V4q3DcMj4d/CRmKWTHQxYQshSyJJnE
bXamYmcqYreM2T2COPWDn8QshayQhZClkCXJbCJ27QFPe0fsVhGaasTuuWIsZoWskAWELIUsSQZ/
XezSmJ1bKQ7lwKdcInbPqayYFbJCFhCyFLIkGUXEzsXsGRH7bJTmELFilkIWELIUsiQpYidi9syI
XRunOUXskpAVsxSygJClkCXJ5CN2KmbPitilkZpbxE6F7FZTWfeYFbJCFkJWyFLIkmQwhzs9E7Nn
RuxcrOYYsWKWR4dsSAJClkKWJEXs6CnFYzF7Zjh2v3fOEXt0yIpZIStkIWSFLIUsSQa3Ujx0UnGI
4ShixSyPC1lAyApZClmSjCpixyawIbwhFrHLYrZ98JPDn4SsvyuAkKWQJcmkI7Z7wFOo4eiN+fKp
rOtlhay/L4CQpZAlyeQiduk9Y//8X8QVsw5/opAFhCyFLElmGbFXkfdktv2cE7RCFhCyQpZCliRP
j9i5kIWprOtlhSwgZIUshSxJnnqbHdNYMWvNWMgCELIUsiQZ1SRWxFoxNpkVsgCELIUsSR4WsVaK
EdJUVsymGbLd15wQBIQshSxJZrxObBqbb8iKWSErZAEhSyFLkiIW0U5lxayQXRKyW73ubPEcA4Qs
hSxJZn5drJViU9mtQtbhT0JWyELIClkKWZLcLWJNY8WsmBWyQhYQshSyJJlkxApZK8avrhgLWiEr
ZCFkSSFLUsQetlIsYk1lXS8rZIUshKyQpZAlydMPdzKNFbNHxqw1YyErZCFkSSFLUsSKWAhZClkh
CyFLIUuS+awUC1mIWSErZAEhSyFLkiIWycXs1gc/OfxJyApZCFlSyJIUsQ54QtRTWSErZMMM2a/m
4/dj8/E18rsfb7fH7+39s/nV+4hfzef7798b+wKJ8uvz/f64dOw+FLE9hkKWQpYkT74u1jQWa0N2
r5i1ZixkwwzZ74h9GwnZ71h7bz5/tT62X2mtj8mHhzidCNkYH8OsQ/ZSls1FdApZkjxxEiti8epU
ds/JrKAVsqeH7K/P5n1iinibErYmiN9R9tF8dT7mPbeKHXhsln5cDI9hliFbV8XPH1zIClmSXBex
VoqR01RWyArZ80L2PoX9OwX8/BgJ2f708HG6eJ0ktqNsq8De+Gtu/v1HJqtNII9hbiF7j9CWRdXU
Sz6/rpri4XOFrJAlyfPWiU1jEXLMWjMWsiGE7G0C+PWxeCL7vU57ja6NJ4k/P8e302HX/jkeV3xf
CMIV3/86zZ7/sx/8GGYXsr0I7VtU9cjn101VDH2OkBWyJBlHxApZMXv0irHJrJAN6rCn0ZCdvr6z
vyK7zbWmS6LuGoMfg9eprrvW9Jnvf3/M2tPt4VXjIx7DTEP20pQzEXu1vCyY4K6Z4lLIkrRSvON1
saaxiGUqK2aFbKgh2wu92wd1prrPXmPa+7pr4/MxWm+/Pvv1Xvv+UycWD4X0Po9h5iHbjdHHWO1M
W2+BagorZEkyzIg1jYWYpZDdNmTHQ+46SXycSs6H2dLrS+dCdmjyeg3UqSnnVt9/4DG7HqC14Gu/
9hhmH7KPQdqduN5PIL5+TNFUdfv/n/9cClmSFLGwYixmhWxKIdu+72znGtDFX2uLiexwrPYOU9rh
+z/7s237GArZ+XXg1jW0RdFZJy4v4lLIkmRQEWulGLFNZR3+JGRjCtm/oXiNrt6hRz9RtqLCXrlG
9vmQffEa2RdDduvHMMOQbV0fOxmkQ9fRfk9nhaWQJckQItY0FmKWQvaIkG1PEu8Rdv/cpfdXHf85
lp9a/Oxq8avf/2cNePDPuOTPv+NjKGRnQtZhTkKWJEUshKwVYyGbXcj+Dch2YO0xTVxwH9f7FPXx
45Yf9rTN9+99m5/Hcmqqe8hjKGSHQtYkVsiSZDi32RGyELMUsgeFbG9yeN71ndeJ7Pv70AG0R9zO
pnPbnZlb8IT4GOYXsqaxQpYkRSyErJgVstmFbG+SOBJ1R5y4e78OtXNo06HruJ3vvWASHNJjKGQp
ZEkygJViBzzhqJA9Yirrelkhe2jIRsiyk4EhZIWskCXJACPWNBZilkJWyELIClkhS5JJR6yQRcwr
xoJWyApZIStkhayQJclEItY0FrlMZYWskBWyQlbITt4fdivL5iI6hSxJhzuZxkLMWjMWskIWQlbI
UsiSzHkSK2KR44qxyayQFbIQskJWyJLkjhFrpRimsmI2xZANSUDIUsiSZETrxKaxELNiVsgKWQhZ
ClmSFLFAZCvGYvbYkAWErJClkCXpulgrxTCVdfiTkAWELIUsSYpYIYtQQlbMCllAyIYQsnXVFKOH
ORVNVYtKIUtSxIpYiNkQVowFrZAFsg/ZS7nyhOLykklE1k1VLH9cyouQJSliRSxMZV0vK2QBIduE
ezueHCa06x4fIUvS4U7HH+4kZJFjzFozFrJAviE7uEY8FadDUZd4zF7KVXEvZEmK2OMjVsgi95AV
s0IWyChku1FaNpdDPjcu66rYPVKFLEkrxUIWYlbMCllAyK4MtLeiauoXrx0tqjrJkL1fO3xurAtZ
kiJWxCKOmD3y4CcxK2SBzEK2PVF9YTX4YTU5xalsK9afin0hS1LE7nnAk4iFqazrZfcI2fZrUigC
QrZz3eerk9RQVm93D/6TT2kWsiRTvS7WNBZiVswKWSELIbtyXXaDg5raU9nUbsnTCv7vSD/vsCsh
SzLFSayIhRVj95gNOWSfeV3aWiELIbvbumw467f7XUdcNMXcvWR3/rMLWZJHRqyVYmDbqazrZYWs
kIWQDXBdNpQDkfabXC90Rcy+PXnvXm+2SaayTmwaixxC9qyYtWYsZAEhm23IPp7KPLpC3LnP7NJr
joUsSRErYiFmTWaFrJCFkBWy553sfMDpzUKWZIrXxVopRi4he/bhT7nGrJAFkgpZ18juvYa8x+nN
QpZkKhFrGgsxK2aFrJCFkHVqcXAHQ71+SyMhS1LECllYMRazQlbIQsjuGF1p30f2nHvzClmSqUes
aSxMZY8N2VwPfxKyQGIh+3j95wvXdB5wbaiQFbIk04hY01iIWTErZIUshOymU9nnrm19PNV3j3iL
dbXYNbIkRayIhZANOWRziVkh+8ivz/fRO2N8fD1+7NdH6/ffP5tf/a/WfL7//r3uJ2bFV/Mx8Nj1
HqOJxzmkxzuakH2cyq6dqHY+N8FDntatX7ejfoPrjoUsyYRusyNkIWbFrJANI2QfYmkiZL+D9735
/HWPtbd+6bY+Jt+IHY/TfsSOxWwoj3dEIdtdDV4StN343S/cTnfN2nT7XrI7HXglZEmKWCCtmD3r
4KecYlbIDoTV4LRv+uO+Q+uj+ep8zHuuFfvrs3mfmbLept/tx/tvjL4NPpYhPN5xhexozC415eti
H1enx/6sDyvaO0a9kCUZ+0qxA54gZMOZyuZyvayQHZggzq6m9j/ucWJ4DbJ2aG0Vhxt/zc2//30K
+/fx+PwYCdnrNLb/9a6Be/+ckx7vJEJ24D6oS4z/mtj2dHkkQFdG/p6PiZAlGWPEmsZCyIpZIRtI
yP5MEeenev0J4fdK8jWkNp4O3qaUb7Ox1v45HtekX4i8Fd//Gp23P/vXWMj+xOnQ9Pvnc+6P38GP
d4ohuyzeUlojXhCyK2J271sPCVmSIhZIeyp79opxikErZPsB9fHVnioOx9bUNZv9tddnf5zH99JL
Qu0aeB+D1/quu370me8//piOrB4P7xz3fu+IxzuPkM3GhSE7dB1s252uiRWyJFOJWCvFELJxTGWF
bNohO3Vi8VAEPoTeLbo6E8n1P8XjAUgrT+C9/0yPP+/t12e/3mvff23IDj9Owyve+zzeQpYBKGRJ
xnS4k2ksxGxcMZvqmrGQ7YfSqunhYAxfp4OPk9352Fp6je7cn2Fo8jp+TeqW33/PkN3+8RayFLIk
TWIPj1ghCyvGJrNCdvvb78yt7C65PvS7vzrXdY5eK7rHRHb45+wdkBTARHbpavF+j7eQpZAlGWHE
xrpSLGJhKnv+VDaVmBWy24Xs31C8hlRv4vgTWivK6pVrZJ8P2de+/+KQXXXY0zGPt5ClkCVpndg0
FhCzQjaykJ0Iq0X3l21PB+9hde+opfeoHY/B5acWP7ta/Pr3Xx6ya26/c/DjLWQpZEmKWBELpLhi
nFLMCtn+BLIXUAsmhH8/tx1Ne0wIF9zH9T5Fffy45Yc9vfb9l4ds63Ct9uN2i+YFf869H28hSyFL
0nWxVoqB1KayqRz+JGQHprJDTk32etPAgYngTtdsjk1k39+H/hzH3KJmacj2rsdt+fE1F9TnPN5C
lkKWZHYRaxoLiFkhG8M1sgNxNVNDvengSBgfcYuY+zWynT/Hxiu224Ts8OM9F59nPt5ClkKWpIgV
sUByK8YxBq2QTYtlpytDyFLIkhSxVooBU1khK2SFrJAVshSyJFM63Mk0Ftg3ZEOJ2VjXjIWskIWQ
pZAlKWJFLCBko4pZIStkIWQpZElaKRaygJiNKmaFLJBFyF6acuxI7rUWVVOLTyFLUsSKWGCTmA3h
4KcYY1bIAkL2OcuLCBWyJBOOWCEL5DeVjel62VdDNiQBIXtkyIpZIUsyuetit5rGClmIWTErZIUs
hOx21lVT3EK0aKp6WfgWVf3E16CQJRnTJFbEAufGbKgrxqEG7bMhCwjZ2EK2FaAPYTrlpRwJ1lbo
msoKWZIvR6yVYkDIhjqVFbKAkD01ZC/lc+E59nl1VTj8SciSTGSd2DQWELOxrRkLWSCLkL1PUMvL
ys+9TWXL5rLk1ylkSUa1TixigbBiNqQV45Ans0IWELJCVsiSzHSd2EoxYCoba8wKWSCLkK2bqnhx
tbi7QixkhSzJ6NeJTWOBMENWzApZQMh2g/Spw576ATwauBSyJEUsgM1CVswKWSDrkH28bc7cJLV7
39nHU4tvBz2tiWIKWVLEBnldrJViwFQ2xsOfhCyQS8h2AnSNt+tqezHsPrJClmSMEWsaC4jZ2GNW
yAIZhexwjE7ZCdX2qrFprJAlmX3ECllg/5gNfcX4rKAVskBuITu6Prxg7fgWsiaxQpZk7BFrGguY
ysZ8vayQBbINWQpZkrkd7mQaC4jZVNaMhSwgZClkSYpYEQsIWSELCNlEV4spZElaKRaygJgNIGaF
LJBdyE4FrKAVsiRFrIgFQo3ZEA9+OuvwJyELZBWyayLWLXaELEkRK2IBU9kwD38SskA2IVs3VTFy
f9jR04l/LKqmFpxClmT218UKWeD8kA05Zo9cMxayQC4h247TRWH6GL6j0UshSwpYEQvglKlszpNZ
IQtkErKX8pnrXluryOVFdApZkhMRa6UYgKnscTErZIEsQvY+XS2qetXn1lVhvVjIkoxsndg0FhCz
qceskA2Zr+bj93+bj6+x3//VfL4/XvI49rFfH62Pe//8/ZkjX2v8myHukL1PVlevCN9Wkp1gLGRJ
5hqxQhYIM2ZDXjHeO2aFbNgROx6n/Ygdi9lfn++/f/29+fzV+rrdD/r6aH0MhKyQFbIko78u1jQW
MJVNOWaFbID8+mzeZ6as33Hama7+jdE/n/PRfHWDt/Vx35/b/5h3FZtyyFotFrIkc4hY01hAzOYS
s0J2ywnqqxPN+xT273T082MkZK/T2HaMPgbu/XP6E9jHCe01gPtfC0mFrMOehCxJEStigVRjNvQV
4z1iVsi2MvLjHocP15Quirx2hE5d1zr/NW6T0a+xkP35XkPXuv58zn262p/Itv+cprEZhazb7whZ
knlErJViwFQ29JgVsvuE7MfH0LWny6att5Xfq68cnjQWstfV4+Gd497vTV0j218zRroh2wnTyTht
R6+1YiFLMvjDnUxjATGbW8wK2W7I9qP19usro3T+pODXQnZ4ijp8mNPDz3L7vc4EGKmHbGdVeLEO
eRKyJEUsgJhCNocVYyHbjb2hyev4Nalrp71f6z5ps5Adnx5ff6bH1Whxm2zIro1ZEStkSYa+Uixk
ATGbY8wK2WWx2TsgKYCJ7NLV4pEv3rpHbec62tFrc5FIyC4JWgErZEmKWAAxhmwuMStktw3ZQ66R
XXXY08TPef383oT3J2yVbOohSyFLMpWIdcATIGRzu15WyHZD9tnV4i1OLV4asmtuvzM3jb2H7P1z
+icdQ8hSyJIi1jQWgJgNJmaFbDdk+4G47LCnLe4juzRkW5Pfdmz+fPzctbh//zztzzORFbIUsiRF
rJAF0ovZ2FaM1wStkO1PZN/fhy4ZPOEWNZPXql6nsn0n+7M3fR2YwLpGNuaQfeZUYgc/CVmSsUas
aSwgZFOaygrZV0L2T7B2IvGsFdvZoOzH7Fx89qaxDxNlpxYLWSErZEkhG3zEmsYCYjbFmF27Zixk
h0IWELJCVsiSJrEiFkAiMRvDivHayayQFbJIKmQpZEm+ErFWigGYysYRs0JWyELIUsiSQjaCSaxp
LCBmxayQFbIQshSyJEWsiAWyitlYVoyXxKyQBYQshSzputhIItZKMSBkc5nKzh3+JGQBIUshS4pY
01gAmYRsKjErZAEhSyFLilgRCyDDqWxsK8btoBWygJClkCVFrJViAKayUV0vK2QBIUshSzrcyTQW
gJiNas1YyAJClkKWFLEZRayQBYSskAWErJClkCWtFAtZAGL24JgVskBSIVs3VfH9Q74VVVOLRCFL
UsSKWEDMJnLwk5AFkg3ZS1P+/JBv5WXg14umqoWjkCVFbI4HPIlYQMimNJUVsoCQpZAlXRdrGgtA
zEYVs0IWSCpkW6vFD9EqZIUsaRIrYgGI2XRWjIUskFTI/tNcyrfbD7qtZXMRnUKWjCxirRSLWEDI
pjmVFbJAYiH7T101hZAVsqSQjWoSaxoLIISQjSlmhSyQWsjuFrNCVsiSIlbEAshlKht6zApZIMWQ
HT0EyjWyQpZ0XayVYgBCNv6prJAFhCyFLCliTWMBiNmoYlbIAlmELIUsKWJzi1ghC4jZlFeM9znc
lExbIUshS4rYoFeKRSwgZFOfyooSMtuQva4bO9hJyJIi1jQWgJiN/5Y8Xa//G+F/M8l1BhqyUwEr
aIUsKWJFLAAhm1bIilky+pBdE7FXHRAlZEm32RGyAMSsmCWF7CnWTVU8Rmp5GfnYS/kYs0XV1IJT
yJIiVsQCyDJmY7m3rJglUwzZdpwuCtPH8B2NXgpZ0kqxA54AmMq6XpYUsnt4KZ+57rW1ilxeRKeQ
JUWsaSwAMStmSSF7/FpxUdWrPreuCuvFQpYUsSIWgJBNasVY0JJRhOx9srp6Rfi2kuwEYyFLilgr
xQByDtmUprJClhSyFLKkw51MYwGIWWvGpJC1WixkSaYwiT0iYoUsACvGJrOkw54c9iRkycAi1kqx
iAVgKitmSbffcfsdIUtaJ04kYoUsADErZsm0Q7YTppNx2o5ea8VClhSxIhaAmE10xVjMksGHbGdV
eLEOeRKypOtiRSwAIZvuVNbhT2TwIbs2ZkWskCVFbIiHOwlZAGJWzJKZheySoBWwQpYUsSIWgJjN
d8VY0FLIBhuyFLKkiLVSDEDImsq6XpYUshSyZJaHO5nGAsg9ZFOKWWvGFLJClkKWFLEiFoCQFbKk
kKWQJa0UC1kAELNilhSyFLKkiBWxAMSsg58c/kQKWQpZMpeIFbIAhGzaU1khSyEr3ChkKWSTiNgj
p7FCFoCYtWZMClkKWdIkVsQCELMHrRhbMyaFLIUsGX3EWikWsQDymspaMyaFLIUsaZ3YNBYAoolZ
a8akkH3JS/knlsrmIhyFLGmdWMQCgMmsySwZfsjWTVV8x9JbUTW1eBSypHViK8UAYCorZsmwQ/bS
lD+x9FZexKOQJa0Tm8YCwKEhK2ZJIWsiK2RJEStiASDaqayYJYXsci/lLZjKi3gUsqTrYq0UA4Cp
rMOfyBhOLa6rpngzmRWypIg1jQUAMStmyZiukX1aJx4LWVLEClkAYtaK8dyKsaClkBWyQpYUsdms
FItYAKayrpclhayQFbKkw51MYwFAzFozJqO/RpZClhSxIhYAhKyQJYUshSxFrJAVsgDErJgVsxSy
FLKkiBWxAJBBzKZ48JPDnyhkT7tu1vWwQpYUsQ54AiBkTWUd/kQhG0zIrjn4SdAKWTKv62JNYwFA
zFozppANLmSfOb24aKpabApZMv1JrIgFgPND1mSWFLId66YqHiO1vIx87KV8jNmiamrBKWQpYjvX
+1gpFrEAhKyprJilkN3XdpwuCtPH8B2NXgpZWic2jRWyAMSsmBWzFLJ7eCmfue61tYpcXkSnkKWI
FbFCFoCYtWIsZilkj18rLqp61efWVWG9WMhSxGZxXaxpLACYyjr8iQwqZO+T1dUrwreVZCcYC1mK
WNNYIQtAzIpZMUshK2QpZCliRSwAiNmsV4wFLYWs1eKNw/+YeBeyFLFWigFAyOY7lRWyFLIOe9r4
NkVClkI21TcPprEAIGatGZNuv5OM9+AXshSxIlbEAoCQNZmlkD03ZDthOhmn7ejNZq24//gIWVop
FrJCFgDErJilkD01ZDurwovN4JCnumqKE//sQpYiVsQCgJDN9+AnMUshu3nMph6xA49FWblGliI2
g4h1wBMAxBOyuUxlXS9LIfty0OZxq53bicwPq9YOe6LrYk1jhSwAiFkxSyEbaMjyFrIPJzILWZrE
ilgRCwBWjN1jlkI2oNvv5DFpdfsdcn3EWikWsgBgKut6WTKwkG3FWRYnEAtZ0jrx+dNYIQtAzIpZ
a8YUsltdD/uwRss9QvZt9cnQQpbWiUUsAIhZK8YmsxSyJrJClsx+ndhKMQCYyopZMvbDni5l53Re
Wi2mdWLTWCELAGJWzJKhn1pcV03xZjIrZCliRayIBQArxmKWjOka2afN5cRjIUvXxVopFrEAYCrr
8CcKWSErZIUsRaxpLAAIWTErZilkhayQJUVsOJNYEQsA509lc1wxFrTM4xpZClmK2Ewi1koxAJjK
ul6WFLJCVsjS4U7WiYUsAIhZa8YUssd6KXNaDxaypIgVsgAgZIUsGXnItuLMbXeELK0UC1khCwBi
VsySUR32VF7EqpCliBWxIhYAkozZ3A5+cvgTTWQpZClinVIsYgHAVNbhTxSyQR32dClvwVReBGtI
Clm6LtY0FgDErJi1ZkwhO2ZdNcWbyayQpUmsiBWxAGDF2GSWjOka2ad14rGQZegRa6VYxAKAkDWV
FbMUskJWyNI6sWmskAUAMStmKWSFLIUsRayIBQAha8VYzFLIUsjSdbFWikUsAAhZU1kxSyFLIUsR
axorZAFAzIpZClkhSyFLERttxApZAEhjxdiasfdTjDpku9fNFk1Vf/9eXRVuzyNkKWKtFItYAEhy
Kpv7ZNZ7KkYasmMHP3VC9ufXy4vQFLJ0uJNprJAFgDRi1pqxmGWUITt1evE9ZC/l4++JWSFLESti
AQBC1ooxhewJ1k1VtAL1ujpcV03RCdl+zLr1jpCllWIhCwAQs2KWQvZoL+UtmIqqvv/6SMh2V4wf
PodCliJWxAIAIo5Z18uKWUYSsrcJa/cQp4mQfZjiOvxJyFLEOuAJAGAq63pZCtkz1op7k9XJkG1P
Za0XC1mKWNNYAICYFbMUsicc8tQ7uGkmZO8ryUJWyFLEilgAQJoha8VY0FLIUshSxFopBgBEEbKm
sq6XZaKrxaPX1lLI0m12TGMBAGLWmjGF7CGHPXUnq5Mh27rvbHkRnUKWJrEiFgCQZMzmvmJsMsso
br/zEKWjIft439neSjKFLHeJWCvFQhYAhKyprJilkB2cyrYmswMh275/rLViIUvrxDlNY4UsAIhZ
MStmhWxgIfuwKrxYhzwJWYpYEQsAyCNmrRiLWQYZsv2VYRErZOm6WCvFIhYAhKyprMOfGHjILgla
AStkKWJNYwEAYlbMilkhG1zIUshSxIpYEQsAYtaK8bIVY0ErZMUbhayIFbFWigEAprKul6WQpZCl
w51MY4UsAAhZMWvNmEKWQpYiVsQCAISs/+0WskJWuFHIWin2P4ZCFgAgZsUshSyFLEWsiBWxACBm
Hfzk8CcKWQpZith0D3gSsgAgZE1lHf5EIUshS9fFRjWNFbIAIGbFrDVjClkKWZrEilgAQNIxa8XY
ZFbIkkI2m4gVslaKAQCmsmKWQpZCltaJTWOFLACIWTErZilkKWQpYkUsAEDMWjEWsxSyFLKui6WV
YgCAqayYpZCd89KUP1G0vWVzEZ1CliLWNBYAIGTFrJgVskKWQlbEilgRCwCIdyorZsWskBWyQpYi
1kqxiAUAmMq6xyxdI9vyUrbCtGiqelkQlxexKWQpYk1jAQBiVsyKWSF7tHXVFD/BVFT1yvCdil4K
WRHrf6zCjVghCwBi1orx+SvGglbIPu2l/JmwlpdDPo9CVsRaKRaxAABTWTErZIXsJtfOrl4Tvk1l
XSMrZOlesaaxAAAxK2atGQtZIUshK2JFrIgFAAhZIUshO2TdVMWLq8VF1dSiU8iKWCErZAEAYlbM
ilkhe/g1siumsnVV3E85do2skBWxIlbEAgDErIOfHP4kZM86tXh2Vbj3sU4tFrIiVsQ64AkAIGRN
ZR3+JGRP8GHCukL3kRWyQlbExhKxQhYAxKyYtWbMxEL28fCmJZrEClkBK2JFLABAyFoxNpkVssEE
1P0k475OKBay7F7H4X90RCwAQMiayopZIUsKWevEDncSsgAAMStmxayQnTu12KRVyFLEilgAgJi1
YixmGdt9ZN0PVsjSdbGJrRQLWQCAqazDn5hkyLauh3U/WCFLEZvYNFbIAgDErJiliSyFrIj1PyYi
FgAgZq0Yn7ZiLGiF7OBtd9wXVshSxFopBgAIWVNZ18syjlOL66op3kxmhSwd7mQaCwAQs2LWmjFj
ukb2aZ14LGRFrIgVsQAAIStkTWaFrJClkLVSLGSFLABAzFLMClkhK2QpYkUsAAChh6yYFbNClkKW
ItYBTwAARBGyYtb1skKWQpauizWNBQBAzIpZClkKWZNYilgAgJgVs+4xK2SjD9k/19i6RlbIphOx
QjbOlWIhCwBILWQd/uR6WSG71EvpsCcha52YUU5jhSwAQMxSzGYYspfSqcVC1joxRSwAAFaMTWYZ
S8jWVVO8cPud8iI4hax1YivFIhYAIGRNZcWskD1rGltebr9eV0Xv17ofL2KFrHVi01ghCwAQs2JW
zArZg62bqvgJ06Jq6sFrZvurw7fItVYsZEWsiBWxAAAxa8VYzArZ408d/o6loqpHVo6LpqrHA9hU
Vsi6LtZKsYgFAAhZU1mHPwnZU0K2H6RTvze+ekwhK2JNY4UsAEDMilkxK2RPCtn71LU3rW1PbLsr
yRSyIlbEilgAgJC1YhzYirGgzSZkWwc7DU1db6vHrpMVsiLWSrGIBQAIWVNZ18sK2RMOexqaut7W
h4emrhOHQVHIOtzJNFbIAgDErJi1Zixkd3PyBOJbrPYPfJqMXApZEStihSwAQMgKWSErZHfztiI8
EKzt32sH6y1wHfYkZK0UC1khCwAQs2JWzArZE7xdCztwK57u73V1+x0hK2JFrIgFAIhZBz85/EnI
nnqtbD9O7wdC9TSNFbIi1gFPIhYAIGRNZR3+JGRP9e/KcP962LmpLYWs62JNY4UsAEDMillrxkKW
FLImsSJWxAIAxKwVY5NZIUshm0PEClkrxQAAmMpSzApZClnrxKaxQhYAADErZoWskKWQFbEiVsQC
AISsFWMxK2QnnDh5+GXL5iI6hazrYq0Ui1gAgJA1lXX4k5AVshSyItY0FgAAMStmxayQFbJCVsRS
xAIAkHTMWjHeZsVY0MZwjezf+8dew3T4PrJDQVxexKaQFbFWioUsAEDImsq6XlbIHm1dNcVPMBVV
vTJ8p6KXQtbhTqaxQhYAIGbFrDVjIbuDl/JnwlpeDvk8ClkRK2JFLABAyApZk1khu8m1s6vXhG9T
WdfIClkrxUJWyAIAxKyYFbNCVshSyIpYEQsAgJh18JOYFbJD1k1VvLhaXFRNLTqFrIh1wJOIBQAI
WVNZ18sK2cOvkV0xla2r4n7KsWtkhazrYk1jhSwAAGJWzArZs04tnl0V7n2sU4uFrEmsiBWxAADE
ErJi1j1mk7qP7MOEdYXuIytkj4hYIWulGAAAIWsq63pZITtzeNMSTWKFrHVi01ghCwCAmLVmLGSD
Caj7ScZ9nVAsZK0Ti1gRCwBArDFrxdhkNuGQpZC1TmylWMgCAGAqSzErZClkrRObxgpZAICYFbNi
VshSyIpYilgAAMSsFWMxm3PI9m6ts1TXzQpZ18VaKRaxAACYyopZIRvJ7XeErJAVsaaxQhYAADHL
PGI2rJBdddsdIStkRaxJrIgFACCVmLVivM+KcapBG1TIXkpRKmRFbCoRa6UYAAAhayrretkMQrZu
qkLEClmHO1knFrIAAOQasmLWmnGEIXtpyp9YKqpaPApZEStiRSwAAEKWQlbIUshaKRayQhYAIGbF
rJgVsrusFgtZIStiRayIBQAg35h18JPDn6I67Ol2652iamrxKGRFrFOKhSwAAKay3m85/Cn8+8ha
Lxayros1jRWyAACIWTFrzTiqkP1tXTXF9RY8JrNC1iRWxIpYAACyjVkrxiazUR329Lxu2yNk5yNW
yFopBgAAprJiNu6YFbLMKmS9cJnGAgAAMcv4Y1bIMvmQFbEiFgAAxB2z7U0wQStmw7xGlkLWdbFW
ikUsAABC1vWyYlbIMseQFbGmsUIWAIC0YtaasZgVskw6ZEWsiBWxAACkHbJiNu+YTShk/1xj6xpZ
IStirRSLWAAAUg5ZU1n3mA03ZC9lpIc9XQ+s2vLnqJuqWP4YlBchK2JNY4UsAABilmnHbHAheylj
PbW4HZxb/hzrTnPOOWRNYkWsiAUAIJ+YtWK8/4pxyEEbVsjWVVO8cPudvSJufYBvGLIrp9O5hmz3
L5wXoXxXioUsAACmskz/etmgQvYhBsvL7dfrquj9Wvfjz4vYodXf7UL29mc/OdRjCVkvPKaxQhYA
ADHL9NeMAwrZVhAWVVMPTiX7gXgPvRPWikcnyNv9LPdYP/f635BDVsSKWBELAICQ9d5NyL6de1DS
W1NU9UgwFk1VjwfwcRPLgetWy2qHa2Qn4l7Iui5WyApZAADErJjNNGaDDNl+kE793vjq8V62133v
P9Mehz21gvmgP1tMIStiRayIBQBAzDr4Kc/DnyIJ2Xsk9qa17YntQVPL4XDeIWRbBz19PyZDJxgP
TanTD1kR64AnEQsAgJA1lc338KdIQrZ1rejQZPK2epzW7Xfuk9+iKebuJbtzxIcasl5YTGOFLAAA
YlbM5rdmHORhT0NT11vUDQXbxGFQMYfs6nvqrojZZ29xZBIrYkUsAABC1oqxyayQXXoC8S1W+6u0
k5Ebbch2b+szskLcuc/s4Op1IiHrXrFWikUsAABC1lRWzAYXso+3s+mEW/v32sHaDrlTD0TaOmTb
18POXAf78LjtM5UOKWS9gJjGClkAAMSsmM07ZsMK2YF12vaEcW7V9rjb7xyzWvzs47bH43B2yIpY
EStiAQAQs1aMxWywIdtdqX2MsqFTe8O4Pc3ZIdu+JdDS9eJYQtY6sZViIQsAgJA1lXX4U+Ah214Z
Hl6pnZra5hqy7RXrlEJWxJrGCtl9+fP3GgAAMcvYYjbckI1OIStiRayIjStg2wIAkGLMWjE+dsX4
yKAVsgmuFqdwjayItVIsYo+LWDELADCVZWzXywYUstfrX2dO6J066Cih2++su+a1/b3XP34hh6wX
BtNYIXtMxIpZAICYZUxrxmmF7BkrvXtNZNfcUueAWxAdGbIiVsSK2GMidu7XAQAQshSyu4Vs+yTj
hEK2c3rz2NdsT273msYeGbJWioWskD02YsUsAEDMMsaYPSVkH+NrQ6NaLW4H+EiAPkxl593z9OYj
QlbEilgRe07EilkAQA4x6+CntA5/OmkiO3E/2Bc89zY8O4Tsipjd44CnI0NWxDrgScSeG7FiFgBg
KsuYDn86b7W4fV1n9BG7Y8jOPV47XRN7Vsj6i28aK2TPi1gxCwBIPWTFbDprxkkc9sR4Q9YkVsSK
2LAiVswCAHKZyorZuNeMhSxPC9nuE9tfdivFQjaMiBWzAABTWYa+ZhxQyDLXkPUX3DRWyO4XsqFE
MQBAzIpZQbtlzApZnhKyIlbEilgTWQCAmLVibDKbQcgOnHR80EFH3DZkrRNbKRax4cesiAUAmMoy
5JgNImQv5cx9YGdOON771jPcLmRFrGmskA0/ZkUsAEDMMvSYPTdke4E6cNuaQO6jKmRfD1kRK2JF
bPgxK2IBALnFrBXjOGM2sPvIdkO2fW/W7u93fm9smssgQlbEWikWseHHrIgFAJjKeg8Zy+FPJ4Vs
93rXgUlsbxo7dFuex5g1lQ0zZEWsaayQDT9mRSwAQMyK2Zhi9pyQbU9jJw5sqqti/uPasevwp+BC
VsSKWBEbfsyKWACAkLVifPaK8dqgPSVkb4c7DU5Zh6atCz/OenFQIStirRSL2PBjVsQCAISsqWyM
18ueELILw/NhrXhk9bgXxtMfx3NC1l9Q01ghG0fMAgAgZsVsLGvGJ4Rs6/rYqVXghevHQjbMkBWx
IlbIxhWzAAAIWSErZDcI2Xuczh/iJGTDClkrxUJWyMYVtAAAiFkxG1vMnhuyo6vFS6+PXfr1eFTI
iljXxYpYAAAQe8w6+Cn8w5/OvUZ2yW135uLUqcXBhKyIPT9iXRsLANgamxswlfV+M8TDn045tbh9
W52hteH2WnFR1QvXiuc/lseErL+A1omFLACkEbCupYeYFbOhrhmfcx/ZhxOJOzHbPuRpZq344T6z
ro89LWRNYkWsiAWAtCNWzCLXmLViHO5k9pyQ7UxSxxyfsLauizWNPTVku3vs/tK5LlbEAkCaEStm
YSrr/WdIMXtayM7G7NC1sZ1J7ptrY4MJWX/RTGOFLACkF7Fzvw6IWZ4Vs6eG7Ficjt5uZyhkRexp
IStiRayIBYD0I1bMQshaMQ4xZs8P2WejV8CeGrLWia0Ui1gAyCdixSxyD1lT2fAOf4orZBlEyIpY
01ghCwD5RayYhZgVsyHFrJDlqpAVsSJWxAJAvhErZpF7zFoxDmfF+I9ClqtD1l8kK8VCFgDyjFgx
C1NZIRtKzApZPjWR5bG2QzZmAQDxR6yYxRak8L7Ge9TzFbIUskJWyAJAhiEbShRDyApZClnuFrIA
ACCtkDWRBRArvWYRbhSyAACIWRELQMhSyAIAgCRiVsQCELIUsgAAIJqYFbEAhCyFLAAAiCZmRSwA
IUshCwAAoolZEQtAyFLIAgCAaGJWxAIQshSyAAAgmpgVsQCELIUsAACINmYBQMhSyAIAgGhiFgCE
LIUsAACIJmgBQMhSyAIAAACAkKWQBQAAACBkSSELAAAAQMhSyAIAAACAkKWQBQAAACBkhRuFLAAA
AAAhSyELAAAAAEKWQhYAAACAkBWyFLIAAAAAhCyFLAAAAAAIWQpZAAAAAEJWyFLIAgAAABCyFLIA
AAAAIGQpZAEAAAAIWSFLIQsAAABAyFLIAgAAAICQpZAFAAAAIGSFLIUsAAAAACFLIQsAAAAAQpZC
FgAAAICQFbIUsgAAAACELIUsAAAAAAhZClkAAAAAQlbIUsgCAAAAELIUsgAAAAAgZClkAQAAAEDI
UsgCAAAAELIUsgAAAAAgZClkAQAAAEDIUsgCAAAAELIUsgAAAAAgZClkAQAAAEDIUsgCAAAAELIU
sgAAAAAgZClkAQAAAEDIUsgCAAAAELIUsgAAAAAgZClkAQAAAEDIUsgCAAAAELIUsgAAAAAgZClk
AQAAAEDIUsgCAAAAELIUsgAAAAAgZClkAQAAAEDIUsgCAAAAELIUsgAAAAAgZClkAQAAAEDIUsgC
AAAAELIUsgAAAAAgZClkAQAAAEDIUsgCAAAAELIUsgAAAAAgZClkAQAAAEDIUsgCAAAAELIUsgAA
AAAgZClkAQAAAEDIUsgCAAAAELIUsgAAAAAgZClkAQAAAEDIUsgCAAAAELIUsgAAAAAgZClkAQAA
AEDIUsgCAAAAELIUsgAAAAAgZClkAQAAAEDIUsgCAAAAELIUsgAAAAAgZClkAQAAAEDIUsgCAAAA
ELIUsgAAAAAgZClkAQAAAEDIUsgCAAAAELIUskIWAAAAgJClkAUAAAAAIUshCwAAAEDIUsgKWQAA
AABClkIWAAAAAIQshSwAAAAAIUsKWQAAAABClkIWAAAAAIRsytZVU/zE5KNFU9VCFgAAAICQFY7B
eGnKwYDtWjYXIQsAAABAyDKOiN0/ZoUsAAAAACHLWeuqeAjVoqp7H3MpOzFbXoQsAAAAACHL86ex
5WVp8O4zlRWyAAAAAIQsp72UK6asdVMVy6JXyAIAAAAQstx9rXhopXhqxVjIAgAAABCyDN57yO5z
Ox4hCwAAAEDIcp/raYuqqV0jCwAAAEDIMqU1ZCELAAAAQMjyPOuqKZ6Yxr6tuj8tSZIkSYalkE0h
YlfedscTnyRJkqSQ5Xm359np3rF7OvbkI3PQ85+e/57/9PwnPfd3+D4ebBHrhZz0/Cc9/0nPf1LI
cuPb7Ox3QrEXctLzn/T8Jz3/SSHLDaybqmhFbHnxZCY9/0nPf9Lzn/TcF7IxHOq03y12vJCTnv+k
5z/p+U8KWW4csUVT1Z7MpOc/6flPev6TnvtCNlgvTZlgxHohpxdzz396/nss6PlPeu4L2QyuiS0v
nsyk5z/p+U96/pOe+0I2ZB9usbPOGKLXCzm9mHv+0/Of9PwnPfeFbMLTWCFLejEnPf9Jz3/Sc1/I
RnRtrJAlvZiTnv+k5z/puS9kSZIkSZJpBbMHgSRJkiQpZEmSJEmSFLIkSZIkSQpZkiRJkqSQJUmS
JElSyJIkSZIkKWRJkiRJkkKWJEmSJEkhS5IkSZKkkCVJkiRJClmSJEmSJIUsSZIkSZJClkFZV03x
9ta8/ba8eDyYx3P90aKpao8PU/HSlAPP86KqPTb0Ou8xovf4QpZpvuERsszpjX3fsrl4vBixl3Lu
Oe7NPL3Oe52n9/hClgm+6RGyzPfNjTc5jNu6KjzH6XXe3wHysPf4QpbneSl7L+5Clqm/uR9ar+xN
scqLx45xr1MWVVNPvd57jtPrvMeO3uMLWab0r5dClrmu1Ty+EfKv9Yz4X97H3qA/xK4VY3qd9zpP
7/GFLKOzbqri/kJetV7YhSyT/RfJ2X99b/+98HeBsb5pmX5z3n4j7/Anep33+NF7fCHLaFdw/jyp
ayHLDJ7rS960t6da/i4wyrXiuTfy7Y/trh+TXudJ7/GFLGN4w3N9wReyZPcNjrVLpvpG/vFf661W
0us86T2+kGVc6watf4kXsmRnPdOkihH/C/zykPVGnl7nPSb0Hl/IMuJ/hRSypGsHmcJr+7LXcBMp
ep33Ok/v8YUsozwMofviLWRpHcd1g8xnVVLI0uu813l6jy9kmcQqjZClNzeuGWSOIes1n17nSe/x
hSyjeJMz/OItZOlfMb25oYks6XWe9B5fyPKYf3kZ9f7mZMkTWMgy1ee/NzcUskKWItbrPFO/5vus
9/hClvu9kV94b0Ehy9xCtr1a6Vop5vBm5q5Ti5nbP/B4nWfi6/InvscXstztjXz7yfuMTvRjeiHb
fhM//eJPxjh1ch9Z0us88/oHzDPf4wtZJv8kJ8M77MPzm/n9y3zvY02p6HWe9B5fyNKTnIzlzY11
Sqa8qTA9ZXUfTXqdJ73HF7LM9PoqMuY3+d7cMIPrAcemst7o0+s86T2+a2TpSU7Gd62U5zdzWans
rQ0/nN7qukF6nSe9xxey9CQnw7X75n2F/i4w3VUzhzzR67zXeXqPL2TpSU5G8a/03uAwuxXjV+6z
THqdJ73HF7IUsuTZ10x5g0PPfYc70eu813l6jy9kSZIkSZLZKmRJkiRJkkKWJEmSJEkhS5IkSZKk
kCVJkiRJClmSJEmSJIUsSZIkSZJCliRJkiQpZEmSDMhLebsZe1HVHo9NvTTlz2P7VlRNfdrXiPfx
qwafk3VTFT+PyVvZXDzXSFLIkiSFLIXs2V7KqeekkCVJIUuSFLJCVshG9ZwUsiQpZEmSQlbIClnP
SZIUsiRJigYKWc9JkhSyJEmKBiHrOUmSFLIkSSG7QzS0vmbb8vJEvL11r4XcOOz2+FnLy8oI3eBr
jPw57l/nea8HL92+f+97FU1VT3xez+GPH/0z9P6brLhG9uX/viQpZEmSTDxkhwJ0LEiHrati8vOL
qtooZHf+Wf/+bPMR+vLXqKummP1zvPbf9iFkB8PwMUzn/hu+jf15Ng3Z1//7kqSQJUky+ZBdEg4z
ATETMrMhdODPuijWynIyQl//Gmv+HM9PIe8hWwxHc2vquzhih55zm4XsBs9FkhSyJEmmH7LdNdLu
1+oFTm/ltRsfncAYipwnQ3bzn3XJZHEuQp/4Go8/51CQtYNvu8dr/Os8/pmGn08zf+5Fz8npkH39
vy9JClmSJNMP2Yf11pHrH2c+7iEuxkKpu0b7TJgF8rNu8TXawTY+bX39nqsPYbj0Ot2pOHz4cw38
TK+E7Ab/fUlSyJIkmUHIPkTZzHSr/bHt77csyhYG4K4/azuipgNo/Gfd4mu8/lg8E7LbHAjWnspu
G7JbPBdJUsiSJJlByC6N0N4kbOhk3rmpYfvzn4i3MH7Wjf68E9eUbnkq76rHbNLOqvMOIfv6f1+S
FLIkSWYQssuni+NhtuaWOq/cfieUn3W7P+/4LW62m6Lev8eKFdzFB3dtGbJb/PclSSFLkmRmIbvk
GsyBMFsVFFuF7Ik/68Z/3qUnBb8+cV8Zh6eG7JP/fUlSyJIkaSJrIrvvRHb82tPtYnZ5yM59/2tc
7nWNrIksSQpZkqSQ3eMaysGTbQO9Rna3n/WoP+9AWL70mK04mGryz7XfYU+v//clSSFLkmQWIbvm
pNjhE3AfDwEK5dTi/X7Wrb/G3BrtinB+OmRXTEMfrp8979Ti7U9jJkkhS5JkNCF72L1ZuxPGkO8j
O/OzbvE1lodYSCHbnRK7jyxJClmSJM8I2X/6p+d2v1bvQKJevM0EztAhQk9e1xjGz7rB1+ieDDw4
gex8nydWaJeuFj8+rv1AHT6UauBrtv9cg/+Np6fRr//3JUkhS5JkNCH79tJps/MHDc1eP7n2Z3k6
QI75WYuqmj6oaYOvseT2O28vTGPXhOxzz6WBrzly8vF9BXturXqD/74kKWRJkswhZJcGxHQ4zN1K
ZjYON43ZmciZeuz+/mwLThx++Ws8Xm+7Khi3Dtl/lt7X9jJzjfDwn2n4OuWx/0Yb/PclSSFLkmQO
ITv9NWdPkZ2MkJ/v157WbXHS7Ms/60B0DZ1wPBndW3yN8XBb/md5PWSnJqoPK76zJwZPPSYrDrp6
+b8vSQpZkiT5qluHLEmSQpYkSb429ZuelrllCkmSQpYkyeBCdmyFdcnHkCRJIUuS5PErw29LDgwy
jSVJUsiSJHm2Cw+eErEkSQpZkiQDXjN+mzndliRJClmSJEmSpJAlSZIkSVLIkiRJkiQpZEmSJEmS
Kfj/zFS4GhP8I6IAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Death Hcy versus placebo.JPG" FILE_TYPE="JPG" ID="FIG-10" MODIFIED="2017-08-08 10:43:03 -0500" MODIFIED_BY="[Empty name]" NO="10" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial Sequential Analysis for homocysteine-lowering interventions versus placebo on death from any cause. The diversity-adjusted required information size (DARIS) was calculated based on an expected relative risk reduction (RRR) of 12% from proportion event in control (Pc) group of 11.7% with an alpha of 5% and beta of 20%. Cumulative Z-curve (blue line) reached futility area which means that no more trials are needed.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot death 3 Jan 2016.PNG" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2017-08-08 10:00:57 -0500" MODIFIED_BY="[Empty name]" NO="11" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of comparison: 1 Homocysteine-lowering interventions versus placebo, outcome: 1.4 Death from any cause.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7IAAAKlCAYAAAD2JNBjAAA9C0lEQVR42u3dy3HjSAItUNkxdjDg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</FILE>
</FIGURE>
<FIGURE FILENAME="Contour-enhanced funnel plots for meta-analysis of death 3 Jan 2016.PNG" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2017-08-08 10:01:15 -0500" MODIFIED_BY="[Empty name]" NO="12" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Contour-enhanced funnel plot of comparison: 1 Homocysteine-lowering interventions versus placebo, outcome: 1.4 Death from any cause.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA7cAAAKqCAYAAADhW6nyAABF9ElEQVR42u3du3HdWKKGUUYFg9HA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</FILE>
</FIGURE>
<FIGURE FILENAME="Cancer.JPG" FILE_TYPE="JPG" ID="FIG-13" MODIFIED="2017-08-08 10:43:11 -0500" MODIFIED_BY="[Empty name]" NO="13" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial Sequential Analysis for homocysteine-lowering interventions versus placebo on adverse events (cancer). The diversity-adjusted required information size (DARIS) was calculated based on an expected relative risk reduction (RRR) of 10% from proportion event in control (Pc) group of 8.49% with an alpha of 5% and beta of 20%. Cumulative Z-curve (blue line) reached futility area which means that no more trials are needed.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2017-08-04 09:49:05 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2017-08-04 09:49:02 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-10-30 10:27:56 -0500" MODIFIED_BY="[Empty name]">Search strategies 2008</TITLE>
<APPENDIX_BODY MODIFIED="2017-08-04 09:49:02 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<P>#1 MeSH descriptor Vitamin B Complex explode all trees<BR/>#2 &#8221;vitamin b*&#8220;<BR/>#3 folic next acid in Title, Abstract or Keywords<BR/>#4 folate* in Title, Abstract or Keywords<BR/>#5 (homocyst* near/6 lower*)<BR/>#6 (homocyst* near/6 reduc*)<BR/>#7 pyridoxin*<BR/>#8 cobalamin*<BR/>#9 cyanocobalamin*<BR/>#10 pyridoxol*<BR/>#11 MeSH descriptor Vitamins this term only<BR/>#12 (vitamin* and homocyst*)<BR/>#13 multivitamin*<BR/>#14 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13)<BR/>#15 MeSH descriptor Cardiovascular Diseases this term only<BR/>#16 MeSH descriptor Myocardial Ischemia explode all trees<BR/>#17 MeSH descriptor Brain Ischemia explode all trees<BR/>#18 MeSH descriptor Cerebrovascular Disorders this term only<BR/>#19 (coronary near/6 disease)<BR/>#20 angina<BR/>#21 myocardial next infarct*<BR/>#22 heart next infarct*<BR/>#23 (stroke or strokes)<BR/>#24 (cerebr* near/6 accident*)<BR/>#25 (cerebr* near/6 infarct*)<BR/>#26 (brain near/6 infarct*)<BR/>#27 apoplexy<BR/>#28 cardiovascular next disease*<BR/>#29 (cardiovascular near/6 event*)<BR/>#30 MeSH descriptor Hyperhomocysteinemia explode all trees<BR/>#31 hyperhomocyst*<BR/>#32 cva<BR/>#33 (#15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25)<BR/>#34 (#26 or #27 or #28 or #29 or #30 or #31 or #32)<BR/>#35 (#33 or #34)<BR/>#36 (#14 and #35)<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">LILACS (accessed through Biblioteca Virtual em Saúde)</HEADING>
<P>((Pt ENSAYO CONTROLADO ALEATORIO OR Pt ENSAYO CLINICO CONTROLADO OR Mh ENSAYOS CONTROLADOS ALEATORIOS OR Mh DISTRIBUCIÓN ALEATORIA OR Mh METODO DOBLE CIEGO OR Mh METODO SIMPLECIEGO OR Pt ESTUDIO MULTICÉNTRICO) or ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw clinic$)) AND NOT ((Ct ANIMALES OR Mh ANIMALES OR Ct CONEJOS OR Ct RATÓN OR MH Ratas OR MH Primates OR MH Perros OR MH Conejos OR MH Porcinos) AND NOT (Ct HUMANO AND Ct ANIMALES)) [Palavras] and MH Vitamina B 12 OR Cobamidas OR Hidroxocobalamina OR Complejo Vitamínico B OR Ácido Fólico OR Ácidos Pteroilpoliglutámicos OR Tetrahidrofolatos OR Formiltetrahidrofolatos OR Vitamina B 6 OR Piridoxal OR Fosfato de Piridoxal OR Piridoxamina OR Piridoxina OR Homocisteína OR Vitaminas or TW vitamin$ or tw cobalamin$ or tw cianocobalamin$ or tw cyanocobalam$ or tw cobamid$ or tw hidroxocobalam$ or tw Hydroxocobalam$ or ((tw complejo or tw complex$) and tw vitamin$ and tw b) or (tw acid$ and (tw folic$ or tw ptero$)) or tw Tetrahidrofolatos or tw Formiltetrahidrofolatos or (tw vitamin$ or (tw b or tw b6 or tw b12)) or tw Piridoxal or tw Pyridoxal or ((tw Fosfat$ or tw phosphate$) and (tw Piridoxal or tw pyridoxal)) or tw Piridox$ or tw Pyridox$ or tw Homocisteína or tw Homocysteine) AND (MH Enfermedades Cardiovasculares or Isquemia Miocárdica or Ex C14.280.647$ or Isquemia Encefálica or Ex C10.228.140.300.150$ or Trastornos Cerebrovasculares or hiperhomocisteinemia or Accidente Cerebrovascular or ((tw apoplexia or tw derrame or tw trastorno$ or tw accident$ or tw acidente or tw stroke$ or tw disease$ or tw enfermedad$ or tw doenca$ or tw event$ or tw infart$ or tw isquemia or tw disorder$) and (tw miocardio or tw myocard$ or tw cerebr$ or tw cardiovascul$ or tw heart or tw cardiovascul$ or tw encefal$)) or tw hyperhomocyst$ or tw hiperhomocisteinemia) [Palavras]</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE</HEADING>
<P>1 exp Vitamin B Complex/<BR/>2 vitamin b.tw.<BR/>3 folic acid.tw.<BR/>4 folate$.tw.<BR/>5 ((homocystein$ or homocystin$) adj3 (low$ or reduc$)).tw.<BR/>6 pyridoxin$.tw.<BR/>7 cobalamin$.tw.<BR/>8 cyanocobalamin$.tw.<BR/>9 pyridoxol$.tw.<BR/>10 Vitamins/<BR/>11 or/1-10<BR/>12 Cardiovascular Diseases/<BR/>13 exp Myocardial Ischemia/<BR/>14 exp Brain Ischemia/<BR/>15 Cerebrovascular Disorders/<BR/>16 (coronary adj3 disease$).tw.<BR/>17 angina.tw.<BR/>18 myocardial infarct$.tw.<BR/>19 heart infarct$.tw.<BR/>20 heart attack$.tw.<BR/>21 (stroke or strokes).tw.<BR/>22 (cerebr$ adj3 (accident$ or infarct$)).tw.<BR/>23 (brain adj3 infarct$).tw.<BR/>24 apoplexy.tw.<BR/>25 (cardiovascular adj2 (disease$ or event$)).tw.<BR/>26 Hyperhomocysteinemia/<BR/>27 hyperhomocyst?in?emi$.tw.<BR/>28 or/12-27<BR/>29 11 and 28<BR/>30 randomized controlled trial.pt.<BR/>31 controlled clinical trial.pt.<BR/>32 Randomized controlled trials/<BR/>33 random allocation/<BR/>34 double blind method/<BR/>35 single-blind method/<BR/>36 or/30-35<BR/>37 exp animal/ not humans/<BR/>38 36 not 37<BR/>39 clinical trial.pt.<BR/>40 exp Clinical Trials as Topic/<BR/>41 (clin$ adj25 trial$).ti,ab.<BR/>42 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ti,ab.<BR/>43 placebos/<BR/>44 placebo$.ti,ab.<BR/>45 random$.ti,ab.<BR/>46 research design/<BR/>47 or/39-46<BR/>48 47 not 37<BR/>49 38 or 48<BR/>50 49 and 29</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Embase</HEADING>
<P>1 exp Vitamin B Group/<BR/>2 vitamin b.tw.<BR/>3 folic acid.tw.<BR/>4 folate$.tw.<BR/>5 ((homocystein$ or homocystin$) adj3 (low$ or reduc$)).tw.<BR/>6 pyridoxin$.tw.<BR/>7 cobalamin$.tw.<BR/>8 cyanocobalamin$.tw.<BR/>9 pyridoxol$.tw.<BR/>10 Vitamins/<BR/>11 or/1-10<BR/>12 Cardiovascular Diseases/<BR/>13 exp ischaemic heart disease/<BR/>14 exp Coronary Artery Disease/<BR/>15 exp Brain Ischemia/<BR/>16 cerebrovascular disease/<BR/>17 stroke/<BR/>18 cerebrovascular accident/<BR/>19 (coronary adj3 disease$).tw.<BR/>20 angina.tw.<BR/>21 myocardial infarct$.tw.<BR/>22 heart infarct$.tw.<BR/>23 heart attack$.tw.<BR/>24 (stroke or strokes).tw.<BR/>25 (cerebr$ adj3 (accident$ or infarct$)).tw.<BR/>26 (brain adj3 infarct$).tw.<BR/>27 apoplexy.tw.<BR/>28 (cardiovascular adj2 (disease$ or event$)).tw.<BR/>29 Hyperhomocysteinemia/<BR/>30 hyperhomocyst?in?emi$.tw.<BR/>31 or/12-30<BR/>32 11 and 31<BR/>33 controlled clinical trial/<BR/>34 random$.tw.<BR/>35 randomized controlled trial/<BR/>36 follow-up.tw.<BR/>37 double blind procedure/<BR/>38 placebo$.tw.<BR/>39 placebo/<BR/>40 factorial$.ti,ab.<BR/>41 (crossover$ or cross-over$).ti,ab.<BR/>42 (double$ adj blind$).ti,ab.<BR/>43 (singl$ adj blind$).ti,ab.<BR/>44 assign$.ti,ab.<BR/>45 allocat$.ti,ab.<BR/>46 volunteer$.ti,ab.<BR/>47 Crossover Procedure/<BR/>48 Single Blind Procedure/<BR/>49 or/33-48<BR/>50 32 and 49</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Web of Science</HEADING>
<P># 11 TS=(#10 and (random* or blind* or placebo* or comparative or comparison or prospective or controlled or trial or evaluation or rct))<BR/># 10 #7 or #8 or #9<BR/># 9 TS=(#6 and (&#8221;cerebrovascular accident*&#8220; or hyperhomocyst*))<BR/># 8 TS=(#6 and (angina or stroke or strokes or cva or infarction*))<BR/># 7 TS=(#6 and (cardiovascular or myocardial or coronary or cardiac or &#8221;heart disease*&#8220;))<BR/># 6 #1 or #2 or #3 or #4 or #5<BR/># 5 TS=(homocyst* same (lower* or reduc*))<BR/># 4 TS=(vitamin* and homocyst*)<BR/># 3 TS=folate*<BR/># 2 TS=&#8221;vitamin B&#8220;<BR/># 1 TS=(pyridoxin* or cobalamin* or cyanocobalamin* or pyridoxol* or &#8221;folic acid&#8220;)<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2017-08-04 09:49:03 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-10-30 10:28:05 -0500" MODIFIED_BY="[Empty name]">Search strategies 2012</TITLE>
<APPENDIX_BODY MODIFIED="2017-08-04 09:49:03 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<P>#1 MeSH descriptor Vitamin B Complex explode all trees<BR/>#2 (vitamin b)<BR/>#3 folic acid<BR/>#4 folate*<BR/>#5 ((homocystein* or homocystin*) near/3 (low* or reduc*))<BR/>#6 (pyridoxin*)<BR/>#7 (cobalamin*)<BR/>#8 (cyanocobalamin*)<BR/>#9 (pyridoxol*)<BR/>#10 MeSH descriptor Vitamins, this term only<BR/>#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)<BR/>#12 MeSH descriptor Cardiovascular Diseases, this term only<BR/>#13 MeSH descriptor Myocardial Ischemia explode all trees<BR/>#14 MeSH descriptor Brain Ischemia explode all trees<BR/>#15 MeSH descriptor Cerebrovascular Disorders, this term only<BR/>#16 (coronary near/3 disease*)<BR/>#17 (angina)<BR/>#18 (myocardial infarct*)<BR/>#19 (heart infarct*)<BR/>#20 (heart attack*)<BR/>#21 (stroke or strokes)<BR/>#22 (cerebr* near/3 (accident* or infarct*))<BR/>#23 (brain near/3 infarct*)<BR/>#24 (apoplexy)<BR/>#25 (cardiovascular near/2 (disease* or event*))<BR/>#26 MeSH descriptor Hyperhomocysteinemia, this term only<BR/>#27 hyperhomocyst?in?emi*<BR/>#28 (#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27)<BR/>#29 (#11 AND #28)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE</HEADING>
<P>1 exp Vitamin B Complex/<BR/>2 vitamin b.tw.<BR/>3 folic acid.tw.<BR/>4 folate$.tw.<BR/>5 ((homocystein$ or homocystin$) adj3 (low$ or reduc$)).tw.<BR/>6 pyridoxin$.tw.<BR/>7 cobalamin$.tw.<BR/>8 cyanocobalamin$.tw.<BR/>9 pyridoxol$.tw.<BR/>10 Vitamins/<BR/>11 or/1-10<BR/>12 Cardiovascular Diseases/<BR/>13 exp Myocardial Ischemia/<BR/>14 exp Brain Ischemia/<BR/>15 Cerebrovascular Disorders/<BR/>16 (coronary adj3 disease$).tw.<BR/>17 angina.tw.<BR/>18 myocardial infarct$.tw.<BR/>19 heart infarct$.tw.<BR/>20 heart attack$.tw.<BR/>21 (stroke or strokes).tw.<BR/>22 (cerebr$ adj3 (accident$ or infarct$)).tw.<BR/>23 (brain adj3 infarct$).tw.<BR/>24 apoplexy.tw.<BR/>25 (cardiovascular adj2 (disease$ or event$)).tw.<BR/>26 Hyperhomocysteinemia/<BR/>27 hyperhomocyst?in?emi$.tw.<BR/>28 or/12-27<BR/>29 11 and 28<BR/>30 randomized controlled trial.pt.<BR/>31 controlled clinical trial.pt.<BR/>32 randomized.ab.<BR/>33 placebo.ab.<BR/>34 drug therapy.fs.<BR/>35 randomly.ab.<BR/>36 trial.ab.<BR/>37 groups.ab.<BR/>38 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37<BR/>39 exp animals/ not humans.sh. (3663238)<BR/>40 38 not 39<BR/>41 29 and 40<BR/>42 (200808* or 200809* or 20081* or 2009* or 2010* or 2011* or 2012*).ed.<BR/>43 41 and 42</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Embase</HEADING>
<P>1 exp Vitamin B Complex/<BR/>2 vitamin b.tw.<BR/>3 folic acid.tw.<BR/>4 folate$.tw.<BR/>5 ((homocystein$ or homocystin$) adj3 (low$ or reduc$)).tw.<BR/>6 pyridoxin$.tw.<BR/>7 cobalamin$.tw.<BR/>8 cyanocobalamin$.tw.<BR/>9 pyridoxol$.tw.<BR/>10 Vitamins/<BR/>11 or/1-10<BR/>12 Cardiovascular Diseases/<BR/>13 exp Myocardial Ischemia/<BR/>14 exp Brain Ischemia/<BR/>15 Cerebrovascular Disorders/<BR/>16 (coronary adj3 disease$).tw.<BR/>17 angina.tw.<BR/>18 myocardial infarct$.tw.<BR/>19 heart infarct$.tw.<BR/>20 heart attack$.tw.<BR/>21 (stroke or strokes).tw.<BR/>22 (cerebr$ adj3 (accident$ or infarct$)).tw.<BR/>23 (brain adj3 infarct$).tw.<BR/>24 apoplexy.tw.<BR/>25 (cardiovascular adj2 (disease$ or event$)).tw.<BR/>26 Hyperhomocysteinemia/<BR/>27 hyperhomocyst?in?emi$.tw.<BR/>28 or/12-27<BR/>29 11 and 28<BR/>30 random$.tw.<BR/>31 factorial$.tw.<BR/>32 crossover$.tw.<BR/>33 cross over$.tw.<BR/>34 cross-over$.tw.<BR/>35 placebo$.tw.<BR/>36 (doubl$ adj blind$).tw.<BR/>37 (singl$ adj blind$).tw.<BR/>38 assign$.tw.<BR/>39 allocat$.tw.<BR/>40 volunteer$.tw.<BR/>41 crossover procedure/<BR/>42 double blind procedure/<BR/>43 randomized controlled trial/<BR/>44 single blind procedure/<BR/>45 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44<BR/>46 (animal/ or nonhuman/) not human/<BR/>47 45 not 46<BR/>48 29 and 47<BR/>49 (200808* or 200809* or 20081* or 2009* or 2010* or 2011* or 2012*).dd.<BR/>50 48 and 49</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Web of Science</HEADING>
<P>#24 #23 AND #22<BR/>#23 Topic=((random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*))<BR/>#22 #21 AND #9<BR/>#21 #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11<BR/>#20 Topic=(hyperhomocyst$in$emi*)<BR/>#19 Topic=((cardiovascular near/2 (disease* or event*)))<BR/>#18 Topic=(apoplexy)<BR/>#17 Topic=((brain near/3 infarct*))<BR/>#16 Topic=((cerebr* near/3 (accident* or infarct*)))<BR/>#15 Topic=((stroke or strokes))<BR/>#14 Topic=(heart attack*)<BR/>#13 Topic=(heart infarct*)<BR/>#12 Topic=(myocardial infarct*)<BR/>#11 Topic=(angina)<BR/>#10 Topic=((coronary near/3 disease*))<BR/>#9 #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1<BR/>#8 Topic=(pyridoxol*)<BR/>#7 Topic=(cyanocobalamin*)<BR/>#6 Topic=(cobalamin*)<BR/>#5 Topic=(pyridoxin*)<BR/>#4 Topic=(((homocystein*) near/3 (low$ or reduc*))) OR Topic=(((homocystin*) near/3 (low or reduc*)))<BR/>#3 Topic=(folate*)<BR/>#2 Topic=("folic acid")<BR/>#1 Topic=("vitamin b")</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2017-08-04 09:49:04 -0500" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-10-30 10:28:15 -0500" MODIFIED_BY="[Empty name]">Search strategies 2014</TITLE>
<APPENDIX_BODY MODIFIED="2017-08-04 09:49:04 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<P>#1 MeSH descriptor Vitamin B Complex explode all trees<BR/>#2 (vitamin b)<BR/>#3 folic acid<BR/>#4 folate*<BR/>#5 ((homocystein* or homocystin*) near/3 (low* or reduc*))<BR/>#6 (pyridoxin*)<BR/>#7 (cobalamin*)<BR/>#8 (cyanocobalamin*)<BR/>#9 (pyridoxol*)<BR/>#10 MeSH descriptor Vitamins, this term only<BR/>#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)<BR/>#12 MeSH descriptor Cardiovascular Diseases, this term only<BR/>#13 MeSH descriptor Myocardial Ischemia explode all trees<BR/>#14 MeSH descriptor Brain Ischemia explode all trees<BR/>#15 MeSH descriptor Cerebrovascular Disorders, this term only<BR/>#16 (coronary near/3 disease*)<BR/>#17 (angina)<BR/>#18 (myocardial infarct*)<BR/>#19 (heart infarct*)<BR/>#20 (heart attack*)<BR/>#21 (stroke or strokes)<BR/>#22 (cerebr* near/3 (accident* or infarct*))<BR/>#23 (brain near/3 infarct*)<BR/>#24 (apoplexy)<BR/>#25 (cardiovascular near/2 (disease* or event*))<BR/>#26 MeSH descriptor Hyperhomocysteinemia, this term only<BR/>#27 hyperhomocyst?in?emi*<BR/>#28 (#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27)<BR/>#29 (#11 AND #28)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE</HEADING>
<P>1 exp Vitamin B Complex/<BR/>2 vitamin b.tw.<BR/>3 folic acid.tw.<BR/>4 folate$.tw.<BR/>5 ((homocystein$ or homocystin$) adj3 (low$ or reduc$)).tw.<BR/>6 pyridoxin$.tw.<BR/>7 cobalamin$.tw.<BR/>8 cyanocobalamin$.tw.<BR/>9 pyridoxol$.tw.<BR/>10 Vitamins/<BR/>11 or/1-10<BR/>12 Cardiovascular Diseases/<BR/>13 exp Myocardial Ischemia/<BR/>14 exp Brain Ischemia/<BR/>15 Cerebrovascular Disorders/<BR/>16 (coronary adj3 disease$).tw.<BR/>17 angina.tw.<BR/>18 myocardial infarct$.tw.<BR/>19 heart infarct$.tw.<BR/>20 heart attack$.tw.<BR/>21 (stroke or strokes).tw.<BR/>22 (cerebr$ adj3 (accident$ or infarct$)).tw.<BR/>23 (brain adj3 infarct$).tw.<BR/>24 apoplexy.tw.<BR/>25 (cardiovascular adj2 (disease$ or event$)).tw.<BR/>26 Hyperhomocysteinemia/<BR/>27 hyperhomocyst?in?emi$.tw.<BR/>28 or/12-27<BR/>29 11 and 28<BR/>30 randomized controlled trial.pt.<BR/>31 controlled clinical trial.pt.<BR/>32 randomized.ab.<BR/>33 placebo.ab.<BR/>34 drug therapy.fs.<BR/>35 randomly.ab.<BR/>36 trial.ab.<BR/>37 groups.ab.<BR/>38 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37<BR/>39 exp animals/ not humans.sh. (3663238)<BR/>40 38 not 39<BR/>41 29 and 40<BR/>42 (2012* or 2013* or 2014*).ed.<BR/>43 41 and 42</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Embase</HEADING>
<P>1 exp Vitamin B Complex/<BR/>2 vitamin b.tw.<BR/>3 folic acid.tw.<BR/>4 folate$.tw.<BR/>5 ((homocystein$ or homocystin$) adj3 (low$ or reduc$)).tw.<BR/>6 pyridoxin$.tw.<BR/>7 cobalamin$.tw.<BR/>8 cyanocobalamin$.tw.<BR/>9 pyridoxol$.tw.<BR/>10 Vitamins/<BR/>11 or/1-10<BR/>12 Cardiovascular Diseases/<BR/>13 exp Myocardial Ischemia/<BR/>14 exp Brain Ischemia/<BR/>15 Cerebrovascular Disorders/<BR/>16 (coronary adj3 disease$).tw.<BR/>17 angina.tw.<BR/>18 myocardial infarct$.tw.<BR/>19 heart infarct$.tw.<BR/>20 heart attack$.tw.<BR/>21 (stroke or strokes).tw.<BR/>22 (cerebr$ adj3 (accident$ or infarct$)).tw.<BR/>23 (brain adj3 infarct$).tw.<BR/>24 apoplexy.tw.<BR/>25 (cardiovascular adj2 (disease$ or event$)).tw.<BR/>26 Hyperhomocysteinemia/<BR/>27 hyperhomocyst?in?emi$.tw.<BR/>28 or/12-27<BR/>29 11 and 28<BR/>30 random$.tw.<BR/>31 factorial$.tw.<BR/>32 crossover$.tw.<BR/>33 cross over$.tw.<BR/>34 cross-over$.tw.<BR/>35 placebo$.tw.<BR/>36 (doubl$ adj blind$).tw.<BR/>37 (singl$ adj blind$).tw.<BR/>38 assign$.tw.<BR/>39 allocat$.tw.<BR/>40 volunteer$.tw.<BR/>41 crossover procedure/<BR/>42 double blind procedure/<BR/>43 randomized controlled trial/<BR/>44 single blind procedure/<BR/>45 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44<BR/>46 (animal/ or nonhuman/) not human/<BR/>47 45 not 46<BR/>48 29 and 47<BR/>49 (2012* or 2013* or 2014*).dd.<BR/>50 48 and 49</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Web of Science</HEADING>
<P>#24 #23 AND #22<BR/>#23 Topic=((random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*))<BR/>#22 #21 AND #9<BR/>#21 #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11<BR/>#20 Topic=(hyperhomocyst$in$emi*)<BR/>#19 Topic=((cardiovascular near/2 (disease* or event*)))<BR/>#18 Topic=(apoplexy)<BR/>#17 Topic=((brain near/3 infarct*))<BR/>#16 Topic=((cerebr* near/3 (accident* or infarct*)))<BR/>#15 Topic=((stroke or strokes))<BR/>#14 Topic=(heart attack*)<BR/>#13 Topic=(heart infarct*)<BR/>#12 Topic=(myocardial infarct*)<BR/>#11 Topic=(angina)<BR/>#10 Topic=((coronary near/3 disease*))<BR/>#9 #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1<BR/>#8 Topic=(pyridoxol*)<BR/>#7 Topic=(cyanocobalamin*)<BR/>#6 Topic=(cobalamin*)<BR/>#5 Topic=(pyridoxin*)<BR/>#4 Topic=(((homocystein*) near/3 (low$ or reduc*))) OR Topic=(((homocystin*) near/3 (low or reduc*)))<BR/>#3 Topic=(folate*)<BR/>#2 Topic=("folic acid")<BR/>#1 Topic=("vitamin b")</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2017-08-04 09:49:05 -0500" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2017-06-01 13:33:25 -0500" MODIFIED_BY="Arturo J Martí-Carvajal">Search strategies 2017</TITLE>
<APPENDIX_BODY MODIFIED="2017-08-04 09:49:05 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<P>#1 MeSH descriptor Vitamin B Complex explode all trees</P>
<P>#2 (vitamin b)</P>
<P>#3 folic acid</P>
<P>#4 folate*</P>
<P>#5 ((homocystein* or homocystin*) near/3 (low* or reduc*))</P>
<P>#6 (pyridoxin*)</P>
<P>#7 (cobalamin*)</P>
<P>#8 (cyanocobalamin*)</P>
<P>#9 (pyridoxol*)</P>
<P>#10 MeSH descriptor Vitamins, this term only</P>
<P>#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)</P>
<P>#12 MeSH descriptor Cardiovascular Diseases, this term only</P>
<P>#13 MeSH descriptor Myocardial Ischemia explode all trees</P>
<P>#14 MeSH descriptor Brain Ischemia explode all trees</P>
<P>#15 MeSH descriptor Cerebrovascular Disorders, this term only</P>
<P>#16 (coronary near/3 disease*)</P>
<P>#17 (angina)</P>
<P>#18 (myocardial infarct*)</P>
<P>#19 (heart infarct*)</P>
<P>#20 (heart attack*)</P>
<P>#21 (stroke or strokes)</P>
<P>#22 (cerebr* near/3 (accident* or infarct*))</P>
<P>#23 (brain near/3 infarct*)</P>
<P>#24 (apoplexy)</P>
<P>#25 (cardiovascular near/2 (disease* or event*))</P>
<P>#26 MeSH descriptor Hyperhomocysteinemia, this term only</P>
<P>#27 hyperhomocyst?in?emi*</P>
<P>#28 (#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27)</P>
<P>#29 (#11 AND #28)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE OVID</HEADING>
<P>1 exp Vitamin B Complex/</P>
<P>2 vitamin b.tw.</P>
<P>3 folic acid.tw.</P>
<P>4 folate$.tw.</P>
<P>5 ((homocystein$ or homocystin$) adj3 (low$ or reduc$)).tw.</P>
<P>6 pyridoxin$.tw.</P>
<P>7 cobalamin$.tw.</P>
<P>8 cyanocobalamin$.tw.</P>
<P>9 pyridoxol$.tw.</P>
<P>10 Vitamins/</P>
<P>11 or/1-10</P>
<P>12 Cardiovascular Diseases/</P>
<P>13 exp Myocardial Ischemia/</P>
<P>14 exp Brain Ischemia/</P>
<P>15 Cerebrovascular Disorders/</P>
<P>16 (coronary adj3 disease$).tw.</P>
<P>17 angina.tw.</P>
<P>18 myocardial infarct$.tw.</P>
<P>19 heart infarct$.tw.</P>
<P>20 heart attack$.tw.</P>
<P>21 (stroke or strokes).tw.</P>
<P>22 (cerebr$ adj3 (accident$ or infarct$)).tw.</P>
<P>23 (brain adj3 infarct$).tw.</P>
<P>24 apoplexy.tw.</P>
<P>25 (cardiovascular adj2 (disease$ or event$)).tw.</P>
<P>26 Hyperhomocysteinemia/</P>
<P>27 hyperhomocyst?in?emi$.tw.</P>
<P>28 or/12-27</P>
<P>29 11 and 28</P>
<P>30 randomized controlled trial.pt.</P>
<P>31 controlled clinical trial.pt.</P>
<P>32 randomized.ab.</P>
<P>33 placebo.ab.</P>
<P>34 drug therapy.fs.</P>
<P>35 randomly.ab.</P>
<P>36 trial.ab.</P>
<P>37 groups.ab.</P>
<P>38 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37</P>
<P>39 exp animals/ not humans.sh. (3663238)</P>
<P>40 38 not 39</P>
<P>41 29 and 40</P>
<P>42 (2014* or 2015* or 2016*).ed.</P>
<P>43 41 and 42</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Embase OVID</HEADING>
<P>1 exp Vitamin B Complex/</P>
<P>2 vitamin b.tw.</P>
<P>3 folic acid.tw.</P>
<P>4 folate$.tw.</P>
<P>5 ((homocystein$ or homocystin$) adj3 (low$ or reduc$)).tw.</P>
<P>6 pyridoxin$.tw.</P>
<P>7 cobalamin$.tw.</P>
<P>8 cyanocobalamin$.tw.</P>
<P>9 pyridoxol$.tw.</P>
<P>10 Vitamins/</P>
<P>11 or/1-10</P>
<P>12 Cardiovascular Diseases/</P>
<P>13 exp Myocardial Ischemia/</P>
<P>14 exp Brain Ischemia/</P>
<P>15 Cerebrovascular Disorders/</P>
<P>16 (coronary adj3 disease$).tw.</P>
<P>17 angina.tw.</P>
<P>18 myocardial infarct$.tw.</P>
<P>19 heart infarct$.tw.</P>
<P>20 heart attack$.tw.</P>
<P>21 (stroke or strokes).tw.</P>
<P>22 (cerebr$ adj3 (accident$ or infarct$)).tw.</P>
<P>23 (brain adj3 infarct$).tw.</P>
<P>24 apoplexy.tw.</P>
<P>25 (cardiovascular adj2 (disease$ or event$)).tw.</P>
<P>26 Hyperhomocysteinemia/</P>
<P>27 hyperhomocyst?in?emi$.tw.</P>
<P>28 or/12-27</P>
<P>29 11 and 28</P>
<P>30 random$.tw.</P>
<P>31 factorial$.tw.</P>
<P>32 crossover$.tw.</P>
<P>33 cross over$.tw.</P>
<P>34 cross-over$.tw.</P>
<P>35 placebo$.tw.</P>
<P>36 (doubl$ adj blind$).tw.</P>
<P>37 (singl$ adj blind$).tw.</P>
<P>38 assign$.tw.</P>
<P>39 allocat$.tw.</P>
<P>40 volunteer$.tw.</P>
<P>41 crossover procedure/</P>
<P>42 double blind procedure/</P>
<P>43 randomized controlled trial/</P>
<P>44 single blind procedure/</P>
<P>45 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44</P>
<P>46 (animal/ or nonhuman/) not human/</P>
<P>47 45 not 46</P>
<P>48 29 and 47</P>
<P>49 (2014* or 2015* or 2016*).dd.</P>
<P>50 48 and 49</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Web of Science</HEADING>
<P>#26 #25 AND #24</P>
<P>#25 TS=((random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*))</P>
<P>#24 #23 AND #10</P>
<P>#23 #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11</P>
<P>#22 TS=(hyperhomocystein$emi*)</P>
<P>#21 TS=(hyperhomocystin$emi*)</P>
<P>#20 TS=(cardiovascular near/2 (disease* or event*))</P>
<P>#19 TS=(apoplexy)</P>
<P>#18 TS=((brain near/3 infarct*))</P>
<P>#17 TS=((cerebr* near/3 (accident* or infarct*)))</P>
<P>#16 TS=((stroke or strokes))</P>
<P>#15 TS=(heart attack*)</P>
<P>#14 TS=(heart infarct*)</P>
<P>#13 TS=(myocardial infarct*)</P>
<P>#12 TS=(angina)</P>
<P>#11 TS=((coronary near/3 disease*))</P>
<P>#10 #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1</P>
<P>#9 TS=(pyridoxol*)</P>
<P>#8 TS=(cyanocobalamin*)</P>
<P>#7 TS=(cobalamin*)</P>
<P>#6 TS=(pyridoxin*)</P>
<P>#5 TS=((homocystin*) near/3 (low or reduc*))</P>
<P>#4 TS=((homocystein*) near/3 (low$ or reduc*))</P>
<P>#3 TS=(folate*)</P>
<P>#2 TS=("folic acid")</P>
<P>#1 TS=("vitamin b")</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">LILACS (accessed through Biblioteca Virtual em Saúde)</HEADING>
<P>((Pt ENSAYO CONTROLADO ALEATORIO OR Pt ENSAYO CLINICO CONTROLADO OR Mh ENSAYOS CONTROLADOS ALEATORIOS OR Mh DISTRIBUCIÓN ALEATORIA OR Mh METODO DOBLE CIEGO OR Mh METODO SIMPLECIEGO OR Pt ESTUDIO MULTICÉNTRICO) or ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw clinic$)) AND NOT ((Ct ANIMALES OR Mh ANIMALES OR Ct CONEJOS OR Ct RATÓN OR MH Ratas OR MH Primates OR MH Perros OR MH Conejos OR MH Porcinos) AND NOT (Ct HUMANO AND Ct ANIMALES)) [Palavras] and MH Vitamina B 12 OR Cobamidas OR Hidroxocobalamina OR Complejo Vitamínico B OR Ácido Fólico OR Ácidos Pteroilpoliglutámicos OR Tetrahidrofolatos OR Formiltetrahidrofolatos OR Vitamina B 6 OR Piridoxal OR Fosfato de Piridoxal OR Piridoxamina OR Piridoxina OR Homocisteína OR Vitaminas or TW vitamin$ or tw cobalamin$ or tw cianocobalamin$ or tw cyanocobalam$ or tw cobamid$ or tw hidroxocobalam$ or tw Hydroxocobalam$ or ((tw complejo or tw complex$) and tw vitamin$ and tw b) or (tw acid$ and (tw folic$ or tw ptero$)) or tw Tetrahidrofolatos or tw Formiltetrahidrofolatos or (tw vitamin$ or (tw b or tw b6 or tw b12)) or tw Piridoxal or tw Pyridoxal or ((tw Fosfat$ or tw phosphate$) and (tw Piridoxal or tw pyridoxal)) or tw Piridox$ or tw Pyridox$ or tw Homocisteína or tw Homocysteine) AND (MH Enfermedades Cardiovasculares or Isquemia Miocárdica or Ex C14.280.647$ or Isquemia Encefálica or Ex C10.228.140.300.150$ or Trastornos Cerebrovasculares or hiperhomocisteinemia or Accidente Cerebrovascular or ((tw apoplexia or tw derrame or tw trastorno$ or tw accident$ or tw acidente or tw stroke$ or tw disease$ or tw enfermedad$ or tw doenca$ or tw event$ or tw infart$ or tw isquemia or tw disorder$) and (tw miocardio or tw myocard$ or tw cerebr$ or tw cardiovascul$ or tw heart or tw cardiovascul$ or tw encefal$)) or tw hyperhomocyst$ or tw hiperhomocisteinemia) [Palavras]</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2017-07-13 15:21:46 -0500" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2017-01-03 10:12:32 -0600" MODIFIED_BY="Arturo J Martí-Carvajal">Domains for assessing of risk of bias in included studies</TITLE>
<APPENDIX_BODY MODIFIED="2017-07-13 15:21:46 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Generation of the allocation sequence</HEADING>
<UL>
<LI>Low risk of bias, if the allocation sequence was generated by a computer or random number table, drawing of lots, tossing of a coin, shuffling of cards or throwing dice.</LI>
<LI>Unclear, if the trial was described as randomised but the method used for the allocation sequence generation was not described.</LI>
<LI>High risk of bias, if a system involving dates, names or admittance numbers was used for the allocation of patients. These studies are known as quasi-randomised and we excluded them from the review when assessing beneficial effects.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Low risk of bias, if the allocation of patients involved a central independent unit, on-site locked computer, identical-appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes.</LI>
<LI>Unclear, if the trial was described as randomised but the method used to conceal the allocation was not described.</LI>
<LI>High risk of bias, if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomised. We excluded the latter from the review when assessing beneficial effects.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding (or masking)</HEADING>
<P>We assessed each trial (as low, unclear or high risk) with regard to the following levels of blinding.</P>
<UL>
<LI>Blinding of clinician (person delivering treatment) to treatment allocation.</LI>
<LI>Blinding of participant to treatment allocation.</LI>
<LI>Blinding of outcome assessor to treatment allocation.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<UL>
<LI>Low risk of bias, if the numbers and reasons for dropouts and withdrawals in all intervention groups were described or it was specified that there were no dropouts or withdrawals.</LI>
<LI>Unclear, if the report gave the impression that there had been no dropouts or withdrawals but this was not specifically stated.</LI>
<LI>High risk of bias, if the number or reasons for dropouts and withdrawals were not described.</LI>
</UL>
<P>We further examined the percentage of dropouts overall in each trial and per randomisation arm and we evaluated whether intention-to-treat analysis was performed or could be performed from the published information.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective outcome reporting</HEADING>
<UL>
<LI>Low risk of bias, if pre-defined or clinically relevant and reasonably expected outcomes were reported on.</LI>
<LI>Unclear, if not all pre-defined or clinically relevant and reasonably expected outcomes were reported on or were not reported on fully, or it was unclear whether data on these outcomes were recorded or not.</LI>
<LI>High risk of bias, if one or more clinically relevant and reasonably expected outcomes were not reported on; data on these outcomes were likely to have been recorded.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other bias</HEADING>
<UL>
<LI>Low risk of bias, the trial appeared to be free of other components that could put it at risk of bias.</LI>
<LI>Unclear, the trial may or may not be free of other components that could put it at risk of bias.</LI>
<LI>High risk of bias, there were other factors in the trial that could put it at risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Overall risk of bias</HEADING>
<P>We considered studies to have an overall low risk of bias if they did not have high risk of bias in any of six individual domains (random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data or selective reporting), and if a definitive risk of bias assessment could be made for the majority (at least five of six) of domains. We did not include &#8216;Other bias&#8217; in our overall assessment.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2017-07-31 09:19:24 -0500" MODIFIED_BY="Heather Maxwell" NO="6">
<TITLE MODIFIED="2014-12-19 05:55:34 -0600" MODIFIED_BY="[Empty name]">Definitions of myocardial infarction (MI), stroke, unstable angina and death</TITLE>
<APPENDIX_BODY MODIFIED="2017-07-31 09:19:24 -0500" MODIFIED_BY="Heather Maxwell">
<TABLE COLS="6" ROWS="12">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Trial</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Myocardial infarction</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Stroke</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Angina pectoris</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Death</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P/>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-B_x002d_PROOF-2015" TYPE="STUDY">B-PROOF 2015</LINK>
</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-BVAIT-2009" TYPE="STUDY">BVAIT 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-CSPPT-2015" TYPE="STUDY">CSPPT 2015</LINK>
</P>
</TD>
<TD>
<P>Criteria for ischaemic symptoms or corresponding electrocardiographic changes plus evidence of myocardial damage.</P>
</TD>
<TD>
<P>Medical records and imaging data</P>
</TD>
<TD>
<P>Not measured</P>
</TD>
<TD>
<P>Evidence for death included death certificates from hospitals or reports of home visit by investigators</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-HOPE_x002d_2-2006" TYPE="STUDY">HOPE-2 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 of the following 3 criteria were met: typical symptoms, increased cardiac-enzyme levels and diagnostic electrocardiographic changes.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Focal neurologic deficit lasting more than 24 hours. Computed tomography or magnetic resonance imaging was recommended to identify the type of stroke (ischaemic or haemorrhagic). When these tools were not available, the stroke was classified as of uncertain type</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cardiovascular causes were unexpected deaths presumed to be due to ischaemic cardiovascular disease and occurring within 24 hours after the onset of symptoms without clinical or postmortem evidence of another cause, deaths from myocardial infarction or stroke within 7 days after the event, deaths associated with cardiovascular interventions within 30 days after cardiovascular surgery or within 7 days after percutaneous interventions, and deaths from congestive heart failure, arrhythmia, pulmonary embolism or ruptured aortic aneurysm. Deaths from uncertain causes were presumed to be due to cardiovascular causes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of the joint European Society of Cardiology/American College of Cardiology Committee for the<BR/>redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69. [Erratum, J Am Coll Cardiol 2001;37:973.]: source not available</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Li-2015a" TYPE="STUDY">Li 2015a</LINK>
</P>
</TD>
<TD>
<P>Not measured</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not measured</P>
</TD>
<TD>
<P>Not measured</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-NORVIT-2006" TYPE="STUDY">NORVIT 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See supplementary appendix: <A HREF="http://www.nejm.org">www.nejm.org</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See supplementary appendix: <A HREF="http://www.nejm.org">www.nejm.org</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See supplementary appendix: <A HREF="http://www.nejm.org">www.nejm.org</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See supplementary appendix: <A HREF="http://www.nejm.org">www.nejm.org</A>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Definitions are too long to summarise in this table</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-SEARCH-2010" TYPE="STUDY">SEARCH 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="https://www.ctsu.ox.ac.uk/research/research-archive/searchs/search-study-protocol/view">https://www.ctsu.ox.ac.uk/research/research-archive/searchs/search-study-protocol/view</A>
</P>
<P>Accessed: 7 January 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="https://www.ctsu.ox.ac.uk/research/research-archive/searchs/search-study-protocol/view">https://www.ctsu.ox.ac.uk/research/research-archive/searchs/search-study-protocol/view</A>
</P>
<P>Accessed: 7 January 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="https://www.ctsu.ox.ac.uk/research/research-archive/searchs/search-study-protocol/view">https://www.ctsu.ox.ac.uk/research/research-archive/searchs/search-study-protocol/view</A>
</P>
<P>Accessed: 7 January 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<A HREF="https://www.ctsu.ox.ac.uk/research/research-archive/searchs/search-study-protocol/view">https://www.ctsu.ox.ac.uk/research/research-archive/searchs/search-study-protocol/view</A>
</P>
<P>Accessed: 7 January 2015</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Definitions are too long to summarise in this table</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-SU.FOL.OM3-2010" TYPE="STUDY">SU.FOL.OM3 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Myocardial infarction (ICD-10 (International Classification of Diseases, 10th revision) codes I21.0&#8211;I21.9) was defined on the basis of 2 or more of the criteria: typical chest pain, electrocardiographic changes consistent with myocardial infarction and cardiac enzyme increase</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>An acute cerebral ischaemic event was defined as an ischaemic cerebrovascular accident based on clinical criteria confirmed by computed tomography or magnetic resonance imaging and a Rankin score 3 at inclusion (ICD-10 codes I63.0&#8211;I63.9)</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acute coronary syndrome without myocardial infarction (ICD-10 codes I20.0&#8211;I20.1) was initially defined by the presence of 3 criteria: typical chest pain, electrocardiographic changes consistent with coronary artery disease without myocardial infarction and evidence of coronary artery disease (myocardial infarction, angina with angiographic evidence of stenosis &gt; 50% in one or more coronary arteries, or angina pectoris corroborated by coronary angiography or exercise testing, or coronary angioplasty or coronary artery bypass graft procedure). Suspected acute coronary syndrome without characteristic electrocardiographic evidence of myocardial infarction provided there was angiographic evidence of coronary artery disease</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-VISP-2004" TYPE="STUDY">VISP 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>New ECG changes including Q waves or marked ST-T changes plus abnormal cardiac enzymes, cardiac symptoms plus abnormal enzymes or symptoms plus hyperacute ECG changes resolving with thrombolysis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Evidence of sudden onset of focal neurologic deficit lasting at least 24 hours accompanied by an increased NIHSS Score in an area that was previously normal. When the sudden onset of symptoms lasting at least 24 hours was not accompanied by an increased NIHSS Score in an area that was previously normal, then recurrent stroke was diagnosed using cranial CT or MRI evidence of new infarction consistent with the clinical presentation</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-WAFACS-2008" TYPE="STUDY">WAFACS 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>According to World Health Organization criteria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>A new neurologic deficit of sudden onset that persisted for more than 24 hours or until death within 24 hours</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Death due to cardiovascular disease was confirmed by examinations of autopsy reports, death certificates, medical records and information obtained from the next kin or other family members. Death from any cause was confirmed by the endpoint committee on the basis of a death certificate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-WENBIT-2008" TYPE="STUDY">WENBIT 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>According to the Joint European Society of Cardiology/American College of Cardiology Committee. Eur Heart J. 2000;21:1502-13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>According to Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, et al. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol. 2001;38:2114-30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>According to Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR et al. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol. 2001; 38:2114-30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>If death occurred within 28 days after the onset of an event, the event was classified as fatal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;15 included RCTs in the quantitative synthesis&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;RCTs contributed to the following outcomes of interest:&lt;/b&gt;&lt;br&gt;&lt;span&gt;Myocardial infarction: 12&lt;br&gt;Stroke: 12&lt;br&gt;First unstable angina: 4&lt;br&gt;Death from any cause: 11&lt;br&gt;Serious adverse events: 8&lt;/span&gt;&lt;/p&gt;" WIDTH="350">
<FLOWCHARTBOX TEXT="&lt;p&gt;2008: 8 RCTs included (11 references) - 3 studies ongoing (3 references)&lt;/p&gt;&lt;p&gt;2012: 4 new RCTs included (21 references) and 11 additional references to previously included studies = total of 12 included RCTs (43 references)&lt;/p&gt;&lt;p&gt;2014: 0 new RCTs included and 4 additional references to previously included studies = total of 12 included RCTs (47 references)&lt;/p&gt;&lt;p&gt;2017: 3 new RCTs included and 15 additional references related to the 2 new trials = total of 15 included RCTs (61 references)&lt;/p&gt;" WIDTH="350">
<FLOWCHARTBOX TEXT="&lt;p&gt;2008: 19 publications obtained in full text + 4 additionally identified references = 23&lt;/p&gt;&lt;p&gt;2012: 59 publications obtained in full text&lt;/p&gt;&lt;p&gt;2014: 17 publications obtained in full text&lt;/p&gt;&lt;p&gt;&lt;span&gt;2017: 37 publications obtained in full text&lt;/span&gt;&lt;/p&gt;" WIDTH="225">
<FLOWCHARTBOX TEXT="&lt;p&gt;After de-duplication&lt;/p&gt;&lt;p&gt;2008: 4318 unique records&lt;/p&gt;&lt;p&gt;2012: 1393 unique records&lt;/p&gt;&lt;p&gt;2014: 653 unique records&lt;/p&gt;&lt;p&gt;2017: 1073 unique records&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;2008 search: 4318 records identified&lt;/p&gt;&lt;p&gt;2012 search: 1705 records identified&lt;/p&gt;&lt;p&gt;2014 search: 888 records identified&lt;/p&gt;&lt;p&gt;2017 search: 1464 records identified&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;1 additional record identified through other sources:&lt;/p&gt;&lt;p&gt;International Clinical Trials Registry Platform search portal&lt;/p&gt;"/>
<OUT TEXT="&lt;p&gt;2008: 4299 abstracts excluded (after title or abstract examination)&lt;/p&gt;&lt;p&gt;2012: 1334 abstracts excluded&lt;/p&gt;&lt;p&gt;2014: 636 abstracts excluded&lt;/p&gt;&lt;p&gt;2017: 1036 abstracts excluded&lt;/p&gt;" WIDTH="250"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;2008: 9 studies (9 references) excluded&lt;/p&gt;&lt;p&gt;2012: 25 new studies (27 references) excluded = total of 34 studies (36 references)&lt;/p&gt;&lt;p&gt;2014: 10 new studies (13 references) excluded = total of 44 studies (49 references)&lt;/p&gt;&lt;p&gt;2017: &lt;span&gt;22 new studies (22 references) excluded = total of 66 studies (71 references)&lt;/span&gt;&lt;/p&gt;" WIDTH="250"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>